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In the unfortunate event of islet beta cell failure, the unequivocal patho-physiological marker of 
type 1 diabetes, insulin treatment is the only life-saving therapy. There is general agreement, 
however, that even when insulin treatment is well tolerated and carried out in a diligent way, 
metabolic derangements and the feared long-term complications still occur (1-3).  
Beta cell replacement therapy, achieved by transplantation of whole pancreas or isolated islets 
of Langerhans, has emerged as the logical alternative to insulin injections. Transplantation of 
the whole pancreas is a complex procedure that can lead to good and long term metabolic 
control. However, transplantation is not devoid of complications, mainly secondary to 
surgery and heavy immunosuppressive therapy (4). Therefore, pancreas transplantation is 
recommended only to selected groups of patients, especially if performed as a solitary (not 
combined to a kidney graft) pancreas transplantation (5, 6). 
ISLET CELL TRANSPLANTATION
Since the late 1980’s, the feasibility of isolating and purifying human islets from pancreatic 
organs of deceased donors raised hope that purified pancreatic islet cells, rather than an 
entire gland, could cure diabetes (7). However, the supply of human donor pancreases 
from deceased donors as sources of islets is insufficient. Even in the most successful trials, 
multiple transplantations are necessary to obtain (temporary) normalization of hyperglycemia 
in the recipients (8-10). Despite significant efforts to improve the yield of isolated islets, to 
choose better culture conditions and preserve higher numbers of isolated islets for clinical 
transplantation, it became evident that the number of deceased donors available each year 
for islets would  never be able to meet the demand. 
The paucity of organ donors is one of the limiting factors to success and long-term function 
of islet transplants.  It is now known that the quality of the isolated islets is strongly affected 
by the medical conditions of the organ donor, the cause of death and pre-existing diseases 
(11). Islet quality is moreover influenced by the events that characterize the procedure of 
organ donation and harvesting; instances that, together, lead to or contribute to exacerbation 
of tissue ischemic damage, thus deterioration of the organs (12). There is no ‘healthy’ organ 
donor after severe events such as strokes, or motorcycle accidents causing intracranial 
hemorrhage, the most common causes of irreversible brain damage. Brain death itself can 
be the cause, among many effects, of metabolic imbalance, including abnormal, typically 
very high, blood glucose levels (13). Combined, these factors increase the risk of worsening 
the quality of the islets. 
There are additional logistic problems, such as the fact that the hospitals where organ 
retrieval takes place, are often far away from the centers that prepare the islets. Islet isolation 
is a rather long (6 to 8 hours) and not trivial procedure, requiring well-trained teams available 
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on a 24/7 basis to meet the time constrains of the organ donation programs. Despite 
organizational coordination efforts between the procurement agencies and the isolation 
centers, prolonged storage time of the pancreas, an obvious negative condition, is practically 
unavoidable. Marked improvements in the storage procedures and selection of preservatives 
have contributed to increasing the survival of the tissue (14-16) but, in practice, 8 to 12 hours 
on average separate the time of harvesting from the time of processing. 
The ultimate therapeutic strategy for the cure of diabetes, envisions the ability to ‘generate’ 
beta cells in the laboratory from immature human cell sources that would be capable of 
proliferating and differentiating into insulin producing cells, in a well controlled process. This 
definitive strategy would not only treat patients, but also eliminate the problem of the poor 
availability and quality of human donor pancreases (17, 18). Ongoing studies, still in their 
infancy, will hopefully offer tangible results, meaning protocols transferable to clinical use. 
Meanwhile, we have the possibility to explore a readily-available, fully-differentiated and 
functional product existing in nature, namely animal islets.
 XENOTRANSPLANTATION
The concept of turning to animal tissue for transplantation in humans is well-established. 
However, pioneer experiments of xenotransplantation using vascularized organs, as well as 
isolated cells, made it clear that humans and large mammals, in spite of their physiological 
similarities, exhibit stringent tissue incompatibilities. Mainly because of recent improvements 
in genetic engineering techniques, and a better understanding of the molecular mechanisms 
that regulate the immune responses across species, xenotransplantation has now regained 
scientific consideration (19). 
For various reasons the pig is considered the preferred source of pancreatic xeno-islets. Pig 
insulin, which differs from the human type by only one amino acid, is active and well tolerated 
in humans. For years prior to the production of human recombinant insulin, patients were 
successfully treated with injections of insulin extracted from swine. Evidence that pig islets 
can be used for transplantation into humans was originally provided, in particular, by studies 
conducted during the 1980’s in Sweden (20).  Moreover, pig islet cells can be successfully 
isolated and purified from adult pigs with a method that is similar to the one used for human 
islets, with the advantage that the total islet mass isolated from adult pigs is larger than in 
humans (21). Advantages of using pigs as a supply of islet cells for transplantation are, at 
least in theory, numerous. Besides the benefit of a basically unlimited tissue supply, we 
anticipate a higher quality of the donor organs, as a direct consequence of the absence of 
brain death. We could, for instance, plan elective organ harvesting, therefore minimizing cold 
ischemia and consequently improving islet yields (22). Overall, the quality of the isolated 
islets would be higher.
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What are the major obstacles to successful pig islet transplantation in humans? 
Xenotransplantation, like to a lesser extent in allotransplantation, entails the problem of 
rejection. Rejection of the graft (i.e., the implanted cells) across species is more aggressive 
than between individuals of the same species. Generalized suppression of the immune 
system in the recipients by pharmacological agents, while not optimal, is an effective way 
to control rejection. Administration of immunosuppressants is a necessary, but not fully 
benign, procedure that requires life-long use of drugs that restrain the immune responses. 
Such immunosuppressive protocols, at the doses and in the combinations currently adopted 
in clinical trials, would not be sufficient to prevent the prompt and massive rejection that 
characterizes xenotransplantation (20). One of the main reasons why tissues across species 
are readily destroyed is the reactivity mediated by ‘preformed’ or ‘natural’ antibodies in the 
recipients (humans and Old World monkeys) against epitopes on pig donor cells (23). 
α1,3 GALACTOSYL TRANSFERASE KNOCKOUT (GT-KO) PIGS  
What are the preformed antibodies?  Pig tissue expresses the carbohydrate 
galactoseα1,3galactose (Gal) (24). Humans and monkeys have an impaired gene that 
encodes the enzyme α1,3- galactosyltransferase (GT), which mediates the expression of Gal 
on the cell membrane. Accordingly, they do not express such a carbohydrate. Consequently, 
humans promptly generate an antibody-mediated response when exposed to tissues from 
Gal-positive animals and microorganisms. These anti-Gal antibodies are the most important 
preformed antibodies in regard to xenotransplantation. They are able to mount a rapid, 
deleterious reaction that is the major cause of xenograft loss in the first minutes to hours 
after transplantation. This is known as hyperacute rejection (25). To avoid the hyperacute 
rejection of tissue from Gal-positive pigs (i.e., WT pigs), the possibility of generating pigs 
genetically deprived of the activity of the GT-enzyme was considered.
The first step was the cloning of the GT gene of the pig, an assignment completed at the end 
of the year 2000.  Based on the gathered DNA sequence information, it became clear that an 
essential region of the GT gene was located in exon 9, and that the inactivation of the gene, 
once the coding sequence was interrupted, was not fatal for the embryo. Thus, genomic 
sequences encompassing the beginning of exon 9 were used to construct knockout (KO) 
vectors aimed at the targeted insertion of a selectable marker gene, and at the inactivation of 
the GT gene in pig fetal fibroblasts.  Single, or heterozygous, GT gene-knockout cells were 
isolated and used as donors for somatic cell nuclear transfer (cloning) into fecundated eggs 
to produce heterozygous GT gene-knockout pigs (26). University of Pittsburgh scientists 
collaborated with the Virginia branch of the Scottish company, PPL Therapeutics Inc. (now 
Revivicor, Inc.), the same institution in Europe that was responsible for cloning the first 
mammal, ‘Dolly’ the sheep. 
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To produce animals useful for transplantation, it was necessary, however, to also knockout 
the second, yet uncompromised, allele of the gene that was responsible for the expression 
of Gal on the heterozygous GT-knockout pig cells.  By developing a new technical approach, 
different from the one used for knocking-out the first allele, it was then possible to produce 
the first cloned pigs homozygous for α1,3 galactosyl transferase gene-knockout (GT-KO) 
(27).  
The availability of pigs with tissue that lack the most important rejection-inducible determinant, 
and that is presumably more compatible for transplantation in humans, fostered an intensive 
period of experiments. Clinical trials cannot be started without appropriate validation of results 
from rodent studies in preclinical studies, meaning using nonhuman primates. In the past, 
several groups have studied transplantation of (unmodified) porcine islets into nonhuman 
primates, usually with unsatisfactory outcome (28). Clearly, satisfactory and safe preclinical 
studies are mandatory before proceeding to clinical trials.
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OUTLINE OF THIS DISSERTATION
As outlined above, a shortage of human donor organs is the major limiting factor for clinical 
islet allotransplantation. Xenotransplantation, using the pig as the source of islets, is 
considered a potential solution to this problem. Since the development of pigs homozygous 
for α1,3-galactosyltransferase gene-knockout (GT-KO), renewed interest exists in the 
possibility of pig-to-primate xenotransplantation. This thesis involves several aspects of islet 
xenotransplantation in a pig-to-nonhuman primate model and of the xeno-antigenicity of 
donor pig tissue. 
The first aim was to review the current state of pig-to-nonhuman primate islet 
xenotransplantation documented at the time the personal studies reported in this dissertation 
were initiated (Chapter 2). 
The second aim was to focus attention on the nature of xeno-antibodies in primate sera 
directed against pig cells. Anti-pig antibodies are formed against galactoseα1,3galactose 
(Gal) and nonGal epitopes on pig cells. As described above, anti-Gal antibodies are 
responsible for hyperacute rejection of pig grafts. The availability of GT-KO pigs enabled 
us to study the presence of anti-nonGal antibodies in baboons, cynomolgus monkeys and 
humans. Different aspects were studied.  The binding and cytotoxicity of preformed antibodies 
to nonGal antigens were documented in baboons, monkeys, and humans (Chapters 3-
5). Furthermore, we investigated the development of an elicited nonGal antibody response 
after GT-KO pig organ transplantation in baboons (Chapter 3). Additionally, the potential 
difference in anti-nonGal antibody levels in allosensitized compared to nonsensitized humans 
was determined (Chapter 4). Differences in anti-nonGal antibody levels between different 
species (i.e., baboons, monkeys and humans) were determined (Chapter 5). We studied 
specifically the development of anti-nonGal antibodies in infant humans and infant baboons. 
The possible implications for clinical xenotransplantation were addressed (Chapter 6).
The next aim was to study porcine islet xenotransplantation in vivo in a nonhuman primate 
model. The first step was to establish a reproducible and safe model for the induction of 
diabetes in cynomolgus monkeys (Chapter 7). We were then able to study the intraportal 
transplantation of WT and GT-KO pig islets into diabetic cynomolgus monkeys. The rapid 
and massive loss of islets shortly after intraportal transplantation (described earlier as the 
instant blood-mediated inflammatory reaction [IBMIR] by the Uppsala group) was confirmed, 
and an attempt was made to overcome this destruction  by investigating different ways to 
reduce early graft loss (Chapter 8). 
The final aim was to evaluate future perspectives. The current position of clinical islet 
xenotransplantation was discussed (Chapter 9), and a possible alternative to islet 
xenotransplantation, i.e., islet cell regeneration, was described (Chapter 10).
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ABSTRACT
Islet allotransplantation has been shown to have potential as a treatment for type 1 diabetic 
patients. Xenotransplantation, using the pig as a donor, offers the possibility of an unlimited 
number of islets. This comprehensive review focuses on experience obtained in pig-to-
nonhuman primate models, particularly with regard to the different types of islets (fetal, 
neonatal, adult) and isolation procedures used, and the methods to determine islet viability. 
The advantages and disadvantages of the methods to induce diabetes (pancreatectomy, 
streptozotocin) are discussed. Experience in pig-to-nonhuman primate islet transplantation 
studies is reviewed, including discussion of the possible mechanisms of rejection and 
the immunosuppressive regimens used. The research carried out to date has led to 
workable animal models to study islet xenotransplantation, but several questions regarding 
methodology remain unanswered, and details of these practicalities require to be adequately 
addressed. The encouraging porcine islet survival reported recently provides an indicator for 
future immunosuppressive regimens.  
INTRODUCTION
The relative success of the Edmonton protocol has proven that clinical islet allotransplantation 
is possible with a steroid-free immunosuppressive regimen (1). Unfortunately, the problem 
of shortage of human donor islets is the major limiting factor for clinical allotransplantation. 
Xenotransplantation, using the pig as the source of islets, is a potential solution to this 
problem (2). Many groups have studied islet xenotransplantation in different animal models 
and in vitro. Although it is clear that there are still immunological, and possibly other, barriers 
that have to be overcome before islet xenotransplantation will become clinically applicable, 
progress is taking place. We have therefore reviewed work reported in pig-to-nonhuman 
primate models. 
Reviews of the general field of islet xenotransplantation have previously been published 
by MacKenzie et al. and Berney et al. (3, 4), and Mandel reviewed the field of fetal islet 
xenotransplantation (5). We here focus on preclinical trials in nonhuman primates, including 
discussion of the various types of pig islets that have been investigated (e.g., fetal, neonatal, 
adult), the islet isolation procedures used, the methods used to induce diabetes in nonhuman 
primates, the mechanisms by which transplanted pig islets are believed to be rejected, and 
the various immunosuppressive regimens that have been tested.  
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SOURCE, ISOLATION, AND PREPARATION OF PORCINE ISLETS
Strain
Heiser et al. studied the influence of porcine strain on islet yields, comparing young or 
adult crossbreeds, German Landrace, Pietrain, and Munich minipigs; the best and most 
reproducible yields were achieved from Pietrain pigs (6). Toso et al. shared the conclusion 
that Pietrain pigs seem to be most suitable (7). However, data on significant strain differences 
are not conclusive.
Fetal islets
Because of the relative lack of exocrine tissue in the fetal pancreas, the isolation of fetal 
islets requires less complex isolation techniques and is therefore easier (5). Korsgren et al. 
initially advised the use of fetuses ‘as old as possible’, although pancreases of fetuses of 
late gestational age (± day 112-113) were found more difficult to digest (8). More recently, 
fetuses of 70-86 days of gestation have been used as their islets are believed to have better 
survival potential (9, 10). During the isolation process, the pancreatic tissue is simply mixed 
with exogenous digesting enzymes, the mixture is incubated and vigorously stirred for 20 to 
30 minutes, after which the digestion is stopped. This method does not require purification 
prior to islet culture (8, 10). 
Based on results from experiments in mice, Mandel estimated that, considering its growth 
potential, one pig fetus would provide enough islets for one human recipient if rejection 
did not reduce the number (5). Unfortunately, to date, rejection does play a role, and the 
optimum number of islets to reverse diabetes in primates remains to be determined.
Fetal islets are more resistant to ischemic injury after pancreas procurement, probably 
due to the relative lack of exocrine tissue retained within fetal islet cell clusters, and the 
characteristics of fetal tissue itself (5). Precursor cells, that are located in the pancreatic 
ducts and probably in immature islet cells, allow proliferation after transplantation (11).
Ironically, the major disadvantage of fetal islets is their immaturity, which is associated 
with delayed function of the islets after transplantation (8). It may take over two months, 
sometimes up to 6 months before normoglycemia is restored (12, 13); during this period, 
therefore, there is a negligible or poor insulin response to glucose. A second disadvantage is 
the expression of Galactoseα1,3Galactose (Gal) on the surface of fetal pig islets, rendering 
wild-type porcine fetal islets more susceptible to rejection than adult islets, which express no 
or little Gal (discussed below) (14-22).
In view of the relatively simple technique of fetal islet isolation, and the relative low costs 
involved, fetal islets are still popular for rodent studies (Figure 1A), but an increasing ability 
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Neonatal islets
Several groups have isolated islets from pigs within the first postnatal month, usually within 
the first days (22-25) (Figure 1B). Although insulin secretion is delayed after transplantation, 
the period is generally shorter than after fetal islet transplantation (26-28).
Figure 1: 
(A) Fetal pig ICC, transplanted under the 
kidney capsule of  a mouse, stained with anti-
insulin antibodies, (B) Neonatal pig ICC, 
after isolation, stained in vitro with dithizone 
(dithizone stains red for insulin-containing 
cells), (C) Adult pig islets, after purification, 
stained in vitro with dithizone.
to achieve good adult islet isolation has stimulated a move away from fetal islets in primate 
studies. 
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Korbutt et al. (23) established an isolation technique for neonatal islets. Briefly, pancreatic 
tissue from 1 to 3 day old piglets was digested enzymatically using collagenase-type enzymes 
for 16-18 minutes, and the islets were cultured for 9 days, during which albumin, IBMX (3-
Isobutyl-1-methylxanthine, a phosphodiesterase inhibitor and insulin secretagogue), glucose, 
and nicotinamide (but no serum) were added. This resulted in yields of 50,000 neonatal islet 
cell clusters (ICC) per pancreas, compared to an average of 10,000 ICC following mid-
gestational fetal islet isolation. After transplanting the neonatal islets into diabetic nude mice, 
there is however a delay of 6 to 10 weeks before diabetes can be reversed (22). 
Juang et al. (24) compared the characteristics of islets derived from 1 to 3 day-old piglets 
with 1 month-old piglets; their response to glucose stimulation in vitro during incubation, as 
well as the beta cell mass and function after islet harvesting, were similar.
Adult islets
Compared to humans, the peri-insular matrix, ‘the islet capsule’, in adult pigs is poorly 
developed, making the islets susceptible to fragmentation and loss during the isolation 
process. Islets from young adult pigs are particularly fragile. According to some reports, 
young pigs do not have an islet capsule at all (29); others report that young pig islets have 
lower resistance to the digesting enzyme, collagenase (7).
Generally, retired breeders (i.e., sows that have undergone multiple pregnancies) are 
preferred as donors of adult porcine islets (30) (Figure 1C). In humans, pregnancy induces 
increases in the beta cell mass, the beta cell sensitivity to glucose, and its production of 
insulin (31). It is these changes that are assumed to result in better islet yields from retired 
breeders, even though it has been reported in rats that the beta cell mass regresses to 
normal (pre-pregnancy) state within 10 days post-partum (32).
To our knowledge, there are no studies comparing the yields of islets from adult male pigs 
of comparable age with those from female retired breeders. In general, 2-3 year-old pigs 
are preferred over younger pigs (i.e. <14 months) because of the relative structural stability 
(or reduced fragility) of the islets. However, successful islet isolation from younger pigs is 
possible, and reasonably good survival of islets has been achieved (30, 33). 
Other variables influencing islet yields
Retained blood in the pancreas after pancreatectomy results in reduced islet yield, possibly 
through inhibition of  the collagenolytic activities of the digestive enzymes (34). Extensive 
flushing before, during, and directly after pancreatectomy is necessary. The diet of the pig 
can also influence the yield, possibly through stimulation of intrinsic enzymes that are mainly 
responsible for autolysis after pancreas procurement. Nutritional substrates may account for 
lower yields (7); islet isolation from pigs following a diet enriched with soybean oil gave better 
yields than those from pigs following a coconut oil regimen (35).
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The effect of warm and cold ischemia times on islet yields
The period of warm ischemia must be minimal, since, during this period, autolysis of the 
pancreas is induced by proteolytic and lipolytic enzymes (7, 36, 37). When the warm 
ischemia time approached 20 minutes, losses in the number of islets after isolation of up to 
70% were seen (38). 
It seems inadvisable to use pig pancreases with a cold ischemia time (i.e. the period 
that elapses between putting the pancreas in ice after procurement and the start of the 
isolation process) of >12 hours (37). In concordance with the results achieved in human islet 
isolation (39), Brandhorst et al. demonstrated that the two-layer method of isolation, using 
perfluorocarbon as an oxygen carrier, may enable an extension of the acceptable period of 
cold ischemia; improved numbers of pig islets were isolated after 7 hours of cold preservation 
by this technique (40). Recently, their group demonstrated that when perfluorocarbon was 
used in a simplified one-layer method, successful pig pancreas preservation was also 
achieved (41).
The intraductal injection with collagenase-containing solutions before storing the pancreas 
contributes to higher yields (7), and injection of collagenase both intraductally and directly 
into the pancreatic tissue is preferred over intraductal injection alone (7). However, using the 
two-layer method, Brandhorst et al. showed that enzyme administration early after pancreas 
procurement decreased islet graft function if the period of cold ischemia had been prolonged 
(40).
Adult pig pancreatectomy
Surgical techniques for pancreatectomy in the pig have been described by Morel et al. (42). 
The pig pancreas has an anatomical localization and orientation similar to that of the human 
pancreas (42), although variability of blood supply has been reported (43). To avoid leakage 
of digesting enzymes during subsequent digestion, it is greatly preferred that the pancreas 
is excised with an intact pancreatic capsule.
Preparation of adult islets:
Digestion
Continuous exposure to digesting enzymes is of importance, but this must not be too 
prolonged or injury to the islet capsule ensues, damaging the islets themselves. The optimum 
end-point of digestion is difficult to determine. 
Since its introduction by Ricordi et al. in 1990, most groups use semi-automatic isolation 
whereby the islets are shaken in a digestion chamber, and the temperature is controlled 
between 34-37 ºC (36). O’Neil et al. described static incubation in a 37ºC water bath for 25-
65 min; this has proved a relatively simple method, providing good results (30). 
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The digesting enzymes usually include collagenase, which consists of up to 6 enzymes and 
is naturally produced by Clostridium histolyticum. ‘Liberase’ is a purified collagenase that 
has the advantage of less inter-lot variation compared to collagenase (33, 37). Brandhorst 
et al. have shown higher yields and less fragmentation utilizing Liberase HI compared to 
collagenase (44); more recently, Liberase PI has been introduced for pig islet isolation (45). 
Hanks’ balanced salt solution or University of Wisconsin solution are the most widely used 
carriers for the digesting enzymes (7). The pH of the solution isolation medium influences the 
yield, with a pH >7.3 resulting in higher yields (6).
Purification
Digestion is followed by purification of the islets. As it is immunogenic and inflammatory, 
the remaining exocrine tissue is removed. The accepted method is density-gradient 
centrifugation, since islets are slightly less dense than exocrine tissue. Ficoll, Euroficoll, 
Ficoll diatrizoic acid, hyperosmolar bovine serum albumin are employed in this process at 
4ºC (46). Purity levels of 80-90% are usually obtained (7). Optional methods employed are 
immunomagnetic cell separation, whereby immunomagnetically-labeled digested pancreatic 
tissue is separated in a magnetic field (47), and fluorescence activated cell sorting (48-50).
Culture of islets
Fetal and neonatal islets have to be cultured to allow them to reaggregate into islet-like cell 
clusters, which takes at least 4 to 5 days (8, 51, 52). Adult pig islets fragment more easily (53), 
which is a disadvantage to the culture of these islets, as are the risks of infection and loss 
of viability. However, culture allows for some pre-transplantation immunomodulation (54), as 
well as further purification (55); culture is also a form of storage. There is no agreement on 
the optimum period of time for adult islet culture, which has been continued for 24 hours to 
several weeks. There is also no generally-agreed ideal islet culture medium; RPMI 1640 and 
CMRL 1066, supplemented with serum-derived proteins, are the most frequently used. Good 
oxygenation during culture is essential, and the preferred temperature is 22-24˚C (37). 
Cryopreservation provides an alternative to culture as a means of storage, but islet viability 
is always reduced, and subsequent function is also impaired (56). Storage of pig islets may 
be largely unnecessary, as a donor pig will be available on demand.
Viability and functional assays  
Islet viability is strongly influenced by warm and cold ischemia times, the isolation process, 
and the period of storage (whether this be cryo or culture), but it is difficult to evaluate the 
exact influence of each (7, 29, 37). Viability can be determined by electron microscopy (57), 
double fluorescent staining (58), fluorometric membrane integrity (59, 60), or by mitochondrial 
function, measured by oxygen consumption (48, 61). 
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Functional assays include in vitro glucose-stimulated insulin release, and in vivo function is 
determined by transplanting the islets into small animals, such as diabetic immunodeficient 
(NODscid) mice (7, 30, 37), which can be expected to become normoglycemic within days 
(62, 63). An intraperitoneal glucose tolerance test may provide further information (64).
THE INDUCTION OF DIABETES IN NONHUMAN PRIMATES
It is generally preferred to render the recipient diabetic to allow assessment of the capability 
of the graft to induce normoglycemia, even though measurement of pig C-peptide in a 
nondiabetic, nonhuman primate recipient provides an indication of the viability of the 
transplanted islets. 
Spontaneous diabetes
Spontaneous diabetes has been reported in several strains of monkey, including cynomolgus 
and rhesus monkeys (65-67), although their availability is limited, and it is absolutely 
necessary to verify pure type I diabetes. 
Surgical pancreatectomy
Pancreatectomy is not without surgical morbidity and has the disadvantage of loss of exocrine 
pancreatic function (65, 68). There is the potential for continuing function or regeneration of 
beta cells if the pancreatectomy has not been total.
Chemical induction
Increasingly, streptozotocin (STZ), derived from the bacteria Streptomyces achromogenes, 
is being administered intravenously to the potential recipient to induce diabetes. Besides 
antimicrobial and anti-tumor activities, STZ is diabetogenic through oxidative stress resulting 
in selective death of the beta cells (69). Nephrotoxicity and hepatotoxicity are disadvantages 
of  STZ (70-73). In rodents, regeneration of beta cells has been observed, resulting from intra-
islet progenitor cells, that are possibly not affected by STZ treatment (74-77). However, STZ-
induced diabetic monkeys remained diabetic for at least one year, with no significant primate 
C-peptide release after glucose stimulation, and pancreas histology that demonstrated only 
a few insulin-staining cells (70).  
STZ administration to induce diabetes has several potential variables (Table 1).  The first 
relates to the optimal dose of STZ in nonhuman primates. Pitkin et al. and Litwak et al. 
showed that a single dose of 30mg/kg is not sufficient to induce complete diabetes (78, 79). 
Larger doses of 100-150mg/kg were found sufficient (70, 72, 80), but were associated with 
more side effects and complications (70-73, 80). In contrast, Koulmanda et al. reported that 
55mg/kg was sufficient to consistently induce diabetes in cynomolgus monkeys (70), but 
others were less successful (71, 78, 81). Since STZ has a half-life of only 10 min (70), it 
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seems reasonable to anticipate that higher dosages are necessary if it is not administered 
rapidly as a bolus. A significant loss of efficacy will ensue if the STZ is infused slowly over 
a period of minutes. Wijkstrom et al. suggested the dose should be based on body surface 
33
    
First 
author 
Reference  Animals tested 
(n, when stated) 
Weight/age animals 
(when stated) 
STZ dose 
(mg/kg) 
Results                                                    
(C-pep in ng/mL) 
      
Wijkstrom (80) Cyno (26) 3.3 ± 1.2 kg 133 ± 21  
  Rhesus (21) 4.6 ± 1.1 kg 143 ± 17  
46/53 diabetic. Complications were 
dose dependent; death 5/53, renal 
toxicity 8/53, hepatotoxicity 18/53. 
Concluded safe and effective dose: 
1250 mg/m2
      
Koulmanda (70) Cyno (20) 3.1-6 kg/ 3-6 years 55 All groups diabetic (C-pep <0.6)  
  Cyno (4)  100  
      
Contreras (86) Rhesus 3.0-3.8 kg 140 All hyperglycemic (C-pep< 0.6) 
      
Gaur (73) Pigtailed 
macaques (15) 
< 15 kg 10-40,          
1-3 doses 
13/15 hyperglycemic after one injection 
(25 or 40 mg/kg).                                      
Multiple injections affected kidney and 
liver functions. 
      
Thieriault (72) Cyno (11)  1 - 2 kg/ 6-8 months 150 All monkeys hyperglycemic (C-pep < 
0.9) 
      
Litwak (79) Cyno (8)  4.9 ± 0.4 kg/ 6.2 ± 
0.8 years 
30,               
1-3 doses 
3/8 hyperglycemic after 1 dose                
1/8 glucose intolerant after 1 dose          
3/8 hyperglycemic after 2 doses               
1/8 hyperglycemic after 3 doses  
      
Stegall (71) Cyno (>20) 2.5 - 4.4 kg 50 80 % diabetic after 1 dose 
      
Takimoto (81) Rhesus (22) 8.45 ± 1.43 years 10/22 diabetic within 5 days (C-pep < 
0.06) 
   8.3 ± 2.47 years 4/22 non insulin-dependent  
   6.01 ± 0.94 years 
45-55  
8/22 non diabetic 
      
Jones (125) Rhesus (20) 5.2 ± 0.2 kg 30-55  
   5.5 ± 0.4 kg 30-55 
11/20 insulin-dependent                           
9/20 impaired glucose tolerance 
      
Pitkin (78) Rhesus (3) 3.8 - 6.2 kg 30 None diabetic 
  Rhesus (7)  45 5/7 hyperglycemic, 2 glucose intolerant 
    Rhesus (2)   60 All hyperglycemic 
Abbreviations: C-pep= C-peptide; Cyno= Cynomolgus monkey; Rhesus= Rhesus monkey 
Table 1: 
Selected experience in induction of  diabetes by streptozotocin in nonhuman primates
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area (1250mg/m2), rather than body weight (80). The islets of younger nonhuman primates 
may be more difficult to destroy, and this may account for the varying STZ dosages required 
to induce diabetes (70, 81). There is a reported correlation between the dose of STZ and 
the development of renal and hepatic damage, as documented by an increase in blood 
urea nitrogen, creatinine and/or hepatic enzymes, respectively, or by histology (70-73). To 
diminish or prevent kidney damage, hydration both before and after STZ administration is 
recommended (70-72, 82).
Zanosar (Sicor Pharmaceuticals, Inc.) is a form of STZ that is used clinically in patients with 
metastatic islet cell carcinoma and may have fewer side effects than other preparations 
of STZ, perhaps because of greater purity and less variability. Zanosar has consistently 
induced diabetes in nonhuman primates at a single dose of 150mg/kg administered rapidly, 
without significant side effects (S. Deng, personal communication). It would seem that a 
dose of >100mg/kg or 1250mg/m2, administered as a rapid bolus, has the potential to induce 
diabetes consistently.  
Whereas some investigators begin immunosuppressive therapy for islet transplantation one 
week after STZ administration, others wait months to confirm the diabetic state. Administration 
of cyclosporine within 1 to 2 weeks after STZ resulted in renal failure (83). Our own limited 
experience suggests that immunosuppressive therapy within 2 weeks of STZ administration 
may aggravate an STZ-associated glomuleronephropathy.
Alloxan has been used to chemically induce a diabetic state, mainly in rodents. Although 
nonhuman primates have been reported to become diabetic after alloxan administration (65), 
it is generally assumed that alloxan works selectively on rodent beta cells, and is therefore 
not a potent inducer of diabetes in nonhuman primates (84, 85). 
Confirmation of the induction of diabetes
Hyperglycemia has been used to indicate induction of diabetes (71, 78), but C-peptide levels 
are generally measured to confirm it (Table 2). Primate C-peptide levels of <0.9ng/mL were 
considered sufficient to indicate a diabetic state by Thieriault et al., whereas others required 
levels <0.6ng/mL (70, 81, 86) or <0.4ng/mL, as well as an absence (<0.1ng/mL) of C-peptide 
response to arginine challenge (80). Only meticulous recipient total pancreatectomy (but not 
STZ administration) results in a C-peptide level of zero (70). 
Some form of glucose challenge is required to confirm diabetic status (37, 70-73, 78, 79, 81, 
86). Arginine (70 mg/kg over 30 min) (87) stimulates both alpha and beta cell activity; the 
absence of C-peptide and insulin responses after arginine administration confirm diabetes 
(82, 88, 89). Glucagon stimulation is a clinical test that has not yet been described in the 
nonhuman primate setting; it is a simple, quantitative test that measures the responses of 
glucose, insulin, and C-peptide to 1mg glucagon in human adults (90). 
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The effect of STZ on the beta cells can also be evaluated by histological examination of 
a pancreatic biopsy, but this requires a surgical procedure, and some immunostaining for 
insulin is always present. Whereas healthy non-diabetic cynomolgus monkeys have 10-30 
insulin-positive cells per islet (70), Koulmanda et al. reported <5 insulin-positive cells per 
islet after STZ. Litwak et al. reported 18% insulin staining in pancreases of STZ induced 
diabetic monkeys, compared to 61%  insulin staining in control monkeys (79).   
EXPERIENCE IN EXPERIMENTAL PIG-TO-NONHUMAN PRIMATE ISLET 
TRANSPLANTATION 
The pig-to-nonhuman primate islet transplantation experiments reported in the literature are 
summarized in Table 3.
Recipients for nonhuman primate experiments
Species
Macaque monkeys, especially cynomolgus monkeys, have been the major species of choice 
(Table 3). Macaque monkeys are generally smaller than baboons, and therefore have the 
advantage of requiring less expensive housing, husbandry, and drug costs; and fewer pig 
islets are needed to be transplanted. Baboons, though used far less often, are perhaps more 
hardy than macaque monkeys, possibly rendering them less susceptible to surgical and 
other complications.
Diabetic status
The majority of experiments have been performed in non-diabetic recipients (82, 91-96). This 
model allows only evaluation of porcine C-peptide production, and the immune response, 
including measurement of complement activation, anti-pig antibody status, and graft histology 
34
Table 2: REPORTED C-PEPTIDE VALUES IN HUMANS, MONKEYS AND PIGS (NG/ML) 
   Human (ref)  Monkey (ref)  Pig (ref)
_______________________________________________________________________ 
Non-diabetic 
Fasting:  0.5-1.5 (126) 1.5-4.1(11)  0.21-0.63 (127) 
Diabetic    
Challenged:  < 0.48 (1)  <0.5 (80)    
_______________________________________________________________________ 
Table 2: Reported C-peptide values in humans, monkeys, and pigs (ng/ml)
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(94), but not the ability of islet grafts to normalize diabetic status. The advantage of having 
diabetic recipients is the ability to follow blood glucose levels after islet transplantation (66, 
82, 89, 92, 94). Neither the histological presence of islets, nor the documentation of porcine 
C-peptide necessarily correlate with functional reversal of diabetes (9). 
Tethering
Except for one study by Buhler et al. (92), and in our own unreported experience, all 
studies in the pig-to-nonhuman primate model have been carried out in untethered animals. 
Tethers carry indwelling intravascular and/or gastric catheters (Figure 2), and provide an 
advantage in regard to the ease with which blood samples can be obtained and fluids and 
drugs administered, without the need for restraining or sedating the primate (97). This is 
especially advantageous in diabetic monkeys that need frequent blood glucose monitoring. 
However, the intravascular catheters require skillful and careful handling, and the potential 
for introduction of a systemic infection and for hemorrhage or embolism represents a small 
risk.
Site of islet transplantation
The majority of studies have placed the porcine islets under the recipient’s renal capsule 
or intraportally (Table 3), though some have been transplanted subcutaneously (93) or into 
the sternomastoid muscle (92). Sun et al. transplanted islets (encased in alginate capsules) 
intraperitoneally (66, 98).
Figure 2: 
Drawing showing system allowing continuous 
or intermittent hemodynamic monitoring, 
drug and fluid infusion, and blood sampling 
in the nonhuman primate without the need 
for sedation. Venous (femoral or jugular) 
and/or arterial (femoral or carotid) cannulae 
are inserted, tunneled subcutaneously to the 
middle of  the back and brought out through 
a protective flexible metal tube (held in place 
by a jacket).  
32
Figure 2.
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After intraportal islet transplantation, the islets lodge in the small venules of the liver, where 
they produce insulin in response to portal blood glucose values. In an allograft setting, 
capillary vascularization of the islets has been demonstrated to occur within weeks (99). 
The disadvantage of this approach is that direct exposure of the islets to the blood can 
result in an immediate inflammatory response and complement activation (‘instant blood-
mediated inflammatory reaction’ [IBMIR] (94)), and activation of both the humoral and 
cellular responses (see below) (82). Furthermore, obtaining liver biopsies that confirm the 
presence of viable islets, which may be widely-dispersed throughout the liver, is difficult; 
indeed, partial hepatectomy may be required to obtain meaningful histology (B.J. Hering, 
personal communication).  
When placed under the renal capsule, the islets are safer from immediate destruction by the 
immune system, although ischemic injury can be a problem (95). The islets also need to be 
revascularized by the recipient, which usually takes about 10 days (100), but may take 3 to 5 
weeks in the human-to-mouse model (101). Repeated biopsy, though invasive, is relatively 
easy. However, low or no porcine C-peptide production has been reported from subrenal 
capsular islets in the pig-to-nonhuman primate model (Table 3).
Porcine islets transplanted into the subcutaneous tissues showed an early inflammatory 
response, and only a few islets survived for more than 3 days (93). As early as 1996, Sun et 
al. reported survival and C-peptide production of encapsulated porcine islets transplanted 
into the peritoneal cavity in cynomolgus monkeys for up to 804 days, but no further studies 
have been reported (66). 
Number of transplanted islets
The number of islets that can be transplanted intraportally is limited because of the risk of 
portal vein thrombosis. To reduce this risk, the islets are mixed with heparin (usually 70U/kg 
recipient body weight). In our own experience, this dose moderately increases the partial 
thromboplastin time of the recipient, but for <1 hour. The maximum number of islets reported 
to be successfully infused by this route (without complications) has been 32,000 IE/kg  (92), 
although we have recently transplanted 40,000 IE/kg without problem.
There appears to be no strict limitation on the number of islets that can be transplanted 
subcapsularly, although the numbers have not been higher than those for intraportal injection 
(Table 3). However, Soderlund et al. showed that necrosis of the graft was evident on the 
first day, and was progressive to day three; the necrotic areas contained polymorphonuclear 
cells (95). Spreading the islets over a larger surface area reduces the risk of ischemic injury 
(91, 95).   
The immense advantage of porcine islets over human islets is their abundant availability; this 
advantage does not appear to have been fully utilized experimentally.  
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Non-immunological responses to transplanted islets
Data provided largely by the Uppsala group indicate that islets injected intraportally, 
whether they be allo (102) or xeno (94), are subject to IBMIR, which is manifest by 
activation and consumption of platelets, activation of neutrophils and monocytes, and 
activation of the coagulation and complement systems (94, 103). The prior administration 
of soluble complement receptor-1 reduced rapid islet destruction both in vivo and in vitro 
(94), supporting the hypothesis that complement activation plays a major role in IBMIR. 
However, others have reported long-term survival of porcine islets in nonhuman primates 
without the need for specific treatment for IBMIR (89). The immediate and significant loss of 
islets from IBMIR may possibly be reduced by some of the agents primarily administered as 
immunosuppressants, such as those that inhibit cytokine release.  
Immunological response to transplanted islets
Both humoral and cellular rejection of the transplanted islets has been described (Table 3).  
Humoral response
Anti-Gal is the major preformed antibody directed against pig epitopes in humans.  However, 
a lack of Gal expression in the adult pancreas, apart from the lining of blood vessels and 
biliary ducts, has been reported by several groups (15, 16, 18, 19), with occasional Gal 
expression by others (17, 21, 104). In contrast, Gal expression on neonatal  (20, 21) and 
fetal (17) islets is high. Fetal islets from wild-type pigs are therefore presumed to be more 
susceptible to humoral injury than adult islets (17).
No study of islet xenotransplantation in primates to date has used islets from pigs homozygous 
for α1,3galactosyltransferase gene-knockout. The availability of these pigs (105-107) has 
made it important to investigate the potential role in graft destruction played by antibodies 
directed to other (nonGal) pig antigens (104, 108, 109). Hanganutziu-Deicher (HD) antigens 
and other sialic acid antigens have been shown to account for significant antigenicity of adult 
pig islets in vitro (104). Furthermore, nonGal and nonHD antigens have been shown to be of 
importance. Komodo et al. transplanted islets from N-acetylglucosaminyltransferase-III (GnT 
III) pigs, in which both Gal and nonGal antigen expression is down-regulated (110, 111), 
under the renal capsule of monkeys. These modified islets survived longer than wild-type 
islets. Since monkeys, unlike humans, express HD antigens (108), this observation suggests 
the existence of antibodies to nonGal, nonHD antigens (109). 
Organs from pigs transgenic for the human complement regulatory protein, decay-accelerating 
factor (hDAF) are less susceptible to hyperacute rejection after transplantation into primates, 
as the porcine endothelium is protected to some extent from complement-mediated injury 
after contact with human blood. However, both fetal and adult islets from hDAF transgenic 
pigs generated strong cytotoxic and inflammatory responses that were equal to those 
generated by islets from wild-type pigs, suggesting that hDAF was not expressed strongly 
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Table 3: EXPERIENCE WITH PIG-TO-NONHUMAN PRIMATE ISLET TRANSPLANTATION 
     
First author Reference  Donor islets Recipient                                          
(n, when stated)                                
(diabetic status) 
Site and number of islets 
transplanted (when stated)   
(IE or ICC) 
     
Kirchhof (82) WT adult Rhesus (8)                                         
(6 STZ-diabetic, 2 non-diabetic) 
Intraportal, 20 000/kg 
Jie (89) WT adult Cyno (3) (STZ-diabetic) Intraportal, 25 000/kg  
   Cyno (4) (STZ-diabetic) Intraportal, 25 000/kg 
   Cyno (4) (STZ-diabetic) Intraportal, 25 000/kg 
   Cyno (1) (STZ-diabetic) Intraportal, 25 000/kg 
Rijkelijkhuizen (91) WT adult Cyno (4) (non-diabetic) Kidney capsule, 1 500-9 500 
on 4 poles 
   Rhesus (4) (non-diabetic) Kidney capsule; 1 500-9 500 
on 4 poles (n=4),                      
Intraportal; 2 000-8 500 
(n=3)
     
Buhler (92)  WT adult Baboon (3) (pancreatectomized) Intraportal; 10 000/kg 
  Miniature swine adult Baboon (2) (non-diabetic) Intraportal; 14 000/kg and  
32 000/kg 
Cantarovich (93) WT adult  Baboon (4) (non-diabetic)                  
Cyno (1) (non-diabetic) 
Intraportal, 60-180 000 
(n=5),                                 
Additional subcutaneous 
islets, 2000 (n=3) 
Bennet (94) WT adult Cyno (4) (non-diabetic) Intraportal 19 700-20 000/kg 
   Cyno (4) (non-diabetic)  
Soderlund (95) WT fetal Cyno (8) (non-diabetic) Kidney capsule, 4 000  
   Cyno (6) (non-diabetic) Kidney capsule, 4 000  
Mandel (96) hDAF fetal Cyno (non-diabetic) Kidney capsule 
  WT fetal  Cyno (non-diabetic) Kidney capsule 
Sun (66) WT adult Cyno (11) (spontaneously diabetic) Intraperitoneally;  
Unencapsulated (n=2) and 
Encapsulated (n=9);  
1-3 times 30-70 000   
     
Abbreviations: ATG= antithymocyte globulin; C-pep= porcine C-peptide; CyA= cyclosporine; Cyc= cyclophosphamide; cyno= 
cynomolgus monkey; CVF= cobra venom factor; d= posttransplant day; EVL= everolimus; h= hour; ICC= islet cell clusters; IE= 
islet equivalents, LEF= leflunomide; LF 195= deoxyspergualin analog;  min= minute; MMF= mycophenolate mofetil; MMN= 
monomorphonuclear cells; PMN= polymorphonuclear cells; rhesus= rhesus monkey; STZ= streptozotocin; WT= wild type 
                                                                                                                                                 
                                                                                                                                                   (Table 3 is continued overleaf) 
Table 3: Experience with pig-to-nonhuman primate islet transplantation
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Table 3 continued: EXPERIENCE WITH PIG-TO-NONHUMAN PRIMATE ISLET TRANSPLANTATION
Immunosuppressive regimen Result 
None Serum C-pep lost in 12-72h                                                       
Histology: 12-24 h: complement and Ab deposition;                     
48-72 h: CD3/4/8 T cell deposition.  
Anti-CD25, FTY720, EVL Serum C-pep for 39, 47 and 53 d 
Anti-CD25, FTY720, EVL, anti-CD154 Serum C-pep for 57, 68, >73 and >187 d 
Anti-CD25, FTY720, EVL, anti-CD154, LEF Serum C-pep for >76, >111,>140 and >145 d 
Anti-CD25, FK 506 , EVL, anti-CD154, LEF Serum C-pep for > 158 d 
Cyc, CyA, prednisolone Histology: up till day 11 little infiltration (5%).                                 
Serum C-pep <0.33 ng/mL 
ATG, anti-IL 2 receptor Ab, CyA, prednisolon Histology kidney: up till day 53 without infiltration.                         
Serum C-pep <0.33 ng/mL 
No islets in liver detected 
                    
ATG, Cyc, azathioprine Normoglycemia for 15-2 h 
Splenectomy, Whole body+ thymic irradiation, ATG, anti 
Gal immunoadsorption, CVF, CyA, MMF, prednisolone, 
anti-CD154, donor peripheral blood progenitor cell 
infusion 
Serum C-pep till d 3 and 5 
ATG, CyA, LF 195, MMF, prednisolone Serum C-pep for 2 d (n=1)                                                             
Serum C-pep for 1 d (n=1)                                                            
Serum C-pep for 2 h (n=2)                                                             
No serum C-pep (n=1) 
sCR1 Reduced insulin release, suggesting less islet cell damage 
None Plasma insulin increased 60 fold first 10 min 
None Histology: d 1/3/6: increase in PMN cells (mainly 
macrophages), T cells (CD8>CD4) and necrosis (few B cells 
and NK cells). 
CyA, 15-deoxyspergualin Histology: d 6: fewer T cells and necrosis compared to 
untreated monkeys. d 12: CD 8 cells 
Non-immunosuppressed: Histology: d 3; minimal infiltration,     
d 7; massive infiltration PMN and MMN cells.  
Non-immunosuppressed and immunosuppressed with 
CyA, steroids, Cyc / Brequinar Immunosuppressed: Histology: d 7; grafts present (not all 
recipients). Histological survival > 40 d. 
None Encapsulated islets: Insulin independence for 120-804 d and 
serum C-pep (n=7) 
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on the islets (112). It will be necessary to develop promoters that are islet-specific if islets, as 
opposed to vascular endothelial cells, are to be protected by this transgenic approach.
Cellular response
Both in vitro and in vivo studies show cellular rejection of transplanted islets to be important 
(82, 91, 113) (Table 3). Recently, Kirchhof et al. showed that adult islets transplanted 
intraportally into diabetic non-immunosuppressed monkeys were subject to acute cellular 
rejection. Although early IgM binding and complement deposition was reported, islets were 
not hyperacutely rejected. Early reversal of hyperglycemia was demonstrated, together with 
porcine C-peptide production. The islets were subject to CD4+ and Cd8+ cell infiltration, that 
progressively increased until euthanasia after 72 hrs (57).
Also in non-immunosuppressed monkeys, the Uppsala group showed that subcapsular 
islets were infiltrated by mononuclear cells, mostly T cells and macrophages, and no 
immunoglobulin or complement deposition was detected (114, 115).  
Soderlund et al. demonstrated also no immunoglobulin deposition in subcapsular fetal islet 
grafts, but macrophages and T cells (CD8+>CD4+) infiltrated the entire graft, though this 
followed initial necrosis, possibly a result of ischemia (95). Histology from subrenal capsular 
and intraportal grafts showed increasing T cell infiltration before graft loss, with few B cells, 
macrophages and NK cells (91).
Lalain et al. co-incubated pig islets with baboon and human peripheral blood mononuclear 
cells (PBMC), and found early a greater CD4+  than CD8+ T cell response, suggesting  more 
Th2 than Th1 activity (113). The importance of CD4+ T cells was also demonstrated by 
Friedman and colleagues who studied the human lymphocyte response to fetal porcine islets 
in a recombinase-activating gene-deficient (RAG) mouse model (116). Cantarovich et al. 
suggested that T cell-dependent humoral rejection occurs; after an initial infiltration with 
macrophages, they found T cell infiltrates in the graft, and strong antibody responses (93). 
Islets transplanted into the sternomastoid muscle were also reported to be destroyed by 
macrophages and mononuclear cells (92). 
The evidence to date is inconclusive, but rejection of pig islets in nonhuman primates is 
probably a result of an innate response, manifest by macrophage infiltration and possibly 
antibody- and complement-mediated injury, followed by an adaptive response, manifest by 
a major T cell response.  
Suppression of the immune response
Various immunosuppressive regimens have been tested in pig-to-primate islet experiments 
with varying results (Table 3). In all studies in which a multi-drug therapy approach has been 
incorporated, it is difficult to determine the effect of any one agent.  
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Suppression of the humoral response
The administration of cobra venom factor resulted in complete depletion of complement 
(CH50 levels 0%) although its effect on islet survival was not clear (92). Soluble complement 
receptor-1 reduced IBMIR significantly (94). IBMIR has also been partially prevented by the 
administration of dextran sulfate in both in vitro and in vivo models (117, 118).
Extracorporeal immunoadsorption of anti-Gal antibody, which is a time-consuming procedure, 
has been used to prevent antibody-mediated hyperacute rejection (92), but its effect is 
transient, lasting for only a few days (119). In view of the relative or complete absence of 
Gal expression on adult pig islets, it is unlikely that this immunoadsorption played any role 
in extending islet graft survival. 
Suppression of the cellular response
Cyclosporine has been widely used in the past, but, because of nephrotoxic side effects, 
newer drugs are increasingly being used. Antithymocyte globulin and/or an anti-IL2 receptor 
antagonist are widely used (Table 3). When these drugs were added to a cyclosporine-based 
regimen, survival of porcine islets in monkeys was extended significantly; cellular infiltration 
in subrenal capsular islet grafts was delayed from 11 to 53 days (91).  
Immunosuppressive regimens containing sirolimus and tacrolimus, as used in the Edmonton 
protocol (1), have been of interest. Unfortunately, tacrolimus is diabetogenic, even when low 
levels of the drug (4-6 ng/ml) are maintained in the blood. Furthermore, it has been shown 
in rats that the Edmonton regimen induces marked insulin resistance and beta-cell toxicity 
(120). Alternatives to tacrolimus should be explored (121). Mycophenolate mofetil has not 
been used frequently in islet transplantation experiments in nonhuman primates, but is a 
potential alternative to tacrolimus as it is a T and B cell suppressor and less diabetogenic 
(121, 122). Corticosteroids used to be constituents of immunosuppressive regimens (91-93, 
96), but, because of side effects, in particular diabetogenicity, have now been omitted.  
The most successful results to date have been obtained using a regimen that includes several 
newer agents - FTY 720, an anti-CD154 mAb, and leflunomide – in addition to some more 
conventional agents (89). When an anti-CD154 mAb was added to the immunosuppressive 
regimen, survival of the islets increased from 53 days to >187 days (89) (Table 3). These 
results correlate with the long-term islet survival achieved in an anti-CD 154 mAb-based 
regimen in allotransplantation experiments (123, 124).
Assessment of survival of islets after transplantation
Porcine C-peptide levels (9, 66, 82, 89, 91-93, 98) and histology of the graft (Table 3) are 
the most important indicators of graft viability. The intravenous glucose tolerance test, and 
the requirement for exogenous insulin (98) have also been used. Arginine and glucagon 
stimulation tests may also be valuable.
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COMMENT
At the present time, it would seem that adult porcine islets have the best potential, from 
both logistic and immunologic perspectives, to reverse diabetes in primates. Islet isolation 
techniques have improved sufficiently so that large numbers of good-quality adult porcine 
islets can be obtained. Refinements in the induction and maintenance of STZ-induced 
diabetes in nonhuman primates have provided a useful experimental model, although it 
remains uncertain whether STZ induces irreversible diabetes.
However, progress in extending survival of transplanted pig islets in nonhuman primates 
has been slow, although encouraging results have recently been reported (89). With the 
relative plethora of established and novel immunosuppressive agents now available, one 
major problem will be to determine the optimal combination. Particularly in the treatment of 
a disease such as diabetes, that is not rapidly fatal, there is a need to establish clinically-
applicable immunosuppressive regimens that are not associated with life-threatening side 
effects. There will almost certainly be a move away from calcineurin inhibitors, that are 
diabetogenic, towards newer agents, such as FTY 720, leflunomide, and biological agents 
that inhibit costimulation.  
As we have outlined in this review, experimental models have been established in which 
these novel agents can be investigated. However, questions remain, and details of these 
models need to be adequately addressed.
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ABSTRACT
Background:  As pigs homozygous for α1,3-galactosyltransferase gene-knockout (GT-KO) 
are available, primate antibodies to pig nonGal antigens can be studied. 
Methods:  Sera from 56 baboons were tested for binding of IgM and IgG to peripheral 
blood mononuclear cells (PBMC) from both wild-type (WT) and GT-KO pigs by flow 
cytometry.  Complement-dependent cytotoxicity was measured in 39 sera.  Antibody and 
cytotoxicity responses were measured in two baboons exposed to a GT-KO pig heart, one 
not immunosuppressed, and one that received only cobra venom factor. 
Results:  IgM and IgG bound to 95% and 79% of WT PBMC, and 32% and 9% GT-KO 
PBMC, respectively (WT versus GT-KO, p<0.01).  Whereas 97% of sera were cytotoxic to 
WT PBMC, only 64% were cytotoxic to GT-KO PBMC, and the level of cytotoxicity was less 
(mean 60% versus 25% lysis, p<0.05).  In the two baboons exposed to GT-KO hearts, anti-
nonGal antibodies increased markedly, peaking after 2 (IgM) and 3 (IgG) weeks, associated 
with an increase in lysis of GT-KO PBMC. 
Conclusions:  Almost 50% of baboons have preformed cytotoxic antibodies to GT-KO 
PBMC.  After GT-KO organ transplantation, if an elicited antibody response develops, it is 
likely to cause rapid graft rejection.
INTRODUCTION
                 
The recent availability of pigs homozygous for α1,3-galactosyltransferase gene-knockout 
(GT-KO) (1, 2) has enabled pig-to-baboon organ transplantation to be carried out in the 
absence of expression of the pig Galα1,3Gal (Gal) epitopes that are known to be important 
targets for primate anti-pig antibodies (3-6).  Transplantation of hearts (7) and kidneys (8) 
from GT-KO miniature swine into immunosuppressed baboons that expressed either no or 
very low levels of preformed antibodies pre-transplantation against antigens on GT-KO pig 
peripheral blood mononuclear cells (PBMC) (nonGal antigens) was followed by relatively 
prolonged graft survival, extending to 179 days (heart) and 83 days (kidney), with graft failure 
largely a result of the development of a thrombotic microangiopathy that may be a form of 
delayed antibody-mediated rejection.  At graft excision, patchy IgM, IgG, and C4d deposition 
was seen in the majority of the grafts.
Although Zhu has reported a varying incidence of anti-nonGal antibodies (against α-
galactosidase-treated wild-type pig red blood cells) in 10 healthy humans (9), there have 
hitherto been no other definitive reports on the incidence of anti-nonGal antibodies in any 
species of primate or of the extent of cytotoxicity associated with these antibodies towards 
pig cells.  We here report on the incidence and cytotoxicity of preformed antibodies directed 
to nonGal antigens on GT-KO pig PBMC in immunologically-naïve baboons.  We also report 
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on the development of elicited antibodies to nonGal antigens after baboon exposure to 
hearts from GT-KO pigs.
METHODS
Animals
Serum samples were prepared from blood collected from 56 immunologically-naïve baboons 
(not intentionally exposed to pig cells or tissues) (Papio anubis or Papio hamadryas) of all 
blood groups (A, B, AB); the sera came from baboons from various suppliers in the US.  To 
detect the presence of anti-Gal and anti-nonGal antibodies in these sera by flow cytometry, 
PBMC as targets were collected from wild-type (WT) and GT-KO pigs (Revivicor, Inc., 
Blacksburg, VA) (1), both of Large White/Landrace/Duroc cross-breed, and all of blood type 
O.  Although the WT and GT-KO pigs were from the same genetic background, they were not 
from identical clones; however, the only major difference was in the absence of Gal antigens 
in the GT-KO pigs.  Sufficient sera were available from 39 baboons to perform cytotoxicity 
assays, using the same pig cells.  
All animal care procedures were in accordance with the Principles of Laboratory Animal 
Care formulated by the National Society for Medical Research and the Guide for the Care 
and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH publication No. 86-23, revised 
1985).  Protocols were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh.
Isolation of Porcine PBMC
PBMC from several different pigs (WT and GT-KO) were isolated from heparinized blood 
by centrifugation on Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ).  The 
PBMC were not pooled, but PBMC from a single pig were used for multiple sera.  The total 
mononuclear cell fraction was then washed twice with RPMI 1640 media (Gibco, Grand 
Island, NY), filtered and resuspended in FACS Buffer (PBS containing 1% bovine serum 
albumin [Gibco] and 0.1% NaN3) for flow cytometry or in RPMI medium (including 10% FBS) 
for cytotoxicity assay.  
Flow Cytometry
Baboon serum samples (n = 56) were incubated for 30min at 56˚C to inactivate complement. 
Isolated PBMC (1x106 cells/each tube) were incubated with 20μL of baboon serum from 
each sample (20% serum final concentration) or 20μL of FACS buffer as a control for 30min 
at 4˚C.  After incubation, the cells were washed twice in 2mL FACS buffer and centrifuged at 
1800rpm for 5min.  The supernatant was discarded.  To prevent non-specific binding, 10μL of 
goat serum (10% concentration) was added to all the tubes.  Detection of IgG or IgM binding 
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was performed by further incubating the serum with FITC-conjugated goat anti-human IgG (γ 
chain-specific) at 1:50 dilution or IgM (μ chain-specific) at 1:200 dilution (Zymed Laboratories, 
San Francisco, CA) for 30min in the dark at 4˚C.  The samples were washed twice, and the 
cells resuspended with FACS buffer.  Data acquisition was performed with FACScan (Becton 
Dickinson; Mountain View, CA).  Dead cells were excluded from the analysis by forward-
scatter and propidium iodide staining.  IgG and IgM anti-pig antibodies were determined by 
indirect immunoflorescence intensity.  Measurement of mean florescence intensity (MFI) 
was performed on viable cells.  Measurement of indirect immunoflorescence intensity was 
accomplished by Cell Quest software and converted into MFI by WinMDI software.  
Complement-Dependent Cytotoxicity Assay
Baboon serum samples (n = 39) were incubated for 30min at 56˚C to inactivate complement. 
The samples were four-fold serially diluted with RPMI 1640 media (+10% FBS; Gibco) to 
final concentrations of 50%, 12.5%, 3.125%, and 0.78%.  As an interplate control, serum 
from a single human was diluted in the same manner and used on all plates.  Cells were 
loaded into flat-bottomed 96-well plates at a density of 1x106 cells/well (suspended in RPMI 
1640 media + 10% FBS).  The cells were centrifuged at 1800rpm for 7min, the supernatant 
discarded, and the cells incubated with 100μL of diluted baboon or human (interplate control) 
serum for 30min at 4°C.  
After incubation, the cells were washed and further incubated with 100μL of 10% rabbit HLA-
ABC serum (Sigma), as a source of complement, for 45min at 37°C.  Negative control wells 
(100% live cells) were achieved by adding only complement to wells containing either WT 
or GT-KO cells.  Positive control wells (0% live cells) were achieved by adding a detergent 
(polyoxyethylene sorbitan monolaurate; Sigma). Additional negative controls were employed; 
these comprised either cells alone or cells + serum in wells in which no complement or 
detergent was added.
Following incubation, the cells were washed and resuspended in 100μL of RPMI 1640 (+10% 
FBS) and 20μL of tetrazolium compound (CellTiter 96® Aqueous One Solution Reagent; 
Promega, Madison, WI) and incubated for 15h, for the development of color, at 37˚C in a 
5% Co2 humidified atmosphere.  Cell viability was assessed by the capacity of live cells to 
reduce tetrazolium salts into formazan, and the color produced was measured (absorbance) 
using a plate reader (Bio-Tek Instruments, Winooski, VT) at a wavelength of 450nm.  The 
assumption made in this assay was that a cell that is incapable of producing color is a dead 
cell.  
Cell viability was calculated using the following formula:
% live cells = [(A-B)/(C-B)] x 100,
where A equals the absorbance of cells (+ serum and complement), B equals the absorbance 
of cells (+ detergent), and C equals the absorbance of cells (+ complement only).  
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Results were expressed as the percentage of dead cells (% cytotoxicity = 100 - % viability). 
Complement-dependent cytotoxicity values of the varying serum concentrations (50%, 
12.5%, 3.125%, and 0.78%) were calculated, and a curve was generated for each baboon 
sample.  Results were considered acceptable based on graded concentration of human 
interplate control serum that was added to every plate.  Lysis of PBMC of <10% was 
considered of doubtful relevance.
Data Analysis
Statistical analysis of data was performed using Mann-Whitney tests. A p value of <0.05 was 
considered to be statistically significant.  Correlation of cytotoxicity and MFI was assessed 
by linear regression
Heterotopic Heart Transplantation
One non-immunosuppressed baboon and one baboon that received daily therapy with only 
cobra venom factor to deplete complement (both of blood type B) underwent heterotopic 
transplantation (in the abdomen) of hearts from GT-KO pigs (blood type O).  No other 
therapy, except modest anticoagulation with heparin (to maintain the partial thromboplastin 
time at >100sec), was administered. In the non-immunosuppressed baboon, the heart was 
electively excised after 150min (as it proved too large to allow satisfactory closure of the 
baboon’s abdomen), and the graft in the second baboon was excised after being rejected 
on day 8.  In both cases, remnants of the pig aorta and pulmonary artery were left in situ. 
The antibody responses of the two baboons were followed by flow cytometry and cytotoxicity 
assay for >2 months and >1 month, respectively.  In these assays, third party (not donor-
specific) PBMC were used.
RESULTS
Reactivity of Serum from Naïve Baboons with PBMC from WT and GT-KO Pigs
Binding of baboon IgM and IgG to pig PBMC
The presence of preformed xenoreactive antibodies in sera from naïve baboons was 
assessed by flow cytometry.  All but 3 of the 56 sera (95%) showed detectable IgM binding 
to WT PBMC, and 44 sera (79%) showed IgG binding, with binding (IgM and/or IgG) seen 
in 55 sera (98%) (Figure 1A). In contrast, only 18 of the 56 sera (32%) showed detectable 
IgM binding to GT-KO PBMC, and only 5 showed IgG binding (9%); binding was detected in 
20 sera (36%) (Figure 1A).  The incidence of binding of baboon IgM and IgG antibodies to 
GT-KO PBMC was therefore only 34% and 11%, respectively (overall 36%), of that to WT 
PBMC.
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The mean MFI of IgM binding to PBMC was 6.4 (WT) and 4.0 (GT-KO), respectively (p<0.01) 
(Figure 1B).  The mean MFI of IgG binding was 6.2 (WT) and 3.3 (GT-KO), respectively 
(p<0.01).  No baboon showed a high MFI of IgM binding to GT-KO PBMC, although five did 
show a moderately high MFI of IgG binding (Figure 1A).
These results suggest that the greater binding of baboon sera to WT PBMC was due to Gal-
specific antibodies, and the residual binding to GT-KO PBMC was due to the presence of 
antibodies to nonGal antigens.
PBMC was reduced from approximately 60%
(WT) to 25% (GT-KO). Sera from the five
baboons that had high MFI of IgG binding to
GT-KO PBMC did not show particularly high
cytotoxicity levels.
We concluded that approximately two-thirds of
the naı¨ve baboon sera tested contained anti-non-
Gal antibodies that could mediate lysis of PBMC
from GT-KO pigs, though the level of cytotox-
icity was generally weaker than that of WT
PBMC.
Correlation between binding of IgM or IgG and serum
cytotoxicity
Comparisons were made between the flow cyto-
metric data and cytotoxicity of the 39 sera to WT
and GT-KO PBMC. IgM and IgG binding data
were correlated with serum cytotoxicity. Although
a trend toward an increase in cytotoxicity to WT
PBMC was observed to accompany both higher
IgM and IgG MFI, this trend did not reach
statistical significance (data not shown). No corre-
lation was found between MFI (IgM or IgG) and
cytotoxicity to GT-KO PBMC.
Reactivity of sera from baboons after exposure to transplanted
GT-KO pig hearts
To investigate the extent of the elicited antibody
response to non-Gal antigens, serum samples were
collected from two baboons before and at different
time periods after heterotopic transplantation of
hearts from GT-KO pigs. In one non-immunosup-
pressed baboon, the heart remained in situ for only
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Fig. 1. Binding of baboon preformed xenoreactive antibodies to wild type (WT) and a1,3-galactosyltransferase gene-knockout (GT-
KO) pig peripheral blood mononuclear cells (PBMC) (MFI, mean fluorescence intensity). (A) Distribution of serum reactivity of 56
baboons against WT or GT-KO PBMC, IgM (top) and IgG (bottom). Mean reactivity of each group is indicated by a line. Control is
FITC-conjugated secondary antibody only. (B) Mean reactivity (MFI levels ± SD) of serum samples (n ¼ 56) against WT or GT-
KO PBMC, IgM (top) and IgG (bottom). Statistically higher (P < 0.01) reactivity of both IgM and IgG against WT PBMC vs. GT-
KO PBMC was observed.
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Figure 1:
Binding of  baboon preformed xenoreactive antibodies to WT and GT-KO pig PBMC 
[MFI = mean fluorescence intensity].  (A)  Distribution of  serum reactivity of  56 baboons 
against WT or GT-KO PBMC, IgM (top) and IgG (bottom).  Mean reactivity of  each 
group is indicated by a line.  Control is FITC-conjugated secondary antibody only. (B) 
Mean reactivity (MFI levels ± S.D.) of  serum samples (n = 56) against WT or GT-KO 
PBMC, IgM (top) and IgG (bottom).  Statistically higher (p<0.01) reactivity of  both IgM 
and IgG against WT PBMC versus GT-KO PBMC was observed.  
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Complement-dependent cytotoxicity of baboon sera to pig PBMC
Of the 56 baboon serum samples screened for antibody binding by flow cytometry, only 39 
were available in sufficient quantity to allow complement-mediated cytotoxicity assay.  At 
50% dilution, 38 of the 39 sera (97%) were cytotoxic to WT PBMC, whereas only 25 (64%) 
were cytotoxic to GT-KO PBMC (Figure 2A).  Furthermore, the sera caused greater lysis 
of PBMC from WT than from GT-KO pigs (p<0.01) (Figures 2A and B); at 50% dilution, the 
mean lysis of PBMC was reduced from approximately 60% (WT) to 25% (GT-KO). Sera from 
the five baboons that had high MFI of IgG binding to GT-KO PBMC did not show particularly 
high cytotoxicity levels.
We concluded that approximately two-thirds of the naïve baboon sera tested contained anti-
nonGal antibodies that could mediate lysis of PBMC from GT-KO pigs, though the level of 
cytotoxicity was generally weaker than that of WT PBMC.  
Correlation between binding of IgM or IgG and serum cytotoxicity
Comparisons were made between the flow cytometric data and cytotoxicity of the 39 sera to 
WT and GT-KO PBMC.  IgM and IgG binding data were correlated with serum cytotoxicity. 
Although a trend towards an increase in cytotoxicity to WT PBMC was observed to 
accompany both higher IgM and IgG MFI, this trend did not reach statistical significance 
(data not shown).  No correlation was found between MFI (IgM or IgG) and cytotoxicity to 
GT-KO PBMC.
150 min before being electively excised while beat-
ing (as it was too large to close the abdomen
satisfactorily). In the other baboon, that received
only CVF, the heart was excised after rejection on
day 8.
In the first baboon, there was little difference in
baseline anti-pig IgM or IgG reactivity to WT or
(third party) GT-KO pig PBMC (Fig. 3). A clas-
sical immune response was mounted against the
pig organ, with IgM levels peaking after approxi-
mately 2 weeks (Fig. 3A), while IgG peaked after
approximately 3 weeks (Fig. 3B). There was a slow
fall in the level of anti-pig antibody binding to GT-
KO PBMC over the next several weeks. The
response was against non-Gal antigens, as, using
an enzyme-linked immunosorbent assay with
which we have considerable experience [10], the
anti-Gal antibody level did not change (Fig. 4),
confirming the absence of Gal expression on the
GT-KO pig hearts [1].
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Fig. 2. (A) Ability of individual baboon serum samples (at
50% dilution, n ¼ 39) to cause lysis of peripheral blood
mononuclear cells (PBMC) from wild type (WT) or a1,3-ga-
lactosyltransferase gene-knockout (GT-KO) pigs; the mean
cytotoxicity is indicated by lines. Significantly higher lysis of
WT PBMC was observed (P < 0.01). (B) Mean cytotoxicity of
baboon sera at various dilutions against PBMC from either
WT or GT-KO pigs.
0
10
20
30
40
50
60A
B
C
Pre-
Tx
1 7 14 21 28 70
Time after tranplantation (days)
M
FI
WT IgM
GT-KO IgM
0
10
20
30
40
50
60
Pre-
Tx
1 7 14 21 28 70
Time after transplantation (days)
M
FI
WT IgG
GT-KO IgG
0
10
20
30
40
50
60
Pre-
Tx
1 7 14 21 28 70
Time after transplantation (days)
M
FI
0
20
40
60
80
100
Cy
to
to
x
ic
ity
 (%
)
IgM IgG Cytotoxicity
Fig. 3. Flow cytometry data showing (A) IgM and (B) IgG
responses [to both wild type (WT) and a1,3-galactosyltransf-
erase gene-knockout (GT-KO) pig peripheral blood mononu-
clear cells (PBMC)] in a baboon that was exposed to a GT-KO
pig heart for 150 min (on day 0). One hour following heart
transplantation, the levels of IgM and IgG binding were similar
to pre-transplant levels. An increase in IgM binding was ob-
served 4 days after exposure to the heart, and peaked between
days 9 and 14, whereas the IgG response was not detected until
day 7, peaking between days 16 and 21; the increase in IgG was
rather faster and greater to GT-KO than to WT PBMC. (C) A
cytotoxicity assay curve against (third party) GT-KO PBMC
was generated. Lysis of GT-KO PBMC correlated with the
increase in IgM, but was observed approximately 1 week be-
fore any increase in IgG. One week after transplantation, 100%
lysis of GT-KO PBMC was detected, which remained high for
more than 2 months.
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Figure 2:
(A)  Ability of  individual baboon serum samples (at 50% dilution, n = 39) to cause 
lysis of  PBMC from WT or GT-KO pigs; the mean cytotoxicity is indicated by lines. 
Significantly higher lysis of  WT PBMC was observed (p <0.01). (B)  Mean cytotoxicity 
of  baboon sera at various dilutions against PBMC from either WT or GT-KO pigs.
150 min before being electively excised while beat-
ing (as it was too large to close the abdomen
satisfactorily). In the other baboon, that received
only CVF, the heart was excised after rejection on
day 8.
In the first baboon, there was little difference in
baseline anti-pig IgM r I G reactivity to WT or
(third party) GT-KO pig PBMC (Fig. 3). A clas-
sical immune response was mounted against the
pig organ, with IgM levels peaking after approxi-
m tely 2 w eks (Fig. 3A), while IgG peaked after
approximately 3 weeks (Fig. 3B). There was a slow
fall in the level of anti-pig antibody binding to GT-
KO PBMC over the next several weeks. The
response was against non-Gal antigens, as, using
an enzyme-linked immunosorbent assay with
which we have considerable experience [10], the
anti-Gal antibody level did not change (Fig. 4),
confirming the absence of Gal expression on the
GT-KO pig hearts [1].
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Fig. 2. (A) Ability of individual baboon serum samples (at
50% dilution, n ¼ 39) to cause lysis of peripheral blood
mononuclear cells (PBMC) from wild type (WT) or a1,3-ga-
lactosyltransferase gene-knockout (GT-KO) pigs; the mean
cytotoxicity is indicated by lines. Significantly higher lysis of
WT PBMC was observed (P < 0.01). (B) Mean cytotox city of
baboon sera at various dilutions against PBMC from either
WT or GT-KO pigs.
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Fig. 3. Flow cytometry data showing (A) IgM and (B) IgG
responses [to both wild type (WT) and a1,3-galactosyltransf-
erase gene-knockout (GT-KO) pig peripheral blood mononu-
clear cells (PBMC)] in a baboon that was exposed to a GT-KO
pig heart for 150 min (on day 0). One hour following heart
transplantation, the levels of IgM and IgG binding were similar
to pre-transplant levels. An increase in IgM binding was ob-
served 4 days after exposure to the heart, and peaked between
days 9 and 14, whereas the IgG response was not detected until
day 7, peaking between days 16 and 21; the increase in IgG was
rather faster and greater to GT-KO than to WT PBMC. (C) A
cytotoxicity assay curve against (third party) GT-KO PBMC
was generated. Lysis of GT-KO PBMC correlated with the
increase in IgM, but was observed approximately 1 week be-
fore any increase in IgG. One week after transplantation, 100%
lysis of GT-KO PBMC was detected, which remained high for
more than 2 months.
Ezzelarab et al.
404
Proefschrift.indb   54 1/3/2008   6:17:59 PM
Anti-nonGal antibodies in baboons
55
Reactivity of Sera from Baboons after Exposure to Transplanted GT-KO Pig Hearts
To investigate the extent of the elicited antibody response to nonGal antigens, serum samples 
were collected from two baboons before and at different time periods after heterotopic 
transplantation of hearts from GT-KO pigs.  In one non-immunosuppressed baboon, the 
heart remained in situ for only 150min, before being electively excised while beating (as it 
was too large to close the abdomen satisfactorily).  In the other baboon, that received only 
cobra venom factor, the heart was excised after rejection on day 8.   
In the first baboon, there was little difference in baseline anti-pig IgM or IgG reactivity to WT 
or (third party) GT-KO pig PBMC (Figure 3).  A classical immune response was mounted 
against the pig organ, with IgM levels peaking after approximately 2 weeks (Figure 3A), while 
IgG peaked after approximately 3 weeks (Figure 3B).  There was a slow fall in the level of 
anti-pig antibody binding to GT-KO PBMC over the next several weeks.  The response was 
against nonGal antigens, since, using an ELISA with which we have considerable experience 
(10), the anti-Gal antibody level did not change (Figure 4), confirming the absence of Gal 
expression on the GT-KO pig hearts (1). 
150 min before being electively excised while beat-
ing (as it was too large to close the abdomen
satisfactorily). In the other baboon, that received
only CVF, the heart was excised after rejection on
day 8.
In the first baboon, there was little difference in
baseline anti-pig IgM or IgG reactivity to WT or
(third party) GT-KO pig PBMC (Fig. 3). A clas-
sical immune response was mounted against the
pig organ, with IgM levels peaking after approxi-
mately 2 weeks (Fig. 3A), while IgG peaked after
approximately 3 weeks (Fig. 3B). There was a slow
fall in the level of anti-pig antibody binding to GT-
KO PBMC over the next several weeks. The
response was against non-Gal antigens, as, using
an enzyme-linked immunosorbent assay with
which we have considerable experience [10], the
anti-Gal antibody level did not change (Fig. 4),
confirming the absence of Gal expression on the
GT-KO pig hearts [1].
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Fig. 2. (A) Ability of individual baboon serum samples (at
50% dilution, n ¼ 39) to cause lysis of peripheral blood
mononuclear cells (PBMC) from wild type (WT) or a1,3-ga-
lactosyltransferase gene-knockout (GT-KO) pigs; the mean
cytotoxicity is indicated by lines. Significantly higher lysis of
WT PBMC was observed (P < 0.01). (B) Mean cytotoxicity of
baboon sera at various dilutions against PBMC from either
WT or GT-KO pigs.
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Fig. 3. Flow cytometry data showing (A) IgM and (B) IgG
responses [to both wild type (WT) and a1,3-galactosyltransf-
erase gene-knockout (GT-KO) pig peripheral blood mononu-
clear cells (PBMC)] in a baboon that was exposed to a GT-KO
pig heart for 150 min (on day 0). One hour following heart
transplantation, the levels of IgM and IgG binding were similar
to pre-transplant levels. An increase in IgM binding was ob-
served 4 days after exposure to the heart, and peaked between
days 9 and 14, whereas the IgG response was not detected until
day 7, peaking between days 16 and 21; the increase in IgG was
rather faster and greater to GT-KO than to WT PBMC. (C) A
cytotoxicity assay curve against (third party) GT-KO PBMC
was generated. Lysis of GT-KO PBMC correlated with the
increase in IgM, but was observed approximately 1 week be-
fore any increase in IgG. One week after transplantation, 100%
lysis of GT-KO PBMC was detected, which remained high for
more than 2 months.
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Figure 3:
Flow cytometry data showing (A) IgM 
and (B) IgG responses (to both WT 
and GT-KO pig PBMC) in a baboon 
that was exposed to a GT-KO pig heart 
for 150min (on Day 0).  One hour 
following heart transplantation, the 
levels of  IgM and IgG binding were 
similar to pre-transplant levels.  An 
increase in IgM binding was observed 
4 days after exposure to the heart, and 
peaked between days 9 and 14, whereas 
the IgG response was not detected 
until day 7, peaking between days 16 
and 21; the increase in IgG was rather 
faster and greater to GT-KO than to 
WT PBMC.  (C)  A cytotoxicity assay 
curve against (third party) GT-KO 
PBMC was generated. Lysis of  GT-KO 
PBMC correlated with the increase in 
IgM, but was observed approximately 
one week before any increase in IgG. 
One week after transplantation, 100% 
lysis of  GT-KO PBMC was detected, 
which remained high for more than 2 
months. 
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At 50% serum concentration, pre-transplant lysis of GT-KO PBMC (60%) (Figure 3C) was 
less than that of WT PBMC (80%) (not shown).  One week after transient exposure to the 
GT-KO pig heart, lysis to both WT and GT-KO PBMC had increased to 100%, and remained 
high for up to 10 weeks.  The initial increase in cell lysis of GT-KO PBMC appeared to 
correlate with the rise in IgM, but preceded the rise in IgG.
At 50% serum concentration, pre-transplant
lysis of GT-KO PBMC (60%) (Fig. 3C) was less
than that of WT PBMC (80%) (not shown). One
week after transient exposure to the GT-KO pig
heart, lysis to both WT and GT-KO PBMC had
increased to 100%, and remained high for up to
10 weeks. The initial increase in cell lysis of GT-
KO PBMC appeared to correlate with the rise in
IgM, but preceded the rise in IgG.
In the second baboon, the timing of the increases
in anti-non-Gal IgM and IgG and in cell lysis was
comparable to that seen in the first baboon, with
IgM peaking after the first week, IgG peaking at 2
to 3 weeks and increased cytotoxicity being docu-
mented within 7 days of transplantation (not
shown). However, the magnitude of the increases
in the levels of both IgM and IgG was greater in
this baboon, presumably because exposure to the
GT-KO pig heart had been more prolonged
(8 days vs. 150 min) and because the heart under-
went acute humoral xenograft rejection before
being excised. There was a small increase in anti-
Gal IgG level on day 8 (day of rejection) with the
MFI increasing from 1.0 to 2.0, followed by a
reduction to 1.7 by day 35; this did not indicate
sensitization to Gal (although sensitization to Gal
molecules on CVF has been reported in non-
immunosuppressed baboons [11]).
In both baboons, after exposure to a GT-KO pig
heart, in vitro increased binding of elicited IgG to
(third party) GT-KO PBMC occurred a few days
earlier than to WT PBMC (Fig. 3B), possibly as a
response to a greater intensity of non-Gal antigens
on the GT-KO PBMC than on the WT PBMC
(where the presence of Gal epitopes may have
reduced the number of non-Gal antigens exposed,
i.e., the density of non-Gal antigens may be lower
on WT PBMC). The difference in MFI between
GT-KO and WT PBMC (Fig. 3B) was not asso-
ciated with a response to donor-specific transplan-
tation antigens, as third party PBMC were used for
both the GT-KO and WT studies.
Discussion
Organ transplantation from a WT pig into a
nonhuman primate usually results in hyperacute
rejection within minutes to hours [12]. The primary
role of anti-Gal antibodies in this response, first
reported in 1992 [4–6], has recently been overcome
by the breeding of pigs homozygous for GT-KO
[1,2]. However, although the transplantation of an
organ from a GT-KO pig into an immunosup-
pressed nonhuman primate allows extended graft
survival [7], the graft eventually fails from the
development of a thrombotic microangiopathy
that may be a form of delayed antibody-mediated
rejection. The focal deposition of IgM, IgG and
C4d on the graft suggests that a component of this
process may involve the binding of anti-non-Gal
antibodies to the pig vascular endothelial cells.
These antibodies could be either preformed (in
naı¨ve baboons) or elicited (in baboons sensitized
by exposure to GT-KO pig antigens).
The present study investigated the incidence of
preformed anti-non-Gal antibodies in the serum of
naı¨ve baboons, and assessed whether these anti-
bodies are cytotoxic to pig PBMC lacking the Gal
epitope. The results were compared with reactivity
of anti-pig antibodies to WT pig PBMC.
Whereas all but one of 56 baboons had pre-
formed antibodies, mainly IgM, to WT pig PBMC,
less than half had such antibodies to GT-KO
PBMC. Moreover, the cytotoxicity associated with
anti-non-Gal antibodies alone (to GT-KO PBMC)
was significantly weaker than that associated with
anti-Gal + anti-non-Gal antibodies (to WT
PBMC). We were, however, unable to show a
statistical correlation between the presence of these
antibodies and serum cytotoxicity. The comple-
ment-dependent cytotoxicity assay appeared to be
a more sensitive indicator of the presence of anti-
pig antibody than flow cytometry. Our data,
therefore, suggest that GT-KO pigs are preferable
to WT pigs as sources of organs for transplanta-
tion into primates. Nevertheless, anti-non-Gal
antibodies initiated a cytotoxic response; in vivo,
this would be expected to jeopardize long-term
viability of a pig organ graft.
No baboon showed a high MFI of IgM binding
to GT-KO PBMC, although five did show a
moderately high MFI of IgG binding (Fig. 1A).
Although these ‘outliers’ did not demonstrate
increased serum cytotoxicity to GT-KO PBMC,
this needs to be investigated further, as this
observation may be of ‘clinical’ importance.
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Fig. 4. Anti-Gal antibody (IgM and IgG) levels by ELISA for
the first baboon at a serum concentration of 1 : 50. The a1,3-
galactosyltransferase gene-knockout (GT-KO) pig heart was
excised after 150 min, and the baboon was followed 14 weeks.
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Figure 4:
Anti-Gal antibody (IgM and IgG) levels by ELISA for the first baboon 
at a se um conce tration of  1:50.  The GT-KO pig heart was xcised 
after 150 minute , and the baboo  was followed 14 weeks.  No antibody 
response to Gal was documented.
In the second baboon, the timing of the increases in anti-nonGal IgM and IgG and in cell 
lysis was comparable to that seen in the first baboon, with IgM peaking after the first week, 
IgG peaking at 2-3 weeks, and increased cytotoxicity being documented within 7 d ys of 
transplantation (not shown).  However, the magnitude of the increases in the levels f both 
IgM and IgG was greater in this baboon, presumably because exposure to the GT-KO pig 
heart had been more prolonged (8 days versus 150min) and because the heart underwent 
acute humoral xenograft rejection before being excised.  There was a small increase in anti-
Gal IgG level on day 8 (day of rejection) with the MFI increasing from 1.0 to 2.0, followed by 
a reduction to 1.7 by day 35; this did not indicate sensitization to Gal (although sensitization 
to Gal molecules on CVF has been reported in non-immunosuppressed baboons [11]).
In both baboons, after exposure to a GT-KO pig heart, in vitro increased binding of elicited 
IgG to (third party) GT-KO PBMC occurred a few days earlier than to WT PBMC (Figure 3B), 
possibly as a response to a greater intensity of nonGal antigens on the GT-KO PBMC than 
on the WT PBMC (where the presence of Gal epitopes may have reduced the number of 
nonGal antigens exposed, i.e., the density of nonGal antigens may be lower on WT PBMC). 
The difference in MFI between GT-KO and WT PBMC (Figure 3B) was not associated with 
a response to donor-specific transplantation antigens, since third party PBMC were used for 
both the GT-KO and WT studi s. 
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DISCUSSION
Organ transplantation from a WT pig into a nonhuman primate usually results in hyperacute 
rejection within minutes to hours (12).  The primary role of anti-Gal antibodies in this response, 
first reported in 1992 (4-6), has recently been overcome by the breeding of pigs homozygous 
for GT-KO (1, 2).  However, although the transplantation of an organ from a GT-KO pig 
into an immunosuppressed nonhuman primate allows extended graft survival (7), the graft 
eventually fails from the development of a thrombotic microangiopathy that may be a form of 
delayed antibody-mediated rejection.  The focal deposition of IgM, IgG, and C4d on the graft 
suggests that a component of this process may involve the binding of anti-nonGal antibodies 
to the pig vascular endothelial cells.  These antibodies could be either preformed (in naïve 
baboons) or elicited (in baboons sensitized by exposure to GT-KO pig antigens).  
The present study investigated the incidence of preformed anti-nonGal antibodies in the 
serum of naïve baboons, and assessed whether these antibodies are cytotoxic to pig PBMC 
lacking the Gal epitope.  The results were compared with reactivity of anti-pig antibodies to 
WT pig PBMC.  
Whereas all but one of 56 baboons had preformed antibodies, mainly IgM, to WT pig PBMC, 
less than half had such antibodies to GT-KO PBMC.  Moreover, the cytotoxicity associated 
with anti-nonGal antibodies alone (to GT-KO PBMC) was significantly weaker than that 
associated with anti-Gal + anti-nonGal antibodies (to WT PBMC).  We were, however, 
unable to show a statistical correlation between the presence of these antibodies and serum 
cytotoxicity.  The complement-dependent cytotoxicity assay appeared to be a more sensitive 
indicator of the presence of anti-pig antibody than flow cytometry.  Our data, therefore, suggest 
that GT-KO pigs are preferable to WT pigs as sources of organs for transplantation into 
primates.  Nevertheless, anti-nonGal antibodies initiated a cytotoxic response; in vivo, this 
would be expected to jeopardize long-term viability of a pig organ graft. No baboon showed 
a high MFI of IgM binding to GT-KO PBMC, although five did show a moderately high MFI 
of IgG binding (Figure 1A).  Although these ‘outliers’ did not demonstrate increased serum 
cytotoxicity to GT-KO PBMC, this needs to be investigated further, since this observation 
may be of ‘clinical’ importance.
One possible limitation of our study is that only PBMC were used as target cells, whereas 
vascular endothelial cells might have provided different, or more biologically relevant, nonGal 
epitopes, although there is no definite evidence for this (13).  We are currently investigating 
this in our laboratory; preliminary results indicate that binding to PBMC may actually be 
greater than to vascular endothelial cells (Hara H, et al, unpublished), suggesting that PBMC 
provide a biologically relevant target.
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We have also investigated the presence of preformed anti-nonGal antibodies in humans (14); 
these data will be reported separately.  However, baboons would appear to have a slightly 
lower level of anti-nonGal antibodies than humans, both on flow cytometry and complement-
dependent cytotoxicity assay.  This difference will need to be considered when assessing the 
results of GT-KO pig organ transplantation in the pig-to-baboon model.
The capacity of elicited antibodies, collected from the sera of two baboons exposed to 
GT-KO pig hearts, to bind to GT-KO PBMC, and to lyse those cells, was also assessed. 
Immunoglobulins, predominantly of the IgG isotype and specific for undetermined nonGal 
antigens, reached high levels post-transplantation, and were associated with a significant 
increase in cell lysis.  In the case of the baboon that received cobra venom factor therapy, 
the elicited antibody response, restricted to nonGal antigens, was associated with rejection 
of the graft.  The timing of the elicited antibody response (beginning by day 7) was similar to 
that seen previously when baboons were exposed to WT pig antigens, but the amplitude of 
the response would appear to be reduced (15,16).
We found no evidence of continued expression of Gal in the GT-KO pigs, e.g., as a result 
of iGb3 synthetase activity, as has been suggested by others (17,18) since, after exposure 
to GT-KO pig hearts, and despite sensitization to nonGal antigens, there was no increase 
in the level of anti-Gal antibodies.  Previous in vitro studies involving WT cells and either 
immunoadsorption of primate sera or treatment of the cells with a galactosidase have 
suggested that antibodies to nonGal antigens represent only 10-30% of anti-pig IgM and 
20-50% of IgG antibodies in naïve sera (reviewed in 19).  The data observed using GT-KO 
PBMC in the present study would largely agree with these estimates, but would suggest that 
anti-nonGal antibodies may represent a greater proportion of anti-pig antibodies in some 
baboons.
Acute humoral xenograft rejection associated with the presence of preformed or elicited 
anti-nonGal antibodies might therefore be addressed by further modification of the pig 
to reduce the expression of nonGal antigens.  The identification of nonGal specificities 
would therefore be an important step forward. However, the nature of the nonGal antigens 
expressed on GT-KO pig vascular endothelium or PBMC is currently uncertain, although 
several carbohydrates are candidates (20, 21).  It has been demonstrated that there is some 
rearrangement of the carbohydrate pattern of the vascular endothelium in mice after GT-
KO (22), and neoantigens might be exposed, to which some preformed antibodies may be 
directed.  N-glycolylneuraminic acid epitopes, so-called Hanganutziu-Deicher antigens, are 
widely expressed on the endothelial cells of all mammals except humans, and are considered 
to be potential porcine targets for preformed and elicited anti-nonGal antibodies in humans 
(23-25), but not in baboons, which express these epitopes.  It is equally likely, however, that 
the targets for elicited anti-nonGal Abs are proteins, rather than carbohydrates.
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If there are multiple nonGal epitopes against which primates have preformed antibodies, 
then gene-knockout may not prove to be a feasible solution.  However, the lower level of 
endothelial cell activation and cytotoxicity associated with anti-nonGal antibodies, compared 
with anti-Gal antibodies, may allow some protection to be achieved by the presence of one 
or more human complement-regulatory protein.  Although transgenesis for human decay-
accelerating factor or other complement-regulatory proteins has had only a relatively limited 
protective effect against anti-Gal antibodies, this approach may be more successful against 
the weaker anti-nonGal antibodies. 
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ABSTRACT
Background:  The availability of pigs homozygous for α1,3-galactosyltransferase gene-
knockout (GT-KO) has enabled study of the incidence and cytotoxicity of primate antibodies 
directed to antigens other than Galα1,3Gal (Gal), termed nonGal antigens.  
Methods:  Sera from 27 healthy humans and 31 patients awaiting renal allotransplantation, 
who were either unsensitized (PRA<10%) or allosensitized (PRA>70%), were tested by flow 
cytometry for binding of IgM and IgG to peripheral blood mononuclear cells (PBMC) from 
both wild-type (WT) and GT-KO pigs.  Complement-dependent cytotoxicity to WT and GT-
KO PBMC was also measured. 
Results:  IgM and IgG from all 27 (100%) healthy human sera bound to WT PBMC, while 
78% and 63% of these sera had IgM and IgG that bound to GT-KO PBMC, respectively. 
Mean binding to WT PBMC was significantly greater than to GT-KO PBMC.  Whereas 100% 
of sera were cytotoxic to WT PBMC, only 61% were cytotoxic to GT-KO PBMC, and the 
extent of lysis was significantly less.  Neither mean binding of IgM and IgG nor cytotoxicity 
of unsensitized and allosensitized sera to WT and GT-KO PBMC was significantly different 
to that of healthy sera.  
Conclusions:  More than half of the healthy humans tested had cytotoxic antibodies to GT-
KO PBMC, but allosensitized patients will be at no greater risk of rejecting a pig xenograft 
by a humoral mechanism.  
INTRODUCTION
The recent availability of pigs homozygous for α1,3-galactosyltransferase gene-knockout 
(GT-KO) (1,2) has enabled pig-to-baboon organ transplantation to be carried out in the 
absence of expression of the pig Galα1,3Gal(Gal) epitopes that are known to be important 
targets for primate anti-pig antibodies (3-6).  Transplantation of hearts (7) and kidneys (8) 
from GT-KO miniature swine into immunosuppressed baboons that expressed either no or 
very low levels of preformed antibodies pre-transplantation against antigens on GT-KO pig 
peripheral blood mononuclear cells (PBMC) (‘nonGal’ antigens) was followed by relatively 
prolonged graft survival, extending to 179 days (heart) and 83 days (kidney).  Heart graft 
failure was largely a result of the development of a thrombotic microangiopathy that may be 
a form of delayed antibody-mediated rejection.  Kidney grafts from GT-KO pigs transplanted 
into inadequately immunosuppressed baboons developed an elicited antibody response 
directed to nonGal antigens that resulted in rejection of the graft within 8 to 16 days (9).  
It is clear, therefore, that anti-nonGal antibodies can be associated with rejection or injury 
of GT-KO pig organs in baboons.  There have hitherto been no definitive reports on the 
incidence of anti-nonGal antibodies in humans nor of the extent of complement-dependent 
cytotoxicity (CDC) towards pig cells.  We here report on the incidence and cytotoxicity of 
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preformed antibodies directed to nonGal antigens on GT-KO pig PBMC in healthy human 
sera.  
There are several reports suggesting that patients previously sensitized to alloantigens may 
have antibodies that cross-react against pig cells (reviewed in 10), and therefore may be at 
a greater risk from antibody-mediated rejection following pig organ xenotransplantation.  We 
have measured the incidence and cytotoxicity of antibodies directed to nonGal antigens on 
GT-KO pig PBMC in the sera of allosensitized patients awaiting kidney transplantation.  
METHODS
Human Subjects
Serum was collected from 27 healthy volunteers of all ABO blood types who had no history 
suggesting previous exposure to pig antigens or to alloantigens (no pregnancy, blood 
transfusion, organ or cell allotransplant).  A random six sera were tested by enzyme-linked 
immunosorbent assay (ELISA) for allosensitization (see below), and all were negative (ELISA-
PRA<10%).  The sera were used for the detection of anti-pig and anti-nonGal antibodies 
by flow cytometry, and CDC, using wild-type (WT) and GT-KO pig PBMC, respectively, as 
targets.    
Serum was similarly tested from 31 patients awaiting renal transplantation.  These sera 
were evaluated in the Tissue Typing Laboratory of the University of Pittsburgh Medical 
Center using commercial LAT ELISA kits (One Lambda, Canoga Park, CA), according 
to the manufacturer’s instructions, to identify IgG anti-class I and/or class II HLA-specific 
alloantibodies.  Briefly, the HLA antibody was measured by a second enzyme-linked 
colorimetric reaction, and was read at 630nm using an ELISA reader (ELX 800, Bio-Tek). 
All tests were duplicated.  The percentage of patient ELISA versus. positive IgG control was 
determined, and sera were identified as either unsensitized (ELISA-PRA<10%, n=16) or 
allosensitized (ELISA-PRA>70%, n=15).  
Pigs and Isolation of Porcine PBMC
PBMC were collected from WT and GT-KO pigs (both provided by Revivicor, Inc., Blacksburg, 
VA) (1), both of Large White/Landrace/Duroc cross-breed, and all of blood type O.  Although 
the WT and GT-KO pigs were from the same genetic background, they were not from 
identical clones; however, the only major difference was in the absence of Gal antigens 
in the GT-KO pigs.  All animal care procedures were in accordance with the Principles of 
Laboratory Animal Care formulated by the National Society for Medical Research and the 
Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of Health (NIH publication No. 
86-23, revised 1985).  
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PBMC from several different pigs (WT and GT-KO) were isolated from heparinized blood by 
centrifugation over Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ).  The total 
mononuclear cell fraction was washed twice with RPMI 1640 medium (Gibco, Grand Island, 
NY) and then resuspended in FACS buffer (PBS containing 1%BSA and 0.1%NaN3) for flow 
cytometry or in RPMI medium (including 10%FBS) for cytotoxicity assay.  
Flow Cytometry
Human serum samples were incubated for 30min at 56˚C to inactivate complement.  Isolated 
PBMC (1x106 cells/tube) were incubated with 20μL of serum (20% final concentration) or 
20μL of FACS buffer (control) for 30min at 4˚C.  (A 20% serum concentration was selected 
after an initial dilution study.)  After incubation, the cells were washed twice in 2mL FACS 
buffer and centrifuged at 1800rpm for 5min.  The supernatant was discarded.  To prevent 
non-specific binding, 10μL of 10% goat serum was added.  Detection of IgG or IgM binding 
was performed by further incubating the serum with FITC-conjugated goat anti-human IgG 
(γ chain-specific) at 1:50 dilution or IgM (μ chain-specific) at 1:200 dilution (Zymed, San 
Francisco, CA) for 30min in the dark at 4˚C.  The samples were washed twice, and the cells 
resuspended with FACS buffer.  Data acquisition was performed with FACScan (Becton 
Dickinson; Mountain View, CA).  Dead cells were excluded from the analysis by forward-
scatter and propidium iodide staining.  IgG and IgM anti-pig antibodies were determined by 
indirect immunoflorescence intensity.  Measurement of mean florescence intensity (MFI) 
was performed on viable cells.  Measurement of indirect immunoflorescence intensity was 
accomplished by Cell Quest software and converted into MFI by WinMDI software.  
CDC Assay
Human serum was incubated for 30min at 56˚C to inactivate complement.  The samples 
were four-fold serially diluted with RPMI 1640 media (+10% FBS) to final concentrations 
of 50%, 12.5%, 3.125%, 0.78% and 25%, 6.3%, 1.6% and 0.4%.  As an interplate control, 
serum from a single human was diluted in the same manner and used on all plates.  Cells 
were loaded into flat-bottomed 96-well plates at a density of 1x106 cells/well (in RPMI 1640 
media + 10%FBS).  The cells were centrifuged at 1800rpm for 7min, and then incubated with 
100μL of diluted human (interplate control) serum for 30min at 4°C.  
After incubation, the cells were incubated with 100μL of 10% rabbit HLA-ABC serum (Sigma), 
as a source of complement, for 45min at 37°C.  Negative control wells (100% live cells) were 
achieved by adding only complement.  Positive control wells (0% live cells) were achieved 
by adding a detergent (polyoxyethylene sorbitan monolaurate; Sigma). Additional negative 
controls comprised either cells alone or cells + serum in wells in which no complement or 
detergent was added.
Following incubation, the cells were resuspended in 100μL of RPMI 1640 (+10%FBS) and 
20μL of tetrazolium compound (CellTiter 96® Aqueous One Solution Reagent; Promega, 
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Madison, WI) and incubated for 15h, for the development of color, at 37˚C in a 5%CO2 
humidified atmosphere.  Cell viability was assessed by the capacity of live cells to reduce 
tetrazolium salts into formazan, and the color produced was measured (absorbance) using a 
plate reader (Bio-Tek Instruments, Winooski, VT) at a wavelength of 450nm.  The assumption 
made was that a cell incapable of producing color is a dead cell.  
Cell viability was calculated as:
% live cells = [(A-B)/(C-B)] x 100,
where A equals the absorbance of cells (+ serum and complement), B equals the absorbance 
of cells (+ detergent), and C equals the absorbance of cells (+ complement only).  
Results were expressed as the percentage of dead cells (% cytotoxicity = 100 - % viability). 
CDC values at the various serum concentrations were calculated, and a curve was generated. 
Lysis of PBMC of <10% was considered of doubtful relevance.
Statistical Analysis
The results were statistically analyzed by Mann-Whitney U tests or analysis of variance 
(ANOVA).  A p value of <0.05 was considered statistically significant.  Correlation of CDC 
and MFI was assessed by linear regression analysis.  Significance at the 95% or the 99% 
level was calculated using Prism-4 software (Graphpad Software, San Diego, CA).  
RESULTS
Reactivity of Serum from Healthy Humans to PBMC from WT and GT-KO Pigs
Binding of IgM and IgG to pig PBMC
All of the 27 sera (100%) showed some IgM (Figure 1A) and IgG (Figure 1B) binding to WT 
PBMC (% number indicates the percentage of sera with binding to PBMC that was greater 
than the mean control binding [secondary antibody alone] +SEM).  In contrast, 21 of the 27 
sera (78%) showed IgM binding, and only 17 showed IgG binding (63%) to GT-KO PBMC. 
Binding to GT-KO PBMC was detected in a total of 23 of the 27 sera (85%); 4 sera (15%) 
showed no detectable, or negligible, binding to GT-KO PBMC.  The incidence of binding 
of IgM and IgG to GT-KO PBMC was therefore 78% and 63%, respectively, of that to WT 
PBMC.  
 
The mean MFI of IgM binding to WT and GT-KO PBMC control (no serum) was 3.2 and 3.3, 
respectively (not significantly different, NS) (Figure 2A).  The mean MFI of IgM binding to WT 
and GT-KO PBMC was 10.0 and 4.5, respectively (p<0.05).  The mean MFI of IgG binding 
to WT and GT-KO PBMC control (no serum) was 3.2 and 3.3, respectively (NS) (Figure 
2B).  The mean MFI of IgG binding to WT and GT-KO PBMC was 12.4 and 6.2, respectively 
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(p<0.05).  However, one serum showed a moderately high level of IgM binding (and of 
IgG binding and cytotoxicity), and 6 showed moderately high IgG binding to GT-KO PBMC 
(MFI 19.8 - 24.1) (Figure 1A and B); these sera also showed particularly high IgG binding 
to WT PBMC (MFI 10.4 - 49.0).  (These 6 sera, however, did not show a consistently high 
cytotoxicity to GT-KO PBMC).
These results indicate that (i) the greater binding to WT PBMC was due to the presence 
of Gal-specific antibodies, and (ii) the residual binding to GT-KO PBMC was due to the 
presence of antibodies to nonGal antigens.
CDC of sera to pig PBMC
Of the 27 sera screened by flow cytometry, only 18 were available in sufficient quantity to 
allow CDC assay. At 50% serum dilution, all 18 sera (100%) were cytotoxic (>10% killing) 
to WT PBMC, whereas only 11 of the 18 (61%) showed some cytotoxicity to GT-KO PBMC 
(Figures 3A and B).  Furthermore, the sera were significantly more cytotoxic to PBMC from 
WT than GT-KO pigs (p<0.05); at 50% dilution, the lysis of PBMC was reduced from 45% lysis 
(WT) to 19% (GT-KO) (Figure 3B).  However, two sera showed relatively high cytotoxicity to 
GT-KO PBMC; these two sera did not have particularly high IgM or IgG binding to GT-KO 
PBMC. A serum dilution of 12.5% caused lysis of WT PBMC (mean lysis 31%), whereas GT-
KO cells were generally largely resistant (mean lysis 10%) (Figure 3A).  
These results indica e that (i) the greater binding
to WT PBMC was due to the presence of Gal-
specific antibodies and (ii) the residual binding to
GT-KO PBMC was due to the presence of
antibodies to non-Gal antigens.
CDC of sera to pig PBMC
Of the 27 sera screened by flow cytometry, only 18
were available in sufficient quantity to allow CDC
assay. At 50% serum dilution, all 18 sera (100%)
were cytotoxic (>10% killing) to WT PBMC,
whereas only 11 of the 18 (61%) showed some
cytotoxicity to GT-KO PBMC (Fig. 3A,B). Fur-
thermore, the sera were significantly more cytotoxic
to PBMC from WT than GT-KO pigs (P < 0.05);
at 50% dilution, the lysis of PBMC was reduced
from 45% lysis (WT) to 19% (GT-KO) (Fig. 3B).
However, two sera showed relatively high cyto-
toxicity to GT-KO PBMC; these two sera did not
have particularly high IgM or IgG binding to
GT-KO PBMC. A erum dilution of 12.5% caused
lysis of WT PBMC (mean lysis 31%), whereas
GT-KO cells were generally largely resistant (mean
lysis 10%) (Fig. 3A).
We concluded that, whereas all healthy human
sera demonstrate antibodies that are cytotoxic to
WT pig PBMC, only approximately two-thirds of
sera demonstrate anti-non-Gal antibodies that are
cytotoxic to PBMC from GT-KO pigs, and the
level of cytotoxicity is generally relatively weak.
Reactivity of serum from allosensitized humans to PBMC from WT
and GT-KO pigs
Binding of IgM and IgG to pig PBMC
Two sets of sera were available from patients
awaiting kidney transplantation – patients who
were (i) not allosensitized (PRA < 10%, n ¼ 16;
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(Gal-positive) (WT) (grey bar) or a1,3-galactosyltransferase
gene-knockout (GT-KO) (shaded bar) peripheral blood
mononuclear cells (PBMC) – IgM (A) and IgG (B). Statisti-
cally higher (P < 0.05) reactivity of both IgM and IgG against
WT PBMC vs. GT-KO PBMC was observed, irrespective of
the type of serum tested (*P < 0.05). The MFI of IgM binding
of unsensitized sera was sig ificantly lower to WT PBMC than
that of healthy sera.
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These results indicate that (i) the greater binding
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specific antibodies and (ii) the residual binding to
GT-KO PBMC was due to the pr se ce of
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from 45% lysis (WT) to 19% (GT-KO) (Fig. 3B).
However, two sera showed relatively high cyto-
toxicity to GT-KO PBMC; these two sera did not
have particularly high IgM or IgG binding to
GT-KO PBMC. A serum dilution of 12.5% caused
lysis of WT PBMC (mean lysis 31%), whereas
GT-KO cells were generally largely resistant (mean
lysis 10%) (Fig. 3A).
We concluded that, whereas all healthy human
sera demonstrate antibodies that are cytotoxic to
WT pig PBMC, only approximately two-thirds of
sera demonstrate anti-non-Gal antibodies that are
cytotoxic to PBMC from GT-KO pigs, and the
level of cytotoxicity is generally relatively weak.
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whereas only 11 of the 18 (61%) showed some
cytotoxicity to GT-KO PBMC (Fig. 3A,B). Fur-
thermore, the sera were significantly more cytotoxic
to PBMC from WT than GT-KO pigs (P < 0.05);
at 50% dilution, the lysis of PBMC was reduced
from 45% lysis (WT) to 19% (GT-KO) (Fig. 3B).
However, two sera showed relatively high cyto-
toxicity to GT-KO PBMC; these two sera did not
have particularly high IgM or IgG binding to
GT-KO PBMC. A serum dilution of 12.5% caused
lysis of WT PBMC (mean lysis 31%), whereas
GT-KO cells were generally largely resistant (mean
lysis 10%) (Fig. 3A).
We concluded that, whereas all healthy human
sera demonstrate antibodies that are cytotoxic to
WT pig PBMC, only approximately two-thirds of
sera demonstrate anti-non-Gal antibodies that are
cytotoxic to PBMC from GT-KO pigs, and the
level of cytotoxicity is generally relatively weak.
Reactivity of serum from allosensitized humans to PBMC from WT
and GT-KO pigs
Binding of IgM and IgG to pig PBMC
Two sets of sera were available from patients
awaiting kidney transplantation – patients who
were (i) not allosensitized (PRA < 10%, n ¼ 16;
0
5
10
15
20
A
WT-PBMC GT-KO-PBMC
M
FI
***
*
Control
(n=12)
Allosensitized
(n=15)
0
5
10
15
20
B WT-PBMC GT-KO-PBMC
M
FI
* * *
Control
(n=12)
Allosensitized
(n=15)
Healthy
(n=27)
Unsensitized
(n=16)
Healthy
(n=27)
Unsensitized
(n=16)
Fig. 2. Mean reactivity [mean fluorescence intensity (MFI)
levels ± SEM] of sera from 27 healthy humans, 16 unsensi-
tized, and 15 allosensitized patients against wild-type
(Gal-positive) (WT) (grey bar) or a1,3-galactosyltransferase
gene-knockout (GT-KO) (shaded bar) peripheral blood
mononuclear cells (PBMC) – IgM (A) and IgG (B). Statisti-
cally higher (P < 0.05) reactivity of both IgM and IgG against
WT PBMC vs. GT-KO PBMC was observed, irrespective of
the type of serum tested (*P < 0.05). The MFI of IgM binding
of unsensitized sera was significantly lower to WT PBMC than
that of healthy sera.
0
10
20
30
A
M
FI
Control
(n =12)
Allosensitized
(n =15)
Healthy
(n = 27)
Unsensitized
(n =16)
(100%) (100%) (100%)(78%) (75%) (73%)
Mean
: GT-KO PBMC
: WT PBMC
0
10
20
30
40
50
B
(63%) (94%) (38%) (100%) (80%)
(100%)
M
FI
Mean
: GT-KO PBMC
: WT PBMC
Control
(n= 12)
Allosensitized
(n=15)
Healthy
(n =27)
Unsensitized
(n=16)
Fig. 1. Binding of xenoreactive antibodies in sera from healthy
human volunteers and unsensitized or allosensitized patients to
wild-type (Gal-positive) (WT) and a1,3-galactosyltransferase
gene-knockout peripheral blood mononuclear cells (GT-KO
PBMC) (MFI, mean fluorescence intensity). Distribution of
serum reactivity of 27 healthy humans, 16 unsensitized, and 15
allosensitized humans against WT (d) or GT-KO (s) PBMC is
shown – IgM (A) and IgG (B). Mean reactivity of each group is
indicated by a line. Control is FITC-conjugated antibody only.
[% number indicates the percentage of sera with binding to
PBMC that was greater than the mean control binding (sec-
ondary antibody alone) + SEM].
Hara et al.
360
Figure 1:
Binding of  xenoreactive antibodies in sera from healthy human volunteers and unsensitized 
or allosensitized patients to WT and GT-KO PBMC (MFI = mea  fluorescence 
intensity).  Distribution of  serum reactivity of  27 h alth  humans, 16 un ensitized, and 15 
allosensitized humans against WT (●) or GT-KO (○) PBMC is shown - IgM (A) nd IgG 
(B).  Mean reactivity of  each group is indicated by a line.  Control is FITC-conjugated 
antibody only.  (% number indicates the percentage of  sera wit  binding t  PBMC that 
was greater than the mean control binding [secondary antibody alone] +SEM).
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We concluded that, whereas all healthy human sera demonstrate antibodies that are 
cytotoxic to WT pig PBMC, only approximately two-thirds of sera demonstrate anti-nonGal 
antibodies that are cytotoxic to PBMC from GT-KO pigs, and the level of cytotoxicity is 
generally relatively weak. 
Reactivity of Serum from Allosensitized Humans to PBMC from WT and GT-KO Pigs
Binding of IgM and IgG to pig PBMC
Two sets of sera were available from patients awaiting kidney transplantation – patients 
who were (i) not allosensitized (PRA<10%, n=16; ‘unsensitized’), and (ii) allosensitized 
(PRA>70%, n=15; ‘allosensitized’).  
All unsensitized and allosensitized sera (100%) showed some detectable IgM binding 
to WT PBMC (Figure 1A).  Twelve of the 16 unsensitized (75%) and 11 of the 15 (73%) 
allosensitized sera showed detectable IgM binding to GT-KO PBMC (Figure 1A).  The mean 
MFI of IgM binding to WT and GT-KO PBMC was calculated to be 5.8 and 3.8, respectively, 
for unsensitized sera, and 8.3 and 3.8, respectively, for allosensitized sera (NS).  Mean IgM 
binding of both unsensitized and allosensitized sera to WT PBMC was higher than to GT-KO 
PBMC (p<0.05) (Figure 2A).  
Ninety four percent of unsensitized and 100% of allosensitized sera showed some detectable 
IgG binding to WT PBMC (Figure 1B).  Six of the 16 (38%) unsensitized and 12 of the 
15 (80%) allosensitized sera showed detectable IgG binding to GT-KO PBMC (Figure 1B). 
The mean MFI of IgG binding to WT and GT-KO PBMC was calculated to be 9.3 and 3.3, 
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to WT PBMC was due to the presence of Gal-
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from 45% lysis (WT) to 19% (GT-KO) (Fig. 3B).
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toxicity to GT-KO PBMC; these two sera did not
have particularly high IgM or IgG binding to
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GT-KO cells were gener lly largely resistant (mean
lysis 10%) (Fig. 3A).
We concluded that, whereas all healthy human
sera demonstrate antibodies that are cytotoxic to
WT pig PBMC, only approximately two-thirds of
sera demonstrate anti-non-Gal antibodies that are
cytotoxic to PBMC from GT-KO pigs, and the
level of cytotoxicity is generally relatively weak.
Reactivity of serum from allosensitized humans to PBMC from WT
and GT-KO pigs
Binding of IgM and IgG to pig PBMC
Two sets of sera were available from patients
awaiting kidney transplantation – patients who
were (i) not allosensitized (PRA < 10%, n ¼ 16;
0
5
10
15
20
A
WT-PBMC GT-KO-PBMC
M
FI
***
*
Control
(n=12)
Allosensitized
(n=15)
0
5
10
15
20
B WT-PBMC GT-KO-PBMC
M
FI
* * *
Control
(n=12)
Allosensitized
(n=15)
Healthy
(n=27)
Unsensitized
(n=16)
Healthy
(n=27)
Unsensitized
(n=16)
Fig. 2. Mean reactivity [mean fluorescence intensity (MFI)
levels ± SEM] of sera from 27 healthy humans, 16 unsensi-
tized, and 15 allosensitized patients against wild-type
(Gal-positive) (WT) (grey bar) or a1,3-galactosyltransferase
gene-knockout (GT-KO) (shaded bar) peripheral blood
mononuclear cells (PBMC) – IgM (A) and IgG (B). Statisti-
cally higher (P < 0.05) reactivity of both IgM and IgG against
WT PBMC vs. GT-KO PBMC was observed, irrespective of
the type of serum tested (*P < 0.05). The MFI of IgM binding
of unsensitized sera was significantly lower to WT PBMC than
that of healthy sera.
0
10
20
30
A
M
FI
Control
(n =12)
Allosensitized
(n=15)
Healthy
(n = 27)
Unsensitized
(n=16)
(100%) (100%) (100%)(78%) (75%) (73%)
Mean
: GT-KO PBMC
: WT PBMC
0
10
20
30
40
50
B
(63%) (94%) (38%) (100%) (80%)
(100%)
M
FI
Mean
: GT-KO PBMC
: WT PBMC
Control
(n= 12)
Allosensitized
(n=15)
Healthy
(n =27)
Unsensitized
(n=16)
Fig. 1. Binding of xenoreactive antibodies in sera from healthy
human volunteers and unsensitized or allosensitized patients to
wild-type (Gal-positive) (WT) and a1,3-galactosyltransferase
gene-knockout peripheral blood mononuclear cells (GT-KO
PBMC) (MFI, mean fluorescence intensity). Distribution of
serum reactivity of 27 healthy humans, 16 unsensitized, and 15
allosensitized humans against WT (d) or GT-KO (s) PBMC is
shown – IgM (A) and IgG (B). Mean reactivity of each group is
indicated by a line. Control is FITC-conjugated antibody only.
[% number indicates the percentage of sera with binding to
PBMC that was greater than the mean control binding (sec-
ondary antibody alone) + SEM].
Hara et al.
360
These results indicate that (i) t greater binding
to WT PBMC was due to the presence of Gal-
specific antibodies and (ii) the residual binding to
GT-KO PBMC was due to the presence of
antibodies to non-Gal antigens.
CDC of sera to pig PBMC
Of the 27 sera screened by flow cytometry, only 18
were available in sufficient quantity to allow CDC
assay. At 50% serum dilution, all 18 sera (100%)
were cytotoxic (>10% killing) to WT PBMC,
whereas only 11 of the 18 (61%) showed some
cytotoxicity to GT-KO PBMC (Fig. 3A,B). Fur-
thermore, the sera were significantly more cytotoxic
to PBMC from WT than GT-KO pigs (P < 0.05);
at 50% dilution, the lysis of PBMC was reduced
from 45% lysis (WT) to 19% (GT-KO) (Fig. 3B).
However, two sera showed relatively high cyto-
toxicity to GT-KO PBMC; these two sera did not
have particularly high IgM or IgG binding to
GT-KO PBMC. A serum dilution of 12.5% caused
lysis of WT PBMC (mean lysis 31%), whereas
GT-KO cells were generally largely r sistant (mean
lysis 10%) (Fig. 3A).
We concluded that, whereas all healthy human
sera demonstrate antibodies that are cytotoxic to
WT pig PBMC, only approximately two-thirds of
sera demonstrate anti-non-Gal antibodies that are
cytotoxic to PBMC from GT-KO pigs, and the
level of cytotoxicity is generally relatively weak.
Reactivity of serum from allosensitized humans to PBMC from WT
and GT-KO pigs
Binding of IgM and IgG to pig PBMC
Two sets of sera were available from patients
awaiting kidney transplantation – patients who
were (i) not allosensitized (PRA < 10%, n ¼ 16;
0
5
10
15
20
A
WT-PBMC GT-KO-PBMC
M
FI
***
*
Control
(n=12)
Allosensitized
(n=15)
0
5
10
15
20
B WT-PBMC GT-KO-PBMC
M
FI
* * *
Control
(n=12)
Allosensitized
(n=15)
Healthy
(n=27)
Unsensitized
(n=16)
Healthy
(n=27)
Unsensitized
(n=16)
Fig. 2. Mean reactivity [mean fluorescence intensity (MFI)
levels ± SEM] of sera from 27 healthy humans, 16 unsensi-
tized, and 15 allosensitized patients against wild-type
(Gal-positive) (WT) (grey bar) or a1,3-galactosyltransferase
gene-knockout (GT-KO) (shaded bar) peripheral blood
mononuclear cells (PBMC) – IgM (A) and IgG (B). Statisti-
cally higher (P < 0.05) reactivity of both IgM and IgG against
WT PBMC vs. GT-KO PBMC was observed, irrespective of
the type of serum tested (*P < 0.05). The MFI of IgM binding
of unsensitized sera was significantly lower to WT PBMC than
that of healthy sera.
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Fig. 1. Binding of xenoreactive antibodies in sera from healthy
human volunteers and unsensitized or allosensitized patients to
wild-type (Gal-positive) (WT) and a1,3-galactosyltransferase
gene-knockout peripheral blood mononuclear cells (GT-KO
PBMC) (MFI, mean fluorescence intensity). Distribution of
serum reactivity of 27 healthy humans, 16 unsensitized, and 15
allosensitized humans against WT (d) or GT-KO (s) PBMC is
shown – IgM (A) and IgG (B). Mean reactivity of each group is
indicated by a line. Control is FITC-conjugated antibody only.
[% number indicates the percentage of sera with binding to
PBMC hat was greater than the mean control binding (sec-
ondary antibody alone) + SEM].
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Figure 2:
Mean reactivity (MFI levels ± SEM) of  sera from 27 healthy humans, 16 unsensit zed, 
and 15 allosensitized patients against WT (grey bar) or T-KO (shaded bar) PBMC 
- IgM (A) and IgG (B).  Statistically higher (p<0.05) reactivity of  both IgM and IgG 
against WT PBMC versus GT-KO PBMC was observed, irrespective of  the type of  
serum tested (*p<0.05).  The MFI of  IgM binding of  unsensitized sera was significantly 
lower to WT PBMC th n th t f  healthy sera.
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respectively, for unsensitized sera, and 12.3 and 6.6, respectively, for allosensitized sera 
(NS).  Mean IgG binding of unsensitized and allosensitized sera to WT PBMC was higher 
than to GT-KO PBMC (p<0.05) (Figure 2B).  
CDC of sera to pig PBMC 
Thirteen unsensitized and 14 allosensitized sera were available for testing.  (In addition, 12 
healthy human sera were tested again.)  At 25% dilution, all unsensitized and allosensitized 
sera showed cytotoxicity (>10% killing) to WT PBMC, whereas 10 of the 13 unsensitized 
(77%) and 7 of the 14 allosensitized (50%) sera were cytotoxic to GT-KO PBMC.  The mean 
cytotoxicity (at 25% dilution) of unsensitized and allosensitized sera to WT PBMC was 53% 
and 60%, respectively, and to GT-KO PBMC was 16% and 18%, respectively (Figure 4).  ‘‘unsensitized’’) and (ii) allosensitized (PRA >
70%, n ¼ 15; ‘‘allosensitized’’).
All unsensitized and allosensitized sera (100%)
showed some detectable IgM binding to WT
PBMC (Fig. 1A). Twelve of the 16 unsensitized
(75%) and 11 of the 15 (73%) allosensitized sera
showed detectable IgM binding to GT-KO PBMC
(Fig. 1A). The mean MFI of IgM binding to WT
and GT-KO PBMC was calculated to be 5.8 and
3.8, respectively, for unsensitized sera, and 8.3 and
3.8, respectively, for allosensitized sera (NS). Mean
IgM binding of both unsensitized and allosensi-
tized sera to WT PBMC was higher than to GT-
KO PBMC (P < 0.05) (Fig. 2A).
Ninety-four percent of unsensitized and 100% of
allosensitized sera showed some detectable IgG
binding to WT PBMC (Fig. 1B). Six of the 16
(38%) unsensitized and 12 of the 15 (80%)
allosensitized sera showed detectable IgG binding
to GT-KO PBMC (Fig. 1B). The mean MFI of
IgG binding to WT and GT-KO PBMC was
calculated to be 9.3 and 3.3, respectively, for
unsensitized sera, and 12.3 and 6.6, respectively,
for allosensitized sera (NS). Mean IgG binding of
unsensitized and allosensitized sera to WT PBMC
was higher than to GT-KO PBMC (P < 0.05)
(Fig. 2B).
CDC of sera to pig PBMC
Thirteen unsensitized and 14 allosensitized sera
were available for testing (in addition, 12 healthy
human sera were tested again). At 25% dilution, all
unsensitized and allosensitized sera showed cyto-
toxicity (>10% killing) to WT PBMC, whereas 10
of the 13 unsensitized (77%) and seven of the 14
allosensitized (50%) sera were cytotoxic to GT-KO
PBMC. The mean cytotoxicity (at 25% dilution) of
unsensitized and allosensitized sera to WT PBMC
was 53% and 60%, respectively, and to GT-KO
PBMC was 16% and 18%, respectively (Fig. 4).
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Fig. 3. (A) Linear regression of complement-dependent cyto-
toxicity of healthy sera (n ¼ 18) against wild-type (Gal-posit-
ive) (WT) (circle and solid line) and a1,3-galactosyltransferase
gene-knockout (GT-KO) (triangle nd broken line) peripheral
blood mononuclear cells (PBMC). The cytotoxicity of serum at
various concentrations (50%, 12.5%, 3.125%, and 0.78%) was
measured, and individual curves were generated. Significantly
higher (P < 0.05) lysis of WT PBMC was observed. (B) Ability
of individual healthy serum samples (n ¼ 18) (at 50% dilution)
to cause lysis of PBMC from WT (d) or GT-KO (s) pigs;
mean complement-dependent cytotoxicity is indicated by hor-
izontal lines. Significantly higher lysis of WT PBMC was ob-
served (*P < 0.05). The horizontal dotted line indicates 10%
cytotoxicity, below which lysis of PBMC is considered of
doubtful relevance.
0
25
50
75
100
Cy
to
to
x
ic
ity
 (%
)
Allosensitized
(n = 14)
Healthy
(n = 12)
Unsensitized
(n = 13)
Mean
: GT-KO PBMC
: WT PBMC
* * *
Fig. 4. Ability of healthy (n ¼ 12), unsensitized (n ¼ 13), and
allosensitized (n ¼ 14) sera (at 25% dilution) to cause lysis of
peripheral blood mononuclear cells (PBMC) from wild-type
(Gal-positive) (WT) (d) or a1,3-galactosyltransferase gene-
knockout (GT-KO) (s) pigs; mean complement-dependent
cytotoxicity is indicated by horizontal lines. Significantly
higher lysis of WT PBMC was observed (*P < 0.05). The
horizontal dotted line indicates 10% cytotoxicity, below which
lysis of PBMC is considered of doubtful relevance. There was
no difference in cytotoxicity to either WT or GT-KO PBMC
among the three groups of sera (a serum dilution of 25% was
selected as the volumes of allosensitized sera were limited).
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Figure 3:
(A) Linear regression of  
comp lement -de penden t 
cytotoxicity of  healthy sera 
(n=18) against WT (circle and 
solid line) and GT-KO (triangle 
and broken line) PBMC. 
The cytotoxicity of  serum 
at various concentrations 
(50%, 12.5%, 3,125%, and 
0.78%) was measured, and 
individual curves were 
generated.  Significantly 
higher (p<0.05) lysis of  WT 
PBMC was observed.  (B) 
Ability of  individual healthy 
serum samples (n=18) (at 
50% dilution) to cause lysis 
of  PBMC from WT (●) 
or GT-KO (○) pigs; mean 
complement -de penden t 
cytotoxicity is indicated by 
horizontal lines.  Significantly 
higher lysis of  WT PBMC 
was observed (p<0.05). 
The horizontal dotted line 
indicates 10% cytotoxicity, 
below which lysis of  PBMC 
is considered of  doubtful 
relevance.  
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Correlation between PRA against HLA Class I or Class II Antigens and Serum 
Cytotoxicity in Human Sera  
We investigated whether there was any correlation between serum cytotoxicity to pig PBMC 
and anti-HLA class I or class II antibodies (at 25% dilution) (n=27; 13 unsensitized and 14 
allosensitized sera).  No correlation was found between PRA directed to HLA class I or class 
II and cytotoxicity to WT or GT-KO PBMC (Figure 5). 
Comparison of Binding of IgM and IgG and Serum Cytotoxicity between Healthy and 
Allosensitized Sera
The mean MFI of IgM binding of unsensitized sera to WT PBMC was significantly lower 
than that of healthy sera (p<0.05) (Figure 2A).  There was no difference in IgM binding to 
WT or GT-KO PBMC between allosensitized sera and healthy or unsensitized sera.  There 
was no difference in IgG binding to WT or GT-KO PBMC between healthy, unsensitized, or 
allosensitized sera (Figure 2B).  There were no significant differences in cytotoxicity between 
healthy, unsensitized, and allosensitized sera to WT PBMC (Figure 4A) or to GT-KO PBMC 
(Figure 4B).  
‘‘unsensitized’’) and (ii) allosensitized (PRA >
70%, n ¼ 15; ‘‘allosensitized’’).
All unsensitized and allosensitized sera (100%)
showed some detectable IgM binding to WT
PBMC (Fig. 1A). Twelve of the 16 unsensitized
(75%) and 11 of the 15 (73%) allosensitized sera
showed detectable IgM binding to GT-KO PBMC
(Fig. 1A). The mean MFI of IgM binding to WT
and GT-KO PBMC was calculated to be 5.8 and
3.8, respectively, for unsensitized sera, and 8.3 and
3.8, respectively, for allosensitized sera (NS). Mean
IgM binding of both unsensitized and allosensi-
tized sera to WT PBMC was higher than to GT-
KO PBMC (P < 0.05) (Fig. 2A).
Ninety-four percent of unsensitized and 100% of
allosensitized sera showed some detectable IgG
binding to WT PBMC (Fig. 1B). Six of the 16
(38%) unsensitized and 12 of the 15 (80%)
allosensitized sera showed detectable IgG binding
to GT-KO PBMC (Fig. 1B). The mean MFI of
IgG binding to WT and GT-KO PBMC was
calculated to be 9.3 and 3.3, respectively, for
unsensitized sera, and 12.3 and 6.6, respectively,
for allosensitized sera (NS). Mean IgG binding of
unsensitized and allosensitized sera to WT PBMC
was higher than to GT-KO PBMC (P < 0.05)
(Fig. 2B).
CDC of sera to pig PBMC
Thirteen unsensitized and 14 allosensitized sera
were available for testing (in addition, 12 healthy
human sera were tested again). At 25% dilution, all
unsensitized and allosensitized sera showed cyto-
toxicity (>10% killing) to WT PBMC, whereas 10
of the 13 unsensitized (77%) and seven of the 14
allosensitized (50%) sera were cytotoxic to GT-KO
PBMC. The mean cytotoxicity (at 25% dilution) of
unsensitized and allosensitized sera to WT PBMC
was 53% and 60%, respectively, and to GT-KO
PBMC was 16% and 18%, respectively (Fig. 4).
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Fig. 3. (A) Linear regression of complement-dependent cyto-
toxicity of healthy sera (n ¼ 18) against wild-type (Gal-posit-
ive) (WT) (circle and solid line) and a1,3-galactosyltransferase
gene-knockout (GT-KO) (triangle and broken line) peripheral
blood mononuclear cells (PBMC). The cytotoxicity of serum at
various concentrations (50%, 12.5%, 3.125%, and 0.78%) was
measured, and individual curves were generated. Significantly
higher (P < 0.05) lysis of WT PBMC was observed. (B) Ability
of individual healthy serum samples (n ¼ 18) (at 50% dilution)
to cause lysis of PBMC from WT (d) or GT-KO (s) pigs;
mean complement-dependent cytotoxicity is indicated by hor-
izontal lines. Significantly higher lysis of WT PBMC was ob-
served (*P < 0.05). The horizontal dotted line indicates 10%
cytotoxicity, below which lysis of PBMC is considered of
doubtful relevance.
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Fig. 4. Ability of healthy (n ¼ 12), unsensitized (n ¼ 13), and
allosensitized (n ¼ 14) sera (at 25% dilution) to cause lysis of
peripheral blood mononuclear cells (PBMC) from wild-type
(Gal-positive) (WT) (d) or a1,3-galactosyltransferase gene-
knockout (GT-KO) (s) pigs; mean complement-dependent
cytotoxicity is indicated by horizontal lines. Significantly
higher lysis of WT PBMC was observed (*P < 0.05). The
horizontal dotted line indicates 10% cytotoxicity, below which
lysis of PBMC is considered of doubtful relevance. There was
no difference in cytotoxicity to either WT or GT-KO PBMC
among the three groups of sera (a serum dilution of 25% was
selected as the volumes of allosensitized sera were limited).
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Figure 4:
Ability of  healthy (n = 12), unsensi zed (n=13), and allosensitized (n=14) sera 
(at 25% dilution) to cause lysis of  PB C from WT (●) or GT-KO (○) pigs; mean 
complement-dependent cytotoxicity is indicated by horizontal lines.  Significantly 
higher lysis of  WT PBMC was observed (*p<0.05).  The horizontal dotted line 
indicates 10% cytotoxicity, below which lysis of  PBMC is considered of  doubtful 
relevance.  There was no difference in cytotoxicity to either WT or GT-KO PBMC 
between the three groups of  sera.  (A serum dilution of  25% was selected as the 
volumes of  allosensitized  wer  li ited).  
‘‘unsensitized’’) and (ii) allosensitized (PRA >
70%, n ¼ 15; ‘‘allosensitized’’).
All unsensitized and allosensitized sera (100%)
showed some detectable IgM binding to WT
PBMC (Fig. 1A). Twelve of the 16 unsensitized
(75%) and 11 of the 15 (73%) allosensitized sera
showed detectable IgM binding to GT-KO PBMC
(Fig. 1A). The mean MFI of IgM binding to WT
and GT-KO PBMC was calculated to be 5.8 and
3.8, respectively, for unsensitized sera, and 8.3 and
3.8, respectively, for allosensitized sera (NS). Mean
IgM binding of both unsensitized and allosensi-
tized sera to WT PBMC was higher than to GT-
KO PBMC (P < 0.05) (Fig. 2A).
Ninety-four percent of unsensitized and 100% of
allosensitized sera showed some detectable IgG
binding to WT PBMC (Fig. 1B). Six of the 16
(38%) unsensitized and 12 of the 15 (80%)
allosensitized sera showed detectable IgG binding
to GT-KO PBMC (Fig. 1B). The mean MFI of
IgG binding to WT and GT-KO PBMC was
calculated to be 9.3 and 3.3, respectively, for
unsensitized sera, and 12.3 and 6.6, respectively,
for allosensitized sera (NS). Mean IgG binding of
unsensitized and allosensitized sera to WT PBMC
was higher than to GT-KO PBMC (P < 0.05)
(Fig. 2B).
CDC of sera to pig PBMC
Thirteen unsensitized and 14 allosensitized sera
were available for testing (in addition, 12 healthy
human sera were tested again). At 25% dilution, all
unsensitized and allosensitized sera showed cyto-
toxicity (>10% killing) to WT PBMC, whereas 10
of the 13 unsensitized (77%) and seven of the 14
allosensitized (50%) sera were cytotoxic to GT-KO
PBMC. The mean cytotoxicity (at 25% dilution) of
unsensitized and allosensitized sera to WT PBMC
was 53% and 60%, respectively, and to GT-KO
PBMC was 16% and 18%, respectively (Fig. 4).
0102030405060
0
25
50
75
100
Serum concentration (%)
Cy
to
to
x
ic
ity
 (%
)
GT-KO PBMC
WT PBMC
A
0
25
50
75
100
B
Cy
to
to
x
ic
ity
 (%
)
WT
(n = 18)
GT-KO
(n = 18)
*
Fig. 3. (A) Linear regression of complement-dependent cyto-
toxicity of healthy sera (n ¼ 18) against wild-type (Gal-posit-
ive) (WT) (circle and solid line) and a1,3-galactosyltransferase
gene-knockout (GT-KO) (triangle and broken line) peripheral
blood mononuclear cells (PBMC). The cytotoxicity of serum at
various concentrations (50%, 12.5%, 3.125%, and 0.78%) was
measured, and individual curves were generated. Significantly
higher (P < 0.05) lysis of WT PBMC was bserved. (B) Ability
of individual healthy serum samples (n ¼ 18) (at 50% dilution)
to cause lysis of PBMC from WT (d) or GT-KO (s) pigs;
mean complement-dependent cytotoxicity is indicated by hor-
izontal lines. Significantly higher lysis of WT PBMC was ob-
served (*P < 0.05). The horizo tal dotted line indicates 10%
cytotoxicity, below which lysis of PBMC is considered of
doubtful relevance.
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Fig. 4. Ability of healthy (n ¼ 12), unsensitized (n ¼ 13), and
allosensitized (n ¼ 14) sera (at 25% dilution) to cause lysis of
peripheral blood mononuclear cells (PBMC) from wild-type
(Gal-positive) (WT) (d) or a1,3-galactosyltransferase gene-
knockout (GT-KO) (s) pigs; mean complement-dependent
cytotoxicity is indicated by horizontal lines. Significantly
higher lysis of WT PBMC was observed (*P < 0.05). The
horizontal dotted line indicates 10% cytotoxicity, below which
lysis of PBMC is co sidered of doub ful relevance. There w s
no difference in cytotoxicity to either WT or GT-KO PBMC
among the three groups of sera (a serum dilution of 25% was
selected as the volumes of allosensitized sera were limited).
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Correlation between Immunoglobulin Binding and Cytotoxicity in Sera from All 
Groups
In the absence of any relevant difference in immunoglobulin binding or cytotoxicity between 
healthy, unsensitized, or allosensitized sera, we investigated the correlation of immunoglobulin 
isotype with cytotoxicity in 39 sera available for testing (12 healthy, 13 unsensitized, 14 
allosensitized).  A correlation was found between IgM binding and cytotoxicity (at 25% serum 
concentration) to WT PBMC (R2=0.13, p<0.05) (Figure 6A, left), but not between IgG binding 
and cytotoxicity to WT PBMC (R2= 0.07, p>0.05) (Figure 6B, left).  In contrast, correlations 
between both IgM and IgG binding and cytotoxicity to GT-KO PBMC were documented (R2= 
0.27, p<0.01, and R2= 0.28, p<0.01, respectively) (Figures 6A and B, right).  The level of lysis 
of GT-KO PBMC was generally lower than that of WT PBMC, even when the MFI of binding 
was identical.
Correlation between PRA against HLA class I or class II antigens
and serum cytotoxicity in human sera
We investigated whether there was any correlation
between serum cytotoxicity to pig PBMC and anti-
HLA class I or class II antibodies (at 25% dilution)
(n ¼ 27; 13 unsensitized and 14 allosensitized sera).
No correlation was found between PRA directed
to HLA class I or class II and cytotoxicity to WT
or GT-KO PBMC (Fig. 5).
Comparison of binding of IgM and IgG and serum cytotoxicity
between healthy and allosensitized sera
The mean MFI of IgM binding of unsensitized sera
to WT PBMC was significantly lower than that of
healthy sera (P < 0.05) (Fig. 2A). There was no
difference in IgM binding to WT or GT-KO
PBMC between allosensitized sera and healthy or
unsensitized sera. There was no difference in IgG
binding to WT or GT-KO PBMC among healthy,
unsensitized or allosensitized sera (Fig. 2B). There
were no significant differences in cytotoxicity
among healthy, unsensitized and allosensitized sera
to WT PBMC (Fig. 4A) or to GT-KO PBMC
(Fig. 4B).
Correlation between immunoglobulin binding and cytotoxicity in
sera from all groups
In the absence of any relevant difference in
immunoglobulin binding or cytotoxicity among
healthy, unsensitized, or allosensitized sera, we
investigated the correlation of immunoglobulin
isotype with cytotoxicity in 39 sera available for
testing (12 healthy, 13 unsensitized, 14 allosensi-
tized). A correlation was found between IgM
binding and cytotoxicity (at 25% serum concen-
tration) to WT PBMC (R2 ¼ 0.13, P < 0.05)
(Fig. 6A, left), but not between IgG binding and
cytotoxicity to WT PBMC (R2 ¼ 0.07, P > 0.05)
(Fig. 6B, left). In contrast, correlations between
both IgM and IgG binding and cytotoxicity to GT-
KO PBMC were documented (R2 ¼ 0.27,
P < 0.01, and R2 ¼ 0.28, P < 0.01, respectively)
(Fig. 6A,B, right). The level of lysis of GT-KO
PBMC was generally lower than that of WT
PBMC, even when the MFI of binding was
identical.
Discussion
Organ transplantation from a WT pig into a non-
immunosuppressed primate usually results in
hyperacute rejection within minutes to hours
[11,12]. The primary role of anti-Gal antibodies
in this response has been established by several
groups [3–6]. The problem of anti-Gal antibody
has recently been overcome by the breeding of pigs
homozygous for GT-KO [1,2]. However, although
the transplantation of an organ from a GT-KO pig
into an immunosuppressed non-human primate
allows extended graft survival [7], the graft even-
tually fails from the development of a thrombotic
microangiopathy that may be a form of delayed
antibody-mediated rejection. The focal deposition
of IgM, IgG and C4d on the graft suggests that a
component of this process involves the binding of
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Fig. 5. Linear regression of cytotoxicity
(at 25% serum concentration) of unsensi-
tized and allosensitized sera against panel
reactive antibodies (PRA) to HLA class I
(A) or HLA class II (B). Correlation is
shown for cytotoxicity to wild-type (Gal-
positive) (WT) (left) and a1,3-galactosyl-
transferase gene-knockout (GT-KO)
(right) peripheral blood mononuclear cells
(PBMC) (n ¼ 27). There was no significant
correlation between PRA against HLA
class I or II and cytotoxicity to either WT
or GT-KO PBMC.
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Figure 5:
Linear regression of  cytotoxicity (at 25% serum concentration) of  unsensitized and 
allosensitized sera against PRA to HLA class I (A) or HLA class II (B).  Correlation is 
shown for cytotoxicity  to WT (left) and GT-KO (right) PBMC (n=27).  There was no 
significant correlation between PRA against HLA class I or II and cytotoxicity to either 
WT or GT-KO PBMC.  
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DISCUSSION
Organ transplantation from a WT pig into a nonimmunosuppressed primate usually results 
in hyperacute rejection within minutes to hours (11,12).  The primary role of anti-Gal 
antibodies in this response has been established by several groups (3-6).  The problem 
of anti-Gal antibody has recently been overcome by the breeding of pigs homozygous for 
GT-KO (1,2).  However, although the transplantation of an organ from a GT-KO pig into 
an immunosuppressed nonhuman primate allows extended graft survival (7), the graft 
eventually fails from the development of a thrombotic microangiopathy that may be a form of 
delayed antibody-mediated rejection.  The focal deposition of IgM, IgG, and C4d on the graft 
suggests that a component of this process involves the binding of anti-nonGal antibodies to 
the pig vascular endothelial cells.  These antibodies could be either preformed or elicited.  
anti-non-Gal antibodies to the pig vascular endot-
helial cells. These antibodies could be either
preformed or elicited.
The present study investigated the incidence of
preformed anti-non-Gal antibodies in the serum of
healthy and allosensitized humans, and assessed
whether these antibodies are cytotoxic to pig
PBMC lacking the Gal epitope. The results were
compared with reactivity of anti-pig antibodies to
WT pig PBMC.
Whereas all healthy and allosensitized humans
had preformed antibodies to WT pig PBMC, in
approximately one-third such antibodies to GT-
KO PBMC were not detectable. Moreover, the
cytotoxicity associated with anti-non-Gal antibod-
ies was significantly weaker than that associated
with anti-Gal antibodies. Whereas reactivity with
WT pig cells is clearly due to the binding of both
anti-Gal and anti-non-Gal antibodies, reactivity
with GT-KO cells is solely due to the presence of
anti-non-Gal antibodies.
Healthy humans who demonstrated a high MFI
of IgG binding to GT-KO PBMC also had a high
IgG binding to WT PBMC, but did not have a
consistently high serum cytotoxicity to GT-KO
PBMC. These subjects would, therefore, not neces-
sarily appear to be at greater risk for hyperacute
rejection if they were to receive a GT-KO pig
organ. The one healthy subject who had high IgM
binding to GT-KO PBMC (Fig. 1A) also had high
IgG binding and cytotoxicity, and so would appear
to be at higher risk.
Antibody binding, particularly of the IgM
isotype, results in complement fixation and
subsequent cell lysis. This was investigated by a
two-step CDC assay. GT-KO pig PBMC were
significantly less susceptible to lysis by either
healthy or allosensitized sera than WT PBMC.
However, although the absence of the Gal epitope
led to a significant reduction in both the prevalence
and severity of complement-induced lysis, anti-
non-Gal antibodies nonetheless can initiate a
cytotoxic response which, in vivo, could affect
long-term viability of a pig organ graft.
One possible limitation of our study is that only a
random six sera of the 27 healthy human volunteers
from whom sera were obtained were tested by
ELISA for allosensitization. However, none of the
volunteers had been pregnant or had received blood
transfusions or organ allografts. It is therefore
extremely unlikely that any were allosensitized.
A second possible limitation is that only PBMC
were used as target cells, whereas vascular endot-
helial cells might have provided different, or more
biologically relevant (for vascularized organs),
non-Gal epitopes, although there is no definite
evidence for this [13]. Chen et al. [14] reported that
baboon anti-non-Gal antibody binding (both IgM
and IgG) to GT-KO pig porcine aortic endothelial
cells was similar to that to PBMC. We are
currently investigating whether there are differ-
ences between anti-pig antibody binding to PBMC
and vascular endothelial cells; preliminary results
suggest that binding to PBMC may actually be
higher (H. Hara, unpublished data).
In sera from unsensitized patients, the mean
MFI of IgM binding to WT PBMC was signifi-
cantly lower than that in healthy human sera
A
0 10 20 30 40 50 60
0
25
50
75
100
MFI-IgM
Cy
to
to
xi
ci
ty
 (%
)
0 10 20 30 40 50 60
0
25
50
75
100
MFI-IgM
Cy
to
to
xi
ci
ty
 (%
)
B
0 10 20 30 40 50 60
0
25
50
75
100
MFI-IgG
Cy
to
to
xi
ci
ty
 (%
)
0 10 20 30 40 50 60
0
25
50
75
100
MFI-IgG
Cy
to
to
xi
ci
ty
 (%
)
Fig. 6. Correlation between cytotoxicity
(at 25% serum concentration) and IgM (A)
or IgG (B) binding of 39 sera (12 healthy,
13 unsensitized, 14 allosensitized) against
wild-type (Gal-positive) peripheral blood
mononuclear cells (WT PBMC) (left) or
a1,3-galactosyltransferase gene-knockout
peripheral blood mononuclear cells
(GT-KO PBMC) (right). There was signi-
ficant correlation between IgM binding
and cytotoxicity against WT PBMC
(P < 0.05), but not between IgG binding
and cytotoxicity. Significant correlations
were observed between IgM or IgG bind-
ing and cytotoxicity (both P < 0.01) to
GT-KO PBMC.
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Figure 6:
Correlation between cytotoxicity (at 25% serum concentration) and IgM (A) or IgG (B) 
binding of  39 sera (12 healthy, 13 unsensitized, 14 allosensitized) against WT PBMC (left) 
or GT-KO PBMC (right).  There was significant correlation between IgM binding and 
cytotoxicity against WT PBMC (p<0.05), but not between IgG binding and cytotoxicity. 
Significant correlations were observed between IgM or IgG binding and cytotoxicity 
(both p<0.01) to GT-KO PBMC
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The present study investigated the incidence of preformed anti-nonGal antibodies in the 
serum of healthy and allosensitized humans, and assessed whether these antibodies are 
cytotoxic to pig PBMC lacking the Gal epitope.  The results were compared with reactivity of 
anti-pig antibodies to WT pig PBMC.  
Whereas all healthy and allosensitized humans had preformed antibodies to WT pig PBMC, 
in approximately one-third such antibodies to GT-KO PBMC were not detectable.  Moreover, 
the cytotoxicity associated with anti-nonGal antibodies was significantly weaker than that 
associated with anti-Gal antibodies.  Whereas reactivity with WT pig cells is clearly due to 
the binding of both anti-Gal and anti-nonGal antibodies, reactivity with GT-KO cells is solely 
due to the presence of anti-nonGal antibodies. 
Healthy humans who demonstrated a high MFI of IgG binding to GT-KO PBMC also had 
a high IgG binding to WT PBMC, but did not have a consistently high serum cytotoxicity to 
GT-KO PBMC.  These subjects would, therefore, not necessarily appear to be at greater 
risk for hyperacute rejection if they were to receive a GT-KO pig organ.  The one healthy 
subject who had high IgM binding to GT-KO PBMC (Figure 1A) also had high IgG binding 
and cytotoxicity, and so would appear to be at higher risk.
Antibody binding, particularly of the IgM isotype, results in complement fixation and 
subsequent cell lysis.  This was investigated by a two-step CDC assay.  GT-KO pig PBMC 
were significantly less susceptible to lysis by either healthy or allosensitized sera than WT 
PBMC.   However, although the absence of the Gal epitope led to a significant reduction 
in both the prevalence and severity of complement-induced lysis, anti-nonGal antibodies 
nonetheless can initiate a cytotoxic response which, in vivo, could affect long-term viability 
of a pig organ graft.
One possible limitation of our study is that only a random six sera of the 27 healthy human 
volunteers from whom sera were obtained were tested by ELISA for allosensitization. 
However, none of the volunteers had been pregnant or had received blood transfusions or 
organ allografts.  It is therefore extremely unlikely that any were allosensitized.
A second possible limitation is that only PBMC were used as target cells, whereas vascular 
endothelial cells might have provided different, or more biologically relevant (for vascularized 
organs), nonGal epitopes, although there is no definite evidence for this (13).  Chen et al. 
reported that baboon anti-nonGal antibody binding (both IgM and IgG) to GT-KO pig porcine 
aortic endothelial cells was similar to that to PBMC (14).  We are currently investigating 
whether there are differences between anti-pig antibody binding to PBMC and vascular 
endothelial cells; preliminary results suggest that binding to PBMC may actually be higher 
(Hara, H, unpublished).  
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In sera from unsensitized patients, the mean MFI of IgM binding to WT PBMC was significantly 
lower than that in healthy human sera (Figure 2A), although the extent of IgG binding was 
not different (Figure 2B).  We cannot fully explain this observation.  One possible explanation 
is that patients in chronic renal failure are likely to be modestly immunocompromised. 
However, the allosensitized patients would also be expected to be immunocompromised, 
but IgM binding of their sera was not different from that of healthy volunteers.  It could 
also be that unsensitized patients are ‘low responders’, but this reasoning is undermined 
by the observation that their IgG responses were not different from the other two groups. 
Furthermore, there was no difference in serum cytotoxicity between the three groups (Figure 
4).
An important finding from this study is the documentation that sera from allosensitized 
subjects did not show a higher level of binding of preformed antibodies (IgM or IgG) to nonGal 
antigens than did sera from unsensitized or healthy subjects, nor increased cytotoxicity. 
Previously, some reports suggested that sera from allosensitized subjects might be more 
cytotoxic to unmodified pig cells than sera from unsensitized subjects, although other 
reports did not confirm this observation (reviewed in 10).  If the data in the current paper are 
confirmed – that humans previously exposed and sensitized to alloantigens are at no greater 
risk for rejecting a GT-KO pig xenograft by an antibody-mediated mechanism, this will have 
important clinical implications.  Highly allosensitized patients frequently have difficulty in 
obtaining a human donor organ against which they do not have anti-HLA antibodies.  This 
group of patients may therefore be among those first considered for xenotransplantation.  
Previous studies by others have suggested that anti-HLA antibodies can cross-react with 
anti-swine leukocyte antigens (SLA) (reviewed in 10).  In the present study, we could not 
identify any correlation between the presence of anti-HLA antibodies and IgM or IgG binding 
or cytotoxicity to WT or GT-KO pig PBMC.  The possibility of cross-reactivity between anti-
HLA and anti-SLA antibodies cannot be completely ruled out as the SLA types of the pigs 
from which PBMC were obtained have not been determined.  
The significant correlation found between IgM binding and cytotoxicity of sera to WT PBMC 
confirms previous studies (15,16), and supports the fact that xenoreactive IgM is more capable 
of fixing complement, whereas only some isotypes of IgG, and IgA, can fix complement (17-
19).  IgG binding to WT PBMC might have correlated with cytotoxicity if a greater number 
of sera had been available for study.  Although significant correlations between IgM or IgG 
binding and cytotoxicity to GT-KO PBMC were also observed, the level of lysis was generally 
lower than that of WT PBMC even when the MFI of binding was identical (Figure 6).
Our data suggest that GT-KO pigs are more suitable than WT pigs as sources of organs 
for transplantation into humans, since reactivity with preformed antibodies in human serum 
was significantly reduced.  The possibility that a second Gal-sythesizing enzyme in pigs, 
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e.g., iGb3 synthase (20), may be playing a role in rejection of a GT-KO pig organ appears 
unlikely since no changes in anti-Gal antibody levels have been documented after GT-
KO pig heart transplantation in baboons, even when elicited antibodies have developed 
(7,21,22).  However, unidentified nonGal epitopes on the pig vascular endothelium could still 
pose a threat to the viability of a porcine organ transplanted into a human.  With the possible 
exception of N-glycolylneuraminic acid (23), the nature of the nonGal antigens expressed 
on the GT-KO pig vascular endothelium or PBMCs against which humans have preformed 
antibodies is uncertain, and has been discussed previously (24,25).  
If there are multiple nonGal epitopes against which humans have preformed antibodies, 
then gene-knockout may not be a feasible solution.  However, the lower level of endothelial 
cell activation and cytotoxicity associated with anti-nonGal antibodies, compared with anti-
Gal antibodies, may allow protection by the presence of one or more human complement-
regulatory proteins when combined with a GT-KO pig genotype.  Although transgenic pigs 
expressing human decay-accelerating factor or other complement-regulatory protein were 
incompletely protected against anti-Gal antibodies (26,27), this approach may prove more 
successful against the weaker anti-nonGal antibodies. 
There is increasing success in achieving a state of accommodation after allografting across 
the ABO blood group barrier or when there is allosensitization associated with anti-HLA 
antibodies (28).  Such approaches, involving procedures such as pre- and post-transplant 
plasmapheresis and the administration of intravenous immunoglobulin (IVIg) (29), although 
not effective in inducing accommodation to a WT pig xenograft (30-32), may possibly 
prove more successful in the presence of the lower levels of anti-nonGal antibody.  To our 
knowledge, this approach has not yet been tested in the GT-KO pig-to-nonhuman primate 
model.
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ABSTRACT
The recent availability of pigs homozygous for α1,3-galactosyltransferase gene-knockout 
(GT-KO) has enabled study of incidence and cytotoxicity of antibodies of cynomolgus 
monkeys directed to antigens other than Galα1,3Gal (Gal), termed nonGal antigens. To this 
aim, sera from 21 cynomolgus monkeys were tested by flow cytometry for binding of IgM 
and IgG to peripheral blood mononuclear cells (PBMC) from wild-type (WT) and GT-KO 
pigs. The sera were also tested for complement-dependent cytotoxicity to WT and GT-KO 
PBMC.  Anti-WT IgM and IgG were found in 100% and 95%, respectively, and anti-GT-KO 
IgM and IgG in 76% and 66%, respectively, in the sera of the monkeys tested (p<0.01). 
Whereas 100% of sera were cytotoxic to WT PBMC, only 76% were cytotoxic to GT-KO 
PBMC, and the level of cytotoxicity was significantly less (p<0.01). Although the incidence 
and cytotoxicity of antibodies in monkey sera to GT-KO pig PBMC are significantly less than 
to WT PBMC, approximately three-quarters of the monkeys tested had cytotoxic antibodies 
to GT-KO PBMC. This incidence of cytotoxicity is significantly higher than that found in 
baboons and humans, suggesting the baboon may be an easier and possibly more suitable 
model to study antibody-mediated rejection of transplanted GT-KO pig organs and cells. 
INTRODUCTION
The recent availability of pigs homozygous for α1,3-galactosyltransferase gene-knockout 
(GT-KO) (1, 2) has enabled pig-to-nonhuman primate organ and cell transplantation to be 
carried out in the absence of expression of the pig Galα1,3Gal (Gal) epitopes that are known 
to be important targets for primate anti-pig antibodies (3-6). Hyperacute and acute humoral 
xenograft rejection (AHXR) are largely caused by these anti-Gal antibodies. AHXR is believed 
to be a consequence of antibody binding to vascular endothelial cells, whereby anti-Gal as 
well as anti-nonGal antibodies (i.e., antibodies against targets other than Gal antigens) in the 
recipient are of importance. A varying incidence of anti-nonGal antibodies has been reported 
humans by Zhu (6-8). These anti-nonGal antibodies appear to be associated with rejection 
or injury of pig organs or cells in non-human primates (9, 10, and Ezzelarab, M., submitted 
for publication).
In experimental settings, macaque monkeys (i.e., cynomolgus and rhesus monkeys) and 
baboons are frequently used as recipients to study the survival of pig organs and cells. 
Possible differences in anti-nonGal antibodies between species are of importance as they 
may have implications for suitability of the preclinical model.
There have hitherto been no definitive reports on the incidence of anti-nonGal antibodies 
in cynomolgus monkeys, nor of the extent of cytotoxicity associated with these antibodies 
towards pig cells. We here report on the incidence and cytotoxicity of preformed antibodies 
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directed to nonGal antigens on GT-KO pig peripheral blood mononuclear cells (PBMC) in 
immunologically-naïve (not intentionally sensitized) cynomolgus monkeys. We also compare 
the incidence of anti-nonGal antibodies and their cytotoxicity in cynomolgus monkeys with 
results obtained by our group in baboons and humans.
METHODS
Animals
Serum samples were prepared from blood collected from 21 immunologically-naïve 
cynomolgus monkeys (Macaca fascicularis) of all blood groups (A, B, AB, O), purchased 
from different suppliers. To detect the presence of anti-pig and anti-nonGal antibodies in 
these samples, PBMC were collected from GT-KO and unmodified (wild-type, WT) pigs, 
and used as targets in flow cytometry and cytotoxicity assays. The pigs were obtained from 
Revivicor, Inc. (Blacksburg,VA) and were of Large White/Landrace/Duroc cross-breed (1); 
the GT-KO pigs differed from the WT pigs only with regard to the absence of Gal epitopes, 
which was confirmed by several different methods (1).
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and 
Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health (NIH publication No. 86-23, revised 1985). 
Isolation of Porcine PBMC
PBMC from several different pigs (WT and GT-KO) were isolated from heparinized blood; 
the PBMC were not pooled, but PBMC from a single pig were used for testing of several 
sera. Briefly, heparinized blood samples were subjected to gravity centrifugation at 1800rpm 
for 5 min at 20˚C.  Plasma from each sample was then removed, and the remaining cells 
were resuspended in phosphate buffered saline (PBS, Sigma, St. Louis, MO). The final 
dilution of blood to PBS was 2:1. These cells were then layered slowly and carefully over 
5mL Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ) in 15mL Falcon conical 
tubes (Becton Dickinson, Franklin Lake, NJ). The cells were gravity centrifuged at 1500rpm 
for 30 min at 20˚C, and the buffy coat containing the PBMC was isolated and collected in a 
separate tube. The total mononuclear cell fraction was then washed twice, filtered through 
a mesh and resuspended with RPMI 1640 media (Gibco, Grand Island, NY), and live cells 
were counted using trypan blue (Gibco) under light microscopy.
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Flow Cytometry
Isolated PBMC were resuspended in FACS-buffer (PBS containing 1% bovine serum albumin 
[Gibco] and 0.1% NaN3) to a final cell concentration of 12.5x10
6 cells/mL. One million PBMC 
were then removed and incubated with 20μL of heat-inactivated monkey serum (at 56°C for 
30 min), diluted in FACS buffer to 20% serum final concentration, for 30 min at 4˚C.  After 
incubation, the cells were washed twice in 2mL FACS buffer, vortexed and centrifuged at 
1800rpm for 5 min. Cells were then resuspended in 10µL of 10% goat serum in FACS buffer, 
to prevent non-specific binding, and incubated further with 10μL FITC-conjugated goat anti-
human IgG (γ chain-specific) at 1:50 dilution, or with IgM (μ chain-specific) at 1:200 dilution, 
(Zymed Laboratories, San Francisco, CA) for 30 min in the dark at 4˚C. Antibodies bound 
to live cells were analyzed using FACScan (Becton Dickinson, Mountain View, CA). Dead 
cells were excluded from the analysis by forward-scatter and propidium iodide staining (10μL 
added to each sample prior to FACS analysis). Binding of a serum sample was considered 
positive when the mean fluorescence intensity (MFI) was higher than the MFI of the control 
(cells and secondary antibody alone) plus two standard deviations of the mean control 
level.
Complement-Dependent Cytotoxicity Assay
Heat-inactivated monkey serum samples (n=21) were diluted four-fold in RPMI 1640 
media (+10% FBS; Gibco) to final concentrations of 50%, 12.5%, 3.125%, and 0.78%. As 
an interplate control, serum from a single human was diluted in the same manner and its 
complement-dependent cytotoxicity was tested on all plates. Cells were loaded into 96-well 
flat bottom plates at a cell density of 1x106 cells per well in 10% FBS in RPMI 1640 media. 
The plates were centrifuged at 1800rpm for 7 min, the supernatant discarded, and the cells 
were incubated with 100μL of diluted monkey or human serum (control) for 30 min at 4°C. 
Control wells, no serum added, were loaded with 100μL of medium only. After incubation, 
the cells were washed (200μL RPMI 1640 +10% FBS), centrifuged at 1800rpm for 7 min, 
the supernatant discarded, and further incubated with 100μL of 10% rabbit HLA-ABC serum 
(Sigma), as a source of complement, for 45 min at 37°C. Negative control wells (100% live 
cells) were those to which only complement was added; positive control wells (0% live cells) 
were those in which a detergent (polyoxyethylene sorbitan monolaurate; Sigma) was added 
to lyse all cells. Additional negative controls were employed; these comprised either of cells 
alone or cells and serum.  
Following incubation, the cells were washed and resuspended in 100μL of RPMI 1640 
(+10% FBS) and 20μL of MTS (CellTiter 96® Aqueous One Solution Reagent; Promega, 
Madison, WI) and incubated for 15 h, for the development of color, at 37˚C in a 5% CO2 
humidified atmosphere.  Cell viability was assessed by the capacity of live cells to reduce 
tetrazolium salts into formazan, and the color produced was measured (absorbance) using a 
plate reader (Bio-Tek Instruments, Winooski, VT) at a wavelength of 450nm. The assumption 
made in this assay was that a cell that is incapable of producing color is a dead cell. Cell 
Proefschrift.indb   85 1/3/2008   6:18:11 PM
Chapter 5
86
viability was calculated using the following formula:
% live cells = [(A-B)/(C-B)] x 100,
where A equals the absorbance of cells (+ serum and complement), B equals the absorbance 
of cells (+ detergent), and C equals the absorbance of cells (+ complement).  
Results were expressed as the percentage of dead cells (% cytotoxicity = 100 - % viability). 
Complement-dependent cytotoxicity values of the varying serum concentrations (50%, 
12.5%, 3.125%, and 0.78%) were calculated, and a curve was generated for each monkey 
sample. Lysis of PBMC of <10% was considered of doubtful relevance.
Data Analysis
Analysis of indirect immunofluorescence intensity was accomplished by Cell Quest software 
and converted into MFI by WinMDI software. Statistical analysis of data was performed 
using Mann-Whitney U tests. Correlation of cytotoxicity and MFI was assessed by linear 
regression analysis. Significance at the 95% or the 99% level was calculated using prism-4 
software (Graphpad Software, San Diego, CA).
RESULTS
Reactivity of Cynomolgus Monkey Serum Samples to PBMC from WT and GT-KO 
Pigs
Binding of monkey IgM and IgG to pig PBMC by flow cytometry
The presence of preformed xenoreactive antibodies in sera from immunologically naïve 
(not intentionally sensitized) cynomologus monkeys was assessed by flow cytometry. All 21 
serum samples had a detectable IgM binding to WT PBMC, and 16 of 21 sera (76%) showed 
some binding to PBMC from GT-KO pigs (Figure 1A). A similar finding was observed with 
IgG binding; 20 of 21 samples (95%) demonstrated IgG binding to WT PBMC, while only 
14 (67%) bound GT-KO cells (Figure 1A).  In other words, with the flow cytometry assay 
employed in these studies, the incidence of binding of monkey IgM and IgG antibodies to 
GT-KO PBMC was 76% and 70%, respectively, of that to WT PBMC. 
 
The mean MFI of IgM binding to WT PBMC and to GT-KO PBMC was determined to be 
12.14 ± 3.54 and 6.66 ± 2.45, respectively; this mean MFI level of IgM binding to WT PBMC 
was significantly higher than that to GT-KO PBMC (p< 0.01, Mann-Whitney U) (Figure 1B). 
The mean MFI of IgG binding to WT PBMC was 9.96 ± 6.34, and the mean binding of IgG to 
GT-KO PBMC was 4.30 ± 1.17, the difference also achieving statistical significance (p<0.01) 
(Figure 1B). 
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These results would suggest that (i) the greater binding to WT PBMC was due to Gal-
specific antibodies, and (ii) the residual binding to GT-KO PBMC was due to the presence of 
antibodies to nonGal-specific antigens.
Complement-dependent cytotoxicity of monkey sera to pig PBMC
After establishing that monkey serum can contain anti-nonGal antibodies, it was important 
to determine whether these antibodies can cause lysis of cells from GT-KO pigs. Lysis 
was assessed by using a classical two-step complement-dependent cytotoxicity assay. 
The cytotoxicity of the monkey serum samples was tested at various concentrations (50%, 
We concluded that approximately three quarters of
naı¨ve monkey sera tested in this study contained anti-
nonGal antibodies that are cytotoxic to PBMC from GT-
KO pigs, though the extent of cell lysis is generally less
than to WT pig PBMC.
Correlation between binding of IgM or IgG and serum
cytotoxicity
To investigate if one of the immunoglobulin isotypes was
more associated with cytotoxicity, correlation between
cytotoxicity and binding (MFI) was assessed. Correlations
were found between IgM binding to both WT and GT-
KO PBMC and cytotoxicity (at 12.5% serum concentra-
tion) (P < 0.02) (Fig. 3). However, no statistically
significant correlation between IgG binding and cytotoxic-
ity to WT or GT-KO PBMC was observed (Fig. 3).
Discussion
The incidence of binding of monkey serum IgM and IgG
isotypes to PBMC from GT-KO pigs was significantly less
when compared with binding to WT PBMC. However,
we demonstrated that 76% of the tested monkey sera
caused lysis of GT-KO PBMC (compared with 100% lysis
of WT PBMC), although the extent of cell lysis associated
with anti-nonGal antibodies was significantly less. Even
though this confirms the potential advantage of using
GT-KO donor pigs for transplantation into cynomolgus
monkeys, nevertheless, approximately three quarters of
the monkeys had IgM with or without IgG binding to
GT-KO PBMC; as these anti-nonGal antibodies are cyto-
toxic, they are likely to be associated with the develop-
ment of AHXR.
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Figure 1 Binding of cynomolgus monkey serum antibodies to wild-type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig cells
(MFI ¼ mean fluorescence intensity). (a) Distribution of serum reactivity of 21 monkeys against WT or GT-KO peripheral blood mononuclear cells
(PBMC), IgM (top) and IgG (bottom). Mean reactivity of each group is indicated by a line. Control is fluorescein isothiocyanate (FITC)-conjugated
antibody and pig cells only. (b) Mean reactivity (MFI levels ± SEM) of serum samples (n ¼ 21) against WT or GT-KO PBMC, IgM (top) and IgG
(bottom). Statistically higher reactivity of both IgM and IgG against WT PBMC versus GT-KO PBMC was observed (P < 0.01).
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igure 1:
Binding of  cynomolgus monkey serum antibodies to WT and GT-KO pig cells (MFI = 
mean fluoresce ce inte sity).  
(A)  Distribution of  serum reactivity of  21 monkeys against WT or GT-KO PBMC, IgM 
(top) and IgG (bottom).  Mean reactivity of  each group is indicated by a line.  Control is 
FITC-conjugated antibody and pig cells only.  
 (B)  Mean reactivity (MFI levels ± SEM) of  serum samples (n=21) against WT or GT-
 PBMC, IgM (top) and IgG (bottom).  Statistically higher reactivity of  both IgM and 
IgG against WT PBMC versus GT-KO PBMC was observed (p<0.01).  No significant 
diff rence as found between IgM and IgG bin ing to GT-KO PBMC and GT-KO 
control.
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One possible limitation of our study is that only
PBMCs were used as target cells, whereas vascular endot-
helial cells might have provided different, or more biolo-
gically relevant, nonGal epitopes, although there is no
definite evidence for this. We are currently investigating
whether there are differences between antipig antibody
binding and cytotoxicity to PBMC and vascular endothel-
ial cells; preliminary results suggest that there is little dif-
ference and, indeed, binding to PBMC may be higher
(H. Hara et al., unpublished data, Starzl Transplantation
Institute, Pittsburgh, USA). Furthermore, although PBMC
were drawn from WT pigs from the same herd and from
GT-KO pigs from three closely-related clones, neither WT
nor GT-KO PBMC were pooled; the possibility of variable
Gal and nonGal epitope expression between the PBMC
cannot be ruled out, although this is likely to have been
minor.
In other studies by our group, 43% of human
(H. Hara, preliminary data, Starzl Transplantation Insti-
tute, Pittsburgh, USA) and 32% of baboon [Ezzelarab M,
et al., submitted for publication] sera were demonstrated
to have an IgM binding to GT-KO PBMC, which is signi-
ficantly less than the 76% IgM binding of cynomolgus
monkey sera that we report here (P < 0.01). Both human
and monkey sera showed an incidence of 67% IgG bind-
ing to GT-KO PBMC, compared with an incidence of
only 9% of baboon IgG (P < 0.01). The levels of IgG and
IgM binding of all three species are shown in Fig. 4. Fur-
thermore, whereas approximately 50% of both human
and baboon sera demonstrated cytotoxic antibodies
against GT-KO PBMC, the incidence is 76% in monkey
sera (P < 0.01) (Fig. 5). These results suggest that mon-
keys may have stronger antibody-mediated cytotoxic
responses to GT-KO pig grafts than humans and
baboons.
In experimental settings, GT-KO organs have been
transplanted into immunsuppressed baboons; heterotopic
heart graft failure occurred after 2–6 months [11] and
recipients with life-supporting pig kidneys died from
complications of the regimen within 3 months, although
in some transplant kidney function continued [12].
Whereas anti-Gal antibodies could not have been part of
this rejection process, anti-nonGal antibodies could poss-
ibly have been involved. These findings are supported by
a study from Brandl et al. in an hDAF transgenic pig-to-
baboon heart transplantation model using the soluble Gal
saccharides to prevent anti-Gal antibody-mediated hyper-
acute rejection; this center reported that nonGal antibody
titers were increased, and this increase was associated with
the development of AHXR [9].
To our knowledge, there are no reports of transplanta-
tion of GT-KO organs or cells in cynomolgus monkeys.
However, there is an evidence that anti-nonGal antibodies
are associated with AHXR in cynomolgus monkeys; Lam et
al. [10] demonstrated that, when hDAF-transgenic pig
hearts were transplanted into cynomolgus monkeys under
the soluble Gal saccharide-based therapy (to adsorb or
‘neutralize’ anti-Gal antibodies), anti-nonGal antibody lev-
els increased in animals that rejected their grafts.
Although the identity of pig nonGal antigens still
remains uncertain [13], there is evidence that anti-N-glyco-
lylneuraminic acid antibodies, also known as Hanganutziu-
Deicher (HD) antibodies, are present in human serum
[8,14]. As pigs express N-glycolylneuraminic acid on their
cells, this may, in part, account for human anti-nonGal
antibody binding to GT-KO PBMC. However, as baboons
and monkeys express HD antigens themselves (like the
pig), anti-HD antibodies do not contribute to the anti-
nonGal antibodies found in these nonhuman primates spe-
cies. The higher level of anti-nonGal IgM in monkeys
detected in our studies compared with that in humans and
baboons cannot be fully explained, but it is probably rela-
ted to differences in the microbial flora that populate the
gastro-intestinal tract or to other infectious agents to which
these various species have been exposed. Also, the age and
geographic origin, and whether wild-caught or captive-
bred, of the monkeys from which sera were drawn may
have played a role in this [15–17], but unfortunately this
information was not available to us for sufficient monkeys
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Figure 2 (a) Ability of individual monkey serum samples at 12.5%
dilution to cause lysis of PBMC from WT or GT-KO pigs; mean com-
plement-dependent cytotoxicity is indicated by lines. Significantly,
higher lysis of unmodified (WT) PBMC was observed (P < 0.01). (b)
Mean cytotoxicity of monkey serum samples (at various dilutions)
against PBMC from either WT or GT-KO pigs.
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Figure 2:
(A)  Ability of  individual monkey serum samples at 12.5% dilution to cause lysis 
of  PBMC from WT or GT-KO pigs; mean complement-dependent cytotoxicity is 
indicated by lines.  Significantly higher lysis of  unmodified (WT) PBMC was observed 
(p <0.01).
(B)  Mean cytotoxicity of  monkey serum samples (at vari us dilutions) against PBMC 
from either WT or GT-KO pigs.  
12.5%, 3.125%, and 0.78%). In three cases there was insufficient serum to include a 50% 
concentration in the assay. 
The result of the assay was considered acceptabl  when the slope of the human control 
curve was within the 95% confidence limit of the mean of >25 determinations. Cytotoxicity 
results from 19 out of 21 sera fell within this confidence interval; however, there were no 
statistically significant differences whether 19 or 21 sera were included in the data analysis. 
(The sensitivity of the assay was such that only lysis of >10% was considered positive.)
The strength of serum cytotoxicity to both WT and GT-KO PBMC varied between the different 
monkeys. At 12.5% dilution, all the sera were cytotoxic to WT PBMC, whereas only 76% of 
these samples were lytic to PBMC from GT-KO pigs (Figure 2A). Furthermore these sera 
caused greater lysis of PBMC from WT pigs than from GT-KO igs (p<0.01) (Figur s 2A and 
B); at 12.5% dilution, the lysis of PBMC was reduced from approximately 54% (WT) to 30% 
(GT-KO) (Figure 2B). 
We concluded that approximately three quarters of naïve monkey sera tested in this study 
contained anti-nonGal antibodies that are cytotoxic to PBMC from GT-KO pigs, though the 
extent of cell lysis is generally less than to WT pig PBMC.  
Correlation between binding of IgM or IgG and s rum cytotoxicity
To investigate if one of the immunoglobulin isotypes was more associated with cytotoxicity, 
correlation between cytotoxicity and binding (MFI) was assessed. Correlations were found 
between IgM binding to both WT and GT-KO PBMC and cytotoxicity (at 12.5% serum 
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helial cells might have provided different, or more biolo-
gically relevant, nonGal epitopes, although there is no
definite evidence for this. We are currently investigating
whether ther are differences between antipig antibody
binding and cyto oxicity to PBMC and vascular endothel-
ial cells; preliminary results suggest that there is little dif-
ference and, indeed, binding to PBMC may be higher
(H. Hara et al., unpublished data, Starzl Transplantation
Institute, Pittsburgh, USA). Furthermore, although PBMC
were drawn from WT pigs from the same herd and from
GT-KO pigs from three closely-related clones, neither WT
nor GT-KO PBMC were pooled; the possibility of variable
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tute, Pittsburgh, USA) and 32% of baboon [Ezzelarab M,
et al., submitted for publication] sera were demonstrated
to have an IgM binding to GT-KO PBMC, which is signi-
ficantly less than the 76% IgM binding of cynomolgus
monkey sera that we report here (P < 0.01). Both human
and monkey sera showed an incidence of 67% IgG bind-
ing to GT-KO PBMC, compared with an incidence of
only 9% of baboon IgG (P < 0.01). The levels of IgG and
IgM binding of all three species are shown in Fig. 4. Fur-
thermore, whereas approximately 50% of both human
and baboon sera demonstrated cytotoxic antibodies
against GT-KO PBMC, the incidence is 76% in monkey
sera (P < 0.01) (Fig. 5). These results suggest that mon-
keys may have stronger antibody-mediated cytotoxic
responses to GT-KO pig grafts than humans and
baboons.
In experimental settings, GT-KO organs have been
transplanted into im unsuppressed baboons; heterotopic
heart graft failure occurred after 2–6 months [11] and
recipients with life-supporting pig kidneys died from
complications of the regimen within 3 months, although
in some transplant kidney function continued [12].
Whereas anti-Gal antibodies could not have been part of
this rejection process, anti-nonGal antibodies could poss-
ibly have been involved. These findings are supported by
a study from Brandl et al. in an hDAF transgenic pig-to-
baboon heart transplantation model using the soluble Gal
saccharides to prevent anti-Gal antibody-mediated hyper-
acute rejection; this center reported that nonGal antibody
titers were increased, and this increase was associated with
the development of AHXR [9].
To our knowledg , there are no reports of transplanta-
tion of GT-KO organs or cells in cynomolgus monkeys.
However, there is an evidence that anti-nonGal antibodies
are associated with AHXR in cynomolgus monkeys; Lam et
al. [10] demonstrated that, when hDAF-transgenic pig
hearts were transplanted into cynomolgus monkeys under
the soluble Gal saccharide-based therapy (to adsorb or
‘neutralize’ anti-Gal antibodies), anti-nonGal antibody lev-
els increased in animals that rejected their grafts.
Although the identity of pig nonGal antigens still
remains uncertain [13], there is evidence that anti-N-glyco-
lylneuraminic acid antibodies, also known as Hanganutziu-
Deicher (HD) antibodies, are present in human serum
[8,14]. As pigs express N-glycolylneuraminic acid on their
cells, this may, in part, account for human anti-nonGal
antibody binding to GT-KO PBMC. However, as baboons
and monkeys express HD antigens themselves (like the
pig), anti-HD antibodies do not contribute to the anti-
nonGal antibod es found in hese nonhuman primates spe-
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detected in our studies compared with that in humans and
baboons cannot be fully explained, but it is probably rela-
ted to differences in the microbial flora that populate the
gastro-intestinal tract or to other infectious agents to which
these various species have been exposed. Also, the age and
geographic origin, and whether wild-caught or captive-
bred, of the monkeys from which sera were drawn may
have played a role in this [15–17], but unfortunately this
information was not available to us for sufficient monkeys
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Figure 2 (a) Ability of individual monkey serum samples at 12.5%
dilution to cause lysis of PBMC from WT or GT-KO pigs; mean com-
plement-dependent cytotoxicity is indicated by lines. Significantly,
higher lysis of unmodified (WT) PBMC was observed (P < 0.01). (b)
Mean cytotoxicity of monkey serum samples (at various dilutions)
against PBMC from either WT or GT-KO pigs.
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One possible limitation of our study is that only
PBMCs were used as target cells, whereas vascular endot-
helial cells might have provided different, or more biolo-
gically relevant, nonGal epitopes, although there is no
definite evidence for this. We are currently investigating
whether there are differences between antipig antibody
binding and cytotoxicity to PBMC and vascular endothel-
ial cells; preliminary results suggest that there is little dif-
ference and, indeed, binding to PBMC may be higher
(H. Hara et al., unpublished data, Starzl Transplantation
Institute, Pittsburgh, USA). Furthermore, although PBMC
were drawn from WT pigs from the same herd and from
GT-KO pigs from three closely-related clones, neither WT
nor GT-KO PBMC were pooled; the possibility of variable
Gal and nonGal epitope expression between the PBMC
cannot be ruled out, although this is likely to have been
minor.
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monkey sera that we report here (P < 0.01). Both human
and monkey sera showed an incidence of 67% IgG bind-
ing to GT-KO PBMC, compared with an incidence of
only 9% of baboon IgG (P < 0.01). The levels of IgG and
IgM binding of all three species are shown in Fig. 4. Fur-
thermore, whereas approximately 50% of both human
and baboon sera demonstrated cytotoxic antibodies
against GT-KO PBMC, the incidence is 76% in monkey
sera (P < 0.01) (Fig. 5). These results suggest that mon-
keys may have stronger antibody-mediated cytotoxic
responses to GT-KO pig grafts than humans and
baboons.
In experimental settings, GT-KO organs have been
transplanted into immunsuppressed baboons; heterotopic
heart graft failure occurred after 2–6 months [11] and
recipients with life-supporting pig kidneys died from
complications of the regimen within 3 months, although
in some transplant kidney function continued [12].
Whereas anti-Gal antibodies could not have been part of
this rejection process, anti-nonGal antibodies could poss-
ibly have been involved. These findings are supported by
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baboon heart transplantation model using the soluble Gal
saccharides to prevent anti-Gal antibody-mediated hyper-
acute rejection; this center reported that nonGal antibody
titers were increa ed, and this increase was associated with
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However, there is an evidence that anti-nonGal antibodies
are associated with AHXR in cynomolgus monkeys; Lam et
al. [10] demonstrated that, when hDAF-transgenic pig
hearts were transplanted into cynomolgus monkeys under
the soluble Gal saccharide-based therapy (to adsorb or
‘neutraliz ’ anti-Gal antibodies), anti-nonGal antibody l v-
els increased in animals that rejected th ir grafts.
Although the identity of pig nonGal antigens still
remains uncertain [13], there is evidence that anti-N-glyco-
lylneuraminic acid antibodies, also known as Hanganutziu-
Deicher (HD) antibodies, are present in human serum
[8,14]. As pigs express N-glycolylneuraminic acid on their
cells, this may, in part, account for hum anti-nonGal
antibody binding to GT-KO PBMC. However, as baboons
and monkeys express HD antigens themselves (like the
pig), anti-HD antibodies do no contribute to the anti-
nonGal a tibodies found in these nonhuman primates spe-
cies. The higher level of anti-nonGal IgM in monkeys
detected in our studies compared with that in humans and
baboons cannot be fully explained, but it is probably rela-
ted to differences in the microbial flora that populate the
gastro-intestinal tract or to other infectious agents to which
these various species have been exposed. Also, the age and
geographic origin, and whether wild-caught or captive-
bred, of he monkeys from which sera were drawn may
have played a role in this [15–17], but unf rtunately this
information was not available t us fo sufficient onkeys
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Figure 2 (a) Ability of individual monkey serum samples at 12.5%
dilution to cause lysis of PBMC from WT or GT-KO pigs; mean com-
plement-dependent cytotoxicity is indicated by lines. Significantly,
higher lysis of unmodified (WT) PBMC was observed (P < 0.01). (b)
Mean cytotoxicity of monkey serum samples (at various dilutions)
against PBMC from either WT or GT-KO pigs.
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concentration) (p<0.02) (Figure 3). However, no statistically significant correlation between 
IgG binding and cytotoxicity to WT or GT-KO PBMC was observed (Figure 3).
DISCUSSION
The incidence of binding of monkey serum IgM and IgG isotypes to PBMC from GT-KO pigs 
was significantly less when compared to binding to WT PBMC.  However, we demonstrated 
that 76% of the tested monkey sera caused lysis of GT-KO PBMC (compared to 100% 
lysis of WT PBMC), although, the extent of cell lysis associated with anti-nonGal antibodies 
was significantly less. Even though this confirms the potential advantage of using GT-KO 
donor pigs for transplantation into cynomolgus monkeys, nevertheless approximately three 
quarters of the monkeys had IgM with or without IgG binding to GT-KO PBMC; as these 
to draw conclusions in this respect. The target(s) for these
anti-nonGal antibodies needs to be ascertained.
The observed differences in the levels of anti-nonGal
IgM and IgG and cytotoxicity between the species may
be, at least in part, related to the relatively small numbers
in each group. A study involving sera from larger num-
bers of each species may find less variation. A factor that
must also be considered is the isotypes of anti-nonGal
IgG in the three s ecies, which we did not explore.
Although not identified in this study, the ability of the
IgG isotype to activate complement may have been an
important factor in the correlation between antibody and
cytotoxicity. However, if monkeys are confirmed to have
higher levels of anti-nonGal IgM, this may be associated
with a higher incidence of hyperacute rejection of a trans-
planted pig organ than in either baboons or humans.
In addition to this potential role in the rejection of
GT-KO pig organs, anti-nonGal antib dies may also be
important following the adult pig islet transplantation in
primates. As adult pig islets are known to express little or
no Gal [18–21], anti-nonGal antibodies are likely to be
involved in any antibody-mediated rejection process [22–
24].
It has sometimes been considered that the baboon is a
more difficult preclinical model of xenotransplantation
than the macaque monkey. Our data suggest that anti-
body-mediated xenograft rejection of GT-KO pig organs
or cells may be more vigorous in cynomolgus monkeys
than in baboons or humans. With regard to the cytotox-
icity associated with anti-nonGal antibody binding, the
baboon may be closer to the human than the cynomolgus
monkey, and therefore may be the preferred experimental
recipient of GT-KO pig grafts.
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Figure 3 Linear regression of monkey serum cytotoxicity (at 12.5% serum concentration) and immunoglobulin isotype binding to (a) WT and (b)
GT-KO PBMC (n ¼ 21). Correlations were found between IgM binding (top) to both WT and GT-KO PBMC and cytotoxicity; no statistically signifi-
cant correlation was observed between IgG binding (bottom) to WT and GT-KO PBMC and cytotoxicity.
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igure 3:
Linear regression of  monkey serum cytotoxicity (at 12.5% serum concentration) and 
immunoglobulin isotype binding to (A) WT and (B) GT-KO PBMC (n=21). Correlations 
were found between IgM binding (top) to both WT and GT-KO PBMC and cytotoxicity; no 
statistically significant correlation was observed between IgG binding (bottom) to WT and 
G -KO PBMC and cyto oxicity. 
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anti-nonGal antibodies are cytotoxic, they are likely to be associated with the development 
of AHXR.  
One possible limitation of our study is that only PBMC were used as target cells, whereas 
vascular endothelial cells might have provided different, or more biologically relevant, nonGal 
epitopes, although there is no definite evidence for this.  We are currently investigating 
whether there are differences between anti-pig antibody binding and cytotoxicity to PBMC 
and vascular endothelial cells; preliminary results suggest that there is little difference and, 
indeed, binding to PBMC may be higher (Hara H, et al, unpublished data).  Furthermore, 
although PBMC were drawn from WT pigs from the same herd and from GT-KO pigs from 
three closely-related clones, neither WT nor GT-KO PBMC were pooled; the possibility 
of variable Gal and nonGal epitope expression between the PBMC cannot be ruled out, 
although this is likely to have been minor.
In other studies by our group, 43% of human (preliminary data, Hara H.) and 32% of baboon 
(Ezzelarab M, et al, manuscript submitted) sera were demonstrated to have IgM binding to 
GT-KO PBMC, which is significantly less than the 76% IgM binding of cynomolgus monkey 
sera that we report here (p<0.01). Both human and monkey sera showed an incidence of 
67% IgG binding to GT-KO PBMC, compared to an incidence of only 9% of baboon IgG 
(p<0.01). The levels of IgG and IgM binding of all three species are shown in Figure 4. 
Furthermore, whereas approximately 50% of both human and baboon sera demonstrated 
cytotoxic antibodies against GT-KO PBMC, the incidence is 76% in monkey sera (p<0.01) 
was performed under a Sponsored Research Agreement
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Figure 5 Comparison of mean cytotoxicity of human (n ¼ 21),
baboon (n ¼ 39), and monkey (n ¼ 19) serum samples against PBMC
from either WT (top) or GT-KO (bottom) pigs.
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Figure 4 Comparison of binding of human, baboon, and cynomolgus
monkey preformed xenoreactive antibodies to WT and GT-KO pig
PBMC. Mean reactivities of human (n ¼ 21), baboon (n ¼ 56), and
monkey (n ¼ 21) sera against WT or GT-KO PBMC are shown, IgM
(top) and IgG (bottom).
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(Figure 5). These results suggest that monkeys may have stronger antibody-mediated 
cytotoxic responses to GT-KO pig grafts than humans and baboons.
In experimental settings, GT-KO organs have been transplanted into immunsuppressed 
baboons; heterotopic heart graft failure occurred after 2-6 months (11) and recipients with 
life-supporting pig kidneys died from complications of the regimen within 3 months, although 
in some transplant kidney function continued (12).  Whereas anti-Gal antibodies could not 
have been part of this rejection process, anti-nonGal antibodies could possibly have been 
involved. These findings are supported by a study from Brandl et al. in an hDAF transgenic 
pig-to-baboon heart transplantation model using soluble Gal saccharides to prevent anti-
Gal antibody-mediated hyperacute rejection; this center reported that nonGal antibody titers 
were increased, and this increase was associated with the development of AHXR (9). 
To our knowledge, there are no reports of transplantation of GT-KO organs or cells in 
cynomolgus monkeys. However, there is evidence that anti-nonGal antibodies are associated 
with AHXR in cynomolgus monkeys; Lam et al. demonstrated that, when hDAF-transgenic 
pig hearts were transplanted into cynomolgus monkeys under soluble Gal saccharide-based 
therapy (to adsorb or ‘neutralize’ anti-Gal antibodies), anti-nonGal antibody levels increased 
in animals that rejected their grafts (10).
Although the identity of pig nonGal antigens still remains uncertain (13), there is evidence 
that anti-N-glycolylneuraminic acid antibodies, also known as Hanganutziu-Deicher (HD) 
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antibodies, are present in human serum (8, 14). Since pigs express N-glycolylneuraminic 
acid on their cells, this may, in part, account for human anti-nonGal antibody binding to GT-
KO PBMC. However, since baboons and monkeys express HD antigens themselves (like 
the pig), anti-HD antibodies do not contribute to the anti-nonGal antibodies found in these 
nonhuman primates species.  The higher level of anti-nonGal IgM in monkeys detected in 
our studies compared to that in humans and baboons cannot be fully explained, but it is 
probably related to differences in the microbial flora that populate the gastro-intestinal tract 
or to other infectious agents to which these various species have been exposed. Also the 
age, geographic origin, and whether wild-caught or captive-bred, of the monkeys from which 
sera were drawn may have played a role in this (15-17), but unfortunately this information 
was not available to us for sufficient monkeys to draw conclusions in this respect.  The 
target(s) for these antibodies needs to be ascertained.
The observed differences in the levels of anti-nonGal IgM and IgG and cytotoxicity between 
the species may be, at least in part, related to the relatively small numbers in each group.  A 
study involving sera from larger numbers of each species may find less variation.  A factor 
that must also be considered is the isotypes of anti-nonGal IgG in the three species, which 
we did not explore.  Although not identified in this study, the ability of the IgG isotype to 
activate complement may have been an important factor in the correlation between antibody 
and cytotoxicity. However, if monkeys are confirmed to have higher levels of anti-nonGal 
IgM, this may be associated with a higher incidence of hyperacute rejection of a transplanted 
pig organ than in either baboons or humans.  
In addition to this potential role in the rejection of GT-KO pig organs, anti-nonGal antibodies 
may also be important following adult pig islet transplantation in primates. As adult pig islets 
are known to express little or no Gal (18-21); anti-nonGal antibodies are likely to be involved 
in any antibody-mediated rejection process (22-24). 
It has sometimes been considered that the baboon is a more difficult preclinical model of 
xenotransplantation than the macaque monkey. Our data suggest that antibody-mediated 
xenograft rejection of GT-KO pig organs or cells may be more vigorous in cynomolgus 
monkeys than in baboons or humans. With regard to the cytotoxicity associated with anti-
nonGal antibody binding, the baboon may be closer to the human than the cynomolgus 
monkey, and therefore may be the preferred experimental recipient of GT-KO pig grafts.
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ABSTRACT
If an ABO-incompatible heart is transplanted into an infant before natural antibodies have 
developed to the specific donor carbohydrate A/B antigen(s), then B cell tolerance to the 
donor A/B antigen is achieved, and these antibodies never develop.  Anti-carbohydrate 
antibodies play a role in the rejection of wild-type (WT) and α1,3-galactosyltransferase gene-
knockout (GT-KO) pig xenografts. We investigated development of these antibodies in infant 
baboons and humans. Serum samples from infant baboons (n=42) and humans (n=42) 
were tested by flow cytometry for IgM and IgG binding to peripheral blood mononuclear 
cells (PBMC) from WT and GT-KO pigs, and for complement-dependent cytotoxicity. The 
presence of anti-blood group antibodies was tested in baboon serum. In infant baboons and 
humans, cytotoxic anti-Galα1,3Gal antibodies develop during the first 3 months, and steadily 
increase with age, whereas cytotoxic anti-nonGal antibodies are either absent or minimal in 
the majority of cases throughout the first year of life. Anti-blood group antibodies were not 
detected before 16 weeks of age. Our data suggest GT-KO pig organ/cell transplants could 
be carried out in early infancy in the absence of preformed cytotoxic anti-nonGalα1,3Gal 
antibodies.
INTRODUCTION
There is a critical shortage of human organs for transplantation, particularly in infants requiring 
heart transplants. The Toronto group has utilized hearts from ABO blood group-incompatible 
donors to overcome the high mortality in infants waiting for a donor heart (1). They have 
demonstrated that ‘natural’ anti-A or anti-B antibodies (Abs) take several weeks or months to 
develop in infants and that, if an ABO-incompatible heart transplant is performed before the 
development of such Abs, then these Abs never develop (2). They have demonstrated that 
B cell tolerance to the specific A and/or B antigen can be achieved in infants who receive 
immunosuppressive therapy directed only against the T cell response, which is essentially 
similar to that used for ABO-compatible transplant recipients.   
The mechanism by which the primate immune system responds to ABO carbohydrate 
antigens is believed to be similar to that governing the response to carbohydrate antigens 
expressed by xenogeneic tissues from genetically-distant species, such as swine (3). This 
opens the possibility that, if a pig organ is transplanted into an infant before the development 
of anti-pig Abs, then a state of B cell tolerance to pig carbohydrate antigens may result. 
The Toronto group’s work has therefore suggested a method by which the development 
of natural anti-pig Abs could be prevented.  Since an immunosuppressive regimen based 
on a combination of an anti-CD154 monoclonal Ab and mycophenolate mofetil has been 
demonstrated to prevent the T cell-dependent elicited Ab response in pig-to-baboon organ 
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and cell transplant models (4-8), pig organ transplantation could theoretically be carried out 
in infants in the absence of all (natural and elicited) Abs directed to pig antigens.
Natural anti-pig Abs develop in humans during the first few months of life, apparently as 
a response to colonization of the gastrointestinal tract by various microorganisms (9). 
Natural Abs against wild-type (WT) pigs include both those directed to Galα1,3Gal (Gal) 
antigens and those directed to other unidentified antigens, referred to as nonGal; these 
may be carbohydrate or protein antigens.  In contrast, GT-KO pigs express only nonGal 
antigens.  The majority of primate anti-pig Abs are directed to Gal epitopes on the WT pig 
vascular endothelium and certain other tissues (10-13), and which are also present on 
various bacteria and viruses (9).  In nonhuman primates and humans, binding of anti-pig 
Abs, particularly anti-Gal Abs, to transplanted pig organs results in complement activation 
and hyperacute rejection. 
The problem of anti-Gal Abs has been overcome by the generation of pigs homozygous 
for α1,3-galactosyltransferase gene-knockout (GT-KO), which renders them incapable of 
producing the Gal oligosaccharide (14, 15).  However, other preformed anti-pig Abs directed 
to nonGal antigens are present in approximately 50% of adult humans and Old World 
nonhuman primates (16), and are cytotoxic to pig cells, and may result in a delayed form 
of Ab-mediated rejection known as acute humoral xenograft rejection (5, 6, 17).  A method 
of preventing the development of natural anti-pig Abs would therefore greatly enhance the 
prospect of successful pig organ transplantation in primates since it would negate the injury 
caused by such Abs.
The presence of anti-Gal Abs in newborn baboons was initially investigated several years 
ago (18-23).  Only maternal IgG was present in the tested serum samples from neonates. 
Although the transplantation of an unmodified WT pig organ into an untreated baboon during 
the first few weeks of life rapidly led to the development of elicited anti-Gal IgG that caused 
AHXR, the absence of preformed anti-Gal IgM meant that hyperacute rejection did not occur. 
These studies therefore suggested that the transplantation of a WT pig organ very early in 
life, in the presence of no, or only low levels of, anti-pig IgM, is associated with an absence 
of hyperacute rejection. 
However, little is known about the rate of development of anti-pig Abs in the first year of life, 
particularly in regard to anti-nonGal Abs.  We have investigated the development of anti-pig 
Abs, and specifically anti-nonGal Abs, in both infant baboons and humans, and we address 
the implications that our findings may have for pig organ transplantation into newborns. We 
hypothesized that infant humans and baboons would not have significant levels of anti-pig 
Abs in the first few months of life, and that anti-nonGal Abs may increase at a slower rate 
during the first year of life. We also hypothesized that the pattern of change between infant 
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humans and baboons would correlate such that baboons would be considered a suitable 
surrogate for humans in preclinical studies.
MATERIALS AND METHODS
Sources of Serum
Humans
Serum samples (n=42) from humans (age <1-64 weeks) were from patients being assessed 
for a variety of reasons, including cardiac surgical procedures (Loma Linda University, Loma 
Linda, CA, and University of Alberta, Edmonton, Canada). Samples were tested for IgM and 
IgG binding to GT-KO (n=42) and WT (n=33) pig peripheral blood mononuclear cells (PBMC) 
by flow cytometry, and 41 samples were tested for cytotoxicity. 
The Edmonton Health Research Ethics Board required documentation of informed consent 
prior to acquisition of infant serum samples, and this was accomplished.  Because of the 
following caveat, the Loma Linda Institutional Review Board deemed that the need for 
consent from parents or legal guardians was unnecessary.  Loma Linda human serum 
samples, obtained for clinical purposes other than this research, were identified and 
salvaged (before being discarded) by assigned third-party laboratory technicians. Samples 
were labeled on the basis of donor age alone, before delivery to the principal investigators. 
Hence, patient identity and right to know would not be violated or traceable. This represents 
a well-considered difference of opinion between the two human studies review boards, and 
is not germane to the present study.
Baboons
Serum samples (n=56) were collected from 42 baboons (age 6-70 weeks) (OUHSC, 
Oklahoma City, OK).  Forty samples were from 26 colony-raised infant baboons, of which 14 
were tested a second time (23 weeks after the first sampling).  The other 16 samples were 
from baboons maintained under specific pathogen-free (SPF) conditions.  All initial serum 
samples were tested for IgM and IgG binding to WT and GT-KO pig PBMC by flow cytometry 
and for complement-dependent cytotoxicity, but the 14 samples retested after 23 weeks 
were tested only for cytotoxicity. 
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and 
Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health (NIH publication No. 86-23, revised 1985). 
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Sources and Isolation of Porcine PBMC
To detect the presence of anti-pig (Gal+nonGal) and anti-nonGal Abs in these sera, PBMC 
were collected from the blood of a single WT and a single GT-KO (14) pig, to avoid variability 
between different WT and GT-KO pig cells. Both were of Large White/Landrace/Duroc cross-
breed (Revivicor, Blacksburg, VA).  (Several studies in our laboratory have demonstrated that 
there is little variability in IgM/IgG binding and serum cytotoxicity to PBMC from different pigs 
from the same source.)  The PBMC were used as targets in flow cytometry and cytotoxicity 
assays.  The GT-KO pigs differed from the WT pigs only with regard to the absence of Gal 
epitopes (14). Isolation of PBMC was performed by gravity centrifugation, as previously 
described (16).
 Flow Cytometry
IgM and IgG binding to WT and GT-KO PBMC was determined by flow cytometry, as 
previously described (16). Briefly, isolated PBMC were resuspended in FACS-buffer (PBS 
containing 1% bovine serum albumin [Gibco, Grand Island, NY,USA] and 0.1% NaN3) to 
a final cell concentration of 12.5x106 cells/mL. One million PBMC were then removed and 
incubated with 20μL of heat-inactivated primate serum (at 56°C for 30min), diluted in FACS 
buffer to 20% serum final concentration, for 30min at 4˚C.  After incubation, the cells were 
washed twice in 2mL FACS buffer, vortexed and centrifuged at 1800rpm (700g) for 5min. Cells 
were then resuspended in 10µL of 10% goat serum in FACS buffer, to prevent non-specific 
binding, and incubated further with 10μL fluorescein isothiocyanate (FITC)-conjugated goat 
anti-human IgG (γ chain-specific) at 1:50 dilution, or with IgM (μ chain-specific) at 1:200 
dilution, (Zymed Laboratories, San Francisco, CA) for 30min in the dark at 4˚C. Antibodies 
bound to live cells were analyzed using FACScan (Becton Dickinson, Mountain View, CA). 
Dead cells were excluded from the analysis by forward-scatter and propidium iodide staining 
(10μL added to each sample prior to FACS analysis). The mean fluorescence intensity (MFI) 
reading of binding strength correlates with the level of Ab in the serum samples. The high 
number of samples necessitated the flow cytometry experiments to be carried out in different 
batches on different days. In order to correct for differences in isotype controls on different 
days, we used an index.  The MFI reading of the experimental sample was divided by that 
of the (isotype) control sample for that individual batch. The isotype control consisted of the 
MFI reading of PBMC stained with FITC IgM and IgG only, without the addition of serum. 
Whenever the index was >1.1, the sample was considered positive. We classified serum 
samples to have minimal binding (index 1.1-1.5), mild-to-moderate binding (index 1.5-2.5), 
or strong binding (index >2.5). 
51Chromium-release Complement-dependent Cytotoxicity Assay
The complement-dependent cytotoxicity assay measured serum cytotoxicity of PBMC 
that were labeled with 51chromium (51Cr). The three components (serum + complement + 
target cell) were mixed in microtiter-plate wells, and lysis of the target cells was detected by 
measuring the release of 51Cr radioactivity into the cell supernatant.  
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Briefly, 51Cr-labeled target cells were prepared from PBMC that were washed with PBS and 
centrifuged for 4min at 4˚C.  The supernatant was removed, the pellet was resuspended 
with 40μL of 10% FBS, and each 1x106 PBMC was incubated with 51Cr of 50μCi for 60min 
at 37˚C.  Serum samples were incubated for 30min at 56˚C to inactivate complement. The 
samples were four-fold serially diluted with MLR medium (RPMI 1640 media [Gibco] +10% 
FBS) to final concentrations of 25%, 6.0%, 1.5%, and 0.3%.  As an interplate control, pooled 
sensitized human serum was also diluted in this manner and used on all plates. On a round-
bottomed 96-well plate, 0.01x106 51Cr-labeled cells (suspended in 80μL MLR medium) were 
loaded into each well, and incubated with 80μL of diluted serum for 30min at 4°C. After 
incubation, the cells were further incubated with 40μL of 10% rabbit HLA-ABC serum (Sigma, 
St. Louis, MO, USA), as a source of complement, for 45min at 37°C. 
Minimal killing controls (100% live cells) were achieved by adding 80μL MLR medium or 
complement to wells containing cells without serum. Maximal killing controls (0% live cells) 
were achieved by adding detergent (5% (v/v)Triton X-100; Sigma) to wells containing cells 
without serum. 
Following incubation, the cells were centrifuged at 300-400rpm (35g) for 4min. The supernatant 
containing 51Cr released from lysed cells was harvested using the MacrowellTM Tube Strips 
collection system (Molecular Devices, Sunnyvale, CA). Cell killing was assessed by reading 
the 51Cr released from lysed cells using a gamma irradiation counter (INC Biomedical, Costa 
Mesa, CA).
Cell killing was calculated using the following formula:
% cytotoxicity = [(A-C)/(B-C)] x 100,
where A equals the count per minute of sample dead cells (+ serum and complement), B 
equals the count per minute of maximal dead cells (+ detergent), and C equals the count per 
minute of minimal dead cells (+ complement only).  
Complement-dependent cytotoxicity values of the varying serum concentrations (25%, 6.0%, 
1.5%, and 0.3%) were calculated, and a curve was generated for each sample. Results were 
considered acceptable based on the slope of a curve generated by a graded concentration 
of human control serum that was added to every plate. Lysis of <10% was considered of 
doubtful significance.
ABO Blood Typing of Baboons by Buccal Mucosal Smear and Hemagglutination 
Assay for Anti-A/B Antibodies in Baboon Serum
ABH phenotyping of buccal mucosal smears was accomplished in baboons by 
immunohistochemical staining, and presence of anti-A/B antibodies in baboon serum was 
determined by hemagglutination assay, as previously described (24, 25).  
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lyzed cells was harvested using the MacrowellTM Tube
Strips collection system (Molecular Devices, Sunnyvale,
CA, USA). Cell killing was assessed by reading the 51Cr
released from lyzed cells using a gamma irradiation coun-
ter (INC Biomedical, Costa Mesa, CA, USA).
Cell killing was calculated using the following formula:
% cytotoxicity ¼ ½ðA� CÞ=ðB� CÞ� � 100;
where A equals the count per minute of sample dead cells
(+ serum and complement), B equals the count per min-
ute of maximal dead cells (+ detergent), and C equals the
count per minute of minimal dead cells (+ complement
only).
Complement-dependent cytotoxicity values of the vary-
ing serum concentrations (25%, 6.0%, 1.5%, and 0.3%)
were calculated, and a curve was generated for each sam-
ple. Results were considered acceptable based on the slope
of a curve generated by a graded concentration of human
control serum that was added to every plate. Lysis of
<10% was considered of doubtful significance.
ABO blood typing of baboons by buccal mucosal smear
and hemagglutination assay for anti-A/B antibodies
in baboon serum
Blood group antigen (ABH) phenotyping of buccal muco-
sal smears was accomplished in baboons by immunohis-
tochemical staining, and presence of anti-A/B antibodies
in baboon serum was determined by hemagglutination
assay, as previously described [24,25].
Statistical analysis
Analysis of indirect immunofluorescence intensity was
accomplished by cell quest software and converted into
MFI by winmdi software. Statistical analyses were per-
formed using tests for paired data: the Wilcoxon signed
rank test for comparison of medians and the McNemar
test for comparison of proportions. Correlation of MFI or
cytotoxicity with age was assessed by linear regression
analysis. Statistics were calculated using prism-4 software
(Graphpad Software, San Diego, CA, USA) and spss 14.0
for Windows (SPSS, Chicago, IL, USA) and P-values were
compared with the 95% level of significance.
Results
Binding of infant human and baboon serum IgM
and IgG to pig PBMC by flow cytometry
We studied serum samples of infant humans (n = 42)
and infant baboons (n = 56) by flow cytometry for IgM
and IgG binding to WT and GT-KO PBMC.
Humans
IgM binding to WT PBMC was seen as early as 1 week of
age, and binding increased with age, though not signifi-
cantly (P = 0.073) (Fig. 1a). No or only minimal IgM
binding to GT-KO PBMC was seen during the first
30 weeks, and the level of anti-nonGal Abs remained low
throughout the first year, with no correlation with age
(P = 0.129) (Fig. 1a). Binding of IgM to WT and GT-KO
cells is documented in Table 1. IgM binding to both WT
and GT-KO PBMC was lower than in baboons (see
below), which was consistent with cytotoxicity findings
(see below, Fig. 3).
The level of IgG binding to WT PBMC in neonates
was high, and decreased during the course of the next
few weeks and months, although this fall was not signifi-
cant (P = 0.381) (Fig. 1b). (These high IgG levels seen
soon after birth were likely due to maternal IgG.) In con-
trast, the level of IgG binding to GT-KO PBMC was low
in neonates (not significantly different from isotype con-
trol), but increased with age during the first year of life
(P = 0.021), although binding remained low.
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Figure 1 Binding of infant human (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample]. (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P = 0.073, r = 0.316; versus GT-KO, P = 0.129, r = 0.238). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.381, r = )0.158; versus GT-KO, P = 0.021,
r = 0.356).
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lyzed cells was harvested using the MacrowellTM Tube
Strips collection system (Molecular Devices, Sunnyvale,
CA, USA). Cell killing was assessed by reading the 51Cr
released from lyzed cells using a gamma irradiation coun-
ter (INC Biomedical, osta Mesa, CA, USA).
Cell killing was calculated using the following formula:
% cytotoxicity ¼ ½ðA� CÞ=ðB� CÞ� � 100;
where A equals the count per minute of sample dead cells
(+ serum and complement), B equals the count per min-
ute of maximal dead cells (+ detergent), and C equals the
count per minute of minimal dead cells (+ complement
only).
Complement-dependent cytotoxicity values of the vary-
ing serum concentrations (25%, 6.0%, 1.5%, and 0.3%)
were calculated, and a curve was generated for each sam-
ple. Results were considered acceptable based o the slope
of a curve generated by a graded concentration of human
control serum that was added to every plate. Lysis of
<10% was considered of doubtful significance.
ABO blood typing of baboons by buccal mucosal smear
and hemagglutination assay for anti-A/B antibodies
in baboon serum
Blood group antigen (ABH) phenotyping of buccal muc -
s l smears was accomplished in babo ns by immunohis-
tochemical staini g, and presence of anti-A/B a tibodies
in baboon serum was determined by hemagglutination
assay, as previously described [ 4,25].
Statistical analysis
Analysis of indirect immunofluorescence intensity was
accomplished by cell quest software and converted into
MFI by winmdi software. Statistical analyses were per-
formed using tests for paired data: the Wilcoxon signed
rank test for comparison of medians and the McNemar
test for comp rison of proportions. Correlation of MFI or
cytotoxicity with age was assessed by linear regression
analysis. Statistics were calculated using prism-4 software
(Graphpad Software, San Diego, CA, USA) and spss 14.0
for Windows (SPSS, Chicago, IL, USA) and P-values were
compar d with the 95% level of significance.
Results
Binding of infant human and baboon serum IgM
and IgG to pig PBMC by flow cytometry
We studi d serum samples of infant humans (n = 42)
and infant baboons (n = 56) by flow cytometry for IgM
and IgG binding to WT and GT-KO PBMC.
Humans
IgM binding to WT PBMC was seen as early as 1 week of
age, and binding increased with age, though not signifi-
cantly (P = 0.073) (Fig. 1a). No or only minimal IgM
binding to GT-KO PBMC was seen during the first
30 weeks, and the level of anti-nonGal Abs remained low
throughout the first year, with no correlation with age
(P = 0.129) (Fig. 1a). Binding of IgM to WT and GT-KO
cells is documented in Table 1. IgM binding to both WT
and GT-KO PBMC was lower than in baboons (see
below), which was consistent with cytotoxicity findings
(see below, Fig. 3).
The level of IgG binding to WT PBMC in neonates
was high, nd decreased during the course of the next
few weeks and months, although this fall was not signifi-
cant (P = 0.381) (Fig. 1b). (These high IgG levels seen
soon after birth were likely due to maternal IgG.) In con-
trast, the level of IgG binding to GT-KO PBMC was low
in eonates (not significantly different from isotype con-
trol), but i creas d with age during the first year of life
(P = 0.021), although binding remained low.
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Figure 1 Binding of infant human (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample]. (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P = 0.073, r = 0.316; versus GT-KO, P = 0.129, r = 0.238). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.381, r = )0.158; versus GT-KO, P = 0.021,
r = 0.356).
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Statistical Analysis
Analysis of indirect immunofluorescence intensity was accomplished by Cell Quest software 
and converted into MFI by WinMDI software. Statistical analyses were performed using tests 
for paire  data: Wilcoxon sign d r nk test for comparison of medians and McNemar’s test 
for comparison of proportions. Correlation of MFI or cytotoxicity with age was assessed 
by linear regression analysis. Statistics were calculated using prism-4 software (Graphpad 
Software, San Diego, CA) and SPSS 14.0 for Windows (SPSS, Chicago, IL) and p-values 
we e compared o he 95% level of significance. 
RESULTS
Binding of Infant Human and Baboon Serum IgM and IgG to Pig PBMC by Flow 
Cytometry
We studied serum samples of infant humans ( =42) and infant baboons (n=56) by flow 
cytometry for IgM and IgG binding to WT and GT-KO PBMC.
Figure 1:
Binding of  infant human (n=42) serum Abs to WT and GT-KO pig 
PB C. (MFI index = mean fluorescence intensity of  th  serum sample 
divided by the MFI of  the isotype control sample).  
(A) Distribution of  IgM reactivity against WT and GT-KO PBMC. 
Correlation f  MFI index with age of  each gro p is indicated by a line 
(versus WT, p=0.073, r=0.316; versus GT-KO, p=0.129, r=0.238).  
(B)  Distribution of  IgG reactivity against WT and GT-KO PBMC. 
Co relation of  MFI index with age of  each group is indicated by a line 
(versus WT, p=0.381, r= -0.158; versus GT-KO, p=0.021, r=0.356).   
lyzed cells was harvested using the MacrowellTM Tube
Strips collection system (Molecula Devices, Sunn vale,
CA, USA). Cell killing was assessed by reading the 51Cr
released from lyzed cells using a gamma irradiation coun-
ter (INC Biomedical, Costa Mesa, CA, USA).
Cell killing was calculated using the following formula:
% cytotoxicity ¼ ½ðA� CÞ=ðB� CÞ� � 100;
where A equals the count per minute of sample dead ells
(+ serum and complement), B equals the count per min-
ute of maximal dead cells (+ detergent), and C equals the
count per minute of minimal dead cells (+ complement
only).
Complement-dependent cytotoxicity values of th vary-
ing serum concentrations (25%, 6.0%, 1.5%, and 0.3%)
were calculated, and a curve was gen rated for each sam-
ple. Results were considered acceptable based on the slope
of a curve generated by a graded concentration of human
control serum that was added to every plate. Lysis of
<10% was considered of doubtful significance.
ABO blood typing of baboons by buccal mucosal smear
and hemagglutination assay for anti-A/B antibodies
in baboon serum
Blood group antigen (ABH) phenotyping of buccal muco-
sal smears was accomplished in baboons by immun his-
tochemical staining, and presence of ant -A/B a tibodies
in baboon serum was determined y hemaggl tination
assay, as previously described [24,25].
Statistical analysis
Analysis of indirect immunofluorescence inte s ty was
accomplished by cell quest software and converted into
MFI by winmdi software. Statistical analyses were per-
formed using tests for paired data: th Wilcoxon igned
rank test for comparison of medi s and the McNemar
test for comparison of proportions. Correlation of MFI or
cytotoxicity with age was assessed by linear regression
analysis. Statistics were calculated using prism-4 software
(Graphpad Software, San Diego, CA, USA) and spss 14.0
for Windows (SPSS, Chicago, IL, USA) a P-values were
compared with the 95% level of signific nce.
Results
Binding of infant human and baboon serum IgM
and IgG to pig PBMC by flow cytometry
We studied serum samples of infant human (n = 42)
and infant baboons (n = 56) by flow cytometry f r IgM
and IgG binding to WT and GT-KO PBMC.
Humans
IgM binding to WT PBMC was seen as early as 1 week f
ge, an indi g increased with , though not signifi-
cantly (P = 0.073) (Fig. 1a). No or only minimal IgM
binding to GT-KO PBMC was seen during the first
30 weeks, a d the level of ti-nonGal Abs remain d low
throughout the first year, with no correlation with ag
(P = 0.129) (Fig. a). Binding of IgM to WT and GT-KO
cells is documented in Table 1. IgM bin ing to both WT
and GT-KO PBMC was lower than in baboons (see
below), which was consistent with cytotoxicity findings
(se below, Fig. 3).
The leve of IgG binding to WT PBMC in neonates
was high, and decreased during the course of th next
few weeks and m nths, although this fall was not signifi-
cant (P = 0.381) (Fig. 1b). (These high IgG levels seen
soon after birth were likely due to maternal IgG.) In con-
trast, the level of IgG binding to GT-KO PBMC was low
in neonat s (not significa tly differe t from isotype con-
trol), but increased with age during the first year of life
(P = 0.021), lthough binding remaine low.
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Figure 1 Binding of infant human (n = 42) serum a tibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [me n flu rescence inte -
sity (MFI) index = mean fluorescence intensity of the seru sample
divided by the MFI of the isotype control sample]. (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P = 0.073, r = 0.316; versus GT-KO, P = 0.129, r = 0.238). (b)
Distribution of immunoglobulin G reactivity aga nst WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.381, r = )0.158; versus GT-KO, P = 0.021,
r = 0.356).
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Humans 
IgM binding to WT PBMC was seen as early as one week of age, and binding increased with 
age, though not significantly (p=0.073) (Figure 1a).  No or only minimal IgM binding to GT-
KO PBMC was seen during the first 30 weeks, and the level of anti-nonGal Abs remained low 
throughout the first year, with no correlation with age (p=0.129) (Figure 1a). Binding of IgM 
to WT and GT-KO cells is documented in Table 1. IgM binding to both WT and GT-KO PBMC 
was lower than in baboons (see below), which was consistent with cytotoxicity findings (see 
below, Figure 3).
In neonates (age <4 weeks, n = 6), in relation to iso-
type control, IgG binding to WT PBMC was increased up
to approximately four times, while binding to GT-KO
PBMC was minimal (Fig. 1b) (P = 0.046). The maternal
anti-pig IgG present in the sera of neonates would there-
fore appear to be almost entirely anti-Gal Ab.
Baboons
There was no or minimal IgM binding to WT PBMC (as
defined by MFI-index<1.5, see Materials and methods)
documented earlier than 10 weeks of age (n = 4), after
which the incidence and extent of binding steadily
increased with age (P < 0.001) (Fig. 2a). No or only min-
imal IgM binding to GT-KO PBMC was seen before
15 weeks, after which there was some increase, but the
extent of binding remained low throughout the first year,
and there was no correlation with age (P = 0.103)
(Fig. 2a). Binding of IgM to WT and GT-KO cells is doc-
umented in Table 1.
There was a slight increase in the level of IgG binding
to WT PBMC during the first year, though the increase
was not significant (P = 0.444) (Fig. 2b). The levels of
binding to GT-KO PBMC in most cases remained at the
level of the isotype control (MFI-index = 1), and there
was no correlation with age (P = 0.740). Binding is docu-
mented in Table 1.
Sera from colony-raised baboons (n = 26) and SPF
baboons (n = 16) were investigated separately. No signifi-
cant difference in IgM or IgG binding to either WT or
GT-KO pig PBMC was found using sera from these two
groups (data not shown), suggesting that anti-pig Ab for-
mation was not influenced by the SPF environment.
Cytotoxicity of infant human and baboon sera
to pig PBMC
The same serum samples were tested for complement-
dependent cytotoxicity against WT and GT-KO PBMC.
All samples showed a titration curve with reduction in
lysis with increasing dilution (not shown). To demon-
strate correlation of cytotoxicity with age, lysis (¼%
cytotoxicity) at a serum dilution of 25% is shown in
Fig. 3.
Humans
During the first year of life, 39% of infant human sera
were cytotoxic (>10% lysis) to PBMC from WT pigs,
whereas only 17% were cytotoxic to GT-KO PBMC
(P = 0.002) (Fig. 3a). The extent of GT-KO PBMC lysis
was significantly less than that of WT PBMC (median
percentage of lysis 0% vs. 6%, respectively, P = 0.001).
Lysis of WT PBMC increased significantly with age
(P = 0.023), but lysis of GT-KO PBMC (i.e. associ-
ated with anti-nonGal Abs) did not increase with
age (P = 0.803). The median lysis of GT-KO
PBMC throughout the entire first year was 0% (range
0–40%).
Baboons
During the first year of life, 67% of infant baboon sera
were cytotoxic (defined by >10% lysis) to PBMC from
Table 1. Strength of binding of infant baboon and human serum*
immunoglobulin M (IgM) and immunoglobulin G (IgG) to wild type
(WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells by flow cytometry.
Human (n = 42) Baboon (n = 42)
IgM IgG IgM IgG
WT GT-KO WT GT-KO WT GT-KO WT GT-KO
Strength of binding (%)
No binding 34 48 15 53 5 38 60 98
Minimal 15 48 24 38 28 52 17 0
Mild-to-moderate 30 4 40 7 50 10 21 2
Strong 21 0 21 2 17 0 2 0
*Drawn at various times during the first year of life.
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Figure 2 Binding of infant baboon (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample.] (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P < 0.001, r = 0.665; versus GT-KO, P = 0.103, r = 0.255). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.444, r = 0.121; versus GT-KO, P = 0.740,
r = 0.053).
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le 1: 
Strength of  binding of  infant baboon and human 
serum* IgM and IgG to WT and GT-KO PBMC by flow 
cytometry
The level of IgG binding to WT PBMC in neonates  was high, and decreased during the 
course of the next few weeks and months, although this fall was not significant (p=0.381) 
(Figure 1b). (These high IgG levels seen soon after birth were likely due to maternal IgG.) 
In contrast, the level of IgG binding to GT-KO PBMC was low in neonates (not significan ly 
different from isotype control), but increased with age during the first year of life (p=0.021), 
although binding remained low.  
In neonates  (age <4 weeks, n=6), in relation to isotype control, IgG binding to WT PBMC 
was increased up to approximately four times, while binding to GT-KO PBMC was minimal 
(Figure 1b) (p=0.046). The maternal anti-pig IgG present in the sera of neonates would 
therefore appear to be almost entirely anti-Gal Ab.  
Baboons 
There was no or minimal IgM binding to WT PBMC (as defined by MFI-index<1.5, ee 
Materials and Methods) documented earlier than 10 weeks of age (n=4), after which the 
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incidence and extent of binding steadily increased with age (p<0.001) (Figure 2a).  No or 
only minimal IgM binding to GT-KO PBMC was seen before 15 weeks, after which there was 
some increase, but the extent of binding remained low throughout the first year, and there 
was no correlation with age (p=0.103) (Figure 2a).  Binding of IgM to WT and GT-KO cells 
is documented in Table 1.  
There was a slight increase in the level of IgG binding to WT PBMC during the first year, 
though the increase was not significant (p=0.444) (Figure 2b). The levels of binding to GT-
KO PBMC in most cases remained at the level of the isotype control (MFI-index =1), and 
there was no correlation with age (p=0.740). Binding is documented in Table 1.
In neonates (age <4 weeks, n = 6), in relation to iso-
type control, IgG binding to WT PBMC was increased up
to approximately four times, while binding to GT-KO
PBMC was minimal (Fig. 1b) (P = 0.046). The maternal
anti-pig IgG present in the sera of neonates would there-
fore appear to be almost entirely anti-Gal Ab.
Baboons
There was no or minimal IgM binding to WT PBMC (as
defined by MFI-index<1.5, see Materials and methods)
documented earlier than 10 weeks of age (n = 4), after
which the incidence and extent of binding steadily
increased with age (P < 0.001) (Fig. 2a). No or only min-
imal IgM binding to GT-KO PBMC was seen before
15 weeks, after which there was some increase, but the
extent of binding remained low throughout the first year,
and there was no correlation with age (P = 0.103)
(Fig. 2a). Binding of IgM to WT and GT-KO cells is doc-
umented in Table 1.
There was a slight increase in the level of IgG binding
to WT PBMC during the first year, though the increase
was not significant (P = 0.444) (Fig. 2b). The levels of
binding to GT-KO PBMC in most cases remained at the
level of the isotype control (MFI-index = 1), and there
was no correlation with age (P = 0.740). Binding is docu-
mented in Table 1.
Sera from colony-raised baboons (n = 26) and SPF
baboons (n = 16) were investigated separately. No signifi-
cant difference in IgM or IgG binding to either WT or
GT-KO pig PBMC was found using sera from these two
groups (data not shown), suggesting that anti-pig Ab for-
mation was not influenced by the SPF environment.
Cytotoxicity of infant human and baboon sera
to pig PBMC
The same serum samples were tested for complement-
dependent cytotoxicity against WT and GT-KO PBMC.
All samples showed a titration curve with reduction in
lysis with increasing dilution (not shown). To demon-
strate correlation of cytotoxicity with age, lysis (¼%
cytotoxicity) at a serum dilution of 25% is shown in
Fig. 3.
Humans
During the first year of life, 39% of infant human sera
were cytotoxic (>10% lysis) to PBMC from WT pigs,
whereas only 17% were cytotoxic to GT-KO PBMC
(P = 0.002) (Fig. 3a). The extent of GT-KO PBMC lysis
was significantly less than that of WT PBMC (median
percentage of lysis 0% vs. 6%, respectively, P = 0.001).
Lysis of WT PBMC increased significantly with age
(P = 0.023), but lysis of GT-KO PBMC (i.e. associ-
ated with anti-nonGal Abs) did not increase with
age (P = 0.803). The median lysis of GT-KO
PBMC throughout the entire first year was 0% (range
0–40%).
Baboons
During the first year of life, 67% of infant baboon sera
were cytotoxic (defined by >10% lysis) to PBMC from
Table 1. Strength of binding of infant baboon and human serum*
immunoglobulin M (IgM) and immunoglobulin G (IgG) to wild type
(WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells by flow cytometry.
Human (n = 42) Baboon (n = 42)
IgM IgG IgM IgG
WT GT-KO WT GT-KO WT GT-KO WT GT-KO
Strength of binding (%)
No binding 34 48 15 53 5 38 60 98
Minimal 15 48 24 38 28 52 17 0
Mild-to-moderate 30 4 40 7 50 10 21 2
Strong 21 0 21 2 17 0 2 0
*Drawn at various times during the first year of life.
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Figure 2 Binding of infant baboon (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample.] (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P < 0.001, r = 0.665; versus GT-KO, P = 0.103, r = 0.255). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.444, r = 0.121; versus GT-KO, P = 0.740,
r = 0.053).
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In neonates (age <4 weeks, n = 6), in relation to iso-
type control, IgG binding to WT PBMC was increased up
to approximately four times, while binding to GT-KO
PBMC was minimal (Fig. 1b) (P = 0.046). The maternal
anti-pig IgG present in the sera of neonates would there-
fore appear to be almost entirely anti-Gal Ab.
Baboons
There was no or minimal IgM binding to WT PBMC (as
defined by MFI-index<1.5, see Materials and methods)
docume ted earlier than 10 weeks of age (n = 4), after
which the incidence and extent of binding steadily
increased with age (P < 0.001) (Fig. 2a). No or only min-
im l IgM binding to GT-KO PBMC w s seen before
15 weeks, after which th e w s some i crease, but the
extent of binding remained low throughout the first year,
and there was no correlation with age (P = 0.103)
(Fig. 2a). Binding of IgM to WT and GT-KO cells is doc-
umented in Table 1.
There was a slight increase in the level of IgG binding
to WT PBMC during the first year, though the increase
was not significa t (P = 0.444) (Fig. 2b). The levels of
binding to GT-KO PBMC in most cases remained at the
l vel of the isotyp control (MFI-index = 1), and there
was no correlation with age (P = 0.740). Binding is d cu-
mented in Table 1.
Sera from colony-rai ed bab ons (n = 26) and SPF
baboons (n = 16) were inves igated separ tely. No signifi-
cant difference in IgM or IgG binding to either WT or
GT-KO pig PBMC was found using sera from these two
groups (data not shown), sugge ting that anti-pig Ab for-
mation was not influenced by the SPF environment.
Cytotoxicity of infant human and baboon sera
to pig PBMC
The same serum samples were tested for complement-
dependent cytotoxicity against WT and GT-KO PBMC.
All samples showed a titration curve with reduction in
lysis with increasing dilution (not shown). To demon-
strate correlation of cytotoxicity with age, lysis (¼%
cytotoxicity) at a serum dilution of 25% is shown in
Fig. 3.
H mans
During the first year of life, 39% of infant human sera
were cytotoxic (>10% lysis) to PBMC from WT pigs,
whereas only 17% were cytotoxic to GT-KO PBMC
(P = 0.002) (Fig. 3a). The extent of GT-KO PBMC lysis
was significantly less than that of WT PBMC (median
percentage of lysis 0% vs. 6%, respectively, P = 0.001).
Lysis of WT PBMC increased significantly with age
(P = 0.023), but lysis of GT-KO PBMC (i.e. associ-
ated with anti-nonGal Abs) did not increase with
age (P = 0.803). The median lysis of GT-KO
PBMC throughout the entire first year was 0% (range
0–40%).
Baboons
During the first year of life, 67% of infant baboon sera
were cytotoxic (defined by >10% lysis) to PBMC from
Table 1. Strength of binding of infant baboon and human s rum*
immunoglobulin M (IgM) and immunoglobulin G (IgG) to wild type
(WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells by flow cytometry.
Human (n = 42) Baboon (n = 42)
IgM IgG IgM IgG
WT GT-KO WT GT-KO WT GT-KO WT GT-KO
Strength of binding (%)
No binding 34 48 15 53 5 38 60 98
Minimal 15 48 24 38 28 52 17 0
Mild-to-moderate 30 4 40 7 50 10 21 2
Strong 21 0 21 2 17 0 2 0
*Drawn at various times during the first year of life.
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Figure 2 Binding of infant baboon (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample.] (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tion of MFI index with age of each group is indicated by a line (versus
WT, P < 0.001, r = 0.665; versus GT-KO, P = 0.103, r = 0.255). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.444, r = 0.121; versus GT-KO, P = 0.740,
r = 0.053).
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In neonates (age <4 weeks, n = 6), in relation to iso-
type control, IgG binding to WT PBMC was increased up
to approximately four times, while binding to GT-KO
PBMC was minimal (Fig. 1b) (P = 0.046). The maternal
anti-pig IgG present in the sera of neonates would there-
fore appear to be almost entirely anti-Gal Ab.
Baboons
There was no or minimal IgM binding to WT PBMC (as
defined by MFI-index<1.5, see Materials and methods)
documented earlier than 10 weeks of age (n = 4), after
which the incidence and extent of binding steadily
increased with age (P < 0.001) (Fig. 2a). No or only min-
imal IgM binding to GT-KO PBMC was seen before
15 weeks, after which there was some increase, but the
extent of binding remained low throughout the first year,
and there was no correlation with age (P = 0.103)
(Fig. 2a). Binding of IgM to WT and GT-KO cells is doc-
umented in Table 1.
There was a slight increase in the level of IgG binding
to WT PBMC during the first year, though the increase
was not significant (P = 0.444) (Fig. 2b). The levels of
binding to GT-KO PBMC in most cases remained at the
level of the isotype control (MFI-index = 1), and there
was no correlation with age (P = 0.740). Binding is docu-
mented in Table 1.
Sera from colony-raised baboons (n = 26) and SPF
baboons (n = 16) were investigated separately. No signifi-
cant difference in IgM or IgG binding to either WT or
GT-KO pig PBMC was found using sera from these two
groups (data not shown), suggesting that anti-pig Ab for-
mation was not influenced by the SPF environment.
Cytotoxicity of infant human and baboon sera
to pig PBMC
The same serum samples were tested for complement-
dependent cytotoxicity against WT and GT-KO PBMC.
All samples showed a titration curve with reduction in
lysis with increasing dilution (not shown). To demon-
strate correlation of cytotoxicity with age, lysis (¼%
cytotoxicity) at a serum dilution of 25% is shown in
Fig. 3.
Humans
During the first year of life, 39% of infant human sera
were cytotoxic (>10% lysis) to PBMC from WT pigs,
whereas only 17% were cytotoxic to GT-KO PBMC
(P = 0.002) (Fig. 3a). The extent of GT-KO PBMC lysis
was significantly less than that of WT PBMC (median
percentage of lysis 0% vs. 6%, respectively, P = 0.001).
Lysis of WT PBMC increased significantly with age
(P = 0.023), but lysis of GT-KO PBMC (i.e. associ-
ated with anti-nonGal Abs) did not increase with
age (P = 0.803). The median lysis of GT-KO
PBMC throughout the entire first year was 0% (range
0–40%).
Baboons
During the first year of life, 67% of infant baboon sera
were cytotoxic (defined by >10% lysis) to PBMC from
Table 1. Strength of binding of infant baboon and human serum*
immunoglobulin M (IgM) and immunoglobulin G (IgG) to wild type
(WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells by flow cytometry.
Human (n = 42) Baboon (n = 42)
IgM IgG IgM IgG
WT GT-KO WT GT-KO WT GT-KO WT GT-KO
Strength of binding (%)
No binding 34 48 15 53 5 38 60 98
Minimal 15 48 24 38 28 52 17 0
Mild-to-moderate 30 4 40 7 50 10 21 2
Strong 21 0 21 2 17 0 2 0
*Drawn at various times during the first year of life.
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Figure 2 Binding of infant baboon (n = 42) serum antibodies to wild
type (WT) and a1,3-galactosyltransferase gene-knockout (GT-KO) pig
peripheral blood mononuclear cells (PBMC). [mean fluorescence inten-
sity (MFI) index = mean fluorescence intensity of the serum sample
divided by the MFI of the isotype control sample.] (a) Distribution of
immunoglobulin M reactivity against WT and GT-KO PBMC. Correla-
tio of MFI index with age of each group is indicated by a line (v rsus
WT, P < 0.001, r = 0.665; versus GT-KO, P = 0.103, r = 0.255). (b)
Distribution of immunoglobulin G reactivity against WT and GT-KO
PBMC. Correlation of MFI index with age of each group is indicated
by a line (versus WT, P = 0.444, r = 0.121; versus GT-KO, P = 0.740,
r = 0.053).
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Figure 2:
Binding of  infant baboon (n=42) serum Abs to WT and GT-KO pig PBMC. 
(MFI index = mean fluorescence intensity of  the serum sample divided by 
the MFI of  the isotype control sample).  
(A) Distribution of  IgM reactivity against WT and GT-KO PBMC. 
Correlation of  MFI index with age of  each group is indicated by a line (versus 
WT, p<0.001, r=0.665; versus GT-KO, p=0.103, r=0.255).
(B)  Distrib tion of  I G reactivity against WT and GT-KO PBMC. 
Correlation of  MFI index with age of  each group is indicated by a line (versus 
WT, p=0.444, r=0.121; versus GT-KO, p=0.740, r=0.053).   
Sera from colony-rais d baboons (n= 26) and SPF baboons (n=16) were investigated 
separately.  No significant difference in IgM or IgG binding to either WT or GT-KO pig PBMC 
was found using sera from these two groups (data not shown), suggesting that anti-pig Ab 
formation was not influenced by the SPF environment.
Cytotoxicity of Infa t Human and Baboon Sera to Pig PBMC
The same serum samples were tested for comple e t depend nt cyt toxicity against WT 
and GT-KO PBMC. All s mples sho ed a titration curve with reduction in lysis with increasing 
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dilution (not shown). In order to demonstrate correlation of cytotoxicity with age, lysis (= % 
cytotoxicity) at a serum dilution of 25% is shown in Figure 3.
WT pigs, whereas only 24% of sera were cytotoxic to
GT-KO PBMC (P < 0.001). Furthermore, when lysis was
detected, the extent of lysis of GT-KO PBMC was gener-
ally much less than that of WT PBMC (median percent-
age of lysis 0% vs. 29%, respectively, P < 0.001). Lysis
increased significantly with age against both WT PBMC
(P < 0.001) and GT-KO PBMC (P = 0.035) (Fig. 3b).
Lysis of GT-KO PBMC of >10% was rarely documented
in sera from baboons <22 weeks of age (2 of 22 sam-
ples). Importantly, 76% of baboons demonstrated no
detectable cytotoxicity (i.e. >10% lysis) to GT-KO
PBMC.
Sera from 14 infant baboons of different ages were
retested for cytotoxicity against WT PBMC 23 weeks after
the first blood draw. Cytotoxic anti-pig Abs had increased
in these baboons during this interval (median extent lysis
increased from 46% to 61%, P = 0.012) (Fig. 3c and d).
Infant baboons that were older at the time of the first
blood draw showed less increase in cytotoxic anti-pig
Abs, suggesting that most anti-pig Abs are formed early
in the first year of life.
Presence of anti-A or -B blood group antibodies
in infant baboons
Blood groups of baboons were determined by staining of
buccal swabs. Sera from baboons (n = 20) with blood
group A or B were then tested for the presence of anti-B
or -A blood group Abs, respectively. Sera from baboons
with blood group AB were not followed up, as they never
develop anti-A or -B Abs. In the sera tested, we did not
detect any anti-A or -B Abs before the age of 16 weeks
(Fig. 4). Most sera of baboons of 17 weeks and older
demonstrated detectable levels of Abs, although, in some
cases, absence of Abs was seen up to 23 weeks of age.
This suggests that anti-blood group Abs do not develop
in baboons until the fourth month of life, and are present
in most baboons >5 months of age.
All baboons with anti-blood group Abs demonstrated
detectable levels of anti-WT pig IgM, but IgM binding to
WT pig cells was also observed in sera without anti-A/B
Abs. We found a correlation between the presence of
anti-A/B Abs and a higher level of IgM binding to WT
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Figure 3 (a) Ability of human serum samples (n = 41) at 25% dilution to cause lysis of peripheral blood mononuclear cells (PBMC) from wild type
(WT) or a1,3-galactosyltransferase gene-knockout (GT-KO) pigs. Correlation of complement-dependent cytotoxicity with age is indicated by lines.
Significant correlation with age was observed for lysis of WT PBMC (P = 0.023, r = 0.377), but not for lysis of GT-KO PBMC (P = 0.803,
r = 0.040). (b) Ability of baboon serum samples (n = 42), tested at 25% dilution, to cause lysis of PBMC from WT or GT-KO pigs. Correlation of
complement-dependent cytotoxicity with age is indicated by lines. Significant correlation with age was observed for both lysis of WT PBMC
(P < 0.001, r = 0.522) and GT-KO PBMC (P = 0.035, r = 0.330). (c) Ability of baboon serum samples (n = 14), tested at 25% dilution on two
occasions (the second 23 weeks after the first), to cause lysis of PBMC from a WT pig. At the second testing, an increase in cytotoxicity of most
baboon anti-pig antibodies (Abs) was documented (n = 11). (d) The same data presented in (c) have been plotted to show the correlation of com-
plement-dependent cytotoxicity with age (indicated by lines). At the initial testing, a significant correlation was observed between lysis and age
(circles) (P = 0.029, r = 0.582). At the second testing (23 weeks later; triangles), an increase in cytotoxicity of baboon anti-pig Abs (compared with
the initial testing) was documented, but increasing lysis did not correlate with increasing age (P = 0.600, r = 0.153).
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Figure 3:
(A)  A ility of  human serum amples (n=41) at 25% dil tion to cause lysis of  PBMC 
from WT or GT-KO pigs.  Correlation of  complement-dependent cytotoxicity with age 
is indicated by lines.  Significant correlation with age was observed for lysis of  WT PBMC 
(p=0.023, r=0.377), but n t for lysis of  G -KO PBMC (p=0.803, r=0.040). 
(B)  Ability of  baboon serum samples (n=42), tested at 25% dilution, to cause lysis of  
PBMC from WT or GT-KO pi s.  Correlation of  complement-dependent cytotoxicity 
with age is indicated by lines.  Significant correlation with age was observed for both lysis 
of  WT PBMC (p<0.001, r=0.522) and GT-KO PBMC (p=0.035, r=0.330).
(C) Ability of  baboon serum samples (n=14), tested at 25% dilution on 2 ccasions (the
s ond 23 w eks after the first), to cause lysis of  PBMC from a WT pig. At the second 
testing, an increase in cytotoxicity of  most baboon anti-pig Abs w s docum nted (n=11). 
(D) The same data presented in (C) have been plotted to show the correlation of  
complement-dependent cytotoxicity with age (indicated by lines). At the initial testing, a 
significant correlation was observed between lysis and age (circles) (p=0.029, r=0.582).  At 
th  sec nd testi g ( 3 w eks l t r; triangle ), an increase i  cyt toxicity of  baboon anti-
pig Abs (compared with the initial testing) was documented, but increasing lysis did not 
correlate with increasing age (p=0.600, r=0.153).
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Humans 
During the first year of life, 39% of infant human sera were cytotoxic (>10% lysis) to PBMC 
from WT pigs, whereas only 17% were cytotoxic to GT-KO PBMC (p=0.002) (Figure 3a). 
The extent of GT-KO PBMC lysis was significantly less than that of WT PBMC (median 
percentage of lysis 0% vs 6%, respectively, p=0.001).  Lysis of WT PBMC increased 
significantly with age (p=0.023), but lysis of GT-KO PBMC (i.e., associated with anti-nonGal 
Abs) did not increase with age (p=0.803). The median lysis of GT-KO PBMC throughout the 
entire first year was 0% (range 0-40%). 
Baboons 
During the first year of life, 67% of infant baboon sera were cytotoxic (defined by >10% lysis) 
to PBMC from WT pigs, whereas only 24% of sera were cytotoxic to GT-KO PBMC (p<0.001). 
Furthermore, when lysis was detected, the extent of lysis of GT-KO PBMC was generally 
much less than that of WT PBMC (median percentage of lysis 0% vs. 29%, respectively, 
p<0.001). Lysis increased significantly with age against both WT PBMC (p<0.001) and GT-
KO PBMC (p=0.035) (Figure 3b).  Lysis of GT-KO PBMC of >10% was rarely documented 
in sera from baboons <22 weeks of age (2 of 22 samples).  Importantly, 76% of baboons 
demonstrated no detectable cytotoxicity (i.e. >10% lysis) to GT-KO PBMC.
Sera from 14 infant baboons of different ages were retested for cytotoxicity against WT 
PBMC 23 weeks after the first blood draw.  Cytotoxic anti-pig Abs had increased in these 
baboons during this interval (median extent lysis increased from 46% to 61%, p=0.012) 
(Figures 3c and 3d). Infant baboons that were older at the time of the first blood draw showed 
less increase in cytotoxic anti-pig Abs, suggesting that most anti-pig Abs are formed early in 
the first year of life.  
Presence of Anti-A or B Blood Group Antibodies in Infant Baboons 
Blood groups of baboons were determined by staining of buccal swabs. Sera from baboons 
(n=20) with blood group A or B were then tested for the presence of anti-B or A blood group 
Abs, respectively. Sera from baboons with blood group AB were not followed up, since they 
never develop anti-A or B Abs. In the sera tested, we did not detect any anti-A or B Abs before 
the age of 16 weeks (Figure 4). Most sera of baboons of 17 weeks and older demonstrated 
detectable levels of Abs, although, in some cases, absence of Abs was seen up to 23 weeks 
of age. This suggests that anti-blood group Abs do not develop in baboons until the fourth 
month of life, and are present in most baboons >5 months of age.
All baboons with anti-blood group Abs demonstrated detectable levels of anti-WT pig IgM, 
but IgM binding to WT pig cells was also observed in sera without anti-A/B Abs. We found 
a correlation between the presence of anti-A/B Abs and a higher level of IgM binding to 
WT cells (p=0.029), but no correlation was found between the presence of anti-A/B Abs 
Proefschrift.indb   106 1/3/2008   6:18:34 PM
Anti-nonGal antibodies in infants
107
cells (P = 0.029), but no correlation was found between
the presence of anti-A/B Abs and binding of anti-WT IgG
(P = 0.357) or of anti-GT-KO IgM (P = 0.136) or anti-
GT-KO IgG (P = 0.715).
Discussion
Natural anti-pig Abs develop during infancy [18–23], a
finding confirmed in the present study. However, this is
the first investigation of the development of anti-nonGal
Abs in infant humans and baboons and the first demon-
stration of the correlation between age and Ab produc-
tion. Our data suggest that both baboons and humans
probably develop cytotoxic anti-pig IgM early during the
first year, the level of which steadily increases with age
during the first year, but this IgM is largely directed
against Gal targets. Cytotoxic anti-nonGal Abs develop
later, and remain at a minimal level in the majority of
cases (Figs 1–3). This increase in anti-pig Abs with age
during the first year is consistent with that of anti-A/B
Abs.
As described in adults [16], the incidence and extent of
binding of infant human (Fig. 1) and baboon (Fig. 2)
serum IgM and IgG to PBMC from GT-KO pigs was sig-
nificantly less when compared with binding to WT
PBMC. The associated lysis of WT cells was higher in
baboons than in humans (P = 0.031) (Fig. 3), suggesting
that Ab-mediated rejection of a transplanted WT pig
organ may be more problematic in the baboon than in
the human. The increase in anti-pig cytotoxic Abs was
confirmed by sequential measurement of sera from the
same baboon (Fig. 3). More importantly, the cytotoxicity
of infant human anti-nonGal Abs did not increase with
age and was absent in a significant number of cases. This
allows a ‘window of opportunity’ during which a GT-KO
pig organ could be transplanted into a human infant
without the risk of rejection associated with the presence
of natural anti-nonGal cytotoxic Abs. Newborns with
congenital heart disease, for whom no human donor
heart is available, could be possible candidates for receiv-
ing a xenotransplant early in life. As occurs in the case of
ABO-incompatible heart allotransplantation in human
infants [1,2], B-cell tolerance to carbohydrate antigens
may develop when a GT-KO pig heart is transplanted
into a primate recipient that has not yet developed anti-
nonGal Abs.
However, in contrast to ABO-incompatible allotrans-
plantation, the transplantation of pig hearts might be less
successful as cellular components of the innate immune
response may be problematic. Furthermore, immune
responses to other xenoantigens (against which no natural
Abs are present) would need to be suppressed, with the
associated risks of immunosuppressive therapy. But, it is
not definitively known whether immunosuppressive ther-
apy would need to be continued throughout the life of
the recipient. Data from Bailey et al. [26,27] suggest that
the immune response to an allograft in neonates and
infants is rather less vigorous than in later life, and West
et al. [1] have drawn attention to the relative ‘plasticity’
of the neonatal immune system. It would be of great clin-
ical interest to study whether, in this age group, the pre-
vention of a T-cell response for a period of time might
result in T-cell tolerance.
Although our study indicates that anti-nonGal Ab lev-
els in infant sera are frequently absent or low, the pres-
ence of a significant level of natural or elicited anti-
nonGal Abs is almost certain to result in Ab-mediated
rejection [16,28,29]. The target(s) for these anti-nonGal
Abs need to be ascertained [30,31].
Baboons would generally appear to develop anti-A/B
Abs at approximately 4 months of life, which is similar to
the time of their development in humans [1]. A previous
study using adult human and baboon sera showed no sta-
tistically significant correlation between the presence of
anti-Gal Abs and anti-A/B Abs [32], which is confirmed
for IgG Abs by our findings. However, we found a corre-
lation between the presence of anti-A/B Abs and anti-WT
IgM in infant baboons, possibly as both levels are known
to increase during the first year of life.
There is a discrepancy between the high level of
(maternal) anti-pig (Gal) IgG in newborn humans and
the relative absence of IgG in newborn baboons. Some or
all of this discrepancy is likely to be related to the fact
that some human sera were available to us as early as the
first week of life, whereas no baboon sera were available
until the sixth week. However, the relatively lower levels
of IgG seen in the first 3 months in baboons suggest that
there may be a difference between the two species in this
respect, although maternal IgG has been documented in
neonatal baboons previously [20].
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Figure 4 Presence of anti-A or -B blood group antibodies (Abs) in
sera of blood group B or A baboons, respectively, of different ages
(n = 20). (0 = anti-A or -B Abs were not detected; 1 = anti-A or -B
Abs were present).
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Figure 4:
Presence of  anti-A or B 
blood group Ab  in sera 
of  blood group B r A 
baboons, respectively, of  
different ages (n=20). (0 
= anti-A or B Abs were 
not detected; 1= anti-A 
or B Abs were present).
and binding of anti-WT IgG (p=0.357) or of anti-GT-KO IgM (p=0.136) or anti-GT-KO IgG 
(p=0.715).
DISCUSSION
Natural anti-pig Abs develop during infancy (18-23), a finding confirmed in t  present study. 
However, this is the first investigation of the development of anti-nonGal Abs in i fant humans 
and baboons and the first demonstration of the correlation between age and Ab production. 
Our data suggest that both baboons and humans probably develop cytotoxic anti-pig IgM 
early during the first year, the level of which steadily increases with age during the first year, 
but this IgM is largely directed against Gal targets. Cytotoxic anti-nonGal Abs develop later, 
and remain at a minimal level in the majority of cases (Figures 1-3).  This increase in anti-pig 
Abs with age during the first year is consistent with th t of anti-A/B Abs.
As described in adults (16), the incidence and extent of binding of infant human (Figure 1) 
and baboon (Figure 2) serum IgM and IgG to PBMC from GT-KO pigs was significantly less 
when compared to binding to WT PBMC. The associated lysis of WT cells was higher in 
baboons than in humans (p=0.031) (Figure 3), suggesting that Ab-mediated rejection of a 
transplanted WT pig organ may be more problematic in the baboon than in the human. The 
increase in anti-pig cytotoxic Abs was confirmed by sequential measurement of sera from 
the same baboon (Figure 3). More importantly, the cytotoxicity of infant human anti-nonG l 
Abs did not increas  with age nd was absent in a significant number of c ses. This allows 
a ‘window of opportunity’ during which a GT-KO pig organ could be transplanted into a 
human infant without the risk of rejection associated with the presence of natural anti-nonGal 
cytotoxic Abs.  Newborns with congenital heart disease, for whom no human donor heart is 
available, could be possible candidates for receiving a xenotransplant early in life. As occurs 
in the case of ABO-incompatible heart allotransplantation in human infants (1, 2), B cell 
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tolerance to carbohydrate antigens may develop when a GT-KO pig heart is transplanted 
into a primate recipient that has not yet developed anti-nonGal Abs.
However, in contrast to ABO-incompatible allotransplantation, the transplantation of pig 
hearts might be less successful as cellular components of the innate immune response 
may be problematic.  Furthermore, immune responses to other xenoantigens (against which 
no natural Abs are present) would need to be suppressed, with the associated risks of 
immunosuppressive therapy.  But it is not definitively known whether immunosuppressive 
therapy would need to be continued throughout the life of the recipient.  Data from Bailey 
and his colleagues (26, 27) suggest that the immune response to an allograft in neonates 
and infants is rather less vigorous than in later life, and West et al (1) have drawn attention 
to the relative ‘plasticity’ of the neonatal immune system.  It would be of great clinical interest 
to study whether, in this age group, the prevention of a T cell response for a period of time 
might result in T cell tolerance.    
Although our study indicates that anti-nonGal Ab levels in infant sera are frequently absent or 
low, the presence of a significant level of natural or elicited anti-nonGal Abs is almost certain 
to result in Ab-mediated rejection (16, 28, 29). The target(s) for these anti-nonGal Abs need 
to be ascertained (30, 31).  
Baboons would generally appear to develop anti-A/B Abs at approximately 4 months of life, 
which is similar to the time of their development in humans (1).  A previous study using adult 
human and baboon sera showed no statistically significant correlation between the presence 
of anti-Gal Abs and anti-A/B Abs (32), which is confirmed for IgG Abs by our findings. 
However, we found a correlation between the presence of anti-A/B Abs and anti-WT IgM in 
infant baboons, possibly since both levels are known to increase during the first year of life.
There is a discrepancy between the high level of (maternal) anti-pig (Gal) IgG in newborn 
humans and the relative absence of IgG in newborn baboons.  Some or all of this discrepancy 
is likely to be related to the fact that some human sera were available to us as early as the 
first week of life, whereas no baboon sera were available until the sixth week.  However, 
the relatively lower levels of IgG seen in the first 3 months in baboons suggest there may 
be a difference between the two species in this respect, although maternal IgG has been 
documented in neonatal baboons previously (20).  
In summary, our data suggest that GT-KO organ transplants could be carried out in early 
infancy in human recipients in the complete or relative absence of cytotoxic anti-nonGal 
Abs. If immunosuppressive therapy were administered to suppress a T cell-mediated 
elicited Ab response, xenograft rejection resulting from anti-nonGal Abs would be prevented 
(although other potential problems may still arise (33)).  Based on clinical experience of 
heart allotransplantation in infant humans across the ABO barrier, it is possible that B cell 
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tolerance to pig carbohydrate antigens might develop. Future studies should focus on testing 
this in vivo, by implanting tissue/organs from GT-KO pigs into infant baboons.
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ABSTRACT
Introduction: Streptozotocin (STZ) has been widely used to induce diabetes in nonhuman 
primates, although it has been found difficult to achieve complete diabetes without serious 
side effects.  We have investigated different types and dosages of STZ, in order to find a way 
to safely induce complete diabetes in cynomolgus monkeys.  
Materials and methods: After adequate hydration, 10 monkeys received STZ.  Five 
monkeys received conventional STZ (Sigma) at a dosage of 1250mg x m2 (‘high-dose’) (n=4) 
or 60mg/kg (‘low-dose’) (n=1) (Group i). Five monkeys received Zanosar STZ (Sicor) at 
150mg/kg (‘high-dose’) (n=5) (Group ii). 
Results: ‘High-dose’ Group i monkeys became completely diabetic (n=4), but a protein-
losing nephropathy was observed in 3 of the 4 monkeys. The monkey that received 60mg/kg 
STZ failed to become fully diabetic (C-peptide>1.86ng/mL). Group ii (high-dose Zanosar-
treated) monkeys became completely diabetic, but with no apparent side effects. A triphasic 
blood glucose response to STZ was documented in all the high-dose STZ-treated monkeys. 
Low-dose STZ failed to result in a triphasic response.
Conclusions: (1) High-dose Zanosar STZ induced diabetes safely in cynomolgus monkeys 
without side effects. (2) A triphasic blood glucose response suggested the complete induction 
of diabetes.
INTRODUCTION
The growing interest in islet transplantation, supported by results achieved in rodent models, 
has caused an increase in studies with nonhuman primates (1-5). To assess islet survival, 
it is preferred to render the nonhuman primates diabetic. Diabetic animals are valuable not 
only for studying survival after islet transplantation, but also to study several other aspects of 
diabetes, such as neuropathy (6), the influence of hyperglycemia on cardiac tissue (7), and 
metabolic and endocrine changes (8).
Spontaneous diabetes has been reported in cynomolgus and rhesus monkeys (9-11), although 
their availability is limited, and it is necessary to verify the type of diabetes.  Pancreatectomy 
to induce diabetes is not without surgical morbidity, and has the major disadvantage of loss 
of exocrine pancreatic function (9,12). The tight adherence of the pancreas to the intestine 
makes pancreatectomy in the monkey a difficult procedure, and there is also the potential 
for continuing function or regeneration of beta cells if the pancreatectomy has not been 
total. Although nonhuman primates have been reported to become diabetic after alloxan 
administration (9), it is generally assumed that alloxan works selectively on rodent beta cells, 
and is therefore not a potent inducer of diabetes in humans or nonhuman primates (13,14).
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Therefore, streptozotocin (STZ), derived from the bacteria Streptomyces achromogenes, 
is a frequently used method for induction of diabetes in nonhuman primates. Besides 
antimicrobial and anti-tumor activities, STZ is diabetogenic through oxidative stress resulting 
in selective death of the beta cells (15). Nephrotoxicity and hepatotoxicity are disadvantages 
of  STZ (16-19). There is an ongoing discussion with regard to the optimal dose of STZ in 
nonhuman primates since there is a well-documented correlation between the dose of STZ 
and the development of renal and hepatic morbidity.
We here report on our experience with different doses and different types of STZ, in an effort 
to find a safe and consistent way to induce diabetes in nonhuman primates.  We also report 
on the early metabolic responses (e.g., blood glucose levels) after STZ administration, which 
may indicate whether diabetes has been induced successfully and completely.
METHODS
Animals
Ten male cynomolgus monkeys (Macaca fascicularis), weighing 3.2 kg ± 0.7kg (range 2.4kg 
to 4.7kg), were fitted with tethers carrying indwelling intravascular and/or gastric catheters. 
Tethers provide an advantage with regard to the ease with which blood samples can be 
obtained and fluids and drugs administered, without the need for restraining or sedating 
the primate (20).  All animal care procedures were in accordance with the Principles of 
Laboratory Animal Care formulated by the National Society for Medical Research and the 
Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of Health (NIH publication No. 
86-23, revised 1985). 
tethers carrying indwelling intravascular and/or gastric
catheters. Tethers provide an advantage with regard to the
ease with which blood samples can be obtained and fluids and
drugs administered without the need for restraining or
sedating the primate.20 All animal care procedures were in
accordance with the Principles of Laboratory Animal Care
formulated by the National Society for Medical Research and
the Guide for the Care and Use of Laboratory Animals
pre a ed by the Institute of Laboratory Animal Resources,
and published by the National Institutes of Health (NIH
publication No. 86-23, revised 1985).
Inductio of Diabetes
Monkeys were fasting overnight and were prehydrated
with 10 mL/kg/h of 0.9% NaCl iv for 8 to 10 hours before
STZ administration to reduce nephrotoxic adverse effects.
After STZ administration, the rate of fluid infusion was
increased to 15 mL/kg/h for 2 hours. Five monkeys (Group 1)
receive STZ that was purchased from the Sigma Chemical
Company (St Louis, Mo), 4 of them at a dose of 1250 mg/m2
body surface area (equals ~105 mg/kg; defined as Bhigh
dose[) and 1 at 60 mg/kg (defined as Blow dose[; Table 1).
The other 5 monkeys (Group 2) were given Zanosar STZ
(Sicor Phar aceuti als, Irvine, CA) at 150 mg/kg (d fined
as high dose; Table 1). In all cases, STZ was administered
over 1 to 5 minutes (Table 1).
In the 48 hours after STZ induction, frequent blood
samples were drawn for metabolic testing (including glucose,
potassium, HCO3, pH, pCO2, and acid-base balance) using
an i-STAT device for Bbed-side[ metabolic blood screening
(I-STAT Corporation, East Windsor, NJ). Dextrose was
infused continuously; the rate and concentration depending
on the blood glucose level. If a metabolic acidosis devel-
oped, a continuous infusion of sodium bicarbonate was ini-
tiat d and continued at a rat to restore the blood acid-base
balance (range 0.15Y0.9 mEq/h). Baseline and post-STZ
liver and kidney function tests were carried out.
After the successful induction of diabetes, blood glucose
levels were checked at least twice daily, and hyperglycemia
was c ntrolled by the continuous iv infusion of human
recombinant insulin (Humulin R; Eli Lilly, Indianapolis, IN).
Confirmation of Induction of Diabetes
Diabetes was confirmed by the persistence of fasting
hyperglycemia and by the measurement of fasting, random,
and glucose-stimulated primate C-peptide. Efforts to stimu-
late surviving islets were by iv glucose tolerance test
(ivGTT), as described by Koulmanda et al,16 and by the
arginine stimulation test, as described by Wijkstrom et al.2
Serum C-peptide levels were measured by a chemilumines-
cence method (Bayer Centaur, Tarrytown, NY) and radioim-
munoassay (Linco Research, St Charles, MO) using human
antibodies with 100% cross-reactivity with monkey C-peptide.
(Because the molecular structures of human and monkey
C-peptide are identical). A fasting blood glucose level of
greater than 200 mg/dL in combination with a stimulated
C-peptide level of less than 0.5 mg/mL was considered
indicative of diabetes.
Histological Examination
After euthanasia of the monkey, biopsies of the
pancreas, kidney, liver, and heart were taken and fixed in
formalin, embedded in paraffin, and sectioned. Pancreatic
tissue was investigated by immunohistochemistry for the
presence of immuno-reactive proinsulin antibodies (Scytek
Laboratories, Logan, UT) using standard procedures. Kidney,
liver, and heart tissues were stained with hematoxylin and
eosin.
Data Analysis
Mean values and standard error of the mean (SEM)
were calculated using the Prism-4 software (Graphpad
Software, San Diego, CA).
RESULTS
Pre-STZ Data
Pre-STZ C-peptide random values were 2.22 to
4.24 ng/mL measured by chemiluminescence. The ivGTT
showed normal blood glucose curves (Fig.1) and stimulated
C-peptide values up to 7.34 ng/mL at 15 minutes. Arginine
TABLE 1. Dose, Type, and Infusion Time of STZ, and
Post-STZ C-Peptide Values*
Group Dose of STZ (type)
Infusion
Time (min)
C-Peptide
Level (ng/mL)
Group 1
n = 4 1250 mg/m2 (Sigma)† 1Y5 G0.5
n = 1 60 mg/kg (Sigma) 1 1.86
2.93 (after challenge
with glucose)
Group 2
n = 5 150 mg/kg (Zanosar) 1 G0.5
*C-peptide levels measured by chemiluminescence (detection level is 0.5 g/mL).
†’105 mg/kg.
FIGURE 1. Intravenous glucose tolerance tests in nondiabetic
(n = 6; dashed line) and high-dose STZ-diabetic (n = 4)
monkeys (solid line).
Rood et al Pancreas & Volume 33, Number 3, October 2006
288 * 2006 Lippincott Williams & Wilkins
Copyr ight © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1:
Dose, type, infusion time of  streptozotocin (STZ), and post-STZ 
C-peptide values*
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Induction of diabetes
Monkeys were fasting overnight and were pre-hydrated with 10mL/kg/h 0.9%NaCl iv for 8-
10h before STZ administration, to reduce nephrotoxic side effects.  After STZ administration, 
the rate of fluid infusion was increased to 15mL/kg/h for 2h. Five monkeys (Group i) received 
STZ that was purchased from Sigma Chemical Company (St Louis, MO, USA), four of them 
at a dose of 1250mg/m2 body surface area (equals ~105mg/kg, defined as ‘high dose’), and 
one at 60mg/kg (defined as ‘low-dose’)(Table 1). The other five monkeys (Group ii) were 
given Zanosar STZ (Sicor Pharmaceuticals, Irvine, CA, USA) at 150mg/kg (defined as ‘high-
dose’) (Table 1). In all cases, STZ was administered over 1 to 5min (Table 1).
In the 48h after STZ induction, frequent blood samples were drawn for metabolic testing 
(including glucose, potassium, HCO3, pH, pCO2, acid-base balance) using an i-STAT device 
for ‘bed-side’ metabolic blood screening (I-STAT Corporation, East Windsor, NJ, USA). 
Dextrose was infused continuously, the rate and concentration depending on the blood 
glucose level.  If a metabolic acidosis developed, a continuous infusion of sodium bicarbonate 
was initiated and continued at a rate to restore the blood acid-base balance (range 0.15-0.9 
mEq/hr). Baseline and post-STZ liver and kidney function tests were carried out.
After the successful induction of diabetes, blood glucose levels were checked at least twice 
daily, and hyperglycemia was controlled by the continuous iv infusion of human recombinant 
insulin (Humulin R, Eli Lilly, Indianapolis, IN, USA).   
Confirmation of induction of diabetes
Diabetes was confirmed by the persistence of fasting hyperglycemia and by the measurement 
of fasting, random, and glucose-stimulated primate C-peptide.  Efforts to stimulate surviving 
islets were by iv glucose tolerance test (ivGTT), as described by Koulmanda et al. (16), and 
by the arginine stimulation test, as described by Wijkstrom et al. (2)  Serum C-peptide levels 
were measured by a chemiluminescence method (Bayer Centaur, Tarrytown, NY, USA) and 
radioimmunoassay (Linco Research, St. Charles, MO, USA) using human antibodies with 
100% cross-reactivity with monkey C-peptide. (Since the molecular structures of human and 
monkey C-peptide are identical).  A fasting blood glucose level of >200mg/dL in combination 
with a stimulated C-peptide level of <0.5mg/mL was considered indicative of diabetes.  
Histological examination
After euthanasia of the monkey, biopsies of the pancreas, kidney, liver, and heart were 
taken and fixed in formalin, embedded in paraffin, and sectioned. Pancreatic tissue was 
investigated by immunohistochemistry for the presence of immuno-reactive pro-insulin 
antibodies (Scytek Laboratories, Logan, UT, USA) using standard procedures. Kidney, liver, 
and heart tissue was stained with hematoxylin and eosin.
 
Proefschrift.indb   117 1/3/2008   6:18:37 PM
Chapter 7
118
Data analysis
Mean values and standard error of the mean (SEM) were calculated using Prism-4 software 
(Graphpad Software, San Diego, CA, USA).
RESULTS
Pre-STZ data
Pre-STZ C-peptide random values were 2.22-4.24ng/mL measured by chemiluminescence. 
IvGTT showed normal blood glucose curves (Figure 1) and stimulated C-peptide values 
up to 7.34ng/mL at 15 min. Arginine stimulation tests showed an increase of C-peptide 
production to 6.17ng/mL after 2 min. Baseline metabolic blood and urine screening showed 
normal kidney and liver functions.
tethers carrying indwelling intravascular and/or gastric
catheters. Tethers provide an advantage with regard to the
ease with which blood samples can be obtained and fluids and
drugs administered without the need for restraining or
sedating the primate.20 All animal care procedures were in
accordance with the Principles of Laboratory Animal Care
formulated by the National Society for Medical Research and
the Guide for the Care and Use of Laboratory Animals
prepared by the Institute of Laboratory Animal Resources,
and published by the National Institutes of Health (NIH
publication No. 86-23, revised 1985).
Induction of Diabetes
Monkeys were fasting overnight and were prehydrated
with 10 mL/kg/h of 0.9% NaCl iv for 8 to 10 hours before
STZ administration to reduce nephrotoxic adverse effects.
After STZ administration, the rate of fluid infusion was
increased to 15 mL/kg/h for 2 hours. Five monkeys (Group 1)
received STZ that was purchased from the Sigma Chemical
Company (St Louis, Mo), 4 of them at a dose of 1250 mg/m2
body surface area (equals ~105 mg/kg; defined as Bhigh
dose[) and 1 at 60 mg/kg (defined as Blow dose[; Table 1).
The other 5 monkeys (Group 2) were given Zanosar STZ
(Sicor Pharmaceuticals, Irvine, CA) at 150 mg/kg (defined
as high dose; Table 1). In all cases, STZ was administered
over 1 to 5 minutes (Table 1).
In the 48 hours after STZ induction, frequent blood
samples were drawn for metabolic testing (including glucose,
potassium, HCO3, pH, pCO2, and acid-base balance) using
an i-STAT device for Bbed-side[ metabolic blood screening
(I-STAT Corporation, East Windsor, NJ). Dextrose was
infused continuously; the rate and concentration depending
on the blood glucose level. If a metabolic acidosis devel-
oped, a continuous infusion of sodium bicarbonate was ini-
tiated and continued at a rate to restore the blood acid-base
balance (range 0.15Y0.9 mEq/h). Baseline and post-STZ
liver and kidney function tests were carried out.
After the successful induction of diabetes, blood glucose
levels were checked at least twice daily, and hyperglycemia
was controlled by the continuous iv infusion of human
recombinant insulin (Humulin R; Eli Lilly, Indianapolis, IN).
Confirmation of Induction of Diabetes
Diabetes was confirmed by the persistence of fasting
hyperglycemia and by the measurement of fasting, random,
and glucose-stimulated primate C-peptide. Efforts to stimu-
late surviving islets were by iv glucose tolerance test
(ivGTT), as described by Koulmanda et al,16 and by the
arginine stimulation test, as described by Wijkstrom et al.2
Serum C-peptide levels were measured by a chemilumines-
cence method (Bayer Centaur, Tarrytown, NY) and radioim-
munoassay (Linco Research, St Charles, MO) using human
antibodies with 100% cross-reactivity with monkey C-peptide.
(Because the molecular structures of human and monkey
C-peptide are identical). A fasting blood glucose level of
greater than 200 mg/dL in combination with a stimulated
C-peptide level of less than 0.5 mg/mL was considered
indicative of diabetes.
Histological Examination
After euthanasia of the monkey, biopsies of the
pancreas, kidney, liver, and heart were taken and fixed in
formalin, embedded in paraffin, and sectioned. Pancreatic
tissue was investigated by immunohistochemistry for the
presence of immuno-reactive proinsulin antibodies (Scytek
Laboratories, Logan, UT) using standard procedures. Kidney,
liver, and heart tissues were stained with hematoxylin and
eosin.
Data Analysis
Mean values and standard error of the mean (SEM)
were calculated using the Prism-4 software (Graphpad
Software, San Diego, CA).
RESULTS
Pre-STZ Data
Pre-STZ C-peptide random values were 2.22 to
4.24 ng/mL measured by chemiluminescence. The ivGTT
showed normal blood glucose curves (Fig.1) and stimulated
C-peptide values up to 7.34 ng/mL at 15 minutes. Arginine
TABLE 1. Dose, Type, and Infusion Time of STZ, and
Post-STZ C-Peptide Values*
Group Dose of STZ (type)
Infusion
Time (min)
C-Peptide
Level (ng/mL)
Group 1
n = 4 1250 mg/m2 (Sigma)† 1Y5 G0.5
n = 1 60 mg/kg (Sigma) 1 1.86
2.93 (after challenge
with glucose)
Group 2
n = 5 150 mg/kg (Zanosar) 1 G0.5
*C-peptide levels measured by chemiluminescence (detection level is 0.5 g/mL).
†’105 mg/kg.
FIGURE 1. Intravenous glucose tolerance tests in nondiabetic
(n = 6; dashed line) and high-dose STZ-diabetic (n = 4)
monkeys (solid line).
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Figure 1:
ivGTT in nondiabetic (n=6) (dashed line) and high-dose 
STZ-diabetic (n=4) monkeys (solid line).
Clinical response to STZ
All 10 monkeys became consistently hyperglycemic (i.e. blood glucose >200mg/dL) at a 
mean of 30.3h (range 26.5-34.25h) after STZ administration. 
 Group i 
After high-dose Sigma STZ at 1250mg/m2, C-peptide easurement demonstrated that all 
four Group I monkeys became completely diabetic. C-peptide values fell below the 0.5ng/mL 
detection level, which was confirmed by radioimmunoassay, both when fasting and after iv 
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glucose challenge on ivGTT testing. IvGTT blood glucose curves confirmed diabetes (Figure 
1).
Although consistent hyperglycemia was observed, the Group I monkey that received 60mg/
kg Sigma STZ failed to lose complete beta cell function; the fasting post-STZ C-peptide value 
was 1.86ng/mL, and the glucose-stimulated value was 2.93ng/mL.  This monkey showed no 
side effects post-STZ.
Side-effects were observed in the four monkeys that received high-dose Sigma STZ. 
These included vomiting within one hour after STZ administration (n=4), and a protein-
losing nephropathy was observed (n=3), particularly after immunosuppressive drug therapy 
was initiated. Serum protein levels came down to an average of 4.3g/dL (range 3.6-5.1), 
necessitating iv human albumin infusion. Albumin levels decreased proportionately (average 
1.7g/dL, range 1.2-2.3). Furthermore, severe proteinuria was documented using urine test 
strips (Baxter, Deerfield, IL, USA). Serum creatinine levels were stable and within the 
normal range. Liver transaminases, although not measured in the acute phase, did not show 
elevation above the normal range post-STZ.
 Group ii
Group II monkeys became consistently diabetic after 150mg/kg Zanosar STZ administration. 
Fasting blood glucose was >200mg/dL. Fasting and random C-peptide levels fell below the 
detection level of 0.5ng/mL by chemiluminescence, and below the 0.1ng/mL detection range 
by radioimmunoassay. Stimulation with ivGTT and/or arginine did not result in an increase in 
serum C-peptide, and ivGTT blood glucose curves confirmed diabetes (Figure 1).
Apart from vomiting shortly after STZ administration (n=3), no side effects were observed. 
Urinalysis did not show proteinuria, and serum protein and albumin levels were stable, 
indicating the absence of a protein losing nephropathy. 
Triphasic blood glucose response
The presence of indwelling intravascular lines enabled us to draw frequent blood samples 
and monitor the metabolic changes that followed STZ administration. All monkeys that were 
treated with high-dose STZ (1250mg/m2 Sigma STZ or 150mg/kg Zanosar STZ) showed a 
triphasic blood glucose response to STZ (Figures 2 and 3). Initially, over approximately 8h, 
there was a marked increase to a mean of 330mg/dL followed by a steady reduction to 56mg/
dL at 17h (at this point the dextrose infusion was increased).  Metabolic acidosis occurred 
mainly during the second phase, when the blood glucose fell to low levels after the peak at 
8h post-STZ administration, necessitating iv bicarbonate infusion. This was followed by a 
second, and sustained, increase in glucose to a mean of 310mg/dL at 30h (necessitating iv 
insulin administration).
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stimulation tests showed an increase of C-peptide production
to 6.17 ng/mL after 2 minutes. Baseline metabolic blood and
urine screening showed normal kidney and liver functions.
Clinical Response to Streptozotocin
All 10 monkeys became consistently hyperglycemic
(ie, blood glucose level, 9200 mg/dL) at a mean of 30.3 hours
(range, 26.5Y34.25 hours) after STZ administration.
Group 1
After high-dose Sigma STZ at 1250 mg/m2, C-peptide
measurement demonstrated that all 4 Group 1 monkeys
became completely diabetic. C-peptide values fell below the
0.5-ng/mL detection level, which was confirmed by radioim-
munoassay, both when fasting and after iv glucose challenge
on ivGTT testing. The ivGTT blood glucose curves confirmed
diabetes (Fig. 1).
Although consistent hyperglycemia was observed, the
Group 1 monkey that received 60 mg/kg Sigma STZ failed to
lose complete beta cell function; the fasting post-STZC-peptide
value was 1.86 ng/mL, and the glucose-stimulated value was 2.
93 ng/mL. This monkey showed no adverse effects post-STZ.
Adverse effects were observed in the 4 monkeys that
received high-dose Sigma STZ. These included vomitingwithin
1 hour after STZ administration (n = 4), and a protein-losing
nephropathy was observed (n = 3) particularly after immuno-
suppressive drug therapy was initiated. Serum protein levels
came down to an average of 4.3 g/dL (range 3.6Y5.1 g/dL),
necessitating iv human albumin infusion. Albumin levels de-
creased proportionately (average, 1.7 g/dL; range 1.2Y2.3 g/dL).
Furthermore, severe proteinuria was documented using urine
test strips (Baxter; Deerfield, Ill). Serum creatinine levels were
stable and within the reference range. Liver transaminases,
although not measured in the acute phase, did not show ele-
vation above the reference range post-STZ.
Group 2
Group 2 monkeys became consistently diabetic after
150 mg/kg Zanosar STZ administration. Fasting blood
glucose was greater than 200 mg/dL. Fasting and random
C-peptide levels fell below the detection level of 0.5 ng/mL
by chemiluminescence and below the 0.1-ng/mL detection
range by radioimmunoassay. Stimulation with ivGTT and/or
arginine did not result in an increase in serum C-peptide, and
ivGTT blood glucose curves confirmed diabetes (Fig. 1).
Apart from vomiting shortly after STZ administration
(n = 3), no adverse effects were observed. Urinalysis did not
show proteinuria, and serum protein and albumin levels were
stable, indicating the absence of a protein-losing nephropathy.
Triphasic Blood Glucose Response
The presence of indwelling intravascular lines enabled
us to draw frequent blood samples and monitor the metabolic
changes that followed STZ administration. All monkeys that
were treated with high-dose STZ (1250 mg/m2 Sigma STZ or
150 mg/kg Zanosar STZ) showed a triphasic blood glucose
response to STZ (Figs. 2 and 3). Initially, during approxi-
mately 8 hours, there was a marked increase to a mean of
330 mg/dL followed by a steady reduction to 56 mg/dL at
17 hours (at this point the dextrose infusion was increased).
Metabolic acidosis occurred mainly during the second phase
when the blood glucose fell to low levels after the peak at
8 hours post-STZ administration, necessitating iv bicarbonate
infusion. This was followed by a second and sustained
increase in glucose to a mean of 310 mg/dL at 30 hours
(necessitating iv insulin administration).
FIGURE 3. Blood glucose responses (dashed lines) of individual
monkeys (n = 9) during and after the successful induction of
diabetes after receiving high-dose STZ. A triphasic response can
be seen in every case. The aberrant response in 1 monkey
(M38) that was not completely rendered diabetic (after
60 mg/kg STZ) is shown in a solid black line.
FIGURE 2. Representative triphasic blood
glucose response (dashed line) after (Zanosar)
STZ administration in a representative
cynomolgus monkey. Dextrose was
administered continuously (indicated in
mg/h; dotted line), and insulin treatment was
started after 26.5 hours (solid line).
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Figure 2:  
Representative triphasic blood glucose response (dashed 
line) after (Zanosar) STZ administration in a representative 
cynomolgus monkey.  Dextrose was administered 
continuously (indicated in mg/h, dotted line), and insulin 
treatment was started after 26.5h (solid line).
stimulation tests showed an increase of C-peptide production
to 6.17 ng/mL after 2 minutes. Baseline metabolic blood and
urine screening showed normal kidney and liver functions.
Clinical Response to Streptozotocin
All 10 monkeys became consistently hyperglycemic
(ie, blood glucose level, 9200 mg/dL) at a mean of 30.3 hours
(range, 26.5Y34.25 hours) after STZ administration.
Group 1
After high-dose Sigma STZ at 1250 mg/m2, C-peptide
measurement demonstrated that all 4 Group 1 monkeys
became completely diabetic. C-peptide values fell below the
0.5-ng/mL detection level, which was confirmed by radioim-
munoassay, both when fasting and after iv glucose challenge
on ivGTT testing. The ivGTT blood glucose curves confirmed
diabetes (Fig. 1).
Although consistent hyperglycemia was observed, the
Group 1 monkey that received 60 mg/kg Sigma STZ failed to
lose complete beta cell function; the fasting post-STZC-peptide
value was 1.86 ng/mL, and the glucose-stimulated value was 2.
93 ng/mL. This monkey showed no adverse effects post-STZ.
Adverse effects were observed in the 4 monkeys that
received high-dose Sigma STZ. These included vomitingwithin
1 hour after STZ administration (n = 4), and a protein-losing
nephropathy was observed (n = 3) particularly after immuno-
suppressive drug therapy was initiated. Serum protein levels
came down to an average of 4.3 g/dL (range 3.6Y5.1 g/dL),
necessitating iv human albumin infusion. Albumin levels de-
creased proportionately (average, 1.7 g/dL; range 1.2Y2.3 g/dL).
Furthermore, severe proteinuria was documented using urine
test strips (Baxter; Deerfield, Ill). Serum creatinine levels were
stable and within the reference range. Liver transaminases,
although not measured in the acute phase, did not show ele-
vation above the reference range post-STZ.
Group 2
Group 2 monkeys became consistently diabetic after
150 mg/kg Zanosar STZ administration. Fasting blood
glucose was greater than 200 mg/dL. Fasting and random
C-peptide levels fell below the detection level of 0.5 ng/mL
by chemiluminescence and below the 0.1-ng/mL detection
range by radioimmunoassay. Stimulation with ivGTT and/or
arginine did not result in an increase in serum C-peptide, and
ivGTT blood glucose curves confirmed diabetes (Fig. 1).
Apart from vomiting shortly after STZ administration
(n = 3), no adverse effects were observed. Urinalysis did not
show proteinuria, and serum protein and albumin levels were
stable, indicating the absence of a protein-losing nephropathy.
Triphasic Blood Glucose Response
The presence of indwelling intravascular lines enabled
us to draw frequent blood samples and monitor the metabolic
changes that followed STZ administration. All monkeys that
were treated with high-dose STZ (1250 mg/m2 Sigma STZ or
150 mg/kg Zanosar STZ) showed a triphasic blood glucose
response to STZ (Figs. 2 and 3). Initially, during approxi-
mately 8 hours, there was a marked increase to a mean of
330 mg/dL followed by a steady reduction to 56 mg/dL at
17 hours (at this oint the dextrose infusion was increased).
M tabolic acid sis occurred mainly dur g the s cond phase
when the blood glucose fell to l w level after the peak at
8 hours post-STZ administration, necessitating iv bicarbonate
infusion. This was followed by a second and sustained
increase in glucose to a mean of 310 mg/dL at 30 hours
(necessitating iv insulin administration).
FIGURE 3. Blood glucose responses (dashed lines) of individual
monkeys (n = 9) during and after the successful induction of
diabetes after receiving high-dose STZ. A triphasic response can
be seen in every case. The aberrant response in 1 monkey
(M38) that was n t completely rendered diabetic (after
60 mg/kg STZ) is shown in a solid black line.
FIGURE 2. Representative triphasic blood
glucose response (dashed line) after (Zanosar)
STZ administration in a representative
cynomolgus monkey. Dextrose was
administered continuously (indicated in
mg/h; dotted line), and insulin treatment was
started after 26.5 hours (solid line).
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Figure 3: 
Blood glucose responses (da hed lines) of  individual 
monkeys (n=9) during and after the successful induction of  
diabetes after receiving high-dose STZ.  A triphasic response 
can be seen in every case.  The aberrant response in one 
monkey (M38) that was not completely rendered diabetic 
(after 60mg/kg STZ) is shown in a solid black line.
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Histology
Pancreatic tissue sections from monkeys that were treated with high-dose STZ (1250mg/m2 
or 150mg/kg) resulted in low or absent insulin staining (Figure 4). Hematoxylin and eosin 
staining of kidney, liver, and heart sections, taken at the time of euthanasia (not in the acute 
phase following STZ administration) did not show significant lesions in any monkey.
DISCUSSION
Diabetes can be consistently induced after high-dose STZ administration. Both 1250mg/m2 
(~105mg/kg) Sigma STZ as well as 150mg/kg Zanosar STZ resulted in the cessation of C-
peptide production (i.e., to a level below the detection level of the respective assays).  
Chapter 7, Figure 4: 
Insulin-positive cells in pancreatic tissue of  normal monkey (A) and after 
150mg/kg Zanosar STZ (B), 1250mg/m2 (~105mg/kg) Sigma STZ (C), 
and 60mg/kg Sigma STZ (D).  No insulin-positive cells are seen after 
high-dose STZ (B, C); there are still insulin-positive cells present after 
low-dose STZ (D).
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There is an ongoing discussion with regard to the optimal dose of STZ in nonhuman primates. 
Pitkin and Reynolds (21) and Litwak et al. (22) showed that a single dose of 30mg/kg is 
insufficient to induce complete diabetes. Larger doses of 100-150mg/kg were found sufficient 
(16,18,23), but were associated with more side effects and complications (16-19,23). In 
contrast, Koulmanda et al. (16) reported that 55mg/kg was sufficient to consistently induce 
diabetes in cynomolgus monkeys, but others have been less successful with this dosage 
(17,21,24,25), with C-peptide production still detectable (in the range of 0.6 to 0.9ng/mL). 
Wijkstrom et al. (23) suggested the dose should be based on body surface area (1250mg/
m2), rather than body weight. 
The islets of younger nonhuman primates may be more resistant to destruction, and this 
may account for the varying STZ dosages required to induce diabetes (16,24). Furthermore, 
since STZ has a half-life of only 10 min (16), it seems reasonable to anticipate that higher 
dosages are necessary if it is not administered rapidly as a bolus. 
The correlation between the dose of STZ and the development of renal and hepatic damage 
is well-documented. This is demonstrated by an increase in blood urea nitrogen, serum 
creatinine, and/or hepatic enzymes, or by histological injury (16-19). It is therefore of 
importance to find the optimum dose to successfully induce diabetes with minimal or no risk 
of side-effects.
To our knowledge, the present study is the first to describe the safe induction of diabetes 
with high-dose Zanosar STZ, resulting in undetectable (fasting and stimulated) primate C-
peptide. Zanosar STZ is used in patients with metastatic islet cell carcinoma, and may have 
fewer side effects, perhaps because of greater purity and less variability (S. Deng, personal 
communication). At 150mg/kg, we were able to successfully establish diabetes in nonhuman 
primates without residual beta cell function, and without associated morbidity. In contrast, 
high-dose Sigma STZ was associated with adverse effects, although the role of additional 
immunosuppressive therapy in the development of this damage remains uncertain.  
Figures 5A and B present extrapolated data that show the relation between dosages 
calculated on the basis of body surface area and body weight, for monkeys of different body 
weights. These indicate that an STZ dosage of 150mg/kg, when converted to body surface 
area, is much higher than a dose based on body surface area of 1250mg/m2, particularly in 
heavier (older) monkeys (Figure 5A). However, in our experience with monkeys up to 4.7kg, 
we found that 150mg/kg Zanosar STZ safely induced diabetes. Similarly, if the STZ dosage 
is based on a body surface area of 1250mg/m2, heavier (older) monkeys would be receiving 
a dose much lower than 150mg/kg (Figure 5B).
In the present study, a triphasic response in blood glucose was observed during the first 
36h after STZ administration.  Such a response has been described in rodents (26,27) and 
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monkeys (24,28). Interpretation of the triphasic response is that there is an initial decrease 
of insulin release as a result of inflammation and an inability of the beta cells to respond to 
glucose due to impaired glucose oxidation in the beta cell (15,27); this explains the initial rise 
in blood glucose (phase I). Further destruction and disruption of the beta cells results in a 
massive release of insulin, leading to a fall in blood glucose level (phase II). Finally, there is a 
critical loss of beta cells (phase III), resulting in the diabetic state (15,26). We documented a 
peak blood glucose after 8h (compared to 2-7h in the rat), followed by a steady fall until 17h 
(8-12h in the rat) and a subsequent rise with persistent hyperglycemia (>200mg/dL) after 
30.3h (24h in the rat) (26, 27). Since the monkey that did not become successfully diabetic 
lacked this triphasic response (Figure 3), we suggest this response indicates the complete 
and successful induction of diabetes.
surface area and body weight for monkeys of different body
weights. These indicate that an STZ dosage of 150 mg/kg,
when converted to body surface area, is much higher than
a dose based on body surface area of 1250 mg/m2,
particularly in heavier (older) monkeys (Fig. 5A). How-
ever, in our experience with monkeys weighing up to
4.7 kg, we found that 150 mg/kg Zanosar STZ safely
induced diab t s. Simil rly, if the STZ dosage is based on a
body surface area of 1250 mg/m2, heavier (older) monkeys
would be receiving a dose much lower than 150 mg/kg
(Fig. 5B).
In the present study, a triphasic response in blood
glucose was observed during the first 36 hours after STZ
administration. Such a response has been described in
rodents26,27 and monkeys.24,28 Interpretation of the triphasic
response is that there is an initial decrease of insulin release
as a result of inflammation and an inability of the beta
cells to respond to glucose because of impaired glucose
oxidation in the beta cell;15,27 thi explains the initial
rise in blood glucose (phase 1). Further destruction and
disruption of the beta cells results in a massive release of
insulin leading to a fall in blood glucose level (phase 2).
Finally, there is a critical loss of beta cells (phase 3)
resulting in the diabetic state.15,26 We documented a peak
blood glucose after 8 hours (compared to 2Y7 hours in the
rat), followed by a steady fall until 17 hours (8Y12 hours
in the rat), and a subsequent rise with persistent
hyperglycemia (9200 mg/dL) after 30.3 hours (24 hours
in the rat).26,27 Because the monkey that did not become
successfully diabetic lacked this triphasic response (Fig. 3),
we suggest this response indicates the complete and successful
induction of diabetes.
In summary, in Zanosar STZ, we found a safe agent to
completely induce diabetes in monkeys. This may have
important implications for those who are establishing a model
of diabetes in nonhuman primates. We have shown that a
triphasic blood glucose response post-STZ indicates complete
and successful induction of diabetes.
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surface area and body weight for monkeys of different body
weights. These indicate that an STZ dosage of 150 mg/kg,
when converted to body surface area, is much higher than
a dose based on body surface area of 1250 mg/m2,
particularly in heavier (older) monkeys (Fig. 5A). How-
ever, in our exper nce with weighing up to
4.7 kg, we found that 150 mg/kg Zanosar STZ safely
induced diabetes. Similarly, if the STZ dosage is based on a
body surf ce area of 1250 mg/m2, heavier ( lder) monkeys
would be receiving a dose much lower than 150 mg/kg
(Fig. 5B).
In the present study, a triphasic response in blood
glucose was observed during the first 36 hours after STZ
administration. Such a response has bee described in
rodents26,27 and monkeys.24,28 Interpretation of the triphasic
response is that there is an initial decrease of insulin release
as a result of inflammation and an inability of the beta
cells to respo d to glucose because of impaired glucose
oxidation in the beta cell;15,27 this explains the initial
rise in blood glucose (phase 1). Further destruction and
disruption of the beta cells results in a massive release of
insulin leading to a fall in blood glucose level (phase 2).
Finally, there is a critical loss of beta cells (phase 3)
resulting in the diabetic state.15,26 We documented a peak
blood glucose after 8 hours (compared to 2Y7 hours in the
rat), followed by a steady fall until 17 hours (8Y12 hours
in the rat), and a subsequent rise with persistent
hyperglycemia (9200 mg/dL) after 30.3 hours (24 hours
in t rat).26,27 Because the monkey that did not become
successfully diabetic lacked this triphasic response (Fig. 3),
we suggest this response indicates the complete and successful
induction of diabetes.
In summary, in Zanosar STZ, we found a safe agent to
completely induce diabetes in monkeys. This may have
important implications for those who are establishing a model
of diabetes in nonhuman primates. We have shown that a
triphasic blood glucose response post-STZ indicates complete
and successful induction of diabetes.
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Figure 5:  
(A) Extra olated data showing equivalent doses (calculated 
per m2  surface area) of   STZ administration 
at 150 mg/kg body weight for nonhuman primates 
weighing 7kg, 5kg, 3kg, nd 1kg. (B) Extrapolated data 
showing equivalent doses (in mg/kg body weight) of  
STZ administration at 1250 mg/m2 body surface area 
calculated for nonhuman primates weighing 7kg, 5kg, 
3kg, and 1kg.
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In summary, in Zanosar STZ we found a safe agent to completely induce diabetes in 
monkeys. This may have important implications for those who are establishing a model of 
diabetes in nonhuman primates.  We have shown that a triphasic blood glucose response 
post-STZ indicates complete and successful induction of diabetes.
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ABSTRACT
Background: Pig islets constitute a possible resolution to the shortage of human islets 
for transplantation (Tx). After intraportal infusion of porcine islets in primates, many islets 
are lost through what has been termed the instant blood-mediated inflammatory reaction 
(IBMIR). We report on our experience with IBMIR.
Methods: Ten monkeys underwent intraportal porcine islet Tx.  Immunosuppressive therapy 
was with conventional agents (n=3) or based on costimulation blockade (n=7). Treatment 
specific for IBMIR was administered in 8 monkeys, 2 additional monkeys received no such 
therapy (Group 1).  Cobra venom factor (CVF) completely inhibited complement activity in 
4 (Group 2), and dextran sulfate (DS) provided anticoagulation, in 4 (Group 3). Islet graft 
function was monitored by following blood glucose, insulin requirement, and porcine C-
peptide values.
Results: In monkeys that received neither CVF nor DS (Group 1), there was rapid destruction 
of islets, indicated by severe hypoglycemia and the need for dextrose infusion; C-peptide 
levels were initially low and further reduction occurred within the first 5 days. In both Groups 
2 and 3, there was significantly less destruction of islets, and some reversal of diabetes. 
However, when 40,000IEQ/kg were infused, normoglycemia was lost within 5 days, but 
when 80,000IEQ/kg were infused in one case, normoglycemia was more persistent. We 
observed that, even when C-peptide levels were in the normal range for healthy non-diabetic 
pigs, these were not sufficient to maintain normoglycemia in the monkeys.
Conclusions: Although pre-Tx complement depletion or anticoagulation reduces porcine 
islet xenograft loss significantly, neither alone is sufficient to prevent IBMIR. 
INTRODUCTION
Recent experience has demonstrated the feasibility of treating type 1 diabetic patients by islet 
allotransplantation (Tx) (1-3), but the shortage of human donor organs is a major limitation. 
Pig islets form a possible alternative. 
Islets are transplanted most commonly intraportally, due to the potential to produce insulin 
after exposure of the islets to portal blood glucose. The disadvantage of this approach is 
that direct exposure of the pig islets to the blood can result in their early destruction (4, 5), 
a phenomenon termed the ‘instant blood-mediated inflammatory reaction’ (IBMIR). Islets 
injected intraportally, whether they be allo (6,7) or xeno (5) islets, are subject to this response, 
which is manifest by activation and consumption of platelets, activation of neutrophils and 
monocytes, and activation of the coagulation and complement systems (5, 8). Islet Tx also 
results in activation of both humoral and cellular responses and, indeed, the innate immune 
system may be involved in the IBMIR.
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Medium-term survival of porcine islets in nonhuman primates has recently been reported in 
the apparent absence of specific treatment for IBMIR (9, 10). However, there is still a need to 
study and prevent IBMIR, since it would be ideal to obtain normoglycemia with the smallest 
possible number of islets and with minimal immunosuppression.  
The prior administration of soluble complement receptor-1 reduces this rapid islet destruction 
both in vitro and in vivo (5), supporting the hypothesis that complement activation plays 
a major role in IBMIR. Low molecular weight dextran sulfate (DS) has recently been 
demonstrated to block all aspects of IBMIR (11-13), but its effect on islet destruction after Tx 
in a nonhuman primate model has not been previously reported.  
We here report on our experience with IBMIR after the Tx of adult pig islets intraportally into 
cynomolgus monkeys. We have focused primarily on observations made during the first 5 
days after islet Tx. We observed early graft loss, and assessed the protective effect of the 
anti-complement agent, cobra venom factor (CVF) combined with heparin, and of DS, which 
is reported to have both complement-inhibitory and anticoagulant effects (12, 13).
METHODS
Animals
Eight pigs acted as sources of islets.  Six outbred large white (wild-type, WT) pigs (Wally 
Whippo, Enon Valley, PA) were retired breeder sows, and 2 were α1,3-galactosyltransferase 
gene-knockout (GT-KO) female pigs (14) (Revivicor, Blacksburg, VA) that had never been 
pregnant (Table 1). All pigs weighed >150kg. Since isolation of WT pig islets resulted in 
absence of Gal1,3Gal (Gal) expression, we do not believe the source of the islets played 
any role in the outcome of the experiments in this study. However, we and others have 
documented that the pancreas from retired breeders provides a greater number of islets with 
improved insulin production (15, 16).
Ten male cynomolgus monkeys (Macaca fascicularis), weighing 3.3kg±0.7kg (range 
2.4-4.2kg) were recipients of the islets. They were fitted with tethers carrying indwelling 
intravascular and/or gastric catheters, which provide an advantage with regard to the ease 
with which blood samples can be obtained and fluids and drugs administered, without the 
need for restraint or sedation of the primate (17).  
All animal care procedures were in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and 
Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health (NIH publication No. 86-23, revised 1985). 
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Surgical procedures
Under general anesthesia, intravascular lines were inserted in the common carotid artery and 
the jugular veins. In some animals an intragastric line was placed. The animals were tethered 
and remained with indwelling catheters throughout the period of induction of diabetes and 
intraportal islet Tx, which was performed under direct vision through a laparotomy under 
general anesthesia. The numbers of islets transplanted are summarized in Table 1. In 
3 monkeys, additional islets were placed under the kidney capsule, and in one of these 
monkeys they were also placed in an omental pouch (Table 1). 
Induction of diabetes
Diabetes was induced with streptozotocin in nine monkeys. Eight monkeys received high-
dose streptozotocin (105-150mg/kg iv) from Sigma (n=4) or Sicor (Zanosar; n=4), as 
previously described (18). These monkeys became completely diabetic with undetectable 
endogenous C-peptide values. One monkey received a low dose of streptozotocin (60mg/kg) 
and became hyperglycemic, but maintained the capacity to produce insulin endogenously 
(18) (Table 1). One monkey received no streptozotocin.
Islet isolation and preparation
Following pancreatectomy in the anesthetized donor pig, the isolation of pig islets was 
carried out according to a modification of the method described for human islets and further 
optimized for pigs (19, 20). We used Liberase-PI (Roche, Indianapolis, IN) from multiple lots, 
and a large-size (700mL) Ricordi digestion chamber maintained at <34ºC, with very gentle 
mechanical shaking. Enzymatic digestion was discontinued by diluting the enzyme solution 
retired breeder sows, and twowere�1,3-galactosyltransferase
gene-knockout (GT-KO) female pigs (14) (Revivicor, Blacks-
burg, VA) that had never been pregnant (Table 1). All pigs
weighed�150 kg. Because isolation of WT pig islets resulted
in absence of Gal1,3Gal (Gal) expression, we do not believe
the source of the islets played any role in the outcome of the
experiments in this study. However, we and others have
documented that the pancreas from retired breeders pro-
vides a greater number of islets with improved insulin pro-
duction (15, 16).
Ten male cynomolgus monkeys (Macaca fascicularis),
weighing 3.3�0.7 kg (range, 2.4–4.2 kg), were recipients of
the islets. They were fitted with tethers carrying indwelling
intravascular and/or gastric catheters, which provide an ad-
vantage with regard to the ease with which blood samples can
be obtained and fluids and drugs administered without the
need for restraint or sedation of the primate (17).
All animal care procedures were in accordance with the
Principles of Laboratory Animal Care formulated by the Na-
tional Society for Medical Research and the Guide f r the Care
andUse of LaboratoryAnimals preparedby the Institute of Lab-
oratory Animal Resources and published by the National Insti-
tutes of Health (NIH publication No. 86-23, revised 1985).
Surgical Procedures
Under general anesthesia, intravascular lines were in-
serted in the common carotid artery and the jugular veins. In
some animals, an intragastric line was placed. The animals
were tethered and remained with indwelling catheters
throughout the period of induction of diabetes and intrapor-
tal islet Tx, which was performed under direct vision through
a laparotomy under ge eral an sthesi . The numbers of islets
transplanted are summarized in Table 1. In three monkeys,
additional islets were placed under the kidney capsule, and in
one of these monkeys, they were also placed in an omental
pouch (Table 1).
Induction of Diabetes
Diabetes was induced with streptozotocin in nine
monkeys. Eight monkeys received high-dose streptozotocin
(105–150 mg/kg intravenously) from Sigma (n�4) or Sicor
(Zanosar; n�4) as previously described (18). These monkeys
became completely diabetic with undetectable endogenous
C-peptide values. One monkey received a low dose of strep-
t zo ocin (60 mg/kg) and became hyperglycemic but main-
tained the capacity to produce insulin endogenously (18)
(Table 1). One monkey received no streptozotocin.
Islet Isolation and Preparation
After pancreatectomy in the anesthetized donor pig,
the isolation of pig islets was carried out according to a
modification of the method described for human islets and
further optimized for pigs (19, 20). We used Liberase-PI
(Roche, Indianapolis, IN) from multiple lots, and a large-
sized (700 mL) Ricordi digestion chamber maintained at
�34°C with very gentle echanical shaking. Enzymatic
digestion was discontinued by diluting the enzyme solu-
tion with cold RPMI-1640 (Life Technologies, Gaithers-
burg, MD) supplemented with 10% heat-inactivated fetal
calf serum (Life Technologies) (21, 22). Separation of islet-
enriched fractions was performed using discontinuous
gradients (densities of 1.132, 1.108, 1.096, and 1.037) in a
COBE 2991 Cell Separator (Gambro BCT, Lakewood, CO)
(23, 24). Purity was evaluated after dithizone staining of
islet samples and expressed as percent of islets/whole tissue
(23). Islets were cultured overnight in CMRL-1066 me-
dium (Mediatech, Herndon, VA) supplemented with 10%
heat-inactivated porcine serum (Life Technologies) 10
U/mL penicillin, 100 mg/mL streptomycin (Invitrogen,
Carlsbad, CA), and 10 mM nicotinamide (Sigma-Aldrich,
St. Louis, MO) at 37°C in an atmosphere of 95% air and
5% CO2.
TABLE 1. Number and type of islets transplanted, immunosuppressive protocols, and treatment to prevent early graft loss
Monkey
no. IEQ/kg Immunosuppressive protocol
Treatment specific for
IBMIR
M3804a 27,000 WT retired breeder ATG, Tac Heparin 70 U/kg
M3604 40,000 WT retired breeder ATG, Tac, Rapa, rituximab Heparin 70 U/kg
M3404 40,000 WT retired breeder ATG, Tac, Rapa CVF, heparin 70 U/kg
M4804c 40,000 WT retired breeder ATG, anti-CD154 mAb, MMF CVF, heparin 105 U/kg,
prostacyclin, aspirin
M5204 40,000 WT retired breeder ATG, anti-CD154 mAb, MMF CVF, heparin 105 U/kg,
prostacyclin, aspirin
CM9I 40,000 GT-KO non breeder ATG, anti-CD154 mAb, MMF CVF, heparin 140 U/kg,
prostacyclin, aspirin
CM9R 40,000 GT-KO non breeder ATG, anti-CD154 mAb, MMF DS, prostacyclin, aspirin
M8305 40,000 GT-KO non breeder ATG, anti-CD154 mAb, MMF DS, prostacyclin, aspirin
M8405c 80,000 WT retired breeder ATG, anti-CD154 mAb, MMF DS, prostacyclin, aspirin
M8605b,c 40,000 WT retired breeder ATG, anti-CD154 mAb, MMF DS, prostacyclin, aspirin
a Monkey incompletely diabetic.
b Monkey nondiabetic.
c Received additional islets (15,000–20,000 IEQ/kg) under the renal capsule; M4804 also received additional islets (40,000 IEQ/kg) in an omental pouch.
IBMIR, instant blood-mediated inflammatory reaction; ATG, antithymocyte globulin; CVF, cobra venom factor; DS, dextran sulfate; GT-KO, �1,3-
galactosyltransferase gene-knockout; MMF, mycophenolate mofetil; Rapa, rapamycin; Tac, tacrolimus; WT, wild-type.
© 2007 Lippincott Williams & Wilkins 203Rood et al.Table 1: 
Number and type of  islets transplanted, immunosuppressive protocols, and treatment to 
prevent early graft loss
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with cold RPMI-1640 (Life Technologies, Gaithersburg, MD), supplemented with 10% 
heat-inactivated fetal calf serum (Life Technologies) (21, 22). Separation of islet-enriched 
fractions was performed using discontinuous gradients (densities of 1.132, 1.108, 1.096, and 
1.037) in a COBE 2991 Cell Separator (Gambro BCT, Lakewood, CO) (23, 24). Purity was 
evaluated after dithizone staining of islet samples, and expressed as percent of islets/whole 
tissue (23). Islets were cultured overnight in CMRL-1066 medium (Mediatech, Herndon, 
VA), supplemented with 10% heat-inactivated porcine serum (Life Technologies), 10units/
mL penicillin, 100mg/mL streptomycin (Invitrogen, Carlsbad, CA), and 10mM nicotinamide 
(Sigma-Aldrich, St. Louis, MO), at 37ºC, in an atmosphere of 95% air and 5% CO2. 
Islet assessment in vitro and in vivo
Functional properties of the islets, including dynamic perifusion and viability, were 
determined in vitro prior to Tx, as described previously (25).  For glucose challenge assay, 
islets were subjected to low glucose (2.8mM), high glucose (16.7mM), and high glucose plus 
theophylline (10mM) challenges. In vivo Tx studies were conducted in mice, as previously 
described (26).
Immunofluorescence studies
Sections of isolated porcine islets were fixed in 2% paraformaldehyde and frozen.  Using 
standard procedures, islets were stained with fluorescein-labeled Griffonia simplicifolia-1 
isolectin B4 (1:100; Vector laboratories, Burlingame, CA) for Gal expression.  For insulin 
immunostaining, sections were incubated with rabbit anti-insulin IgG (1;250; Santa Cruz 
Biotech, Santa Cruz, CA) followed by Cy3-conjugated goat anti-rabbit secondary antibody 
(Jackson Immunoresearch Laboratories, West Grove, PA).  Stained islets were examined 
under an Olympus Fluoview BX61 confocal microscope (Olympus, Melville, NY).
Islet transplantation
Prior to transplantation, pig islets were counted, and viability was assessed by double 
fluorescent calcein-AM and propridium iodide stain (27). Islet cell viability was >75% in all 
preparations, and purity was >80% islets/whole tissue. Islets were transplanted intraportally 
in plain CMRL-1066, either in heparin (70-140U/kg; Baxter, Deerfield, IL) (n=6) or in DS (MW 
~5000d; 1.5-4.5mg/kg; Fluka, Buchs, Switzerland) (n=4) (Table1).
Immunosuppressive and other drug therapy
The immunosuppressive agents that were administered are summarized in Table 1. Anti-
thymocyte globulin (ATG) (Thymoglobulin®, generously provided by Genzyme, Cambridge, 
MA) was given iv over 7-10h on days -3 (n=10) and -1 (n=9) at 6-10mg/kg and 1-10mg/kg, 
respectively, to reduce the peripheral blood CD3+ T cell count to approximately 500cells/
μL (determined by flow cytometry). To prevent side effects from ATG administration, the 
animals were pretreated with diphenhydramine (5mg/kg iv), metoclopramide (0.5mg/kg iv), 
and methylprednisolone (5mg/kg iv). 
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Tacrolimus (Astellas, Deerfield, IL) therapy was initiated on day -7 at 1.5mg/kg orally 
through an intragastric tube x2 daily, aiming for a trough level of 4-6ng/mL. Rapamycin 
(A.G. Scientific, San Diego, CA) was started on day -7 at 0.5-1.5mg/kg daily orally through 
an intragastric tube, aiming for a trough level of 9-15ng/mL. One monkey (M3604) received 
Rituximab (375mg/m2; Genentech, San Francisco, CA) on day 0 after islet Tx, and again on 
day 5 after Tx. 
A human anti-human CD154 monoclonal antibody (ABI 793, generously provided by 
Novartis Pharma, Basel, Switzerland) was administered at 25mg/kg at days -1, 0, 4, 7, 10, 
14, and then every 5 days to achieve a whole blood trough level of >400ng/mL (determined 
by ELISA) (28). Mycophenolate mofetil (MMF; Roche, Nutley, NJ) was given by continuous 
iv administration at 75-150mg/kg/day iv, beginning on day -4, aiming for a constant level of 
3-5μg/mL. One monkey (M8305) received MMF orally x2 daily.
Heparin was administered with the islets (70-140U/kg), but not when DS was given. CVF 
(Advanced Research Technologies, San Diego, CA) was given to deplete complement from 
day -1 until day 4, and consistently resulted in CH50 values of 0-5% from day 0 before 
islet Tx.  DS was administered as a bolus (3-10mg/kg iv) 15min before islet Tx; in addition, 
1.25-4.5mg/kg was given intraportally with the islets, and thereafter DS was given as a 
continuous iv infusion (at 0.5-2mg/kg/h) for 6 hours - 5 days. (In the initial protocol, DS 
was to be administered for 5 days, but after some minor bleeding complications, the period 
was greatly reduced [see below]). Activated clotting time (ACT) and/or activated partial 
thromboplastin time (aPTT) values were measured regularly. The effects of heparin and DS 
were monitored by measurement of the ACT or aPTT, and the doses modified to prevent 
excessive anticoagulation (i.e., to maintain the ACT <225 and the aPTT <90sec). In 7 
monkeys, prostacyclin (GlaxoSmithKline, Research Triangle Park, NC) was administered 
by continuous iv infusion at 80ng/kg/min, beginning 30min before islet Tx and continued for 
at least 7 days for its suppressive effect on endothelial cell activation, and aspirin (81mg x2 
daily) was started on day -4 for its anti-inflammatory effect and to reduce platelet aggregation 
(Table 1). 
Supportive therapy
After insertion of the intravascular lines, famotidine (0.25mg/kg) or cimetidine (10mg/kg) 
was administered iv x2 daily. When immunosuppressive therapy was initiated, all monkeys 
received daily ganciclovir (5mg/kg iv daily) and levofloxacin (10mg/kg iv daily) or cefazolin 
(10mg/kg iv x2 daily) as prophylaxis against infection. 
Monitoring
Complete blood count, electrolyte levels, and tests for acid-base balance and selected renal 
and hepatic functions, were carried out frequently. Blood glucose values were measured 
at least x2 daily before islet Tx, and more frequently after Tx.  Before islet Tx, regular 
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insulin (Humulin® R; Eli Lilly, Indianapolis, IN) ± 5% dextrose was administered, aiming at 
maintaining the blood glucose between 100-200mg/dL to prevent severe hyper- or hypo-
glycemia.  After islet Tx, the period of normoglycemia in the absence of insulin therapy was 
measured. Complement activity was determined with the Diamedix EZ Complement CH50 
test (IVAX Diagnostics, Miami, FL), according to the manufacturer’s protocol. Porcine C-
peptide levels were measured by radioimmunoassay (Linco Research, St. Charles, MO) at 
approximately 8h and 20h after Tx, and subsequently at intervals of 1-4 days, according to 
the manufacturer’s instructions.
Study groups
Based on whether the monkey received any specific therapy aimed at reducing the IBMIR, 
the islet graft recipients have been divided into 3 groups (Table 1).  Group 1 (n=2) received 
no IBMIR-directed therapy except heparin with the pig islets.  Group 2 (n=4) received 
heparin with the islets and a 5-day course of CVF.  Group 3 (n=4) received DS immediately 
before the islet Tx (as an iv bolus), with the islets (as a second bolus), and subsequently iv 
for between 6h and 5 days, but no heparin or CVF. Three of the four monkeys in Group 2 
and all four in Group 3 received identical immunosuppressive and supportive therapy, and 
therefore are comparable in this respect. In view of the fact that we found that DS had little 
effect on complement activity, Group 2 represented islet Tx in a recipient totally depleted of 
complement (but not significantly anticoagulated), and Group 3 represented islet Tx in an 
anticoagulated recipient (in which complement activity had been only minimally reduced).
Statistical analysis
Statistical analysis of data was performed using Student’s t test (SPSS for Windows version 
13.0 [SPSS Inc., Chicago, IL]).
RESULTS
Quality of porcine islets
Each islet preparation utilized for Tx was assessed for functional properties in vitro as well 
as in vivo.  Islets were subjected to dynamic perifusion using glucose (2.8 vs. 16.7mM) 
with and without theophylline (10mM) as stimuli for insulin secretion.  The ratio between 
stimulated and basal insulin release (stimulation index) was 2.6±0.8 after high glucose 
exposure, and 5.6±1.8 following high glucose and theophylline.  Islet viability was assessed 
using a dual immunofluorescence staining method (calcein-AM and propidium iodide) and 
was >75% in all preparations.  Additionally, using an islet marginal mass composed of 200 
to 350 islets (differences in number to account for variation in islet size) from 6 donor islet 
preparations (including one GT-KO), islets were transplanted under the kidney capsule of 
17 STZ-diabetic immunodeficient (NOD-scid and Rag) mice. Fifteen animals normalized, 1 
did not, and 1 died shortly after surgery.  No statistical difference between WT and GT-KO 
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islets was noted when comparing in vitro or in vivo functional performance.  Morphological 
inconsistency between pig islet preparations, with regard to degree of islet integrity, were 
observed, but were consistent with the difference between truly retired-breeder and merely 
adult islet donors.
Early islet graft loss
Early islet destruction after Tx results in insulin release from the islets, which in turn leads 
to hypoglycemia. As an estimation of the extent of islet graft loss, in the completely diabetic 
monkeys (n=8) we calculated the amount of dextrose administered iv to prevent hypoglycemia 
(blood glucose <80mg/dL) within the first 2h and also within the first 8h after Tx. In order to 
correct for differences in body weight and differences in the number of islets transplanted 
(islet equivalents; IEQ), the amount of dextrose infused was calculated per kg body weight 
of the recipient monkey, and per 10,000IEQ transplanted. As soon as insulin therapy was 
required to reverse hyperglycemia, 5% dextrose was infused at a standard rate of 5mL/h; 
therefore, at this point, we stopped measuring the amount of dextrose infused.
We observed an important difference between the amount of dextrose administered to 
monkeys that did not receive any specific treatment to prevent IBMIR, and thus early loss 
of islets (Group 1), and those that received either CVF (Group 2) or DS (Group 3). In the 
absence of any agent intended to deplete complement and with only one bolus of 70U/kg 
heparin to provide anticoagulation (Group 1), the amount of dextrose that was infused to 
correct hypoglycemia during the first 2h (30mg/kg/10,000IEQ transplanted) and 8h (55mg/
kg/10,000IEQ) was considerable. The dextrose requirement was significantly less in both 
Group 2 (CVF+heparin; 4.7 at 2h [p<0.01] and 21.7 at 8h [p<0.05]) and Group 3 (DS; 2.7 
[p<0.01] and 19.7 [p<0.05] at 2h and 8h, respectively). The dextrose requirements in Groups 
2 and 3 were not significantly different (p=0.47 at 2h and p=0.89 at 8h).
This indicated that CVF or DS protected the porcine islets from early destruction to an 
important extent, but, since a dextrose infusion continued to be necessary, neither CVF nor 
DS prevented this early loss entirely. 
Anticoagulation 
aPTT and ACT values were measured after administration of CVF+heparin (Group 2), and 
DS (Group 3) (Figure 1). The monkeys that were treated with CVF received only one bolus 
of heparin with the islets, which resulted in an increase of aPTT to a mean of 78sec at 15min, 
and 56sec at 60min (Figure 1A); their state of anticoagulation was therefore minimal and 
transient. In monkeys that were treated with DS (initially as an iv bolus, then with the islets, 
and subsequently as a continuous iv infusion for 6h to 5 days), the ACT was monitored 
at intervals. The ACT was maintained between 134-235sec during the first 4-6h after Tx 
(Figure 1B). In Group 3, aPTT was not measured in all cases, but was >150sec after the 
initial bolus injection of DS. In two monkeys, the continuous DS infusion was associated with 
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minor superficial bleeding in the abdominal wound, which resulted in discontinuation of the 
administration of DS at 6h and 30h post-Tx. This complication suggests that the dosage of 
DS being administered was at a maximum from a safety perspective.
Monitoring of complement (CH50) activity
While CVF was able to completely deplete complement, DS (in the doses used in the present 
study) only reduced the CH50 value by approximately 15%, indicating complement was active 
(Figure 1C). There was, however, no obvious difference in the extent of early destruction of 
the islets, as measured by the amount of dextrose needed to prevent hypoglycemia.
Blood glucose values after islet Tx
The effects of the islet graft on blood glucose, starting 8h after Tx, by which time the 
glucose level after islet Tx in two monkeys (M3604,
M3406). Six monkeys showed at least temporary insulin-
independence for periods ranging from �1 to �5 days.
One monkey (M8405) remained normoglycemic through-
out the five-day period of observation without the need for
insulin. Whenever insulin treatment was required (in five
of the six monkeys), in four cases, this was at a lower level
than before Tx. The reduction in insulin requirement to
maintain a blood glucose�200 mg/dL ranged from 0% to
80%. The blood glucose, and independence from insulin,
showed a correlation with the porcine C-peptide value
(discussed subsequently) (Fig. 3).
Porcine C-peptide Values After Islet
Transplantation
The normal range of C-peptide in healthy, nondiabetic
pigs at our facility is 0.2 to 0.6 ng/mL. In monkeys, after the
first eight hr, by which time the early destruction of islets and
release of insulin andC-peptide had largely occurred, porcine
C-peptide levels were measured. Figure 3 indicates these val-
ues in relation to the two different immunosuppressive regi-
mens used and in relation to the agents administered in an
attempt to prevent IBMIR.
When a conventional immunosuppressive protocol was
administered (n�3), in the absence of any therapy directed to-
wards IBMIR(group1,n�2,M3604andM3804), after theTxof
27,000 or 40,000 IEQ/kg, very low C-peptide levels were docu-
mented even on day one (Fig. 3A). In the third animal, when
CVFwas added to this conventional protocol (n�1,M3404), an
increased porcine C-peptide level was documented; however,
follow up of this monkey was p sibl f r only 30 hr because it
required euthanasia for uncontrollable seizures, possibly related
to a high level of tacrolimus.
Porcine C-peptide levels were considerably higher in
monkeys that were treated with the costimulation blockade
regimen (Fig. 3B). No clear differencewas seenwhether treat-
ment was with CVF�heparin (group 2, n�3, dotted line) or
DS (group 3, n�3, continuous lines). There was, however, a
rapid decrease of porcine C-peptide in the single monkey in
which diabetes had not been induced (M8605), which also
received 40,000 IEQ/kg intraportally and the same immuno-
suppressive regimen.
Using the same immunosuppressive regimen, after the
Tx of 80,000 IEQ/kg in one monkey (M8405), the levels of
C-peptide were higher (initially 6.2 ng/mL, reducing to 2.7
ng/mL by day five (Fig. 3C). Blood glucose levels in this mon-
keyweremaintained between 64 to 91mg/dLwithout admin-
istration of exogenous insulin throughout this five-day
period. On day one after the intraportal injection of 80,000
IEQ/kg, there was elevation of ALT (217 IU/L) and AST (387
IU/L), but these had normalized within four days. This mon-
key required euthanasia for a postoperative complication af-
FIGURE 1. Anticoagulation and CH-50 values pre- and
posttransplantation. (A) Activated partial thromboplastin
time values for monkeys treated with cobra venom factor
and a single bolus of heparin with the islets (group 2, n�4).
(pretransplantation�before islet transplantation; 15 min
and 60 min indicate time after islet transplantation). (B) Ac-
tivated clotting time values for monkeys tre ted with
dextran sulfate (as an intravenous bolus before islet trans-
plantation,�a second bolus with the islets,�by continuous
intravenous infusion aft islet transplantation) du ing the
first eight hr posttransplantation (group 3, n�4). CM9R re-
ceived dextran sulfate for only six hr. (C) CH50 values be-
fore and 12 hr after treatment with cobra venom factor
(group 2) and before and 15 min after treatment with dex-
tran sulfate (group 3) (�standard deviation).
FIGURE 2. Blood glucose values of all completely dia-
betic monkeys (n�8) in the first five days after islet trans-
plantation or until insulin administration was started.
Monkeys were treated with conventional immunosuppres-
sive drugs (continuous black lines; n�2), or with a costimu-
lation blockade-based regimen with cobra venom factor
and heparin (dotted red lines, n�3), or a costimulation
blockade-based regimen with dextran sulfate (continuous
green lines, n�3).
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glucose level after islet Tx in two monkeys (M3604,
M3406). S x monkeys showed at least temporary insulin-
independe ce for periods ranging from �1 to �5 days.
O e monkey (M8405) remained normoglycemic through-
out the five-day period of observation without the need for
insulin. Whenever insulin treatment was required (in five
of the six onkeys), in four cases, this was at a lower level
than before Tx. The reduction in insulin requirement to
maintain a blood glucose�200 mg/dL ranged from 0% to
80%. The blood glu ose, and independ nce from insuli ,
showed a correlation with the porcine C-peptide value
(discussed subsequently) (Fig. 3).
Porcine C-peptide Values After Islet
Transplantation
The normal range of C-peptide in healthy, nondiabetic
pigs at our facility is 0.2 to 0.6 ng/mL. In monkeys, after the
fi st eight hr, by which time the early destruction of islets and
release of insulin andC-peptide had largely occurred, porcine
C-peptide levels were measured. Figure 3 indicates these val-
ues in relation to the two different immunosuppressive regi-
mens used and in relation to the agents administered in an
attempt to prevent IBMIR.
When a conventional immunosuppressive protocol was
administered (n�3), in the absence of any therapy directed to-
wards IBMIR(group1,n�2,M3604andM3804), after theTxof
27,000 or 40,000 IEQ/kg, very low C-peptide levels were docu-
mented even on day one (Fig. 3A). In the third animal, when
CVFwas added to this conventional protocol (n�1,M3404), an
increased porcine C-peptide level was documented; however,
follow up of this monkey was possible for only 30 hr because it
required euthanasia for uncontrollable seizures, possibly related
to a high level of tacrolimus.
Porcine C-peptide levels were considerably higher in
monkeys that were treated with the costimulation blockade
regimen (Fig. 3B). No clear differencewas seenwhether treat-
ment was with CVF�heparin (group 2, n�3, dotted line) or
DS (group 3, n�3, continuous lines). There was, however, a
rapid decrease of porcine C-peptide in the single monkey in
which diabetes had not been induced (M8605), which also
received 40,000 IEQ/kg intraportally and the same immuno-
suppressive regimen.
Using the same immunosuppressive regimen, after the
Tx of 80,000 IEQ/kg in one monkey (M8405), the levels of
C-peptide were higher (initially 6.2 ng/mL, reducing to 2.7
ng/mL by day five (Fig. 3C). Blood glucose levels in this mon-
keyweremaintained between 64 to 91mg/dLwithout admin-
istration of exogenous insulin throughout this five-day
period. On day one after the intraportal injection of 80,000
IEQ/kg, there was elevation of ALT (217 IU/L) and AST (387
IU/L), but these had normalized within four days. This mon-
key required euthanasia for a postoperative complication af-
FIGURE 1. Anticoagulation and CH-50 values pre- and
posttransplantation. (A) Activated partial thromboplastin
time values for monkeys treated with cobra venom factor
and a single bolus of heparin with the islets (group 2, n�4).
(pretransplantation�before islet transplanta ion; 15 in
and 60 min indicate time after islet transplantation). (B) Ac-
tivated clotting time values for monkeys treated with
dextran sulfate (as an intravenous bolus before islet trans-
plantation,�a second bolus with the islets,�by continuous
intravenous infusion after islet transplantation) during the
first eight hr posttransplantation (group 3, n�4). CM9R re-
ceived dextran sulfate for only six hr. (C) CH50 values be-
fore and 12 hr after treatment with cobra venom factor
(group 2) and before and 15 min after treatment with dex-
tran sulfate (group 3) (�standard deviation).
FIGURE 2. Blood glucose values of all completely dia-
betic monkeys (n�8) in the first five days after islet trans-
plantation or until insulin administration was started.
Monkeys were treated with conventional immunosuppres-
sive drugs (continuous black lines; n�2), or with a costimu-
lation blockade-based regimen with cobra venom factor
and heparin (dotted red lines, n�3), or a costimulation
blockade-based regimen with dextran sulfate (continuous
green lines, n�3).
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glucose level after islet Tx in two monkeys (M3604,
M3406). Six monkeys showed at least temporary insulin-
independence for periods ranging from �1 to �5 days.
One monkey (M8405) remained normoglycemic through-
ut the five-day period of observation without the need for
insulin. Whenever insulin treatment was required (in five
of the six monkeys), in four cases, this was at a lower level
than before Tx. The reduction in ins lin requirement to
maintain a blood glucose�200 mg/dL ranged from 0% to
80%. The blood glucose, and independence from insulin,
showed a correlation with the porcine C-peptide value
(discussed subsequently) (Fig. 3).
Porcine C-peptide Values After Islet
Transplantation
The normal range of C-peptide in healthy, nondiabetic
pigs at our facility is 0.2 to 0.6 ng/mL. In monkeys, after the
first eight hr, by which time the early destruction of islets and
release of insulin andC-peptide had largely occurred, porcine
C-peptide levels were easured. Figure 3 indicates these val-
ues i relatio to the two different immunosuppressive regi-
mens used and in relation to the agents administered in an
attempt to prevent IBMIR.
When a conventional immunosuppressive protocol was
administered (n�3), in the absence of any therapy directed to-
wards IBMIR(group1,n�2,M3604andM3804), after theTxof
27,000 r 40,000 IEQ/kg, very low C-peptide levels were docu-
men d ev n on day one (Fig. 3A). In the third animal, when
CVFwas added to this convention l protocol (n�1,M3404), an
increase porcine C-peptide l vel was documen d; owever,
follow up of this monkey was possible for only 30 hr because it
required euthanasia for uncontrollabl seizures, po sibly related
to a high level of tacrolimus.
Porcine C-p p de levels were considerably higher in
monkeys that were treat d with the costimulation blockade
regimen (Fig. 3B). No clear differencewas seenwh ther treat-
ment was with CVF�hepa in (grou 2, n�3, dotted line) or
DS (group 3, �3, c tinuous lines). There w s, however, a
rapid decrease f por i e C-peptide in the single monkey in
which iabetes had not b en induced (M8605), w ich also
rece ved 40,000 IEQ/kg intra rtal y and the same immuno-
suppressive regimen.
Using the same immunosuppressive regimen, after the
Tx of 80,000 IEQ/kg in one monk y (M8405), the lev ls of
C-peptide were high r (initially 6.2 ng/mL, reducing to 2.7
n / L by day five (Fig. 3C). Blood gluco e l vels in this mon-
keyweremaintained betwee 64 t 91mg/dLwithout admin-
istrati n of exogenous ins lin throughout this five-day
perio . On day one after the in raportal injection f 80,000
IEQ/kg, th r was elevation of ALT (217 IU/L) and AST (387
IU/L), but these had normalized withi four d ys. This mon-
key requir d eutha asia for a postoperative complication af-
FIGURE 1. Anticoagulation and CH-50 values pre- and
posttransplantation. (A) Activated partial thromboplastin
time values for monkeys treated with cobra venom factor
and a single bolus of heparin with the islets (group 2, n�4).
(pretransplantation�before islet transplantation; 15 min
and 60 min indicate time after islet transplantation). (B) Ac-
tivated clotting time values for monkeys treated with
dextran sulfate (as an intravenous bolus before islet trans-
plantation,�a second bolus with the islets,�by continuous
intravenous infusion after islet transplantation) during the
first eight hr posttransplantation (group 3, n�4). CM9R re-
ceived dextran sulfate for only six hr. (C) CH50 values be-
f re d 12 hr after treatmen with cobra venom f c or
(group 2) and before and 15 min af er treatment with dex-
tran sulfate (group 3) (�sta dard d viation).
FIGURE 2. Blood glucose values of all completely dia-
betic monkeys (n�8) in the first five days after islet trans-
plantation or until insulin administration was started.
Monkeys were treated with conventional immunosuppres-
sive drugs (continuous black lines; n�2), or with a costimu-
lation blockade-based regimen with cobra venom factor
and heparin (dotted red lines, n�3), or a costimulation
blockade-based regimen with dextran sulfate (continuous
green lines, n�3).
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Figure 1: 
Anticoagulation and CH-50 values pre-and post-Tx. 
(A) aPTT values for monkeys treated with CVF and a single bolus of  heparin with 
the islets (Group 2, n=4).  (Pre Tx = before islet Tx; 15 min and 60 min indicate time 
after islet Tx).
(B) ACT values for monkeys treated with DS (as an iv b lus be ore isl t Tx, + a 
second bol  with he isle s, + by con inuous iv infusion after islet Tx) during the first 
8h post-Tx (Group 3, n=4). CM9R r ceive  DS for only 6h. 
(C) CH50 values before and 12h after treatment with CVF (Group 2); and before and 
15min after treatment with DS (Group 3) (± s andard deviation).
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hypoglycemia associated with islet graft destruction was largely completed, and on the need 
for insulin in the first 5 days are summarized in Figure 2. No immediate effect was seen on 
the blood glucose level after islet Tx in 2 monkeys (M3604, M3406). Six monkeys showed at 
least temporary insulin-independence for periods ranging from <1 to >5 days. One monkey 
(M8405) remained normoglycemic throughout the 5 day period of observation without the 
need for insulin. Whenever insulin treatment was required (in 5 of the 6 monkeys), in 4 cases 
this was at a lower level than before Tx. The reduction in insulin requirement to maintain a 
blood glucose <200mg/dL ranged from 0% to 80%. The blood glucose, and independence 
from insulin, showed a correlation with the porcine C-peptide value (discussed below) 
(Figure 5).
 
Porcine C-peptide values after islet Tx
The normal range of C-peptide in healthy, non-diabetic pigs at our facility is 0.2-0.6ng/mL. 
In monkeys, after the first 8h, by which time the early destruction of islets and release of 
insulin and C-peptide had largely occurred, porcine C-peptide levels were measured. Figure 
3 indicates these values in relation to the two different immunosuppressive regimens used, 
and in relation to the agents administered in an attempt to prevent IBMIR.
glucose level after islet Tx in two monkeys (M3604,
M3406). Six monkeys showed at least temporary insulin-
independence for periods ranging from �1 to �5 days.
One monkey (M8405) remained normoglycemic through-
out the five-day period of observation without the need for
insulin. Whenever insulin treatment was required (in five
of the six monkeys), in four cases, this was at a lower level
than before Tx. The reduction in insulin requirement to
maintain a blood glucose�200 mg/dL ranged from 0% to
80%. The blood glucose, and independence from insulin,
showed a correlation with the porcine C-peptide value
(discussed subsequently) (Fig. 3).
Porcine C-peptide Values After Islet
Transplantation
The normal range of C-peptide in healthy, nondiabetic
pigs at our facility is 0.2 to 0.6 ng/mL. In monkeys, after the
first eight hr, by which time the early destruction of islets and
release of insulin andC-peptide had largely occurred, porcine
C-peptide levels were measured. Figure 3 indicates these val-
ues in relation to the two different immunosuppressive regi-
mens used and in relation to the agents administered in an
attempt to prevent IBMIR.
When a conventional immunosuppressive protocol was
administered (n�3), in the absence of any therapy directed to-
wards IBMIR(group1,n�2,M3604andM3804), after theTxof
27,000 or 40,000 IEQ/kg, very low C-peptide levels were docu-
mented even on day one (Fig. 3A). In the third animal, when
CVFwas added to this conventional protocol (n�1,M3404), an
increased porcine C-peptide level was documented; however,
follow up of this monkey was possible for only 30 hr because it
required euthanasia for uncontrollable seizures, possibly related
to a high level of tacrolimus.
Porcine C-peptide levels were considerably higher in
monkeys that were treated with the costimulation blockade
regimen (Fig. 3B). No clear differencewas seenwhether treat-
ment was with CVF�heparin (group 2, n�3, dotted line) or
DS (group 3, n�3, continuous lines). There was, however, a
rapid decrease of porcine C-peptide in the single monkey in
which diabetes had not been induced (M8605), which also
received 40,000 IEQ/kg intraportally and the same immuno-
suppressive regimen.
Using the same immunosuppressive regimen, after the
Tx of 80,000 IEQ/kg in one monkey (M8405), the levels of
C-peptide were higher (initially 6.2 ng/mL, reducing to 2.7
ng/mL by day five (Fig. 3C). Blood glucose levels in this mon-
keyweremaintained between 64 to 91mg/dLwithout admin-
istration of exogenous insulin throughout this five-day
period. On day one after the intraportal injection of 80,000
IEQ/kg, there was elevation of ALT (217 IU/L) and AST (387
IU/L), but these had normalized within four days. This mon-
key required euthanasia for a postoperative complication af-
FIGURE 1. Anticoagulation and CH-50 values pre- and
posttransplantation. (A) Activated partial thromboplastin
time values for monkeys treated with cobra venom factor
and a single bolus of heparin with the islets (group 2, n�4).
(pretransplantation�before islet transplantation; 15 min
and 60 min indicate time after islet transplantation). (B) Ac-
tivated clotting time values for monkeys treated with
dextran sulfate (as an intravenous bolus before islet trans-
plantation,�a second bolus with the islets,�by continuous
intravenous infusion after islet transplantation) during the
first eight hr posttransplantation (group 3, n�4). CM9R re-
ceived dextran sulfate for only six hr. (C) CH50 values be-
fore and 12 hr after treatment with cobra venom factor
(group 2) and before and 15 min after treatment with dex-
tran sulfate (group 3) (�standard deviation).
FIGURE 2. Blood glucose values of all completely dia-
betic monkeys (n�8) in the first five days after islet trans-
plantation or until insulin administration was started.
Monkeys were treated with conventional immunosuppres-
sive drugs (continuous black lines; n�2), or with a costimu-
lation blockade-based regimen with cobra venom factor
and heparin (dotted red lines, n�3), or a costimulation
blockade-based regimen with dextran sulfate (continuous
green lines, n�3).
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Figure 2: 
Blood glucose values of  all completely diabetic monkeys 
(n=8) in the first 5 
days after islet Tx, or until i sulin administration 
was started. Monkeys were treated with conventional 
immunosuppressive drugs (solid black lines; n=2), or with 
a costimulation blockade-based regimen with CVF and 
heparin (dashed lines, n=3), or a costimulation blockade-
based regimen with DS (grey lines, n=3).
When a conventional immunosuppressive protocol was administered (n=3), in the absence 
of any therapy directed towards IBMIR (Group 1, n=2, M3604 and M3804), after the Tx of 
27,000 or 40,000IEQ/kg, very low C-peptide levels were documented even on day 1 (Figure 
3A). In the third animal, when CVF was added to this conventional protocol (n=1, M3404), an 
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ter seven days, at which time histologic examination of the
liver showedmany viable porcine islets, indicated by staining
for insulin (Fig. 4).
Subsequent Follow Up
Although this report is primarily directed to the effects
of the IBMIR seen within the first few days after porcine islet
Tx, follow up was possible in some monkeys. Within the first
14 days, three monkeys had to be euthanized for complica-
tions; four other monkeys lost porcine C-peptide production
within the first 14 days. Three monkeys were followed up for
longer periods. In these, porcine C-peptide production was
documented for periods�1 month, but insulin therapy was
required in all three to maintain the blood glucose �250
mg/dL (Fig. 5A, B). Despite C-peptide levels that were
within, or higher than, the normal range for healthy pigs
(0.2–0.6 ng/mL), insulin was required to maintain a state
of “normoglycemia.”
DISCUSSION
It has been well documented by several groups that
large numbers of pig islets are rapidly lost after their intrapor-
tal Tx into primate recipients (4, 5, 13) (reviewed in [29]), and
we have confirmed this observation in the present study.
Monkeys in group 1 (heparin bolus only) and group 2
(CVF�heparin) demonstrated a low level of anticoagulation
for a short period. Group 3 monkeys, treated with DS, had a
much higher level of anticoagulation and for a longer period.
Therefore, group 1 represented no significant treatment for
IBMIR, group 2 represented absence of complement activity,
and group 3 represented effective anticoagulation without
significant reduction in complement activity.
In the present study, the extent of the initial injury to
the transplanted pig islets from IBMIR was largely estimated
by the amount of dextrose required to prevent serious hypo-
glycemia. Although this is not a perfect primary end point, we
believe it provided some indication of the immediate loss of
islets from IBMIR. A high dextrose requirement (e.g., in
group 1) correlated with a very short period of graft survival
as measured by blood glucose level, insulin requirement, and
the level of porcine C-peptide. Complement depletion with
CVF (group 2) or anticoagulation with DS (group 3) resulted
in an important reduction of early graft loss. Early graft sur-
vival was indicated by higher porcine C-peptide levels (Fig.
3). However, even with complement depletion or anticoagu-
lation, significant early graft loss could not be prevented
completely.
It has been reported that DS alone results in both anti-
coagulation and inhibition of complement activity (12, 13).
Our own observations suggest that although effective as an
anticoagulant, DS was markedly less effective in inhibiting
complement activity. Other agents and approaches therefore
require to be investigated to prevent IBMIR. For example, a
combination of complement depletion (by CVF) and antico-
agulation (by DS) may prove more successful, and this is in-
deed planned as our next study.
The best result was obtained when the number of islets
transplanted was increased to 80,000 IEQ/kg. Normoglyce-
mia, without the need for exogenous insulin, and high
porcine C-peptide levels were documented throughout the
five-day period of observation, indicating that the number of
islets transplanted had compensated for the initial loss that
resulted from IBMIR. We have subsequently repeated this
experiment and have achieved normoglycemia in the absence
of exogenous insulin in a monkey that is currently five weeks
after islet transplantation. It is perhaps important to note that
the normal level of blood glucose in healthy monkeys is 50 to
70 mg/dL; this was the only diabetic monkey in which this
relatively low level, or true normoglycemia, was obtained,
and this was only achieved when porcine C-peptide levels
FIGURE 3. Porcine C-peptide values in the first days of
posttransplantation. (A)Monkeys treatedwith conventional
immunosuppression (n�3) with (dotted line, n�1) or with-
out (continuous lines, n�2) cobra venom factor. All mon-
keys received 40,000 islet equivalents/kg intraportally. (B)
Monkeys treated with costimulation blockade and cobra
venom factor�heparin (group 2, n�3, dotted lines) or dex-
tran sulfate (group 3, n�3, continuous lines) that received
40,000 islet equivalents/kg intraportally (n�6). (C) Mon-
keys treatedwith costimulation blockade and cobra venom
factor�heparin (group 2, n�3, dotted lines) or dextran sul-
fate (group 3, n�4, continuous lines) that received either
40,000 islet equivalents/kg (n�6) or 80,000 islet equiva-
lents/kg (n�1, M8405) intraportally. (Note the different
scale in C).
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Figure 3: 
Porcine C-peptide values in the first days post-Tx.
(A) Monkeys treated with conventional 
immunosuppression (n=3), with ( tte  line, n=1) 
or without (continuous lines, =2) CVF. All monkeys 
received 40,000IEQ/kg intraportally.
(B) Monkeys treated with costimulation blockade and 
CVF+heparin (Group 2, =3, dotted lines) or DS (Group 
3, n=3, continuous lines) that received 40,000IEQ/kg 
intraportally (n=6).
(C) Monkeys treated with costimulation blockade and 
CVF+heparin (Group 2, n=3, dotted lines) or DS 
(Group 3, n=4, continuous lines) that received either 
40,000IEQ/kg (n=6) or 80,000IEQ/kg (n=1, M8405), 
intraportally. (Note the different scale in C)
ter seven days, at which time histologic examination of the
liver showedmany viable porci e sle s, indic ted by staining
for insulin (Fig. 4).
Subsequent Follow Up
Although thi report s pr marily direct d to the effects
of the IBMIR seen within the first few days aft r porcine islet
Tx, follow up was possible in some monkeys. Within the first
14 days, three monkeys had to be euthanized for complic -
ti ns; four other monkeys lost porcine C-peptide production
within the first 14 days. Three monkeys were followed up for
longer periods. In thes , porcine C-peptide production was
documented for periods�1 mo th, bu insulin therapy was
required in all three to maintain the bl od glucose �250
mg/dL (Fig. 5A, B). Despite C-peptide levels that were
within, or higher than, the normal range for healthy pigs
(0.2–0.6 ng/mL), insulin was required to maintain a state
of “nor oglycemia.”
DISCUSSION
It has been well documented by several groups that
large numbers of pig islets are rapidly lost afte their intrapor-
tal Tx into pr mate recipients 4, 5, 13) (reviewed i [29]), and
we have confirmed this bservation in the present study.
Monkeys in group 1 (hepari bolus only) and group 2
(CVF�h parin) demonstrat d a low level of an coagulation
for a short period. Group 3 monk ys, treated with DS, had a
much higher level of an coagulation and for a longer period.
Therefore, group 1 represented no significant reatment for
IBMIR, group 2 repre ted absence of complement activity,
and group 3 repres nted effective an coagulation without
significant reduction in complement activity.
In the present study, he extent of the initial injury to
the transplant d pig islets from IBMIR was largely estimated
by the amount of dextrose required to prevent serious hypo-
glycemia. Although this is not a perfect primary end point, we
believe it provided some indication of the immediate loss of
islets from IBMIR. A high d xtrose requirement (e.g., in
group 1) correlated wit a very short period of gr ft survival
as measure by blood glucose level, insulin requirement, and
the level of porcine C-peptid . Complement depletion with
CVF (g oup 2) or an coagulation with DS (group 3) resulted
in an important reduction of early graft loss. Early graft sur-
vival was indicated by high r porcine C-peptide levels (Fig.
3). However, even with complement depletion or anticoagu-
lat on, significant early graft loss could not be prevented
completely.
It has be n reported that DS a one results in both anti-
coagulation and inhibition of complement activity (12, 13).
Our own b ervations suggest that although effective as an
anticoagulant, DS was mark dly less effective in inhibiting
complement activity. O her agents and approaches therefore
requ re to be investigated to prevent IBMIR. For example, a
c mbination of complement depletion (by CVF) and antico-
agulation (b DS) may prove more successful, and this is in-
dee planned as o r next study.
The best result was obtained when the number of islets
transplanted was increased to 80,000 IEQ/kg. Normoglyce-
mia, without the n ed for exogenous i sulin, and high
porcine C-peptide l vels wer documented throughout the
five- ay period of bservation, indica ing that the number of
i lets transplanted had compensat d for the initi l loss that
resulted from IBMIR. We have subsequ ntly repeated this
experiment nd have achieved normoglycemia in the absence
of exogenous insuli in a monkey that is currently five weeks
after is et transplantation. It is perhaps important to note that
the normal level of blood glucose in healthy monkeys is 50 to
70 mg/dL; is was the only diabetic monkey in which this
relativ ly low lev l, or true normoglycemia, was obtained,
and this was only ac ieved when porcine C-peptide levels
FIGURE 3. Porcine C-peptide values in the first days of
osttr nsplantati . (A)Monk ys treatedwith conventional
immunosuppression (n�3) with (dotted line, n�1) or with-
out (continuous lines, n�2) c bra venom fact r. All mon-
keys received 40,000 islet equivalents/kg intraportally. (B)
Monk ys treated with costimulation blockade and cobra
venom factor�heparin (group 2, n�3, dotted lines) or dex-
tran sulfate (group 3, n�3, continuous lin s) that received
40,000 slet equivalents/kg intraportally (n�6). (C) Mon-
k ys treatedwith costimulation blockade nd c bra venom
factor�heparin (group 2, n�3, dotted lines) or dextran sul-
fate (group 3, n�4, continuous lin s) that r ceived either
40,000 slet equivalents/kg (n�6) or 80,000 slet equiva-
lents/kg (n�1, M8405) intraportally. (Note the different
scale in C).
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increased  porcine C-peptide level was documented; however, follow-up of this monkey was 
possible for only 30h as it required euthanasia for uncontrollable seizures, possibly related 
to a high level of tacrolimus. 
Porcine C-peptide levels were considerably higher in monkeys that were treated with the 
costimulation blockade regimen (Figure 3B). No clear difference was seen whether treatment 
was with CVF+heparin (Group 2, n=3, dotted line) or DS (Group 3, n=3, continuous lines). 
There was, however, a rapid decrease of porcine C-peptide in the single monkey in which 
diabetes had not been induced (M8605), which also received 40,000IEQ/kg intraportally and 
the same immunosuppressive regimen.
Using the same immunosuppressive regimen, after the Tx of 80,000IEQ/kg in one monkey 
(M8405), the levels of C-peptide were higher (initially 6.2ng/mL, reducing to 2.7ng/mL by day 
5 [Figure 3C]). Blood glucose levels in this monkey were maintained between 64-91mg/dL 
without administration of exogenous insulin throughout this 5-day period. On day 1 after 
the intraportal injection of 80,000IEQ/kg, there was elevation of ALT (217IU/L) and AST 
(387IU/L), but these had normalized within 4 days. This monkey required euthanasia for a 
postoperative complication after 7 days, at which time histological examination of the liver 
showed many viable porcine islets, indicated by staining for insulin (Figure 4).
Subsequent follow-up
Although this report is primarily directed to the effects of the IBMIR seen within the first few 
days after porcine islet Tx, follow-up was possible in some monkeys. Within the first 14 days, 
three monkeys had to be euthanized for complications; four other monkeys lost porcine 
C-peptide production within the first 14 days. Three monkeys were followed up for longer 
periods.  In these, porcine C-peptide production was documented for periods >1 month, but 
insulin therapy was required in all 3 to maintain the blood glucose <250mg/dL (Figure 5A and 
B). Despite C-peptide levels that were within, or higher than, the normal range for healthy 
pigs (0.2-0.6ng/mL), insulin was required to maintain a state of ‘normoglycemia’.
Figure 4:
Microscopic section of  the liver in a monkey (M8405) 7 days after the Tx of  
80,000IEQ/kg, demonstrating islet grafted tissue stained for insulin (green 
fluorescence indicates insulin; magnification x20).
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were between 2.7 and 6.2 ng/mL. In the other monkeys, graft
function associated with lower porcine C-peptide levels (0.5–
2.0 ng/mL), which are actually high levels in healthy pigs (Fig.
5), resulted in improvement of the diabetic status, but not in
normoglycemia. A potentially important observation is that
C-peptide levels in healthy nondiabetic monkeys (�1.5
ng/mL in our laboratory) are considerably higher than in
healthy nondiabetic pigs (0.2–0.6 ng/mL). Peculiar charac-
teristics of monkey metabolism and/or of porcine islets may
therefore be relevant to islet function in pig-to-nonhuman
primate Tx models. The metabolic differences between pig
and primate C-peptide are currently under investigation at
our center.
Because the number of porcine islets that could be
made available for any single diabetic patient will be theoret-
ically limitless, this observation may provide a simple way of
overcoming the very considerable barrier raised by IBMIR.
However, to provide 80,000 IEQ per kilogram for an 80-kg
patient might require a total of more than six million IEQ,
although the numbermay be significantly fewer because fast-
ing C-peptide levels in healthy humans (1.18�0.06 ng/mL
[30]) are considerably lower than those in monkeys. Pig islet
insulin production may therefore sustain normoglycemia
more successfully in humans than in monkeys, necessitating
the Tx of significantly fewer porcine islets.
Nevertheless, it would clearly be preferable to reduce
the percentage loss of islets from IBMIR. Furthermore, al-
though the elevation in liver enzymes after islet Tx in the
present study was only transient, there is the potential for
portal vein thrombosis or liver injury after the intraportal Tx
of very large numbers of islets.
In other studies, it has proved difficult to determine
FIGURE 4. Microscopic section of the liver in a monkey (M8405) seven days after the transplantation of 80,000 islet
equivalents/kg demonstrating islet grafted tissue stained for insulin (green fluorescence indicates insulin; magnification
�20).
FIGURE 5. (A) Blood glucose lev-
els, and insulin requirements, pre- and
postislet transplantation in one group 2
monkey (M5204) treated with costimu-
lation blockade and cobra venom
factor�heparin. The arrow indicates
the day of islet transplantation. Al-
though insulin was required to main-
tain blood glucose levels�250mg/dL,
the insulin requirement was reduced
to 25% to 50% of that pretransplanta-
tion. (B) Porcine C-peptide levels and
selected blood glucose levels in the
same group 2 monkey (M5204). The
two continuous horizontal lines indi-
cate the normal range of porcine
C-peptide in healthy nondiabetic pigs,
and the single dotted line indicates the
lower level of monkey C- peptide in
healthy nondiabetic monkeys. Despite
normal or high levels of porcine
C-peptide, the blood glucose re-
mained relatively high, and the mon-
key required some insulin (see Fig.
5A). The rise in porcine C-peptide in
response to a rise in blood glucose in-
dicates survival of viable and func-
tional pig islets.
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Figure 5:
(A) Blood glucose levels, and insulin requirements, pre- and post-islet Tx in one Group 
2 monkey treated with costimulation blockade and CVF+heparin.  The arrow indicates 
the day of  islet Tx.  Although insulin was required to maintain blood glucose levels 
<250mg/dL, the insulin requirement was reduced to 25-50% of  that pre-Tx.
(B) Porcine C-peptide levels and selected blood glucose levels in the same Group 2 
monkey. The two continuous horizontal lines indicate the normal range of  porcine 
C-peptide in healthy non-diabetic pigs, and the single dotted line indicates the lower 
level of  monkey C-peptide in healthy non-diabetic monkeys.  Despite normal or high 
levels of  porcine C-peptide, the blood glucose remained relatively high, and the monkey 
required some insulin (see Figure 5A).  The rise in porcine C-peptide in response to a 
rise in blood glucose indicates survival of  viable and functional pig islets.
were between 2.7 and 6.2 ng/mL. In the other monkeys, graft
function associated with lower porcine C-peptide levels (0.5–
2.0 ng/mL), which are actually high levels in healthy pigs (Fig.
5), resulted in impr veme t of he diabetic status, but not
normoglycemia. A potentially important observation is that
C-peptide levels in healthy nondiabetic monkeys (�1.5
ng/mL in our laboratory) are considerably higher than in
healthy ondi betic pigs (0.2–0.6 ng/mL). Peculiar charac-
teristics of monkey metabolism and/or of porcine islets may
therefore be relevant to islet function in pig-to-nonhuman
primate Tx models. The metabolic differences between pig
and primate C-peptide ar urrently under investigatio at
our center.
Because the number of porcine islets that could be
made available for any single diabetic patient will be theoret-
ically limitless, this observation may provide a simple way of
overcoming the very considerable barrier raised by IBMIR.
However, to provide 80,000 IEQ per kilogram for an 80-kg
patient might require a total of more than six million IEQ,
alth ugh th numb rmay be si ificantly fewer because fast-
ing C-peptide levels in healthy humans (1.18�0.06 ng/mL
[30]) are considerably lower than those in monkeys. Pig islet
insulin production may therefore sustain normoglycemia
more successfully in humans tha in monkeys, necessitating
the Tx of significantly fewer porcine islets.
Nevertheless, it would clearly be preferable to reduce
the percentage loss of islets from IBMIR. Furthermore, al-
though the elevation in live enz mes after islet Tx in the
prese t study w s only transi nt, there is the potential for
portal vein thrombosis or liver injury after the intraportal Tx
of very large numbers of islets.
In other studies, it has proved difficult to determine
FIGURE 4. Microscopic section of the liver in a monkey (M8405) seven days after the transplantation of 80,000 islet
equivalents/kg demonstrating islet grafted tissue stained for insulin (green fluorescence indicates insulin; magnification
�20).
FIGURE 5. (A) Blood glucose lev-
els, and insulin requirements, pre- and
postislet transplantation in one group 2
monkey (M5204) treated with costimu-
lation blockade and cobra venom
factor�heparin. The arrow indicates
the day of islet transplantation. Al-
though insulin was required to main-
tain blood glucose levels�250mg/dL,
the insulin requirement was reduced
to 25% to 50% of that pretransplanta-
tion. (B) Porcine C-peptide levels and
selected blood glucose levels in the
same group 2 monkey (M5204). The
two continuous horizontal lines indi-
cate the normal range of porcine
C-peptide in healthy nondiabetic pigs,
and the single dotted line indicates the
lower level of monkey C- peptide in
ealthy n ndiabetic monkeys. Despite
normal or high levels of porcine
C-peptide, the blood glucose re-
mained relatively high, and the mon-
key required some insulin (see Fig.
5A). The rise in porcine C-peptide in
response to a rise in blood glucose in-
dicates survival of viable and func-
tional pig islets.
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DISCUSSION
It has been well documented by several groups that large numbers of pig islets are rapidly 
lost after their intraportal Tx into primate recipients (4, 5, 13), reviewed in (29), and we have 
confirmed this observation in the present study. 
Monkeys in Group 1 (heparin bolus only) and Group 2 (CVF + heparin) demonstrated a low 
level of anticoagulation for a short period. Group 3 monkeys, treated with DS, had a much 
higher level of anticoagulation and for a longer period. Therefore, Group 1 represented no 
significant treatment for IBMIR, Group 2 represented absence of complement activity, and 
Group 3 represented effective anticoagulation, without significant reduction in complement 
activity.
In the present study, the extent of the initial injury to the transplanted pig islets from IBMIR 
was largely estimated by the amount of dextrose required to prevent serious hypoglycemia. 
Although this is not a perfect primary endpoint, we believe it did provide some indication 
of the immediate loss of islets from IBMIR. A high dextrose requirement (e.g., in Group 1) 
correlated with a very short period of graft survival, as measured by blood glucose level, 
insulin requirement, and the level of porcine C-peptide. Complement depletion with CVF 
(Group 2) or anticoagulation with DS (Group 3), resulted in an important reduction of early 
graft loss. Early graft survival was indicated by higher porcine C-peptide levels (Figure 3). 
However, even with complement depletion or anticoagulation, significant early graft loss 
could not be prevented completely.
It has been reported that DS alone results in both anticoagulation and inhibition of 
complement activity (12, 13). Our own observations suggest that, although effective as 
an anticoagulant, DS was markedly less effective in inhibiting complement activity. Other 
agents and approaches therefore require to be investigated to prevent IBMIR.  For example, 
a combination of complement depletion (by CVF) and anticoagulation (by DS) may prove 
more successful, and this is indeed planned as our next study. 
The best result was obtained when the number of islets transplanted was increased to 
80,000IEQ/kg. Normoglycemia, without the need for exogenous insulin, and high porcine 
C-peptide levels were documented throughout the 5-day period of observation, indicating 
that the number of islets transplanted had compensated for the initial loss that resulted from 
iBMiR1. It is perhaps important to note that the normal level of blood glucose in healthy 
monkeys is 50-70mg/dL; this was the only diabetic monkey in which this relatively low level, 
or true normoglycemia, was obtained, and this was only achieved when porcine C-peptide 
1       We have subsequently repeated this experiment, and have achieved normoglycemia in the absence of 
exogenous insulin in a monkey that is currently 5 weeks after islet Tx.
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levels were between 2.7-6.2ng/mL. In the other monkeys, graft function associated with lower 
porcine C-peptide levels (0.5-2.0ng/mL), which are actually high levels in healthy pigs (Figure 
5), resulted in improvement of the diabetic status, but not in normoglycemia. A potentially 
important observation is that C-peptide levels in healthy non-diabetic monkeys (>1.5ng/mL 
in our laboratory) are considerably higher than in healthy non-diabetic pigs (0.2-0.6ng/mL). 
Peculiar characteristics of monkey metabolism and/or of porcine islets may therefore be 
relevant to islet function in pig-to-nonhuman primate Tx models. The metabolic differences 
between pig and primate C-peptide are currently under investigation at our center.
As the number of porcine islets that could be made available for any single diabetic patient 
will be theoretically limitless, this observation may provide a simple way of overcoming the 
very considerable barrier raised by IBMIR. However, to provide 80,000IEQ per kg for an 
80kg patient might require a total of more than 6 million IEQ, although the number may be 
significantly fewer since fasting C-peptide levels in healthy humans (1.18+/-0.06ng/mL (30)) 
are considerably lower than those in monkeys. Pig islet insulin production may therefore 
sustain normoglycemia more successfully in humans than in monkeys, necessitating the Tx 
of significantly fewer porcine islets. 
Nevertheless, it would clearly be preferable to reduce the percentage loss of islets from 
IBMIR. Furthermore, although the elevation in liver enzymes after islet Tx in the present 
study was only transient, there is the potential for portal vein thrombosis or liver injury after 
the intraportal Tx of very large numbers of islets. 
In other studies, it has proved difficult to determine how much loss of islet function is a 
consequence of IBMIR and how much is a result of rejection. Increasingly, however, the 
loss from IBMIR is becoming more obvious (3, 31). In our own studies using a costimulation 
blockade-based regimen, as originally introduced by Buhler et al (32), T cell-mediated acute 
cellular rejection does not appear to have been a major factor in graft loss, since there has 
been an absence of cellular infiltration in the liver and of a T cell-dependent elicited antibody 
response. Yet islet function has still been lost (Figure 5B), suggesting that the islet mass that 
survived destruction by IBMIR was insufficient to maintain normoglycemia. It may be only 
when the problem of IBMIR has been resolved that low-dose immunosuppressive therapy 
will be able to be fully investigated.
GT-KO pigs have not been used previously as sources of islets for Tx into primates. In this 
present, admittedly very limited, study, as anticipated, we did not find that adult GT-KO pig 
islets were less susceptible than WT pig islets to early destruction.  It has been reported (9) 
that carefully isolated adult WT islets do not express the Gal epitopes against which primate 
anti-pig antibodies are largely directed.  Our own observations also indicate that endocrine 
islet cells, including beta cells, do not express Gal epitopes, although Gal-positive cells can 
be found in small numbers (Figure 6A), most likely as a consequence of imperfect enzymatic 
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separation of the exocrine from the endocrine tissues or from the presence of vascular 
endothelial cells.  In contrast, islets from GT-KO pigs show no staining for Gal (Figure 6B). 
In isolated WT islets, the Gal-stained tissues do not include the insulin-producing beta cells 
(Figure 6C).
However, early function between the GT-KO and WT islets cannot be strictly compared, 
as all WT islets were obtained from retired breeding sows whereas the GT-KO islets were 
not; it has been well-documented that islets from retired breeders have better post-Tx 
characteristics (15, 16). The outcome may well have been different if neonatal or fetal islets 
(that express abundant Galα1,3Gal epitopes) had been transplanted. It has been shown in 
GT-KO mice that transplanted WT neonatal pig islets induce an increase in anti-Galα1,3Gal 
antibody titer, whereas GT-KO neonatal islets do not (14).
In summary, early loss of pig islets occurred after intraportal Tx in monkeys, even when 
attempts were made to inhibit IBMIR by CVF+heparin or DS. If clinical islet xenotransplantation 
is to become a reality, approaches to reduce this initial graft destruction require intensive 
investigation.
Figure 6:
Isolated islets from (A) WT and (B) GT-KO pigs, stained with fluorescein-labeled Griffonia 
simplicifolia 1-isolectin B4 (green), a marker for Gal (magnification x20).
(C) Isolated WT pig islets immunostained for insulin (red) and fluorescein-labeled Griffonia 
simplicifolia 1-isolectin B4 (green), demonstrating that the insulin-producing beta cells do not 
stain for Gal (magnification x40).
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ABSTRACT
Four clinical trials of porcine islet transplantation have been reported, and there are 
verbal reports that clinical trials on much larger scales are continuing in centers in China 
and Russia.  The four reported trials are briefly reviewed and, in the light of the present 
status of experimental islet xenotransplantation, consideration is given to whether such 
trials are currently justified.  The Ethics Committee of the International Xenotransplantation 
Association has (i) emphasized the need for encouraging studies in nonhuman primates 
before clinical trials should be undertaken, (ii) mandatory monitoring for the transfer of 
porcine microorganisms, and (iii) careful regulation and oversight by recognized bodies. 
Other aspects of the topic, such as the need for informed consent, are briefly discussed. 
We conclude that, at the present time, more data documenting convincing efficacy, focused 
on clinically-applicable immunosuppressive regimens, are needed to justify the initiation of 
closely-monitored clinical trials.  A clinical trial may then be justified even though the potential 
risk to the patients, and possibly for society, will not be zero.  
INTRODUCTION
Of all types of experimental xenotransplantation, islet transplantation is probably the closest 
to clinical application on a large scale.  Over the past several years, progress has been 
made in the field of experimental islet xenotransplantation in preclinical nonhuman primate 
models (1), but significant questions remain as to whether progress has been sufficient to 
move towards clinical trials.  Clinical trials of islet xenotransplantation were reported from the 
Soviet Union in the 1980s and 1990s (reviewed in (2)), and four more recent clinical studies 
using pig islets have been reported (3-7); these trials are summarized in Table 1.  In addition, 
however, there are verbal reports that clinical trials on much larger scales are continuing in 
centers in China and Russia.
Clinical Trials Reported To Date
In the early 1990s, Groth et al. (3) in Sweden were the first to report pig islet transplantation 
into immunosuppressed kidney allotransplant patients with diabetes (n=10) (Table 1).  Fetal 
pig islets were transplanted under the renal capsule (n=2) or intraportally (n=8). Diabetes 
was not reversed, although patients with intraportally-transplanted islets excreted porcine C-
peptide in their urine for varying periods of time, to a maximum of 460 days. It is questionable 
whether these patients benefited from the transplanted pig islets, since no reduction of insulin 
requirement was documented. However, the patients were not subjected to unnecessary 
immunosuppressive treatment, since this treatment was already being administered to 
protect their kidney allografts.  
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There have, however, been clinical studies that reported a decrease in exogenous insulin 
requirement after pig islet transplantation.  In New Zealand, Elliott et al. (4) transplanted 
encapsulated neonatal porcine islets into the peritoneal cavity of two patients.  One patient 
was non-immunosuppressed, and the other received immunosuppressive treatment for a 
prior kidney allotransplant (Table 1).  A decrease of insulin requirement was observed and 
urinary porcine C-peptide excretion was detected in both patients for at least 14 months. 
HbA1c (glycosylated Hb) levels indicated better long-term control for up to 27 months in 
the nonimmunosuppressed patient in whom, nine years after islet xenotransplantation, 
viable encapsulated islets were harvested by laparoscopy; these islets demonstrated insulin 
release after glucose stimulation in vitro. At this time, the patient claimed to continue to 
experience better glucose control (than pre-transplantation), although this claim was not 
supported by documented reduced exogenous insulin requirement; an improvement in the 
patient’s HbA1c level was again documented (5). 
More recently, Valdes-Gonzales and his colleagues (6) in Mexico reported transplantation of 
porcine islets, together with porcine Sertoli cells, into steel/Teflon stents placed subcutaneously 
in non-immunosuppressed adolescent diabetic patients. For various reasons, this trial 
received considerable criticism in certain medical journals (8, 9).  Twelve patients received 
transplants, of whom 11 received a second transplant after 6 to 9 months, and 4 were again 
retransplanted after 3 years. In half of the patients, a significant reduction in exogenous 
insulin requirement was documented for up to 4 years, including two patients who became 
temporarily insulin-independent (Table 1).  Although promising data are available from rodent 
allotransplantation (10) and xenotransplantation (11) studies with regard to immunoprotection 
by Sertoli cells, the data available are not conclusive.  Recently, it was reported that co-
transplantation of neonatal porcine Sertoli cells with islets into diabetic rats did not contribute 
to graft survival compared to transplantation of islets alone (12). Moreover, the beneficial 
effect of co-transplantation of porcine Sertoli cells could not be confirmed in a nonhuman 
primate model of porcine islet transplantation; although in this study no subcutaneous stents 
were used, no long-term survival was found when neonatal islets, with or without co-cultured 
Sertoli cells, were transplanted into various sites of nondiabetic nonimmunosuppressed 
macaques (13). 
In 2005, Wang et al. (7) from China reported briefly on the transplantation of neonatal pig 
islets into the hepatic artery of 20 diabetic patients (Table 1).  Various immunosuppressive 
regimens were administered. All patients who received a steroid-based regimen (n=18) 
(some of them in combination with tacrolimus and sirolimus) showed a decrease of insulin 
requirement of 33% to 62% for up to one year, with the presence of porcine C-peptide and 
without changes in human C-peptide production. Furthermore, HbA1c levels were reported 
to be normal during this period. The two patients who were transplanted with a steroid-free 
protocol did not show any improvement in their diabetic status.
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Clinical Trials in Relation to the Principles of the Ethics Committee of the International 
Xenotransplantation Association (IXA)
Physicians and surgeons caring for diabetic patients, particularly those with unstable blood 
glucose levels who are at risk from sudden hypoglycemic attacks, are clearly stimulated by 
a desire to help their patients.  With the limited supply of human islets, some physicians 
may wish to proceed with a clinical trial of xenotransplantation, and do not want to wait 
for confirmatory evidence of a regimen’s efficacy from expensive and time-consuming 
studies of pig islet transplantation in nonhuman primates.  However, several aspects of islet 
xenotransplantation need to be addressed to determine whether clinical trials are currently 
justified.
 
All four of the above trials may have been undertaken before the Ethics Committee of the IXA 
published its principles on clinical trials of xenotransplantation.  Without wishing to be critical 
of these trials, it is of interest to consider whether they would have met the recommendations 
of the Committee.
The Need for Preliminary Studies in Nonhuman Primates
The principles set out by the Ethics Committee, published first in May, 2003 (14), and 
subsequently discussed (14, 15), state the need for adequate pre-clinical data to justify a 
clinical trial, including promising data in a nonhuman primate model.  The duration of survival 
of pig islet grafts in nonhuman primates necessary to justify a clinical trial was not defined 
by the Committee, as it believed this to be a determination that must take into account the 
strengths and limitations of the particular studies.  
Are studies in nonhuman primates essential before embarking on a clinical trial?  They are 
difficult, expensive, and time-consuming.  However, the relative ease with which success 
can be achieved on occasions in rodent models has not been found to be a good indicator 
of success in humans, whereas nonhuman primate studies better reflect the hurdles that 
need to be overcome to achieve clinical success.  In view of the possibility of transferring a 
porcine microorganism to the patient, and perhaps to the community at large, a clinical trial 
should only be undertaken if there is clear evidence of success in a preclinical nonhuman 
primate model.
As far as we are aware, no specific preclinical studies in nonhuman primates were carried 
out, or reported in the peer-reviewed literature, by the above four groups before embarking 
on clinical trials in the aforementioned human studies.  Before the study by Elliott’s group, 
however, Sun et al. had reported normoglycemia after transplantation of encapsulated 
pig islets into non-immunosuppressed spontaneously-diabetic monkeys (16). Nonhuman 
primate models of xenotransplantation are not widely available, and the expense and effort 
involved in these models may preclude this type of research in many centers.  Nevertheless, 
if encouraging data have been obtained from rodent studies, there are centers with the 
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facilities, expertise, and even the financial support, where such research can be carried out 
on a collaborative basis.  Although difficult, it is no longer a persuasive argument that this 
type of research was not available to the group considering embarking on a clinical trial.
Monitoring for Porcine Microorganisms
The IXA Ethics Committee addressed the need for monitoring for transfer of porcine 
infectious agents after transplantation.  The issue of the potential transmission of an 
infectious agent from pig to human continues to be raised, not only with regard to porcine 
endogenous retrovirus (PERV), but also to other porcine viruses, such as the herpes viruses, 
e.g., cytomegalovirus and lymphotropic herpes virus (17, 18). To reduce these risks, the 
Committee recommended that source animals should be obtained from closed colonies from 
which known and potential pathogens have been excluded.  PERV are expressed in porcine 
islets, though expression does not necessarily mean that there will subsequently be release 
of virus (19). Cytomegalovirus, but not lymphotropic herpes virus, can readily be eliminated 
from a pig herd by early-weaning (17). 
Furthermore, the possibility of transmission of microorganisms that have not yet been 
identified, and that could possibly mutate and develop increased virulence, has caused 
concern, and requires careful consideration whenever a clinical trial is proposed.  Monitoring 
for novel organisms, as far as is conceivably possible, needs to be built into the trial.
In the above trials, islets were not always harvested from pigs in closed ‘high-health’ status 
herds (and the definition of ‘high-health’ varies from center to center).  In the Swedish trial, 
which was undertaken before concern was raised on the potential risks of PERV, the islets 
were harvested from non-high-health Swedish Landrace pig fetuses.  In the New Zealand 
trial, the islet-source pigs were from a herd of high-health status, although PERV were 
present. The Mexican trial also used piglets that were bred in New Zealand in a specific 
pathogen (but not PERV)-free environment. No details on pig source in the Chinese trial 
were given in the presented abstract.  
Furthermore, close monitoring of recipients of any pig xenograft was strongly recommended 
by the IXA Ethics Committee.  Monitoring for transmission of infectious disease has been 
carried out in the patients in all four trials, if on occasion this has been retrospectively.  No 
adverse infectious event has resulted to date from any of the trials.  Follow-up of the patients 
who have received transplants of porcine islets demonstrated no evidence that they have 
become infected with PERV (4, 6, 7, 20, 21).  However, in some cases, there was little or 
no evidence of long-term survival of the islets, and it is likely that the PERV were destroyed 
with the islets. Although the absence of recipient infection with a porcine microorganism is 
very encouraging, the data remain inconclusive.  Our understanding of expert opinion is that, 
although more investigation is necessary before pig tissue can be declared completely safe, 
the risk of an adverse effect from PERV is now considered to be low and, indeed, possibly 
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acceptable (22, 23). 
However, as PERV provide only one of many potential infectious risks, every effort must be 
taken to ensure this risk is minimized before clinical trials should be considered justified.  In 
view of the potential infectious risk to the community, even from microorganisms hitherto 
unidentified, the perceived risk/benefit ratio must be very carefully considered, more so than 
with other medical or surgical innovations.  
Regulation / Oversight
The IXA Ethics Committee addressed the need to control infectious disease risks through 
oversight by recognized national bodies (e.g., the Food and Drug Administration [FDA] in 
the US).  As none of the four trials outlined above was carried out in the US, it cannot 
be expected that any of them were monitored by the FDA, but some form of oversight 
with regard to infectious organisms would have been highly advisable.  Furthermore, the 
Committee recommended that any future trial should be conducted with detailed oversight 
by an institutional committee, i.e., be supervised by a recognized official committee at the 
medical center where the trial is taking place (e.g., an Institutional Review Board in the 
US).  
In this respect, those carrying out the Swedish trial obtained approval by their institutional 
human ethics committee, although there appeared to be no ‘national’ oversight, probably 
because no such authority was in existence at that time. The trial by Elliott et al. was carried 
out with approval of ethical and statutory bodies, although it is not clear at what level these 
bodies operated. Those carrying out the Mexican trial obtained consent and oversight from 
institutional and national bodies within Mexico, although no specific ‘xenotransplantation 
authority’ exists in that country. Details on the recently reported trial from China are not yet 
available.
The IXA Ethics Committee also recommended that efforts should be made to work 
towards international guidelines to ensure monitoring of patients who have received a 
xenotransplant. To date, no mechanism is in place to monitor (or prevent) a patient with a 
xenotransplant performed in one country from traveling freely to other countries.  (This is 
important, not only with regard to the xenotransplantation of islets and organs, but also to the 
xenotransplantation of numerous other cell types, such as fetal sheep cells, that are used as 
‘therapy’ for diverse conditions.)  Nonetheless, the recent adoption of resolution WHA57.18 
by the 192 countries represented by the World Health Assembly represents a step towards 
the development of international recommendations and guidelines for well-monitored global 
application of xenotransplantation practices (24). FDA guidelines on xenotransplantation can 
be found through their website (www.fda.gov/cber/xap/xap.htm), which also contains links 
to guidelines from the Council of Europe, EMEA (European Agency for the Evaluation of 
Medicinal products), and World Health Organization.
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Other Considerations
There are several other aspects of clinical trials of xenotransplantation that we have not 
touched on in this brief commentary, but which must be considered by those planning a clinical 
trial.  Adequate facilities for archiving of tissues and/or blood from both the organ-source pig 
and the recipient must be available.  The potential recipient must have been made aware of 
the need for life-long monitoring after the transplant, even if the graft fails to function.  There 
are those who believe that procreation of recipients of xenografts should be avoided until the 
safety of these procedures is assured; this topic must be fully addressed with the potential 
recipient.  In view of these considerations, at this stage in its development, a strong case 
could be made for xenotransplantation to be performed only in patients in whom the xenograft 
would be life-saving.  With the availability of insulin and islet allotransplantation, patients 
with diabetes do not generally fall into this category.  Although the ideal of immunological 
tolerance to porcine islets cannot yet be achieved, the immunosuppressive regimen should, 
at the least, be modest rather than intensive, thus reducing the risks of long-term therapy to 
the patients.
Finally, the question of whether minors (children and adolescents) should be included in 
initial clinical trials remains highly controversial.  Although their inclusion may well be justified 
if the procedure will be life-saving, it would be much less justified if this is not the case.  In 
view of the potential risks and possible restrictions on their lifestyles following receiving a 
xenograft, is it fair to impose these burdens on minors if they are not in a position themselves 
to give fully-informed legal consent?  Space precludes a detailed discussion of informed 
consent for xenotransplantation, but this important topic has been fully considered by the US 
Secretary’s Advisory Committee on Xenotransplantation (25, 26).
CONCLUSIONS
Although valuable data may be obtained from clinical trials of islet xenotransplantation, and 
although efforts towards clinical trials should not be unduly impeded, we have to question 
whether there is sufficient encouraging experimental data in nonhuman primate models to 
warrant further clinical studies at the present time. Over the past years, some data have 
become available from pig-to-nonhuman primate studies (1) but, except for a preliminary 
report by the Minneapolis group on successful survival of pig islets in cynomolgus monkeys 
for periods of several months using an immunosuppressive regimen that is very unlikely to 
be clinically applicable (27), there are no studies that support a conclusion that clinical trials 
are likely to be successful (1).    
Although some patients have required less, or even no, insulin (at least temporarily) after 
pig islet transplantation, and thus the patients have individually benefited from the trial, 
it remains uncertain whether this was related to improved medical management, e.g., 
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meticulous attention to diet, regular monitoring of blood glucose, excellent medical advice 
and management, etc., rather than to the function of the transplanted islets.  Diabetic patients 
are likely to be more carefully monitored and more attentive to maintaining good control of 
their own condition when participating in a well-organized clinical trial.
The future may host more clinical islet xenotransplantation studies. If so, in the opinion 
of the IXA Ethics Committee, it would be mandatory that convincing experimental data 
in nonhuman primate models as to the efficacy of the approach are available to indicate 
the likelihood of a successful outcome and to justify exposure to potential risks. Careful 
monitoring (in collaboration with a recognized national authority) for potential transmission 
of infectious microorganisms is also surely mandatory.  All aspects of the trial should be 
under the supervision of an institutional (and possibly a national) committee or authority. 
Such oversight and monitoring will surely not only safeguard the individual patient and the 
community, but will also increase the likelihood of obtaining valuable data from the trial, even 
if it is not fully successful in achieving its goals.
At this point in time, more experimental data from nonhuman primate models documenting 
convincing efficacy, focused on clinically-applicable immunosuppressive regimens, are 
needed to justify the initiation of clinical trials.  These studies should also be designed to 
provide further data on the safety of the procedure, particularly with regard to the transfer of 
porcine viruses (including, but not limited to, PERV) to the nonhuman primate recipient of 
the porcine islets.  A carefully-monitored clinical trial may then be justified even though the 
potential risk to the patients, and possibly for society, would not be zero.  
What results are required in a nonhuman primate model of porcine islet transplantation to 
justify progress to a clinical trial remain uncertain.  The criteria for a clinical trial are particularly 
difficult to determine for patients with diabetes, since the disease is not as rapidly fatal as 
many other conditions for which xenotransplantation offers hope.  A strong case could be 
made for a consensus meeting, and/or the setting up of an expert advisory committee (as 
convened by the International Society of Heart and Lung Transplantation in 2000 (28)) to 
determine these criteria.   
ACKOWLEDGEMENT
  
The authors thank Emanuele Cozzi, Chairman of the IXA Ethics Committee, for his valuable 
comments, and Eda Bloom of the US FDA for providing information regarding US and 
international guidelines on clinical xenotransplantation.
Proefschrift.indb   156 1/3/2008   6:18:52 PM
Clinical islet xenotransplantation
157
REFERENCES
1. Rood PP, Buhler LH, Bottino R, Trucco M, Cooper DK. Pig-to-nonhuman primate islet 
xenotransplantation: a review of current problems. Cell Transplant 2006; 15 (2): 89-104.
2. Hering B, Ricordi C. Islet transplantation for patients with type 1 diabetes. Graft 1999; 2 (1): 12-27.
3. Groth CG, Korsgren O, Tibell A, et al. Transplantation of porcine fetal pancreas to diabetic patients. 
Lancet 1994; 344 (8934): 1402-1404.
4. Elliott RB, Escobar L, Garkavenko O, et al. No evidence of infection with porcine endogenous 
retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant 2000; 9 (6): 895-
901.
5. Elliott RB, Escobar L, Tan PLJ, Vasconcellos D, Emerich F, Thanos C. Long term survival of alginate 
encapsulated piglet islets in a patient with type 1 diabetes. Abstract OP-054, presented at the 10th 
Congress of the International Pancreas and Islet Transplantation Association in Geneva 2005.
6. Valdes-Gonzalez RA, Dorantes LM, Garibay GN, et al. Xenotransplantation of porcine neonatal 
islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol 2005; 153 (3): 419-427.
7. Wang W, Zhaohui M, Bin Y, et al. Intra-hepatic artery transplantation of newborn porcine islets 
(NPI) into 20 type 1 diabetic patients with steroids immunosuppression protocol. Abstract OP-056, 
presented at the 10th Congress of the International Pancreas and Islet Transplantation Association 
in Geneva 2005.
8. McKenzie IF, d’Apice AJ, Cooper DK. Xenotransplantation trials. Lancet 2002; 359 (9325): 2280-
2281.
9. Check E. Diabetes trial stirs debate on safety of xenotransplants. Nature 2002; 419 (6902): 5.
10. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell 
aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46 
(2): 317-322.
11. Dufour JM, Rajotte RV, Korbutt GS, Emerich DF. Harnessing the immunomodulatory properties of 
Sertoli cells to enable xenotransplantation in type I diabetes. Immunol Invest 2003; 32 (4): 275-
297.
12. Wang DZ, Skinner S, Elliot R, et al. Xenotransplantation of neonatal porcine islets and Sertoli cells 
into nonimmunosuppressed streptozotocin-induced diabetic rats. Transplant Proc 2005; 37 (1): 470-
471.
13. Isaac JR, Skinner S, Elliot R, et al. Transplantation of neonatal porcine islets and sertoli cells into 
nonimmunosuppressed nonhuman primates. Transplant Proc 2005; 37 (1): 487-488.
14. Sykes M, d’Apice A, Sandrin M. Position paper of the Ethics Committee of the International 
Xenotransplantation Association. Xenotransplantation 2003; 10 (3): 194-203.
15. Sykes M, Sandrin M, D’Apice A. Guidelines for xenotransplantation. N Engl J Med 2003; 349 (13): 
1294-1295.
16. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalization of diabetes in spontaneously diabetic 
cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. 
J Clin Invest 1996; 98 (6): 1417-1422.
17. Mueller NJ, Livingston C, Knosalla C, et al. Activation of porcine cytomegalovirus, but not porcine 
lymphotropic herpesvirus, in pig-to-baboon xenotransplantation. J Infect Dis 2004; 189 (9): 1628-
1633.
18. Mueller NJ, Fishman JA. Herpesvirus infections in xenotransplantation: pathogenesis and 
approaches. Xenotransplantation 2004; 11 (6): 486-490.
19. Blusch JH, Patience C, Martin U. Pig endogenous retroviruses and xenotransplantation. 
Xenotransplantation 2002; 9 (4): 242-251.
20. Heneine W, Tibell A, Switzer WM, et al. No evidence of infection with porcine endogenous retrovirus 
Proefschrift.indb   157 1/3/2008   6:18:52 PM
Chapter 9
158
in recipients of porcine islet-cell xenografts. Lancet 1998; 352 (9129): 695-699.
21. Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous 
retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999; 285 
(5431): 1236-1241.
22. Fishman JA, Patience C. Xenotransplantation: infectious risk revisited. Am J Transplant 2004; 4 (9): 
1383-1390.
23. Fishman J. Xenosis and xenotransplantation: current concepts and challenges (Abstract PL5.2). 
Xenotransplantation 2005; 12 ((5)): 370.
24. Sykes M. Commentary: World Health Assembly resolution 57.18 on xenotransplantation. 
Transplantation 2005; 79 (6): 636-637.
25. US Department of Health and Human Services Secretary’s Advisory Committee on 
Xenotransplantation (SACX). Informed consent in clinical resarch involving xenotransplantation. 
http://www4.od.nih.gov/oba/sacx.html.
26. Cooper DK. Draft reports for public comment from the US Secretary’s Advisory Committee on 
Xenotransplantation. Xenotransplantation 2005; 12 (4): 255-257.
27. Jie T, Graham M, Wijkstrom M, et al. Pancreatic islet xenotransplants restore normoglycemia and 
insulin independence in immunosuppressed non-human primates. Abstract O471, presented at the 
20th International Congress of the Transplantation Society in Vienna; Transplantation 2004; 78 (2): 
185.
28. Cooper DK, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the 
International Society for Heart and Lung Transplantation: the present status of xenotransplantation 
and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung 
Transplant 2000; 19 (12): 1125-1165.
Proefschrift.indb   158 1/3/2008   6:18:52 PM
P. P.M. Rood*, R. Bottino*, A.N. Balamurugan, C. Smetanka, D. Ayares, C.G. Groth, N. Murase, D.K.C. 
Cooper, M. Trucco. Transplantation, 2007;83(2):202-210
P.P.M. ood, R. Bottino, A.N. Balamurugan, Y. Fan, D.K.C. Cooper, M. Trucco Pharmaceutical
Research 6 2 27 42
Proefschrift.indb   159 1/3/2008   6:18:53 PM
Proefschrift.indb   240 1/3/2008   6:19:44 PM
Islet cell regeneration
161
ABSTRACT
Type 1 diabetes (T1D) is an autoimmune disease, the clinical onset of which most frequently 
presents in children and adolescents who are genetically predisposed. T1D is characterized 
by specific insulin-producing beta cell destruction. The well-differentiated and specialized 
islet beta cells seem to physiologically retain the ability to compensate for the cells lost by 
reproducing themselves, while undifferentiated cell sources may help in generating new ones, 
even while the autoimmune process takes place. Diabetes clinical onset, i.e., establishment 
of a detectable, chronic hyperglycemia, occurs at a critical stage when autoimmunity, having 
acted for a while, supersedes the regenerative effort and reduces the number of beta cells 
below the physiologic threshold at which the produced insulin becomes insufficient for the 
body’s needs. Clinical solutions aimed at avoiding cumbersome daily insulin administrations 
by the re-establishment of physiologic insulin production, like whole pancreas or pancreatic 
islet allotransplantation, are limited by the scarcity of pancreas donors and by the toxic 
effects of the immunosuppressive drugs administered to prevent rejection. However, new 
accumulating evidence suggests that, once autoimmunity is abrogated, the endocrine 
pancreas properties may be sufficient to allow the physiological regenerative process to 
restore endogenous insulin production, even after the disease has become clinically 
manifest. Knowledge of these properties of the endocrine pancreas suggests the testing of 
reliable and clinically-translatable protocols for obliterating autoimmunity, thus allowing the 
regeneration of the patient’s own endocrine cells.  The safe induction of an autoimmunity-
free status might become a new promising therapy for T1D.
INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disease in which autoreactive T cells specifically 
target and destroy the insulin-producing beta cells of the endocrine pancreas. While the beta 
cells are selectively destroyed, other non-beta cells, contained in the islets of Langerhans 
or in the exocrine pancreas, are left more or less intact (1). In the early 1920s, prior to the 
discovery of insulin, T1D was almost invariably a fatal disease. With the discovery of insulin, 
the subcutaneous administration of animal-extracted and subsequently human recombinant 
insulin became the praxis.  Since that time, however, studies have shown that only strict 
control of glycemic levels over the years can significantly reduce – but not completely revert 
– the incidence of diabetic complications (2-6).  As a result, T1D still contributes to the high 
rate of cardiovascular, microvascular, neuropathic, and retinopathic diseases experienced 
by our population (7).  
Despite marked progress achieved with structural modification, better formulation, 
and improved mode of administration of insulin, that offer more precise management of 
glucohomeostasis, diabetics must monitor their blood glucose levels many times a day in 
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order to determine the appropriate quantity of insulin that needs to be injected.  Strict glycemic 
control entails a sustained effort that a patient must make over many decades, frequently 
beginning in childhood.  Uncontrollable hyperglycemia and/or the peril of hypoglycemia – 
both potentially life-threatening conditions – impose severe limitations on life-style, as well 
as health care of patients.  Taking into consideration the many variables that may affect 
glucose regulation in an individual, like hormonal changes, quantity and composition of food 
intake, different basal metabolism, and even psychological stress, good metabolic control is 
difficult to achieve even by diligent patients. Thus, insulin replacement therapy alone does 
not completely protect these individuals from severe consequences, suggesting that more 
appropriate treatments are needed to get closer to a cure for T1D (8).  
Transplantation of the whole pancreas, usually coupled with kidney transplantation, has been 
considered as one possible therapeutic option. It requires, however, major surgery and, as 
with any other cell or solid organ allotransplantation, life-long suppression of the immune 
system of the recipient through administration of immunosuppressive drugs at doses that 
are frequently associated with toxic effects. This approach has been used almost exclusively 
in patients with complicated diabetes (9).  In the case of simultaneous pancreas and kidney 
(SPK) transplantation, it has been reported that recipients experience benefits in terms of life 
expectancy (10). Pancreas transplantation alone (PTA) is proposed for a more limited cohort 
of diabetic patients: adults with frequent unpredictable hypoglycemic events and overall 
difficult glycemic control.  However, whole pancreas transplantation is not considered as a 
treatment for diabetic children, due to the severe secondary effects of immunosuppression 
and a low survival rate when compared with the survival of waiting-list patients receiving 
conventional insulin therapy, mainly associated with surgical complications and infections 
(11-16).  
In contrast, improved protocols for the transplantation of pancreatic islets have provided 
new hope for the treatment of T1D (15-17).  Islet cells are the defective cell population 
that diabetic individuals need; their transplantation overcomes the need for management 
of the acinar tissue of the pancreas and the consequent exocrine secretion typical of whole 
pancreas implants, which is often the main cause of complications (17). Islet transplantation 
can be carried out under local anesthesia using a relatively simple and low-risk procedure 
that a larger number of potential recipients can tolerate safely.  In light of the proven feasibility 
of islet transplantation in animals, and autotransplantations to prevent diabetes in patients 
in whom the pancreas had to be surgically removed, approximately 750 patients with T1D 
received allogeneic islet transplants between 1974 and 2000 (15).  
The main reason for such a limited number was the rather poor outcome of this intervention 
until five years ago when the Edmonton group reinvigorated this field by reporting their 
experience treating 7 patients consecutively who became insulin-independent (18).  Insulin-
independency was the result of a successful approach that involved the use of a larger islet 
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mass (obtained combining two to three donor islet transplantations), the employment of 
freshly-isolated islets (using media devoid of xenogeneic proteins and processed shortly 
after organ harvesting), and a new steroid-free immunosuppressive ‘cocktail’ (18).  Other 
transplant centers around the world have now repeated this exciting observation, and 
have obtained initial success rates of as high as 50% to 80% in terms of providing insulin-
independence during the first year (19).  However, the initial enthusiasm has been tempered 
by follow-up studies in which a gradual loss of islet function with time has been observed 
(20); the percentage of insulin-free patients decreased to less than 10% after 5 years (21). 
The reasons for immediate or late failure are not completely clear. The procedure of isolation 
per se contributes to impair the quality of the islets, and may constitute the basis for the 
major problems encountered after grafting in the liver of the diabetic recipient (25-29). 
The endocrine pancreas represents approximately 1-2% of the entire pancreatic mass, and 
constitutes a pellet of tissue of no more than 2-5ml.  Such an islet-enriched cell suspension 
can be implanted via intraportal injection into the recipient’s liver, where transplanted islets 
lodge in the hepatic capillary sinusoids where they are abundantly exposed to portal blood. 
In light of long-term islet survival in animal studies, the liver has been favored as the best 
site for islet engraftment in clinical trials.  However, the liver site is not ideal for the islets 
and presents important disadvantages: A thrombotic/inflammatory reaction is elicited when 
islets come into direct contact with the recipient’s blood. The detrimental effects of this 
instant blood-mediated inflammatory reaction (IBMIR), observed in particular when the islets 
are transplanted intraportally, seem to provide an additional explanation for the relatively 
low success rate of clinical islet transplantation (30).  Also, steatosis of the hepatocytes 
surrounding the islet graft has been documented relatively soon after transplantation 
(23,31).  
Finally, the immunosuppressive drugs necessary to avoid recurrence of autoimmunity 
and allo-rejection are quite toxic, not only to the kidney of the recipient, but also to the 
transplanted beta cells themselves that eventually die demanding additional transplantations 
(32-34). The number of available donor organs will continue to limit the number of diabetic 
patients who can be treated even in the event that transplantation-based approaches, 
coupled with clinically more acceptable immunosuppressive protocols, prove superior in 
reestablishment of long-term euglycemia, reduced incidence of T1D complications, as well 
as overall improved patient health (7,35). 
Vigorous research is being performed to improve this situation.  Islet allotransplantation 
has recently been achieved from single deceased obese donors in 8 of 8 T1D recipients 
(36), and from a single living donor where islets, obtained by distal pancreatectomy, were 
donated from a mother to her diabetic daughter (37).  However, diabetes in this latter case 
was the iatrogenic result of treatment for chronic pancreatitis; it is well known that islet 
autotransplantation following total pancreatectomy to treat chronic pancreatitis frequently 
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results in long-term prevention of diabetes, persisting for more than 13 years post-
transplantation (38).  Longitudinal studies performed over the next several years will indicate 
the success of these procedures, and whether they meet the long-term metabolic needs of 
the transplanted individuals.  
These results illustrate the urgent need for exploration of additional avenues in order to 
realize the goal of curing T1D. For example, regeneration of endocrine pancreas function has 
been documented after partial pancreatectomy, and in streptozotocin-treated animal models, 
including mice (39) and rats (40-42), and there are sporadic reports involving spontaneous 
remission in T1D patients (13,43), as well as evidence for islet neogenesis in non-diabetic 
obese adult individuals (44).  The potential of the pancreas to heal itself seems to be more 
efficient once autoimmunity is controlled (45).  Recent research efforts involving adult stem 
cells and gene therapy continue to show great potential in animal models.  Combining these 
independent efforts into a unified approach for treating T1D is the challenge awaiting us in 
our effort to cure this chronic disease.
Type 1 diabetes is an autoimmune disease
In 1993 the paper of Lamperer et al. (46) reported the first unquestionable evidence that 
also in humans T1D can be transferred by bone marrow (BM) cells.  T1D was observed in a 
woman, aged 29, four years after transplantation of BM from her HLA-identical brother with 
T1D.  At diagnosis of diabetes the recipient was positive for high-titre islet cell antibodies 
(ICA), whereas she had been ICA negative before transplantation.  Chromosomal analyses 
verified that all circulating leukocytes were of male donor type.  This further confirmed the 
autoimmune nature of the disease fulfilling the first requirement proposed by J.F. Bach (1) 
to reach this conclusion.  The other three criteria are that: 1) the disease course can be 
slowed or prevented by immunosuppressive therapy; 2) the disease is associated with 
manifestations of humoral or cell-mediated autoimmunity directed against the target organ; 
and 3) the disease can be experimentally induced by sensitization against an autoantigen 
present in the target organ.  All these characteristics defining an autoimmune disease find 
their origin in abnormalities of the physiologic process that brings the T cells to maturation.
In an healthy individual, the maturation of the T cells, coming from cell precursors present in 
the BM, takes place in the thymus, where they undergo a positive and a negative selection. 
Both positive selection and negative selection depend on interactions between the T cell 
receptor (TCR), Major Histocompatibility Complex (MHC) molecule, and antigenic peptide. 
Positive selection occurs as thymic stromal cells bearing MHC molecules, containing self-
peptide fragments, engage TCR molecules on the developing thymocytes and direct their 
continued maturation into functionally mature T-cells. T-cells with ‘useless’ receptors (i.e., 
those that cannot bind with sufficient affinity the MHC molecule) are not driven to mature 
and expand, and these cells eventually die in the thymus. Negative selection refers to the 
set of events that specifically eliminate or alternatively ‘anergize’ potentially autoreactive 
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Figure 1:  
Theoretical basis of  Tian’s approach (62) for abrogation of  
autoimmunity in the NOD mouse.
In the thymus, peptides (in red) from self  antigens are presented to 
the various (A, B, and C) immature double-positive (CD8, in grey, and 
CD4, lighter gray) T cells via the MHC molecule.  When, as for the 
A cell, the TCR has a very low affinity for the MHC molecule/self-
peptide complex the developing T cell does not receive the necessary 
positive signal to survive.  If  the affinity between the MHC molecule/
self-peptide complex and the TCR is too high, as for the B cell, the 
T cell undergoes negative selection and dies inside the thymus.  In 
contrast, the T cell shown in C,  receives a positive survival signal 
because of  the high-affinity interactions between its TCR and the MHC 
molecule; an affinity, however, that is not further enhanced by the 
presence of  a self-peptide in its groove, so that the negative selection 
does not take place.  This T cell matures and enters the circulation to 
protect the body from foreign (non-self) invaders, with which it is able 
to efficiently interact.  In T1D, the D cell binds to an MHC molecule 
conferring susceptibility to diabetes.  The self-peptide is not presented 
properly. The T cell, then, even if  potentially autoreactive (D has the 
same TCR as B), is not subjected to negative selection, and is free to 
leave the thymus to circulate in the blood.  The approach taken by 
Tian and colleagues (62) can be illustrated by imagining that the I-Ag7 
molecule, able to confer susceptibility to the disease carrying a non-
Asp-57 beta chain (in green), is supplemented, in the hematopoietic 
cells of  the NOD mouse, with a non-diabetogenic MHC molecule, 
i.e., an Asp-57+ beta chain (in yellow), like the one interacting with 
A, B, or C. Once the cells are returned into the donor, the new MHC 
molecule (orange and yellow chains) allows the restoration of  an 
efficient negative selection in the thymus (as for B), sufficient to delete 
autoreactive T cells and consequently to prevent diabetes (108). 
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cells, thereby inducing ‘tolerance’ to self (i.e., self-tolerance). During negative selection, 
factors such as affinity for self-antigen and antigen load likely influence the final outcome of 
cell death or clonal anergy. Thus, the peripheral T-cell repertoire of each person (including 
identical twins) is unique and is a consequence of both the random generation of TCRs in the 
initial unselected thymocyte pool as well as of positive and negative selection events.
More specifically, peptides from antigens of self-tissues are presented to the various 
immature double-positive CD4+ and Cd8+ T cells entering into the thymus (Figure 1). T cells 
that preferentially bind to MHC class II molecules mature into CD4+ cells. The involvement 
of CD4+ T cells is unquestionably proven to be of primary importance in the etiology of the 
disease.  Class II molecules are heterodimers composed of an alpha and a beta chain 
that together form the molecule’s antigen-combining site. When the TCR has a very low 
affinity for the MHC molecule/self-peptide complex (in the cartoon presented in Figure 1, 
contours of the MHC molecule/self-peptide complex do not fit with the contours of the TCR 
molecule), the developing T cell does not receive the necessary positive signal to survive 
and exit the thymus for release into the periphery.  However, if the affinity between the MHC 
molecule/self-peptide complex and the TCR is too high (in the cartoon presented in Figure 
1, the contours of the MHC molecule/self-peptide complex fit precisely into the contours of 
the TCR molecule), the T cell undergoes negative selection and dies inside the thymus.  
In contrast, the T cell that receives a positive survival signal because of the high-affinity 
interactions between its TCR and the MHC molecule, but shows an affinity that is not further 
enhanced by the presence of a self-peptide in its groove, so that the negative selection does 
not take place, matures and enters the circulation to protect the body from foreign (non-self) 
invaders, with which it is able to efficiently interact.  
The immunological basis of T1D can be found in T cells that bind to an MHC molecule 
unable to properly present self-peptides. These T cells, then, even if potentially autoreactive 
are not subjected to negative selection, and are free to leave the thymus to circulate in the 
blood. T cells that are potentially reactive to self-antigens, but fail to be deleted inside the 
thymus, are able to attack tissues of the body expressing these same antigens, generating 
autoimmunity.
In the late eighties, in collaboration with Dr. McDevitt, Stanford University, we were able to 
map and identify the most influential single hereditary susceptibility factor in T1D: a single 
amino acid of the beta chain of a class II HLA-DQ histocompatibility molecule (47,48). 
Although T1D is recognized to be a multigenic disease (49), in humans the principal genetic 
susceptibility component was proposed to be any allelic form of the HLA-DQ molecule 
that lacks a charged amino acid at position 57 of its beta chain.  Conversely, resistance to 
disease is associated with the inheritance of HLA-DQ alleles containing a charged amino 
acid such as aspartic acid, at the same position (Asp-57).  Physical explanation of the 
unusual importance of this particular single amino acid location for the development of the 
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autoimmune characteristics of T1D, came with the elucidation of the crystal structure of the 
HLA-DQ8 molecule, a non-Asp-57 molecule, which confers the highest susceptibility to the 
disease (50). The most important feature of the susceptibility HLA-DQ8 molecule relevant to 
diabetes immunology is that its crystal structure is identical to the homologous I-Ag7 molecule 
present in the non-obese diabetic (NOD) mouse (51). This strain of mouse spontaneously 
develops T1D with etiopathogenetic characteristics very similar to the disease in humans. 
The peptide binding-site of the majority of human HLA-DQ and murine I-A molecules have 
an Asp-57 that points into the groove. In these allelic forms, Asp-57 forms an electrostatic 
salt bridge with the arginine in juxtaposition (i.e., in position 76) of the alpha chain of the 
molecule (Arg-76), which also points into the groove. HLA-DQ8 and I-Ag7 lack Asp-57 and 
this variation disrupts the electrostatic interaction, leaving the Arg-76 free to interact with the 
aqueous environment and with any peptide able to lodge inside the binding groove of the 
molecule (52,53). The absence of Asp-57 allows the binding of peptides that may not find 
Figure 2:  
Schematic representation of  Tian’s approach (62) for abrogation 
of  autoimmunity in the NOD mouse.
NOD BM stem cells are ex vivo transfected with an H-2 I-A 
beta chain conferring resistance to diabetes (i.e., an ASP57+ beta 
chain, in yellow).  The transplanted cells are re-infused in the 
myeloablated donor that will become a chimera carrying the I-Ag7 
beta chain (in green) able to confer susceptibility and the resistance 
beta chain.  Since the effect of  the resistance molecule is dominant 
over the other susceptibility molecule, progression to diabetes 
will be avoided by deleting autoreactive T cells in the repopulated 
thymus.
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appropriate lodging inside other Asp-57+ molecule grooves, and may jeopardize an efficient 
presentation by the histocompatibility molecule to T-cells because of incorrectly positioned 
self-peptides.  The susceptibility status can be correlated, in immunological terms, with 
impaired peptide lodging, impaired peptide presentation to T-cells with consequent reduction 
in positive selection of regulatory T cells or by the impaired negative selection of self-reactive 
T cells.  Indirect evidence supporting these hypotheses derives from transgenic NOD mice 
that express class II genes other than I-Ag7, which do not develop diabetes (54-57), and from 
the fact that transplantation of allogeneic BM from strains that do not spontaneously develop 
diabetes, also prevents the occurrence of diabetes in NOD mice (58-61).
Recently, instead of approaching the problem using an alloreactive BM transplant, with all 
its inherent severe contraindications (e.g., GVHD), Tian et al. (62) transfected ex vivo the 
gene encoding a resistant, Asp-57+ beta chain into the BM cells isolated from the diabetes-
prone NOD mouse itself (Figure 2). T1D was prevented by the presence of a ‘diabetes-
resistant’ MHC molecule at the surface of hematopoietic stem cells of genetically susceptible 
(i.e., carrying a ‘diabetes-susceptible’ allele) NOD mice. The expression of the newly formed 
diabetes-resistant molecule in the re-infused hematopoietic cells, was sufficient to prevent 
T1D onset in the NOD mouse even in the presence of the native, diabetogenic non-Asp57, 
I-Ag7 molecule. Mechanistically, the authors suggested a model in which a subset of the 
engineered BM cells – i.e., hematopoietic precursor cells – migrate, populate the thymus and 
become antigen-presenting cells involved in the negative selection of thymocytes that would 
otherwise mature into autoreactive T-cells. In fact, diabetes-free NOD mice exhibited neither 
emergence into the blood stream of T cells capable of responding to putative autoantigens, 
nor the presence of beta-cell-reactive T cells in the pancreatic islets themselves (i.e., no 
insulitis).
Endocrine pancreas regeneration properties
In both physiologic and pathologic conditions, Lipsett and Finegood (63) attributed the rescue 
of beta cell mass to increased beta cell replication, increased beta cell size, decreased beta 
cell death, and the differentiation of possibly existing beta cell progenitors.  
In favor of the postulated differentiation of beta cells from progenitor ductal cells is the 
observation that occasional hormone-positive cells can be found embedded in normal 
pancreatic ducts (64). The number of these duct-associated endocrine cells increases 
physiologically as a consequence of severe insulin resistance in obese individuals or during 
pregnancy (65,66). Similar histological changes are observed under conditions of tissue 
injury and repair after partial pancreatectomy, duct ligation, cellophane wrapping of the 
gland, or IFN-γ over-expression driven by the insulin promoter (67-70).  Even then, within 
the ducts, only a small number of cells become insulin-positive.  This suggests that, even if 
some precursor exists, the process of the formation of endocrine cells in tissues other than 
islets (i.e., neogenesis) is not a common property of the duct epithelium. 
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However, alpha and beta cells seem to develop from a possibly common, non–hormone-
expressing, yet Pdx1-positive, precursor (71).   These endocrine progenitors may be located 
in physically close proximity to the duct, but may not actually be components of the ductal 
epithelium (72). At any rate, these hypothetical precursors are present in extremely small 
numbers so that lineage analysis becomes very difficult.  Considering the lack of known 
appropriate markers, it becomes even more difficult to quantify their contribution to normal 
endocrine cell turnover.  However, single cell precursors, able to regenerate all kinds 
of cells present in the islet have been successfully isolated from both the ducts and the 
islets themselves (73,74).  Thus, the working hypothesis of those who are proposing that 
pancreatic ductal cells can transiently regain a less differentiated state and then become 
beta cells seems legitimate (75).  Increased metabolic demand and tissue injury seem to be 
efficient in activating this physiologic process of cellular homeostasis (76).  
On this basis, it may also be possible to accommodate the results of Dor and colleagues 
(77) who proposed instead that new beta cells can arise only from the pre-existing beta 
cells themselves, whether in the normal adult pancreas or after pancreatectomy. As a direct 
consequence, the number of beta cells should become virtually defined at a certain point 
in time and, afterwards, glycemia should be controlled only by that defined cellular pool. 
The data also argue against the possibility of deriving beta cells from adult stem cells in 
vivo.  While the results of van der Kooy and Taniguchi (73,74) do not contest the proven 
yet limited ability of a beta cell to divide, the failure of Dor et al. (77) to observe cells that 
differentiated from stem or precursor cells might actually be explained by the experiments 
of Gershengorn’s group at the NIH that document the possible transition from epithelial-to-
mesenchymal (EMT) cells and vice versa (78). The authors hypothesized that precursor 
cells could be obtained from insulin-expressing cells that lose their beta cell identity. After 
expansion, these cells could potentially be redifferentiated into insulin-expressing beta cells 
via mesenchymal-to-epithelial transition (MET). Indeed, the authors describe some, though 
rather limited, success in their Science paper. 
After several days of culture of human islets in serum-containing medium, adherent cells 
start to migrate out from the islets, and form a monolayer of ‘fibroblast-like’ cells. Gradually, 
the population of cells down-regulate insulin and other islet-specific protein expression, 
but increase mesenchymal progenitor cell marker vimentin production. These cells can be 
passaged more than 30 times and expanded by a factor of >1012 in vitro. The authors named 
the cells human islet-derived precursor cells (hIPCs). Interestingly, when serum was taken 
away from the culture medium, the hIPCs stopped proliferating and formed aggregates of 
various size. After two weeks culture of aggregates under serum free condition, islet-specific 
marker expression, such as insulin and glucagon, were up-regulated 1000 fold. The authors 
argued that under the serum-containing culture condition, islet cells undergo EMT and 
become hIPCs, whereas under the serum-free condition, hIPCs undergo MET and start to 
differentiate back into islet cells.
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free area of islet vs. whole pancreatic tissue. The need for this
new parameter A arose from the observation that in diabetic
NOD mice rendered hematopoietic chimeras, a new mor-
phological state of the endocrine pancreas can be recognized.
The insulitis-free state obtained by the abrogation of the
autoimmune process must be distinguished from the normal,
physiologic condition of the pancreas. The islets in the
diabetic chimeric NOD mice, although cleared from insulitis,
are significantly reduced in size, display an altered morphol-
ogy, and contain cells, none of which has insulin content. In
unmanipulated control NOD mice, Index N (insulitis score/
A) increased in less than 25 weeks from 0.01 (characteristic of
physiological condition) to 0.1 (reflecting the hyperglycemic
condition in overtly diabetic mice); at this point, the animal
dies. In contrast, the chimeric NOD mice were followed to 32
weeks of age and did not become diabetic (Fig. 4). Fourteen
Fig. 3. Scoring of the different stages of destruction of islets of Langerhans during
diabetogenesis. Specimens of pancreata from NOD mice of different age were stained
with H&E. Magnification for A to G, �400; for H, �1000. (A) Score 0: normal
pancreatic tissue. Neither morphological abnormalities nor mononuclear cell (MNC)
infiltration or retention in the pancreatic vessels are present. (B) Score 1: MNC
vascular retention (yellow arrows). No evident pathological features in pancreatic
morphology. (C) Score 2: MNC perivascular infiltration (yellow arrows) of the vessels
adjacent to the islets; islets maintain a normal morphology. (D) Score 3: MNC
infiltration in the periphery of the islets (yellow arrows) and in the perivascular area of
the adjacent vessels (compare to intact area distant from the islets, green arrows). (E)
Score 4: the insulitis in the periphery of islets (yellow arrows) is associated with
apoptosis (red arrows). (F) Score 5: the infiltration of islets by MNC (yellow arrows) is
advanced, but not exceeding one third of islet section. (G) Score 6: more than one third
of the endocrine tissue of the islet is infiltrated by the MNC (yellow arrows). This stage
of insulitis is consistently concomitant with extensive apoptosis, presumably of both
endocrine and infiltrating cells (H: red arrows) (60).
6 Rood et al.
Figure 3: 
Scoring of  the different stages of  destruction of  islets of  Langerhans during diabetogenesis.
Specimens of  pancreata from NOD mice of  different age were stained with H&E. Magnification 
for A to G x400, for H x1000. (A) Score 0: Normal pancreatic tissue. Neither morphological 
abnormalities nor mononuclear cell (MNC) infiltration or retention in the pancreatic vessels 
are prese t. (B) Score 1: MNC vascular retention (yellow rows). No evident pathological 
features in pancreatic morphology. (C) Score 2: MNC perivascular infiltration (yellow arrows) 
of  the vessels adjacent to the islets; islets maintain a normal morphology. (D) Score 3: MNC 
infiltration in the periphery of  the islets (yellow arrows) and in the perivascular area of  the 
adjacent vessels (compare to intact area distant from the islets, green arrows). (E) Score 4: The 
insulitis in the per phery of  islets (yellow arrows) is associated with apoptosis (red arrows). (F) 
Score 5: The infiltration of  islets by MNC (yellow arrows) is advanced, but not exceeding one 
third of  islet section. (G) Score 6: More than one third of  the endocrine tissue of  the islet is 
infiltrated by the MNC (yellow arrows). This stage of  insulitis is consistently concomitant with 
extensive apoptosis, presumably of  both endocrine and infiltrating cells (H: red arrows) (60).
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If a small number of beta-cells can indeed undergo EMT, and dedifferentiate into precursor 
cells, in Dor’s pulse-and-chase labeling system (77) these cells will still be positively labeled. 
While Dor and colleagues’ explanation inferred a direct replication of beta cells, Gershengorn 
and colleagues’ data (78) suggest that beta-cells can dedifferentiate into precursor cells, 
which lose beta cell specific marker, while regaining proliferating potential at the same time. 
Upon proper stimuli, these precursor cells will redifferentiate back into mature beta cells to 
support islet growth and function.   
Further studies are necessary to ultimately define the possible existence and significance 
of different sources of precursor cells contributing to beta cell regeneration. However, an 
unconventional type of precursor cell (73,74), possibly located in close proximity and/or 
inside the endocrine tissue, seems to be present in the pancreas. When metabolic demand 
increases, these precursors are activated, possibly via various secreted factors that under 
normal conditions guarantee the cellular homeostasis of the islets of Langerhans.  
The balance between autoimmunity and regenerative activity
The physiologic equilibrium between lost and newly generated beta cells can be altered 
by the action of beta cell–specific, autoreactive T cells (79). Once the killing activity of 
activated diabetogenic T cell clones overcomes the regenerative compensatory activity of 
the gland, the number of functional beta cells progressively decrease until they become too 
few to maintain gluco-homeostasis in the body. After the clinical onset of the disease, even 
if the regenerative properties of the pancreas remain functional, the continued presence of 
autoreactive T cells consistently nullifies the reparative effort. Islet cells transplanted from a 
healthy monozygotic twin were quickly killed by these same autoreactive T cells present in 
the body of the genetically identical, diabetic recipient twin (80).
The autoimmune response can be successfully averted in the NOD mouse by the successful 
induction of mixed allogeneic chimerism. The transplantation of BM from a diabetes-resistant 
animal into a diabetic recipient following a sublethal dose of total body irradiation (TBI), is 
sufficient to block and eventually also reverse the systematic invasion and inflammation of 
the islets by autoreactive T cells that results in insulitis (58-61).
The allogeneic chimerism induced in pre-diabetic NOD recipients is multilineage and 
increases with time: four weeks after BM transplantation (BMT) chimerism may reach 
levels of over 90% (60).  In this study, to assess the damage and reparative processes 
in the pancreata prior to and upon therapeutic intervention, a new morphometric scoring 
system (called Index N) was utilized; this is comprised of both the degree of insulitis, defined 
by a very detailed scoring system (Figure 3), and a relative number ‘A’:  the measure of 
pathology-free area of islet versus whole pancreatic tissue. The need for this new parameter 
‘A’ arose from the observation that in diabetic NOD mice rendered hematopoietic chimerae, 
a new morphological state of the endocrine pancreas can be recognized.  The insulitis-free 
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state obtained by the abrogation of the autoimmune process, must be distinguished from 
the normal, physiologic condition of the pancreas. The islets in the diabetic chimeric NOD 
mice, although cleared from insulitis, are significantly reduced in size, display an altered 
morphology and contain cells, none of which has insulin content. In unmanipulated control 
NOD mice, Index N (insulitis score/A) increased in less than 25 weeks from 0.01 (characteristic 
of physiological condition) to 0.1 (reflecting the hyperglycemic condition in overtly diabetic 
mice); at this point the animal dies.  In contrast, the chimeric NOD mice were followed to 32 
weeks of age, and did not become diabetic (Figure 4). Fourteen weeks after BMT, arrest of 
the destructive processes and total normalization of Index N were observed in all chimeras 
subjected to non-lethal doses of TBI. Once normalized, Index N remained at a plateau for 14 
weeks (length of observation), confirming that normalization of the structure and function of 
the insulin-secreting tissue in the endogenous pancreas of chimeric NOD mice was stable 
and long lasting (61). To prove that the insulin-producing tissue of the endogenous pancreas 
can undergo a reparative process, direct detection of proliferating (i.e., BrdU-positive) cells 
can be performed.  In the endogenous endocrine pancreas, and in islet allografts of diabetic 
experimental mice, some proliferating (i.e., BrdU-positive) cells were also positively stained 
for insulin, revealing the regenerative capacity of the tissue (61).
Figure 4:  
Chimerism abrogates and reverses destruction of  islets of  Langerhans in NOD 
mice prior to the clinical onset of  diabetes.
NOD mice (8–12 weeks of  age) were rendered hematopoietic chimeras by the 
administration of  T-cell-depleted allogeneic BM into recipients conditioned by 
lethal (A) and nonlethal (B) doses of  TBI. Pancreata of  these chimerae were 
evaluated for the degree of  endocrine pancreas destruction and graded according 
to Index N. Gray diamonds, squares, and triangles reflect the kinetics of  Index 
N in mice rendered chimeric at 8, 10, and 12 weeks, respectively. Black circles 
show progression of  islet destruction with age evaluated in unmanipulated control 
NOD mice. This curve was not extended further since untreated animals did not 
survive long after reaching an Index N over 0.1 (61).
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Figure 5:  
Schematic representation of  the protocol used to test regeneration (or 
rescue) of  the beta cell in diabetic NOD mice. 
In NOD mice, the infiltration of  autoreactive T cells into the islets of  
Langerhans (resulting in insulitis) begins at around 4 weeks of  age. At 20 
to 23 weeks, ~85% of  female mice are diabetic, i.e., their glycemia is > 300 
mg/dl.  When successfully transplanted with bone marrow (BMT) from 
a non-diabetes-prone donor and hematopoietic chimerism is established, 
the NOD mouse no longer shows signs of  autoimmune activity. However, 
while there is no more evidence of  insulitis in the endogenous pancreas, 
there is also no sign of  insulin production (no red staining).  Three to four 
months after BMT, new insulin-positive cells (shown in red) are present 
throughout the endogenous pancreas.  Thus, when the islets transplanted 
under the kidney capsule (to maintain euglycemia until regeneration takes 
place), are removed by nephrectomy, the mice remain non-diabetic (61). 
For “Index N” morphometric scoring system see ref. 60.
Normalization of the endocrine pancreas observed in prediabetic NOD mice could also 
be achieved in these same animals after onset of the overt disease (61). Spontaneously 
diabetic NOD mice were rendered hematopoietic chimeras by transplanting them with BM 
from B6-GFP mice (81). The rationale for the use of green fluorescent protein (GFP)-positive 
BM cells was to track the fate of donor-derived hematopoietic stem cells (HSCs) and to 
elucidate their possible role in the restoration of the recipient endocrine pancreas. The NOD 
mice received B6-GFP BM cells along with islet grafts to allow their survival during the time 
required to reestablish an endogenous insulin production (Figure 5). These animals became 
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Figure 6:  
Regeneration (or rescue) of  
the endogenous pancreas 
in a diabetic NOD mouse 
after obliteration of  the 
autoimmune process via 
allogeneic BMT.
(A) The regenerated 
endocrine tissue of  a chimeric 
NOD mouse becomes 
evident after ~4 months 
from the BM transplant 
and takes the shape of  cell 
agglomerates that resemble 
but are not identical to islets 
of  a non-diabetic animal. 
Insulin is in red (61). (B) 
Comparison between an 
islet of  Langerhans of  a 
non-diabetic B6 mouse (A) 
with insulin stained green, 
and a newly formed insulin 
producing cell agglomerate 
(in red) in the pancreas of  
a diabetic NOD mouse 
treated with BM cells from 
a non-diabetes-prone, B6-
GFP-transgenic donor (B). 
It is possible to observe that 
the latter does not have the 
well organized cell structure 
of  a normal islet and that the 
majority of  the transplanted 
BM cells (in green) do 
not directly participate in 
the regeneration of  the 
endogenous pancreas:  there 
are no double-positive 
(orange) cells in the newly-
formed islets.  The donor 
cells appear to be located 
close to possibly existing 
juxta-ductal precursor cells, 
which may be activated by 
BM cell–secreted factors 
(45).
A
B
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euglycemic within 24 hours following transplantation, and remained so for the period of 
observation. After surgical removal of islet-graft-bearing kidneys, performed 17–26 weeks 
after islet transplantation, the mice remained euglycemic. Direct assessment of the insulin 
content in the islets from the endogenous pancreases that were harvested from euthanized 
animals 18 days following nephrectomy, revealed insulin-positive beta cells in quantities and 
morphologies similar to those of the normal mouse pancreas (Figure 6A). donor-derived 
GFP-positive cells were detected in the pancreas, but these cells were considered transient 
circulating, mature blood cells or HSCs not directly involved with the restoration of the 
endocrine pancreas since insulin+ cells were not GFP+ too (Figure 6B) (45,61). It was actually 
calculated that, in the cured recipient, insulin-producing cells (that were genetically marked 
to indicate they are of donor origin) were extremely rare, occurring in 2 out of 100,000 beta 
cells. These cells may actually be the result of sporadic cell fusion processes (82). 
A subject of ongoing debate is whether either or both the transplanted BM and the co-
transplanted beta cells are necessary for promoting an efficient regenerative process, 
independent of their ability to block autoimmunity or preserve euglycemia, respectively. 
They may, for example, secrete factors that are useful to sustain efficient regeneration. 
Recent results from the groups of Biason-Lauber, Bouwens, and Rabinovitch are particularly 
germane to this issue.  In the first case, the ability of PAX4 to favor regeneration of the 
endocrine pancreas was proven (83). The combinations of epidermal growth factor (EGF) 
and leukemia inhibitory factor (LIF) (84), or EGF and gastrin (85), were able to convert in 
vitro exocrine or ductal pancreatic cells, respectively, into insulin-producing cells. Additional 
factors with a possibly useful activity seem to be those used to increase the islet cell mass 
in transgenic mice or in gene-therapy-treated human islets (86-89). Also, the use of insulin-
like growth factor-1 (IGF-1) seems to be useful to promote and/or accelerate islet cell 
regeneration (90,91), as appears to be the case for glucagon-like peptide 1 (GLP-1), as 
described by Farilla et al. (92).
In the rat, experimental evidence supports the notion that precursor cells in both endocrine 
and exocrine tissue are not susceptible to damage by streptozotocin (STZ), i.e., they are 
not Glut-2-positive. STZ, like alloxan, uses Glut-2 as the receptor to get into the target cells 
that it eventually kills (40,93,94). Also, even in neonatal STZ-treated rats, a combination of 
activin A and betacellulin, for example, promoted regeneration of pancreatic beta cells and 
improved glucose metabolism (41). 
Endocrine pancreas regeneration in non-human primates
As previously anticipated, in the year 2000, the clinical possibility of transplanting islets 
into the livers of diabetic patients was documented; rejection was avoided thanks to an 
immunosuppressive regimen that reduced the use of tacrolimus and sirolimus, removed 
the use of steroids, and instead used daclizumab, an antibody against the IL-2 receptor 
molecule (18). However, as previously discussed, the Edmonton protocol soon showed its 
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limits. The first limiting factor was the immunosuppressive protocol, which was associated 
with side effects, and allowed this type of transplantation in certain adult recipients only (95). 
The second limiting factor was the need for more than one islet donor for each recipient.  
To respond to the latter limiting aspect of the Edmonton protocol, some groups looked at a 
theoretically-unlimited source of transplantable islets. An unlimited source of islets can be 
found in animals able to produce an insulin very similar to human insulin and in quantities 
that may satisfy the insulin requirements of an individual of an average body weight. Based 
on these two parameters, the pig seemed to be the animal of choice. There is only one 
amino acid difference between human and pig insulin, and the pig is large enough to supply 
large amounts of donor islets. Pig insulin was successfully used to treat diabetic children for 
years before recombinant human insulin became available. Also, evidence that pig islets can 
be used for human transplantation was provided by studies conducted, in particular, in the 
1990’s in Sweden (96). This possibility was not further explored when it became clear that 
the alpha1,3 galactose (alpha1,3Gal) epitopes present on pig tissues were the targets of 
antibodies, normally found in human serum, that are able to quickly reject xenotransplants. 
This rapid, deleterious reaction is known as ‘hyperacute rejection’ (HAR).  HAR is the major 
cause of tissue destruction within a few hours after xenotransplantation.  The best way 
to obviate HAR was to work towards the generation of pigs genetically deprived of the 
activity of the enzyme alpha1,3 galactosyltransferase (alpha1,3GT) and, consequently, free 
of alpha1,3Gal epitopes at their cell surface (97). In the spring of 2003 (98), our effort of 
many years (99,100) to generate alpha1,3GT double knockout (DKO) pigs was successfully 
completed. DKO pigs are better suited as donors for xenotransplantation than their wild-type 
counterparts since, once their tissues are transplanted into humans or Old World monkeys, 
they are not targets for a HAR. Adult islet cells from wild-type animals express only low levels 
of alpha1,3Gal epitopes (101). However, other cells contaminating each preparation used for 
transplantation do express alpha1,3Gal epitopes at high levels.
Experiments in chemically diabetic (i.e., STZ-treated) monkeys indicated that pig islets can 
substitute for endogenous islets, producing enough insulin (monitored by pig C-peptide) to 
control the recipient animal glycemia (102,103). More pertinent to this discussion, however, 
is the observation that, using a non-calcineurin inhibitor-based immunosuppressive protocol, 
it has been observed that the monkeys’ own pancreatic endocrine tissue is able to regenerate 
within a period of time similar to that determined for the diabetic mouse. Preliminary studies 
show that all the insulin+ and Glut-2+ cells disappear in the pancreata of monkeys treated 
with STZ, but insulin+ and Glut-2+ cells re-appear after 3 to 4 months of treatment. After STZ 
treatment, the endocrine pancreas of the monkey was no longer able to produce sufficient 
quantities of insulin to satisfy the need of the animal, which consequently became diabetic. 
Monkey C-peptide levels remained <0.5ng/ml for the entire duration of all experiments in 
which conventional immunosuppressive cocktails were used, and the arginine-stimulation-
test was always blunted when performed during follow-up. Regenerative properties may 
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have been overpowered by the effects of the diabetogenic calcineurin inhibitors administered 
to the monkey. Also, regeneration did not spontaneously take place, at least at a detectable 
pace, since STZ-treated non-transplanted monkeys continued to need insulin injections after 
the induction of diabetes. In contrast, in the absence of diabetogenic immunosuppressive 
agents, using instead an anti-CD154 monoclonal antibody to block the recipient’s immune 
rejection (104), the monkeys transplanted with DKO pig islets not only produced pig C-
peptide but eventually (more than three months after STZ treatment) recovered the ability 
to produce monkey C-peptide. New insulin-producing cells are appearing with time in the 
monkey’s endogenous pancreas eventually forming islet-like conglomerates of cells (Figure 
7) (Bottino, et al). 
Figure 7:  
Newly formed insulin-producing cells in the diabetic monkey. 
After 3 to 4 months from STZ injection and diabetes induction, insulin-
producing cells are appearing in the monkey endogenous pancreas, eventually 
forming islet-like conglomerates of  insulin-positive cells indicated by the 
arrows.  Immunofluorescence on the left (insulin in green) and H&E on the 
right, of  two consecutive tissue sections (Magnification 20x).
If regeneration can occur not only in rodents but also in the monkeys, we can also expect the 
endocrine tissue to regenerate in humans once autoimmunity has properly and successfully 
been abrogated. There is some evidence that supports this expectation.
Endocrine pancreas regeneration in humans
A group from Ulm in Germany recently reported the case of a 13 year old caucasian boy 
who, after conventional onset of T1D (i.e., the boy presented with a history of polyuria, 
polydipsia, weight loss, and serum glucose up to ~ 500 mg/dL, glucosuria and ketonuria), 
needed lower and lower insulin doses over time, allowing his physician to completely 
discontinue insulin therapy after 11 months (43). The authors also reported that: ”Without 
further treatment, HbA1c, and fasting glucose levels remained normal throughout the entire 
follow up of currently 4.5 years”, and that serum autoantibodies to GAD65, IA-2, insulin, and 
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ICA “were initially positive but showed a progressive decline or loss during follow-up.”  A 
similar case was recently reported by David Harlan’s group (13). 
The main message we draw from all these reports is that within the endocrine pancreas, 
once the insult of autoimmunity is abrogated, the physiologic process of regeneration can 
continue efficiently, eventually replenishing the population of insulin-producing cells to a 
number sufficient to maintain euglycemia, thus curing the diabetic patient. While this process 
takes place, the recipient’s glycemia must be controlled by additional, independent measures. 
In rodents, the most commonly used technique has been to transplant into the recipient 
islets from the same BM donor. However, the successful engraftment of the transplanted BM 
(necessary to abrogate the autoimmunity) and/or islets (necessary to maintain euglycemia) 
would have to be promoted and maintained without the use of calcineurin inhibitors that 
will eventually not only kill the autoreactive T cells of the recipient, but also limit beta 
cell neogenesis, thereby undermining the success of the transplant (32-34). The use of 
these diabetogenic immunosuppressive agents may also interfere with the observed rise 
of regulatory T cells, a possible explanation for the long-lasting immunoregulatory cell–
dominant condition observed in cured animals (105). Adoptive transfer experiments in which 
both diabetogenic lymphocytes from diabetic NOD mice and splenocytes from treated, long-
term diabetes-free NOD mice were transplanted into NODscid recipients, with no signs of 
induction of diabetes, support this hypothesis (106,107).  
On these bases it seems that not only in animals, but in humans as well, the abrogation 
of autoimmunity could allow the physiologic regeneration of insulin-producing beta cells in 
the host endocrine pancreas, even after the onset of the disease, if a non-diabetogenic 
immunosuppressive protocol is implemented. These are the premises on which reliable and 
more clinically-translatable alternatives than allogeneic BMT or allogeneic or xenogeneic 
pancreatic islet transplantations should be found to cure our young diabetic patients.
Readjusting the efficiency of the first T cell signal
On this basis it seemed useful to extend the previously described experimental protocol 
proposed by the Harvard group to implement a new one that is more transferable to 
clinical trials (108): If Tian’s approach (62) to abrogate autoimmunity can facilitate a 
possible recovery of autologous insulin-producing cells also in the diabetic individual, safe 
induction of an autoimmunity-free status might become a new promising therapy for T1D. 
The working hypothesis to be tested considers the use of BM-enriched hematopoietic 
precursor cells, instead of the non-fractionated BM cell population used by Tian et al., as 
the recipients of the MHC class II beta chain gene that confers resistance to the disease, 
to abrogate autoimmunity. Enriched precursors will be more successfully transfected and 
more easily accepted by the recipient than the total BM cells.  Also, differing from Tian’s 
approach, overtly diabetic (rather than prediabetic) individuals would be treated by the re-
infusion of transfected BM-enriched precursors. Autoimmunity will be efficiently abrogated 
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if the enriched precursors are able to generate the right derivative cells and in sufficient 
numbers to efficiently repopulate the thymus, by negatively-selecting possibly autoreactive 
T cell clones and promoting peripheral tolerance mediated by T regulatory cells.  In the 
absence of both autoimmunity and diabetogenic immunosuppressive protocols, by adopting 
alternative means to correct hyperglycemia, the regenerative property of the autologous 
endocrine pancreas should repopulate the gland with enough insulin-producing cells to 
restore euglycemia. Also, to avoid the use of radiation to eliminate the activated T cell clones 
present in the diabetic patient, as in Tian et al. (62), an antibody-based preconditioning 
may be used instead.  Finally, it should be determined how long after its onset disease 
reversal remains possible, and the measures to be considered in case this reversal property 
becomes less efficient with time.  
First, all these steps have to be successfully tested in the NOD mouse, as an animal model in 
which diabetes spontaneously develops as a direct consequence of an autoimmune process, 
very similar to the one we observe in humans.  Then it would be useful to try to reproduce 
the most promising results in non-human primates. Even if non-human primates do not 
spontaneously develop autoimmunity, and consequently do not spontaneously develop T1D, 
this model can be used for testing the safety of the proposed protocol. The concept that a 
physiologic regenerative capacity may be present in humans will obtain much more support 
once it has been demonstrated in a closely-related species, such as the monkey.
The proposition of considering the use of this same approach for a possible clinical trial may 
be complicated by the presence of more than one susceptibility molecule in humans, i.e., 
not only the HLA-DQ molecule like in the NOD mouse, but also the HLA-DR. However, the 
efficiency of Tian’s gene-based treatment, even in the presence of the native, diabetogenic 
molecule, may offer solutions also to the problem of dealing with more than one susceptibility 
molecule (108,109).  It is expected that the protective allele will act in an epistatic or dominant 
manner over the susceptibility allele, also in the case of the DR molecule (109).  Thus, to 
cover all the bases, both a new DQ and a new DR beta chain should be co-transfected into 
the precursor cells.
For preventing diabetes progression in pre-diabetic NOD animals by transfected BM precursor 
cell reconstruction, a combination of AutoMACs with Flow Sorter approaches was used to 
isolate Sca1+, c-Kit+ and lin- BM cells for transplantation into myeloablated recipients. The 
isolation of BM was performed on 8-week-old F1 NOD/NOD H2b congenic males. F1 donors 
were chosen to mimic a syngeneic transplant yet with the possibility of recognizing donor 
from recipient cells in the reconstituted animal. All NOD female recipients remained alive 
after sub-lethal radioactive conditioning and showed an evident chimerism in the blood two 
weeks after receiving enriched BM precursor cells (Fan, unpublished observation). 
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These preliminary experiments were performed using retroviruses carrying only the GFP 
gene or the GFP gene plus the gene of the I-A beta chain conferring resistance to the 
disease. However, in light of a possible clinical trial, the use of a retrovirus for performing 
a successful resistance beta chain transfection, as proposed by Tian et al. (62), should 
be avoided since it is associated with the problem of its preferential insertion in positions 
of the recipient’s cell genome that may facilitate the activation of oncogenes, a problem 
already sadly encountered in human gene therapy treatments (110). It would be safer to 
utilize phage integrases (111) to guide the stable and irreversible insertion of DNA at specific 
locations within the genome to satisfy the need for a safe, yet everlasting, synthesis of the 
beta chain conferring resistance, even in the offspring of the successfully-transfected BM 
precursor cells. 
Some influencing factors of retrovirus activity, besides the preferential position of the insertion 
in the genome, include the presence of regulatory and bacterial elements in the insertion 
construct itself, and the number of integrated constructs. Efficient, targeted, single-copy 
integrations would be helpful for the improvement of transgene efficiency. Phage integrases 
catalyze site-specific, unidirectional recombination between two short att recognition sites. 
Recombination results in integration when the att sites are present on two different DNA 
molecules, and deletion or inversion when the att sites are on the same molecule. 
By using the integrases, all the insertion sites can be recognized because of their limited 
number.  Hopefully they will be found in positions that do not alter the activation of any 
important gene.  In the case that possibly dangerous locations are recognized – a case that, 
statistically, seems to be quite remote – these insertion sites could be obliterated molecularly 
before transfecting the ‘therapeutic’ genes. This is theoretically possible by culturing in vitro 
for a few divisions the HSC transfected with the corrective recombinant DNA associated with 
an antibiotic-resistance gene, so to select only the ‘treated’ ones.  The hope here is that they 
will remain able to properly repopulate the recipient’s BM and thymus, and that they will not 
result in any additional non-recognized dangerous insertion.  However, in practical terms, it 
can only be concluded that the risk imposed by the use of this new system will dramatically 
reduce, but not completely exclude, the problems associated with the use of retroviruses.
Irradiation was used in the original experiments of Tian et al. (62) for removing activated 
T cells from the recipient.  However, it would be worthwhile to systematically substitute for 
irradiation different, antibody-based, immuno-reductive conditioning protocols. Monoclonal 
antibodies can be tested as an alternative to, or in association with, the use of Thymoglobulin 
or Campath. Examples are in protocols originally described by Lucienne Chatenoud in which 
the anti-CD3 antibody was successfully used to prevent the onset of the disease in prediabetic 
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NOD mice. It was also possible to reverse recent-onset disease by restoring the lost self-
tolerance to beta cell antigens in the same strain of mice (105).  Another possibility, proposed 
by Dale Greiner’s group in Worcester (112), consists in the use of an anti-CD154 antibody. 
The potentially dangerous thrombogenic characteristics of some anti-CD154 antibodies may 
not be too worrisome if the treatment can be, as in this case, very limited in time.  A third 
protocol involved the use of an anti-CD20 monoclonal antibody. A chimeric mouse-human 
immunoglobulin G with this specificity (Rituximab) has shown efficacy in the treatment of 
some autoimmune diseases (113).  More recently, Rituximab has also been successfully 
used to improve the outcome of allogeneic HSC (e.g., enriched CD34+) transplantations 
into patients who suffered chronic graft-versus-host disease (114). Its efficacy in inhibiting 
the activation of a number of T cell clones in the recipient, by blocking his/her B lymphocyte 
activity, could be tested here with the aim of pre-conditioning the recipient before performing 
transfected BM precursor cell autotransplantation.
Reducing the effects of second T cell signals
Thymic or central tolerance must be complemented by the peripheral regulation mediated by 
cell-antigen-specific T cells.  Dendritic cells (DCs) are the primary antigen-presenting cells 
(APCs) of the immune system that control the activation of naive T cells (115-117). For full 
activation of naive CD4+ T lymphocytes to occur, a second signal is necessary besides the 
already described presentation of the antigen to the TCR in the context of the MHC class II 
molecule present at the surface of the DC. Once properly activated, the T cell up-regulates 
the CD154 molecule (CD40 ligand) at its cell surface, thereby promoting the initiation of the 
second signal. The interaction of CD154 with the CD40 molecule results in the up-regulation 
of CD80 and CD86 at the surface of the APC. Up-regulated CD80 and CD86 will engage 
the CD28 molecule present on the T cell. The full activation of the T cell is the result of this 
second signal costimulation. 
In the absence of the interactions between CD80, CD86, and CD28, the T cell will either 
enter a state of functional silence, termed anergy, or will be primed for apoptosis, perhaps in 
a CD95-CD95L (Fas-FasL)-dependent manner (118). Converging lines of evidence indicate 
that the phenotype of the DC surface can play an important role in the development of 
tolerance to self-antigens, and that it can be manipulated to induce allogeneic as well as 
autoimmune hyporesponsiveness (119). Phenotypically ‘immature’ DCs, defined by low level 
expression of cell surface CD40, CD80, and CD86, can elicit host immune suppression in 
allotransplantation and autoimmunity. 
The first use of DC to prevent T1D in NOD mice was documented by Clare-Salzler et al. (120), 
who demonstrated that transfer of pancreatic lymph node DC derived from 8 to 20 week-old 
NOD mice into prediabetic NOD mice conferred significant protection from T1D, insulitis, and 
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adoptive transfer of T1D.  The latter was possibly due to the presence of regulatory T cells 
which attenuated these pathologic processes. More recently, Morel and colleagues have 
shown prolongation of a diabetes-free state in NOD recipients of BM-derived syngeneic DC 
(121,122). NOD DC exhibit strong immunostimulatory capacity, underlined by hyperactivation 
of NF-kappa B (123–125). In fact, the inhibition of NF-kappa B, using short, double-stranded 
transcriptional decoys, render NOD DC less immunostimulatory.  The administration of these 
engineered DC into NOD prediabetic mice prevents the development of diabetes (126). 
A complementary approach is that of engineering DC in a way in which the expression of 
the costimulatory molecules CD40, CD80, and CD86 only would be suppressed at the cell 
surface (107). Unlike the intervention on NF-kappa B or the use of anti-CD40L antibodies 
and CTLA4-Ig, this approach limits the cell population that is targeted, because the treatment 
is performed ex vivo and does not involve systemic dissemination of proteins which, in 
the instance of CTLA4-Ig and anti-CD40L, have exhibited toxic effects (127,128). The ex 
vivo treatment of BM-derived NOD DCs with a mixture of antisense oligodeoxynucleotides 
(AS-ODN), targeting the CD40, CD80, and CD86 transcripts, confers specific suppression 
of the respective cell surface proteins (107). A single injection of these engineered DCs 
into syngeneic prediabetic female NOD mice significantly delays the incidence of T1D and 
abolishes any sign of insulitis. More than one injection of AS-ODN-treated DCs maintain the 
NOD mice diabetes-free indefinitely without affecting the response of T cells to alloantigens. 
Splenocytes with an increased prevalence of CD4-CD25-CD62L+ T cells, from ODN-treated 
NOD DCs transferred into NODscid recipients, together with splenocytes from a diabetic 
donor, reduce dramatically the onset of the disease the latter are normally able to induce 
(107). 
The use of AS technology specifically targeting the transcripts of key DC cell surface proteins 
involved in T cell activation and regulation could be a useful technique to complement central 
regulation mediated by a newly-populated thymus, and might make T1D cell therapy more 
efficient (45).
Infusion in situ of appropriate factors able to speed up the physiologic regenerative 
process  
The physiologic regenerative potential of the endocrine pancreas seems to be still quite 
high immediately after (or very close to) the onset of the disease when, in general, there still 
are some insulin-producing cells able to secrete sufficient insulin to make C-peptide testing 
possible, i.e., over the minimum level detectable by the appropriate assays.  In the mouse 
and in the monkey (e.g., cynomolgus), the regenerative process seems to take more than 3 
months to substitute enough beta cells to allow the detection of an influence on the control 
of the glycemia of the animal.  Even at this point in time, both of these animals do not yet 
have perfect control of the glycemia, since intravenous glucose tolerance tests (IVGTTs) are 
still far from normal.  However, this result would constitute already a great advantage for the 
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diabetic patient, even if we do not know for sure whether, at a longer time after clinical onset, 
the reparative process may still work and at the same speed observed immediately after 
onset. Preliminary studies in animals seem to indicate that the regenerative process works 
proportionally more slowly as the time from onset of the disease increases.  If eventually the 
regenerative process ceases to activate, it would be useful to know when that time is, i.e., 
when the time from onset has become ‘too long’. 
To help the system to activate the regenerative process, or to speed up a possibly very 
slow physiologic recovery, even after protracted diabetes insulin therapy, it would be useful 
to test those different factors that have been proven to be efficient in better achieving this 
goal (84,85). For other factors, like PAX4 (83), HGF (87), IGF-1 (90,91), or GLP-1 (92), the 
insulin promoter should be used to construct the cassettes eventually introduced into the 
vector.  In a recent study (Wang et al., unpublished data), the capacity of adeno-associated-
virus (AAV)-mediated pancreatic gene transfer was reexamined using the recently available, 
novel serotypes of AAV coupled with an improved double-stranded AAV vector DNA cassette, 
which facilitates rapid and stronger transgene expression (129). The advantage of using 
AAV vectors consists in their lack of immunogenicity, associated with their limited insertion 
capabilities, that, particularly in dividing cells, eventually leads to loss of expression of the 
carried gene. It has been shown that robust and relatively long-term gene transfer can be 
achieved by these vectors in the vast majority, if not all, of the islets. Gene transfer efficiency 
and vector distribution in the islets are determined by the choice of AAV serotype vectors, as 
well as by the delivery methods. The pancreatic exocrine acinar cells are highly susceptible 
to AAV8 infection. To minimize the unwanted gene transfer to non-endocrine pancreatic 
and non-pancreatic tissues seen after i.p. or i.v. delivery, we explored a topical route by 
retrograde delivery into the pancreatic duct, similar to the technique ERCP (endoscopic 
retrograde cholangio-pancreatography) commonly used in patients with pancreatitis. Since 
the pancreatic beta cell is, by definition, the most important target in gene transfer and 
therapy for diabetes, we explored the use of the insulin promoter to minimize non-specific 
transgene expression in unintended cells, such as the pancreatic acinar cells and those 
beyond the pancreas. As expected, 2 weeks after delivery of AAV8-insulin-promoter-GFP 
vector in adult mice, strong GFP expression was readily detected exclusively in the islets, 
but not in the exocrine acinar cells. 
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CONCLUSION
For decades, efforts have been made to find successful treatments for T1D, such as insulin 
replacement, pancreas transplantation, and islet transplantation (whether they be allo 
or xeno).  Despite progress in the field of transplantation, this has not yet resulted in a 
permanent solution.
Rodent studies have given us hope for a new direction:  regeneration of the patient’s own 
beta cells.  Preliminary studies in primates support anecdotal examples suggesting that beta 
cell regeneration might be possible also in humans.  If abrogation of autoimmunity can be 
safely achieved in a diabetic patient with an autotransplant of precursor cells transfected with 
HLA class II beta chain genes conferring resistance to the disease, while correcting his/her 
hyperglycemia using conventional insulin administration or an islet allotransplant, ‘Nature’ 
will be left to heal the rest. It should also be possible to speed up the natural process of 
healing by endoscopic retrograde intraductal delivery of factors known to promote beta cell 
regeneration. Should this approach work satisfactorily, our young patients will be cured for 
good, without the need for long-term drug therapies associated with the known troublesome 
consequences. 
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The ultimate goal is to find a cure or permanent treatment for type-1 diabetes, which would 
prevent its notorious long-term complications and abrogate the restrictions that insulin 
therapy constitutes for daily life. Pancreas transplantation and islet allotransplantation (using 
a human donor organ) are potential solutions, although not ideal for reasons such as surgical 
complications and organ shortage.
A potential solution to the problem of organ shortage can be found in xenotransplantation, 
using the pig as the source of islets. With the production of pigs homozygous for α1,3-
galactosyltransferase gene-knockout (GT-KO), a new era has started in the field of pig to 
primate xenotransplantation. Clinical trials cannot be started without appropriate validation 
of results obtained from rodent studies in a preclinical model, which necessitates nonhuman 
primate studies.
This dissertation began with a review of prior experience with pig-to-nonhuman primate 
islet transplantation (Chapter 2). The type of porcine islets used was discussed, i.e., fetal, 
neonatal and adult islets. It would seem that adult porcine islets have the best potential, 
from both logistic and immunologic perspectives, to reverse diabetes in primates. Islet 
isolation techniques have improved sufficiently so that large numbers of good-quality adult 
porcine islets can be obtained. Models for diabetes in nonhuman primates were described. 
Refinements in the induction and maintenance of streptozotocin (STZ)-induced diabetes in 
nonhuman primates provided a useful experimental model, although it remains uncertain 
whether STZ induces irreversible diabetes. However, progress in extending survival of 
transplanted pig islets in nonhuman primates has been slow, although encouraging results 
have recently been reported (1, 2). 
With the relative plethora of established and novel immunosuppressive agents now available, 
one major problem will be to determine the optimal combination. Particularly in the treatment 
of a disease such as diabetes, that is not rapidly fatal, there is a need to establish clinically-
applicable immunosuppressive regimens that are not associated with life-threatening side 
effects. There will almost certainly be a move away from calcineurin inhibitors, that are 
diabetogenic, towards newer agents, such as leflunomide, and biological agents that inhibit 
costimulation. Experimental models have been established in which these novel agents can 
be investigated. However, as one reviews the literature, questions remain, and details of 
these models need to be adequately addressed.
ANTI-NONGAL ANTIBODIES
Transplantation of a wild-type (WT) pig graft into a nonimmunosuppressed primate usually 
results in hyperacute rejection within minutes to hours (3, 4). The primary role of anti-Gal 
antibodies in this response has been established by several groups (5-8). The problem 
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of anti-Gal antibodies has recently been overcome by the breeding of pigs homozygous 
for α1,3-galactosyltransferase gene-knockout (GT-KO) (9, 10). However, although the 
transplantation of an organ from a GT-KO pig into an immunosuppressed nonhuman 
primate allows extended graft survival (11), the graft eventually fails from the development 
of a thrombotic microangiopathy that may be a form of delayed antibody-mediated rejection. 
The focal deposition of IgM, IgG, and C4d on the graft suggests that a component of this 
process involves the binding of anti-nonGal antibodies to the pig vascular endothelial cells. 
These antibodies could be either preformed or elicited.  
In addition to this potential role in the rejection of GT-KO pig organs, anti-nonGal antibodies 
may also be important following adult pig islet transplantation in primates. As adult pig islets 
are known to express little or no Gal (12-15), anti-nonGal antibodies are likely to be involved 
in any antibody-mediated rejection process (16-18). 
Anti-nonGal antibodies in baboons
in Chapter 3 we investigated the incidence of preformed anti-nonGal antibodies in the serum 
of naïve baboons, and we assessed whether these antibodies are cytotoxic to pig peripheral 
blood mononuclear cells (PBMC) lacking the Gal epitope.  The results were compared with 
reactivity of anti-pig antibodies to WT pig PBMC.  
Whereas all but one of 56 baboons had preformed antibodies, mainly IgM, to WT pig PBMC, 
less than half had such antibodies to GT-KO PBMC. Moreover, the cytotoxicity associated 
with anti-nonGal antibodies alone (to GT-KO PBMC) was significantly weaker than that 
associated with combined anti-Gal+anti-nonGal antibodies (to WT PBMC).  Our data suggest 
that GT-KO pigs are preferable to WT pigs as sources of organs for transplantation into 
baboons. Nevertheless, anti-nonGal antibodies initiated a cytotoxic response; in vivo, this 
would be expected to jeopardize long-term viability of a pig organ graft.
The capacity of elicited antibodies, collected from the sera of two baboons exposed to 
GT-KO pig hearts, to bind to GT-KO PBMC, and to lyse those cells, was also assessed. 
Immunoglobulins, predominantly of the IgG isotype and specific for undetermined nonGal 
antigens, reached high levels post-transplantation, and were associated with a significant 
increase in cell lysis. The timing of the elicited antibody response (beginning by day 7) was 
similar to that seen previously when baboons were exposed to WT pig antigens, but the 
amplitude of the response would appear to be reduced (19, 20).
We found no evidence of continued expression of Gal in the GT-KO pigs, e.g., as a result 
of iGb3 synthetase activity, as has been suggested by others (21, 22) since, after exposure 
to GT-KO pig hearts, and despite sensitization to nonGal antigens, there was no increase 
in the level of anti-Gal antibodies.  Previous in vitro studies involving WT cells and either 
immunoadsorption of primate sera or treatment of the cells with a galactosidase have 
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suggested that antibodies to nonGal antigens represent only 10-30% of anti-pig IgM and 
20-50% of anti-pig IgG antibodies in naïve sera (reviewed in (23)).  The data observed 
using GT-KO PBMC in the present study would largely agree with these estimates, but 
would suggest that anti-nonGal antibodies may represent a greater proportion of anti-pig 
antibodies in some baboons.
Anti-nonGal antibodies in humans
in Chapter 4 we reported on the incidence of preformed anti-nonGal antibodies in the serum 
of healthy and allosensitized humans, and we assessed whether these antibodies are 
cytotoxic to pig PBMC lacking the Gal epitope.  The results were compared with reactivity of 
anti-pig antibodies to WT pig PBMC.  
Whereas all healthy and allosensitized humans had preformed antibodies to WT pig PBMC, 
in approximately one-third antibodies to GT-KO PBMC were not detectable.  Moreover, 
the cytotoxicity associated with anti-nonGal antibodies was significantly weaker than that 
associated with anti-Gal antibodies, corresponding to our findings in baboons (Chapter 3). 
Whereas reactivity with WT pig cells is clearly due to the binding of both anti-Gal and anti-
nonGal antibodies, reactivity with GT-KO cells is solely due to the presence of anti-nonGal 
antibodies.  However, although the absence of the Gal epitope led to a significant reduction 
in both the prevalence and severity of complement-induced lysis, anti-nonGal antibodies 
nonetheless can initiate a cytotoxic response which, in vivo, could affect long-term viability 
of a pig graft.
An important finding from this study is the documentation that sera from allosensitized 
subjects did not show a higher level of binding of preformed antibodies (IgM or IgG) to nonGal 
antigens than did sera from unsensitized or healthy subjects, nor increased cytotoxicity. 
Previously, some reports suggested that sera from allosensitized subjects might be more 
cytotoxic to unmodified pig cells than sera from unsensitized subjects, although other 
reports did not confirm this observation (reviewed in (24)). Recently, it has been confirmed 
by others that  humans previously exposed and sensitized to alloantigens are at no greater 
risk for rejecting a GT-KO pig xenograft by an antibody-mediated mechanism (25). Highly 
allosensitized patients frequently have difficulty in obtaining a human donor organ against 
which they do not have anti-HLA antibodies. This group of patients may therefore be among 
those first considered for xenotransplantation.  
Similar to our findings in baboons, our study suggests that GT-KO pigs are more suitable 
than WT pigs as sources of organs or tissue for transplantation into humans, since reactivity 
with preformed antibodies in human serum was significantly reduced. However, unidentified 
nonGal epitopes on the pig vascular endothelium could still pose a threat to the viability of a 
porcine graft transplanted into a human.  
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Acute humoral xenograft rejection (AHXR) associated with the presence of preformed or 
elicited anti-nonGal antibodies might therefore be addressed by further modification of the 
pig to reduce the expression of nonGal antigens.  The identification of nonGal specificities 
would therefore be an important step forward.  However, the nature of the nonGal antigens 
expressed on GT-KO pig vascular endothelium or PBMC is currently uncertain, although 
several carbohydrates are candidates (26, 27).  It has been demonstrated that there is some 
rearrangement of the carbohydrate pattern of the vascular endothelium in mice after GT-
KO (28), and neoantigens might be exposed, to which some preformed antibodies may be 
directed. N-glycolylneuraminic acid epitopes, so-called Hanganutziu-Deicher antigens, are 
widely expressed on the endothelial cells of all mammals except humans, and are considered 
to be potential porcine targets for preformed and elicited anti-nonGal antibodies in humans 
(29-32), but not in baboons, which express these epitopes.  It is equally likely that the targets 
for elicited anti-nonGal antibodies are proteins, rather than carbohydrates.
If there are multiple nonGal epitopes against which humans have preformed antibodies, 
then gene-knockout may not be a feasible solution.  However, the lower level of endothelial 
cell activation and cytotoxicity associated with anti-nonGal antibodies, compared with anti-
Gal antibodies, may allow protection by the presence of one or more human complement-
regulatory proteins when combined with a GT-KO pig genotype.  Although transgenic pigs 
expressing human decay-accelerating factor or other complement-regulatory proteins were 
incompletely protected against anti-Gal antibodies (33, 34), this approach may prove more 
successful against the weaker anti-nonGal antibodies. 
There is increasing success in achieving a state of accommodation after allografting across 
the ABO blood group barrier or when there is allosensitization associated with anti-HLA 
antibodies (35).  Such approaches, involving procedures such as pre- and post-transplant 
plasmapheresis and the administration of intravenous immunoglobulin (36), although not 
effective in inducing accommodation to a WT pig xenograft (37-39), may possibly prove more 
successful in the presence of the lower levels of anti-nonGal antibody.  To our knowledge, 
this approach has not yet been tested in the GT-KO pig-to-nonhuman primate model.
Another potential way to avoid rejection caused by anti-nonGal antibodies, is to transplant 
porcine tissue or organs before anti-nonGal antibodies have developed during infancy. This 
is described in Chapter 6, and will be discussed below.
Anti-nonGal antibodies in monkeys
Chapter 5 describes the presence of anti-nonGal antibodies in monkey sera, and compares 
the levels of anti-nonGal antibodies between monkeys, baboons and humans. The incidence 
of binding of monkey serum IgM and IgG isotypes to PBMC from GT-KO pigs was significantly 
less when compared to binding to WT PBMC.  However, we demonstrated that 76% of 
the tested monkey sera caused some lysis of GT-KO PBMC (compared to 100% lysis of 
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WT PBMC), although, the extent of cell lysis associated with anti-nonGal antibodies was 
significantly less. 
Even though this confirms the potential advantage of using GT-KO donor pigs for 
transplantation into cynomolgus monkeys (as we described for baboons and humans), 
nevertheless approximately three quarters of the monkeys had IgM with or without IgG 
binding to GT-KO PBMC. Only 43% of human and 32% of baboon sera were demonstrated 
to have IgM binding to GT-KO PBMC, which is significantly less than the 76% IgM binding of 
cynomolgus monkey sera (p<0.01). Both human and monkey sera showed an incidence of 
67% IgG binding to GT-KO PBMC, compared to an incidence of only 9% of baboon IgG. 
Furthermore, whereas approximately 50% of both human and baboon sera demonstrated 
cytotoxic antibodies against GT-KO PBMC, the incidence is 76% in monkey sera. Because of 
the cytotoxicity associated with these anti-nonGal antibodies, they are likely to be associated 
with the development of AHXR. These results suggest that monkeys may have stronger 
antibody-mediated cytotoxic responses to GT-KO pig grafts than humans and baboons.
To our knowledge, there are no reports of transplantation of GT-KO organs or cells in 
cynomolgus monkeys. However, there is evidence that anti-nonGal antibodies are associated 
with AHXR in cynomolgus monkeys; Lam et al. demonstrated that, when hDAF-transgenic 
pig hearts were transplanted into cynomolgus monkeys under soluble Gal saccharide-based 
therapy (to adsorb or ‘neutralize’ anti-Gal antibodies), anti-nonGal antibody levels increased 
in animals that rejected their grafts (40).
It has sometimes been considered that the baboon is a more difficult preclinical model of 
xenotransplantation than the macaque monkey. Our data suggest that antibody-mediated 
xenograft rejection of GT-KO pig organs or cells may be more vigorous in cynomolgus 
monkeys than in baboons or humans. With regard to the cytotoxicity associated with anti-
nonGal antibody binding, the baboon may be closer to the human than the cynomolgus 
monkey, and therefore may be the preferred experimental recipient of GT-KO pig grafts.
Anti-nonGal antibodies in infants
Natural anti-pig antibodies develop during infancy (41-46), a finding confirmed by our study 
(Chapter 6).  However, we were the first to investigate the development of anti-nonGal 
antibodies in infant baboons and humans, and to demonstrate the correlation between age 
and antibody production. Our data suggest that both baboons and humans develop cytotoxic 
anti-pig IgM early during the first year, the level of which steadily increases with age during 
the first year, but this IgM is largely directed against Gal targets. Cytotoxic anti-nonGal 
antibodies develop later, and generally remain at a minimal level. This increase in anti-pig 
antibodies with age during the first year is consistent with that of anti-A/B antibodies.
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As we described in adults (47), the incidence and extent of binding of infant baboon and 
human serum IgM and IgG to PBMC from GT-KO pigs was significantly less when compared 
to binding to WT PBMC. The associated lysis of WT cells was higher in baboons than in 
humans, suggesting that antibody-mediated rejection of a transplanted WT pig organ may 
be more problematic in the infant baboon than in the infant human. The increase in anti-
WT cytotoxic antibodies was confirmed by sequential measurement of sera from the same 
baboon. More importantly, the cytotoxicity of infant human anti-nonGal antibodies did not 
increase with age and was absent in a significant number of cases. This allows a ‘window 
of opportunity’ during which a GT-KO pig organ could be transplanted into a human infant 
without the risk of rejection associated with the presence of natural anti-nonGal cytotoxic 
antibodies.  As occurs in the case of ABO-incompatible heart allotransplantation in human 
infants (48, 49), B cell tolerance to carbohydrate antigens may develop when a GT-KO 
pig heart is transplanted into a primate recipient that has not yet developed anti-nonGal 
antibodies.
Immune responses to other xenoantigens (against which no natural antibodies are present) 
would need to be suppressed, but it is not definitively known whether immunosuppressive 
therapy would need to be continued throughout the life of the recipient. Data from Bailey and 
his colleagues (50, 51) suggest that the immune response to an allograft in neonates and 
infants is rather less vigorous than in later life, and West et al (49) have drawn attention to 
the relative ‘plasticity’ of the neonatal immune system. It would be of great clinical interest 
to study whether, in this age group, the prevention of a T cell response for a period of time 
might result in T cell tolerance.
Baboons would generally appear to develop anti-A/B antibodies at approximately 4 months 
of life, which is similar to the time of their development in humans (49). A previous study 
using adult human and baboon sera showed no statistically significant correlation between 
the presence of anti-Gal antibodies and anti-A/B antibodies (52), which is confirmed for IgG 
antibodies by our findings. However, we found a correlation between the presence of anti-
A/B antibodies and anti-WT IgM in infant baboons, possibly since both levels are known to 
increase during the first year of life.
Our data suggest that GT-KO organ transplants could be carried out in early infancy in 
human recipients in the complete or relative absence of cytotoxic anti-nonGal antibodies. 
If immunosuppressive therapy were administered to suppress a T cell-mediated elicited 
antibody response, xenograft rejection resulting from anti-nonGal antibodies would be 
prevented (although other potential problems may still arise (53)). Based on clinical 
experience of heart allotransplantation in infant humans across the ABO barrier, it is possible 
that B cell tolerance to pig carbohydrate antigens might develop. Future studies should focus 
on testing this in vivo, by implanting tissue/organs from GT-KO pigs into infant baboons.
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PIG-TO-MONKEY ISLET TRANSPLANTATION
Induction of diabetes
Chapter 7 presents the first study to describe the safe induction of diabetes in nonhuman 
primates with high-dose Zanosar STZ, resulting in undetectable (fasting and stimulated) 
primate C-peptide. Zanosar STZ is used in patients with metastatic islet cell carcinoma, and 
may have fewer side effects than the widely used Sigma STZ, perhaps because of greater 
purity and less variability. 
There has been discussion with regard to the optimal dose of STZ in nonhuman primates. 
Pitkin et al. and Litwak et al. showed that a single dose of 30mg/kg is insufficient to induce 
complete diabetes (54, 55). Larger doses of 100-150mg/kg were found sufficient (56-58), 
but were associated with more side effects and complications (54, 57-60). In contrast, 
Koulmanda et al. reported that 55mg/kg was sufficient to consistently induce diabetes in 
cynomolgus monkeys (56), but others have been less successful with this dosage (54, 60-
62), with C-peptide production still detectable (in the range of 0.6 to 0.9ng/mL). Wijkstrom 
et al. suggested the dose should be based on body surface area (1250mg/m2), rather than 
body weight (58). 
The islets of younger nonhuman primates may be more resistant to destruction, and this 
may account for the varying STZ dosages required to induce diabetes (56, 62). Furthermore, 
since STZ has a half-life of only 10 min (56), it seems reasonable to anticipate that higher 
dosages are necessary if it is not administered rapidly as a bolus. 
The correlation between the dose of STZ and the development of renal and hepatic damage 
is well-documented. This is demonstrated by an increase in blood urea nitrogen, serum 
creatinine, and/or hepatic enzymes, or by histological injury (56, 57, 59, 60). It is therefore 
of importance to find the optimum dose to successfully induce diabetes with minimal or no 
risk of side-effects.
We have demonstrated that diabetes can be consistently induced after high-dose STZ 
administration. Both 1250mg/m2 (~105mg/kg) Sigma STZ as well as 150mg/kg Zanosar 
STZ resulted in the cessation of C-peptide production (i.e., to a level below the detection 
level of the respective assays). At 150mg/kg, we were able to successfully establish diabetes 
in nonhuman primates without residual beta cell function, and without associated morbidity. 
In contrast, high-dose Sigma STZ was associated with adverse effects, although the role 
of additional immunosuppressive therapy in the development of this damage remains 
uncertain.
Furthermore, we observed a triphasic response in blood glucose during the first 36h after 
STZ administration. Such a response has been described in rodents (63, 64) and monkeys 
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(62, 65). Interpretation of the triphasic response is that there is an initial decrease of insulin 
release as a result of inflammation and an inability of the beta cells to respond to glucose due 
to impaired glucose oxidation in the beta cell (63, 66); this explains the initial rise in blood 
glucose (phase I). Further destruction and disruption of the beta cells results in a massive 
release of insulin, leading to a fall in blood glucose level (phase II). Finally, there is a critical 
loss of beta cells (phase III), resulting in the diabetic state (64, 66).  We documented a peak 
blood glucose after 8h (compared to 2-7h in the rat), followed by a steady fall until 17h 
(8-12h in the rat) and a subsequent rise with persistent hyperglycemia (>200mg/dL) after 
30.3h (24h in the rat) (63, 64).  Since a monkey that did not become successfully diabetic 
lacked this triphasic response, we suggest this triphasic response indicates the complete 
and successful induction of diabetes.
Reduction of early graft loss after intraportal pig-to-monkey islet transplantation
After establishing a model of diabetes in cynomolgus monkeys, we could begin to study 
pig-to-monkey islet transplantation in diabetic monkeys (Chapter 8). It has been well 
documented by several groups that large numbers of pig islets are rapidly lost after their 
intraportal transplantation into primate recipients (67-69, reviewed in 70), and we have 
confirmed this observation. In our study, the extent of the initial injury to the transplanted 
pig islets from IBMIR was largely estimated by the amount of dextrose required to prevent 
serious hypoglycemia, due to massive destruction of islets. A high dextrose requirement 
correlated with a short period of graft survival, as measured by blood glucose level, insulin 
requirement, and the level of porcine C-peptide.  Complement depletion with cobra venom 
factor (CVF) or anticoagulation with dextran sulfate (DS), resulted in an important reduction 
of early graft loss, resulting in increased survival of the islet graft. Early graft survival was 
indicated by higher porcine C-peptide levels. However, even with complement depletion or 
anticoagulation, significant early graft loss could not be prevented completely.
It has been reported that DS alone results in both anticoagulation and inhibition of 
complement activity (69, 71). Our own observations suggest that, although effective as 
an anticoagulant, DS was markedly less effective in inhibiting complement activity. Other 
agents and approaches therefore require to be investigated to prevent IBMIR.  For example, 
a combination of complement depletion (by CVF) and anticoagulation (by DS) may prove 
more successful. 
The best result was obtained by our group when we doubled the number of islets transplanted 
to 80,000IEQ/kg in one monkey. Normoglycemia, without the need for exogenous insulin, 
and high porcine C-peptide levels were documented throughout the 5-day period of 
observation, indicating that the number of islets transplanted had compensated for the 
initial loss that resulted from IBMIR. It is perhaps important to note that the normal level of 
blood glucose in healthy monkeys is 50-70mg/dL. The monkey that was transplanted with 
80,000IEQ/kg, was the only diabetic monkey in which this relatively low blood glucose levels, 
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or true normoglycemia, was obtained, and this was only achieved when porcine C-peptide 
levels were between 2.7-6.2ng/mL. In the other monkeys, graft function associated with 
lower porcine C-peptide levels (0.5-2.0ng/mL), which are actually high levels in healthy pigs, 
resulted in improvement of the diabetic status for up to two months, but not in normoglycemia. 
A potentially important observation is that C-peptide levels in healthy non-diabetic monkeys 
(>1.5ng/mL in our laboratory) are considerably higher than in healthy non-diabetic pigs (0.2-
0.6ng/mL).  Peculiar characteristics of monkey metabolism and/or of porcine islets may 
therefore be relevant to islet function in pig-to-nonhuman primate transplantation models. 
As the number of porcine islets that could be made available for any single diabetic patient 
will be theoretically limitless, this observation may provide a simple way of overcoming 
the considerable barrier raised by IBMIR. However, to provide 80,000IEQ per kg for an 
80kg patient might require a total of more than 6 million IEQ (requiring ~15-20 adult retired 
breeder pigs). On the other hand, the number may be significantly fewer since fasting C-
peptide levels in healthy humans (1.18+/-0.06ng/mL (72)) are considerably lower than 
those in monkeys.  Pig islet insulin production may therefore sustain normoglycemia more 
successfully in humans than in monkeys, necessitating the transplantation of significantly 
fewer porcine islets. Nevertheless, it would clearly be preferable to reduce the percentage 
loss of islets from IBMIR. Furthermore, although the elevation in liver enzymes after islet 
transplantation in the present study was only transient, there is the potential for portal vein 
thrombosis or liver injury after the intraportal transplantation of large numbers of islets. 
In other studies, it has proved difficult to determine how much loss of islet function is a 
consequence of IBMIR and how much is a result of rejection. Increasingly, however, the loss 
from IBMIR is becoming more obvious (73, 74). Although medium-term survival of porcine 
islets in nonhuman primates has recently been reported in the apparent absence of specific 
treatment for IBMIR (1, 2), there is still a need to study and prevent IBMIR, since it would 
be ideal to obtain true normoglycemia with the smallest possible number of islets and with 
minimal immunosuppression. In our own studies using a costimulation blockade-based 
regimen, as originally introduced by Buhler et al (19), T cell-mediated acute cellular rejection 
does not appear to have been a major factor in graft loss, since there has been an absence 
of cellular infiltration in the liver and of a T cell-dependent elicited antibody response. It may 
be only when the problem of IBMIR has been resolved that low-dose immunosuppressive 
therapy will be able to be fully investigated.
GT-KO pigs have not been used previously as sources of islets for transplantation into 
primates. In our study, as anticipated, we did not find that adult GT-KO pig islets were less 
susceptible than WT pig islets to early destruction. It has been reported that carefully isolated 
adult WT islets do not express the Gal epitopes against which primate anti-pig antibodies are 
largely directed (9). Our own observations also indicate that endocrine islet cells, including 
beta cells, do not express Gal epitopes, although Gal-positive cells can be found in small 
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numbers, most likely as a consequence of imperfect enzymatic separation of the exocrine 
from the endocrine tissues or from the presence of vascular endothelial cells. In contrast, 
islets from GT-KO pigs show no staining for Gal. In isolated WT islets, the Gal-stained tissues 
do not include the insulin-producing beta cells. 
However, early function between the GT-KO and WT islets cannot be strictly compared, as 
all WT islets were obtained from retired breeding sows whereas the GT-KO islets were not; it 
has been well-documented that islets from retired breeders have better post-transplantation 
characteristics (75, 76). The outcome may well have been different if neonatal or fetal islets 
(that express abundant Gal epitopes) had been transplanted. It has been shown in GT-KO 
mice that transplanted WT neonatal pig islets induce an increase in anti-Gal antibody titer, 
whereas GT-KO neonatal islets do not (10).
Summarizing our pig to monkey islet transplantation experiments: Early loss of pig islets 
occurred after intraportal transplantation in monkeys, even when attempts were made to 
inhibit IBMIR by CVF+heparin or DS administration. This early graft loss requires intensive 
further investigation. However, survival of viable islets up to two months with C-peptide levels 
that are high for pigs was documented. To date, there have been no reports on survival of 
porcine islets with C-peptide levels that would be physiologic for humans. Medium-term 
survival of islets with (for primates) low levels of C-peptide is currently feasible. It would 
be challenging to study functional pig islet survival in nonhuman primates, with C-peptide 
values that are in the normal range for the host. On the other hand, clinically acceptable 
survival of porcine islets may be closer than expected, since reported C-peptide levels for 
humans are lower than for monkeys (Chapter 2, Table 2). This would suggest that islet graft 
function with associated porcine C-peptide levels that would not be able to render a monkey 
normoglycemic, may be able to achieve normoglycemia in a human.
FUTURE PERSPECTIVES
Clinical islet xenotransplantation
Chapter 9 addresses the current position of clinical islet xenotransplantation. Although 
valuable data may be obtained from clinical trials of islet xenotransplantation, and although 
efforts towards clinical trials should not be unduly impeded, we have to question whether 
there is sufficient encouraging experimental data in nonhuman primate models to warrant 
further clinical studies at the present time. Over the past years, some data have become 
available from pig-to-nonhuman primate studies (77) but, except for two reports on 
successful survival of pig islets in cynomolgus monkeys for periods of several months using 
an immunosuppressive regimen that is unlikely to be clinically applicable (1, 2), there are no 
studies that support a conclusion that clinical trials are likely to be successful (77).
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Although some patients have required less, or even no, insulin (at least temporarily) after 
pig islet transplantation, and thus the patients have individually benefited from clinical trials, 
it remains uncertain whether this was related to improved medical management, e.g., 
meticulous attention to diet, regular monitoring of blood glucose, excellent medical advice 
and management, etc., rather than to the function of the transplanted islets. Diabetic patients 
are likely to be more carefully monitored and more attentive to maintaining good control of 
their own condition when participating in a well-organized clinical trial.
The future may host more clinical islet xenotransplantation studies. If so, in the opinion 
of the IXA Ethics Committee, it would be mandatory that convincing experimental data 
in nonhuman primate models as to the efficacy of the approach are available to indicate 
the likelihood of a successful outcome and to justify exposure to potential risks. Careful 
monitoring (in collaboration with a recognized national authority) for potential transmission 
of infectious microorganisms is also surely mandatory.  All aspects of the trial should be 
under the supervision of an institutional (and possibly a national) committee or authority. 
Such oversight and monitoring will surely not only safeguard the individual patient and the 
community, but will also increase the likelihood of obtaining valuable data from the trial, even 
if it is not fully successful in achieving its goals.
At this point in time, more experimental data from nonhuman primate models documenting 
convincing efficacy, focused on clinically-applicable immunosuppressive regimens, are 
needed to justify the initiation of clinical trials.  These studies should also be designed to 
provide further data on the safety of the procedure, particularly with regard to the transfer of 
porcine viruses (including, but not limited to, PERV) to the nonhuman primate recipient of 
the porcine islets. A carefully-monitored clinical trial may then be justified even though the 
potential risk to the patients, and possibly for society, would not be zero.  
The results required in a nonhuman primate model of porcine islet transplantation to justify 
progress to a clinical trial remain uncertain. The criteria for a clinical trial are particularly 
difficult to determine for patients with diabetes, since the disease is not as rapidly fatal as 
many other conditions for which xenotransplantation offers hope. A strong case could be 
made for a consensus meeting, and/or the setting up of an expert advisory committee (as 
convened by the International Society of Heart and Lung Transplantation in 2000 [78]) to 
determine these criteria.   
Islet cell regeneration
Efforts have been made to find a successful treatment for type-1 diabetes, such as islet 
xenotransplantation.  Despite progress in the field of transplantation, this has not yet resulted 
in a permanent solution. Rodent studies have given us hope for a new direction:  regeneration 
of the patient’s own beta cells, which was reviewed in Chapter 10.  Preliminary studies 
in primates support anecdotal examples suggesting that beta cell regeneration might be 
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possible also in humans.  If abrogation of autoimmunity can be safely achieved in a diabetic 
patient with an autotransplant of precursor cells transfected with HLA class II beta chain 
genes conferring resistance to the disease, while correcting his/her hyperglycemia using 
conventional insulin administration or an islet allotransplant, ‘nature’ will be left to heal the 
rest. It should also be possible to speed up the natural process of healing by endoscopic 
retrograde intraductal delivery of factors known to promote beta cell regeneration. Should 
this approach work satisfactorily, young diabetic patients will be permanently cured, without 
the need for long-term drug therapies associated with known troublesome consequences. 
The highly interesting field of islet cell regeneration is one that should be fully investigated, 
particularly since it aims at a true ‘cure’ for diabetes, while successful islet transplantation 
can possibly only be considered a ‘treatment’. However, at the moment there is insufficient 
evidence to support the assumption that this alternative to islet transplantation will lead to a 
cure for diabetes in the near future. Therefore, further research into islet xenotransplantation 
is fully justified, especially considering the progress that has been made over the past 
decade.
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Het ultieme doel is het vinden van een definitieve behandeling van type 1 diabetes, waarmee 
de notoire lange-termijn complicaties voorkomen kunnen worden, alsmede de beperkingen 
die insulinebehandeling geeft voor het dagelijks leven. Alvleeskliertransplantatie en 
transplantatie van eilandjes van Langerhans van een humane donor zijn potentiële 
oplossingen, alhoewel deze beperkt worden door onder andere chirurgische complicaties 
en het tekort aan donororganen.
Een mogelijke oplossing voor het tekort aan donororganen kan worden gevonden in 
xenotransplantatie, waarbij het varken gebruikt wordt als bron van eilandjes van Langerhans. 
Insuline van varkens werd immers decennia lang succesvol gebruikt voor de behandeling van 
diabetespatiënten. Helaas bestaat het probleem dat organen en weefsel van gewone, ‘wild-
type’ (WT) varkens snel worden afgestoten na xenotransplantatie. Bij deze afstotingsreactie 
spelen antilichamen in het serum van de ontvanger, gericht tegen het varkenstransplantaat, 
een belangrijke rol. Eerder is ontdekt dat zogenaamde anti-Gal antilichamen, gericht tegen 
het ‘Gal-epitoop’ op cellen van varkens, een centrale rol vervullen in de afstoting direct 
na transplantatie van een varkenstransplantaat. Er zijn varkens ontwikkeld die homozygoot 
knock-out zijn voor het α1,3-galactosyltransferase gen; de galactosyltransferase-knock out 
(GT-KO) varkens. Hiermee zijn nieuwe mogelijkheden gecreëerd voor varken naar primaat 
xenotransplantatie, aangezien deze varkens geen Gal-epitoop op hun cellen tot expressie 
brengen. Klinische trials kunnen niet beginnen voordat resultaten van knaagdier studies 
gevalideerd zijn in een pre-klinisch model. Dit legitimeert studies in niet-humane primaten.
Deze dissertatie begint met een review van de voorgaande ervaring met varken-naar-niet-
humane primaat eilandjestransplantatie (Hoofdstuk 2). De soort varkenseilandjes wordt 
besproken, te weten eilandjes van foetale, neonatale en volwassen varkens. Het lijkt dat 
eilandjes van volwassen varkens de beste eigenschappen bezitten, zowel vanuit logistiek 
als immunologisch oogpunt, om diabetes te behandelen in primaten. Met de huidige 
isolatietechnieken kunnen grote hoeveelheden volwassen eilandjes van goede kwaliteit 
worden verkregen.
Verder worden modellen om diabetes te induceren in niet-humane primaten beschreven. 
Een bruikbaar experimenteel model voor inductie van diabetes in niet-humane primaten, is 
gevonden in de toediening van het voor insuline producerende cellen toxische streptozotocin 
(STZ). Het is echter onduidelijk of STZ volkomen irreversibel diabetes induceert. 
Verlenging van de overleving van getransplanteerde varkenseilandjes in niet-humane 
primaten gaat helaas langzaam. Met de vele beschikbare immunosuppressiva zal 
de uitdaging liggen in het bepalen van de optimale combinatie. In het bijzonder bij een 
ziekte zoals diabetes, welke niet snel fataal hoeft te zijn, bestaat de noodzaak om klinisch 
toepasbare protocollen van immunosuppressiva te ontwikkelen die niet geassocieerd zijn 
met potentieel levensbedreigende bijwerkingen. 
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ANTI-NONGAL ANTILICHAMEN
Transplantatie van een orgaan van een gewoon, ‘wild-type’ (WT) varken in een 
immuungesuppresseerde primaat resulteert gewoonlijk binnen enkele minuten tot uren in 
hyperacute afstoting van het orgaan. De rol die anti-Gal antilichamen hierbij hebben, is 
bekend. De rol van andere antilichamen in primaten gericht tegen varkensorganen en/of 
weefsel, zogenaamde anti-nonGal antilichamen, hebben we kunnen onderzoeken nadat de 
GT-KO varkens beschikbaar kwamen. 
Anti-nonGal antilichamen bij bavianen
in Hoofdstuk 3 beschrijven we het voorkomen van deze anti-nonGal antilichamen in het 
serum van bavianen, en we onderzochten of deze antilichamen in staat waren bepaalde 
varkenscellen (Peripheral Blood Mononuclear Cells, PBMC) te beschadigen, door 
cytotoxiciteit van het serum te testen tegen PBMC van GT-KO varkens. Deze resultaten 
hebben we vergeleken met de reactiviteit van anti-varkens antilichamen tegen PBMC van 
WT varkens.
We toonden aan dat vrijwel alle bavianen antilichamen bezaten tegen WT varkenscellen, maar 
slechts de helft bezat deze antilichamen tegen GT-KO varkenscellen. Ook wordt beschreven 
dat deze anti-nonGal antilichamen significant minder cytotoxisch zijn dan de anti-Gal 
antilichamen. Desalniettemin initiëren anti-nonGal antilichamen in de laboratoriumsetting wel 
degelijk een cytotoxische reactie. Deze reactie zou overleving van een GT-KO transplantaat 
in vivo kunnen ondermijnen.
Verder wordt beschreven dat er bij bavianen na transplantatie van GT-KO organen een 
anti-nonGal antilichaam reactie op gang komt. Deze opgewekte anti-nonGal antilichamen 
zijn ook cytotoxisch. Dit illustreert dat anti-nonGal antilichamen ook een rol hebben in de 
afstoting van varkensorganen, alhoewel veel minder krachtig dan de anti-Gal antilichamen.
Anti-nonGal antilichamen bij mensen
in Hoofdstuk 4 rapporteren we over de incidentie van anti-nonGal antilichamen in het serum 
van mensen en over de cytotoxiciteit van deze antilichamen met betrekking tot varkenscellen 
(PBMC). Alle geteste sera bevatten anti-Gal antilichamen, tegenover twee-derde van de sera 
die anti-nonGal antilichamen bevatten. Net als bij bavianen was de cytotoxiciteit van deze 
anti-nonGal antilichamen significant lager dan de cytotoxiciteit van de totale anti-varkens 
antilichamen. Dit betekent dat een GT-KO transplantaat weliswaar geschikter is dan een WT 
transplantaat, maar dat anti-nonGal antilichamen nog steeds een probleem vormen en dat 
zij de overleving van het transplantaat kunnen bedreigen.
Antilichamen kunnen bij mensen gedurende het gehele leven gevormd worden, bijvoorbeeld 
door expositie aan virussen of bacteriën. Zo zijn patiënten die op een wachtlijst staan voor 
Proefschrift.indb   216 1/3/2008   6:19:20 PM
Samenvatting en discussie
217
transplantatie onder te verdelen in patiënten met een lage, en patiënten met een hoge 
reactiviteit van hun serum tegen humane donoren. Patiënten met een hoge reactiviteit 
(zogenaamd allogesensitiseerd) hebben meer moeite een geschikt donororgaan te vinden, 
vanwege de reactiviteit van hun serum tegen het donororgaan. Wij hebben onderzocht of 
patiënten met een hoge reactiviteit ook een hogere reactiviteit tegen xenotransplantaten 
hebben dan niet gesensitiseerde patiënten. Onze resultaten laten zien dat dit niet het geval is. 
Dit betekent dat deze patiënten, die een kleine kans hebben een geschikt humaan donororgaan 
te vinden, mogelijk als eerste in aanmerking komen voor een xenotransplantaat.
Het is van belang om te onderzoeken waar de nonGal-antilichamen precies uit bestaan. 
Tot op heden is er echter pas één antilichaam gedefinieerd dat als anti-nonGal antilichaam 
bij mensen (maar niet bij bavianen of cynomolgus apen) aangemerkt kan worden; het 
Hanganutziu-Deicher antilichaam. Er ligt een belangrijke rol voor toekomstig onderzoek 
om andere anti-nonGal antilichamen te identificeren. Ook zou het interessant zijn om te 
onderzoeken of de anti-nonGal antilichamen uit het serum van de ontvanger weggevangen 
kunnen worden door middel van immunoabsorptie, waarbij de anti-nonGal antilichamen 
geabsorbeerd worden uit het serum. Een andere potentiële mogelijkheid om afstoting door 
anti-nonGal antilichamen te voorkomen is door te transplanteren in het eerste levensjaar, 
voordat deze antilichamen gevormd zijn. Dit wordt in hoofdstuk 6 beschreven.
Anti-nonGal antilichamen bij cynomolgus apen
Hoofdstuk 5 beschrijft de aanwezigheid van anti-nonGal antilichamen in het serum van 
cynomolgus apen en vergelijkt de niveaus van antilichamen tussen cynomolgus apen, 
bavianen en mensen. We vonden wederom een significant lager niveau van anti-nonGal 
antilichamen dan van anti-varkens antilichamen. We toonden echter ook aan dat driekwart 
van de geteste sera anti-nonGal antilichamen bevatten die cytotoxisch zijn, alhoewel 
het niveau van cytotoxiciteit van anti-nonGal antilichamen lager is dan van anti-varkens 
antilichamen.
Bij cynomolgus apen is het niveau van anti-nonGal antilichamen en de cytotoxiciteit van 
deze antilichamen significant hoger dan bij bavianen en mensen. Dit zou betekenen dat de 
baviaan wat betreft anti-nonGal antilichamen dichter bij de mens staat dan de cynomolgus 
aap, en hierdoor geschikter zou kunnen zijn als preklinisch model.
Anti-nonGal antilichamen bij kinderen
Natuurlijke anti-varkens antilichamen ontstaan gedurende de eerste maanden van het 
bestaan. We hebben beschreven in Hoofdstuk 6 dat de ontwikkeling van (cytotoxische) 
anti-nonGal antilichamen bij pasgeborenen heel langzaam op gang komt en dat er geen 
correlatie bestaat tussen het niveau van deze antilichamen en de leeftijd gedurende het 
eerste levensjaar. Daarentegen worden cytotoxische anti-varkens antilichamen vroeg in het 
eerste levensjaar gevormd en het niveau stijgt gedurende dit levensjaar. De ontwikkeling 
Proefschrift.indb   217 1/3/2008   6:19:20 PM
Chapter 11
218
van anti-varkens antilichamen is evenredig met de ontwikkeling van anti-bloedgroep 
antilichamen. In onze studie vonden we dat deze antilichamen bij bavianen op de leeftijd 
van ongeveer vier maanden gevormd zijn.
Dit biedt perspectieven voor eventuele toekomstige transplantatie van GT-KO weefsel 
en/of organen bij pasgeborenen, aangezien zij nog geen antilichamen bezitten die 
antilichaam-gemedieerde afstoting kunnen veroorzaken. Dit principe is al beschreven voor 
harttransplantatie bij pasgeborenen, waarbij gebruik gemaakt is van een hart van een donor 
met een andere bloedgroep. Bij pasgeborenen werden anti-bloedgroep antilichamen niet 
meer gevormd, wanneer het bloedgroep-incompatibele hart getransplanteerd werd voordat 
anti-bloedgroep antilichamen zich ontwikkeld hebben. Dit zou voor anti-nonGal antilichamen 
ook het geval kunnen zijn, waardoor de transplantatie kan plaatsvinden in afwezigheid van 
anti-nonGal antilichamen. Wel dient de T-cel gemedieerde afstoting gesupprimeerd te 
worden, zoals bij klinische harttransplantaties.
TRANSPLANTATIE VAN VARKENSEILANDJES VAN LANGERHANS IN APEN
Ons doel was te bestuderen hoe diabetische apen genezen kunnen worden door transplantatie 
van varkenseilandjes. Om optimaal de functie van het eilandjestransplantaat te bestuderen, 
is het van belang om deze te transplanteren in volledig diabetische apen.
Inductie van diabetes
in Hoofdstuk 7 beschrijven we een model om op een veilige manier diabetes te induceren 
in cynomolgus apen. Dit is de eerste studie over veilige inductie van diabetes in niet-humane 
primaten door middel van een hoge dosis, voor insulineproducerende cellen toxische, Zanosar 
streptozotocin (STZ). Zanosar STZ wordt gebruikt bij patiënten met gemetastaseerde eilandjes 
tumoren en lijkt minder bijwerkingen te hebben dan het veelgebruikte Sigma STZ. Wellicht 
wordt dit veroorzaakt door grotere zuiverheid en minder variabiliteit. Na de behandeling van 
de apen met een hoge dosis Zanosar STZ was er geen C-peptide meer detecteerbaar in het 
serum van de apen. C-peptide is een afsplitsingsproduct van het endogeen geproduceerde 
insuline en daarmee een maat voor de hoeveelheid geproduceerd insuline.
Er is veel discussie geweest over de optimale dosis van STZ om bij niet-humane primaten 
diabetes te induceren. Lage doses zijn veelal onvoldoende gebleken om de beta-cellen van 
de pancreas volledig uit te schakelen. Hoge doses zijn echter geassocieerd met nier- en 
levertoxiciteit. Vandaar dat het van groot belang is om een optimale dosis te vinden waarbij 
volledige diabetes en een minimaal risico op bijwerkingen gewaarborgd worden. Wij hebben 
aangetoond dat diabetes consistent kan worden geïnduceerd met een hoge dosis STZ van 
zowel het Zanosar als het Sigma type. Alleen Zanosar STZ bleek dit te bewerkstelligen met 
weinig tot geen morbiditeit.
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Verder hebben we beschreven dat er bij de inductie van complete diabetes een trifasische 
bloedglucose respons optreedt in de eerste 36 uur. Hierbij stijgt in de eerste fase de 
bloedglucose door een afname van insulineproductie door de beta-cellen. In de tweede fase 
treedt massale destructie van de beta-cellen op wat resulteert in een sterke afname van de 
bloedglucose waarde. In de derde fase stijgt de bloedglucose weer, wat ditmaal betekent 
dat de definitieve diabetische staat is bereikt. Afwezigheid van deze respons betekent 
onvolledige inductie van diabetes.
Reductie van het verlies van eilandjes na intraportale transplantatie van 
varkenseilandjes in apen
Na het ontwikkelen van een model voor inductie van diabetes in cynomolgus apen, konden 
we beginnen met de varken-naar-aap eilandjestransplantatie in diabetische apen (Hoofdstuk 
8). Wij, maar ook andere onderzoeksgroepen, hebben beschreven dat grote hoeveelheden 
eilandjes verloren gaan in de eerste periode na transplantatie van de eilandjes in de 
poortader. Deze reactie wordt de ‘instant blood-mediated inflammatory reaction’ (IBMIR) 
genoemd. Stolling, complement activatie en bloedplaatjes activatie spelen een belangrijke 
rol in de destructie van de eilandjes. Wij hebben een tweetal methoden geïntroduceerd en/of 
getest die deze reactie tegengaan. Complement depletie in de apen door middel van cobra 
venom factor (CVF) en antistolling met behulp van dextran sulfate (DS) heeft geresulteerd 
in een belangrijke afname van het verlies van de eilandjes kort na transplantatie. Dit heeft 
geleid tot (tijdelijke) insuline onafhankelijkheid, langdurig verminderde insulinebehoefte, 
betere controle van bloedglucosewaarden en langdurig functioneren van de eilandjes. 
Echter, zelfs met complementdepletie of anticoagulatie, kon de destructie van eilandjes niet 
volledig voorkomen worden. Er zal in toekomstige studies gezocht moeten worden naar 
andere methoden om afbraak van eilandjes te voorkomen.
Varkens, apen en mensen hebben verschillende normaalwaarden voor serum C-peptide 
niveaus (Hoofdstuk 2, tabel 2). We hebben overleving van varkenseilandjes in apen 
gezien met bijbehorende C-peptide niveaus die hoog zijn in vergelijking met C-peptide 
niveaus in varkens. Momenteel zijn er geen studies bekend waarbij overleving van 
eilandjes gerapporteerd is met C-peptide niveaus die fysiologisch zouden zijn voor de 
mens. Middellange termijn overleving van eilandjes met (voor primaten) lage niveaus van 
C-peptide is momenteel mogelijk. Het zou echter een uitdaging zijn om overleving van 
functionele varkenseilandjes te bestuderen in niet-humane primaten, met C-peptide waarden 
die in de normale range voor de ontvanger liggen. Klinisch acceptabele overleving van 
varkenseilandjes kan echter dichterbij zijn dan verwacht, aangezien C-peptide waarden voor 
mensen lager zijn dan voor apen. De situatie zou kunnen bestaan dat de insulineproductie 
van getransplanteerde eilandjes (met bijbehorende C-peptide niveaus) onvoldoende is om 
een aap normoglycemisch te maken, terwijl diezelfde insulineproductie wel voldoende is om 
normoglycemie bij de mens te bewerkstelligen. 
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Het is moeilijk gebleken om te bepalen hoeveel eilandjes verloren gaan als gevolg van 
IBMIR en hoeveel er verloren gaan als gevolg van afstoting. Toenemend wordt het verlies 
door IBMIR beschreven als belangrijke factor. Alhoewel middellange termijn overleving 
van varkenseilandjes in niet-humane primaten onlangs beschreven is zonder dat hierbij 
specifieke therapie gericht op IBMIR gegeven werd, bestaat nog steeds de noodzaak 
om IBMIR te bestuderen en te voorkomen. Het uiteindelijke doel is namelijk volledige 
normoglycemie te behalen met de kleinst mogelijke hoeveelheid eilandjes en met minimale 
immunosuppressiva. In onze eigen studies hebben we gebruik gemaakt van een zogenoemd 
‘co-stimulatie blokkade’ immunosuppressiva protocol. Hierbij hadden we geen aanwijzingen 
voor een rol van T-cel gemedieerde acute afstoting, aangezien er geen cellulaire infiltraten 
in de lever zijn gevonden en er ook geen T-cel gemedieerde antilichaamreactie opgewekt 
werd bij de ontvanger. Wellicht dat de ontwikkeling van een lage-dosis immunosuppressiva 
protocol pas plaats kan hebben wanneer het probleem van IBMIR opgelost is.
GT-KO varkens zijn niet eerder bestudeerd als donoren van eilandjes voor transplantatie 
in primaten. Zoals verwacht, vonden wij in onze studie niet dat volwassen GT-KO eilandjes 
minder gevoelig waren voor vroege afbraak na transplantatie dan WT eilandjes. Het is 
bekend dat zorgvuldig geïsoleerde volwassen WT eilandjes geen Gal tot expressie brengen, 
het voor primaten voornaamste antigeen waartegen antilichamen bestaan. Onze eigen 
observaties indiceren ook dat endocriene eilandjescellen, inclusief beta-cellen, geen Gal-
epitopen tot expressie brengen. Wanneer er foetale of neonatale eilandjes gebruikt zouden 
zijn (waarbij de WT eilandjes wel Gal tot expressie brengen), zou er naar verwachting wel 
verschil geconstateerd zijn. 
TOEKOMSTPERSPECTIEVEN
Klinische transplantatie van eilandjes van Langerhans
in Hoofdstuk 9 wordt de huidige positie van klinische eilandjes xenotransplantatie besproken. 
Hoewel er waardevolle data verkregen worden uit klinische studies, en hoewel stappen in 
de richting van klinische trials volledig doorgang moeten hebben, moeten we ons afvragen 
of er op dit moment voldoende experimentele data in niet-humane primaat modellen zijn om 
verdere klinische studies te rechtvaardigen. 
Klinische studies uit het verleden hebben laten zien dat sommige patiënten (tijdelijk) minder, 
of zelfs geen insulinetherapie nodig hadden na transplantatie van varkenseilandjes. Deze 
patiënten hebben dus individueel voordeel gehad van klinische trials, alhoewel het onduidelijk 
blijft of dit gerelateerd was aan verbeterde medische behandeling, zoals bijvoorbeeld strikte 
aandacht voor het dieet, strikte bloedglucose metingen, goede medische zorg en advies.
De laatste jaren zijn gegevens beschikbaar gekomen uit varken-naar-niet-humane primaat 
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eilandjestransplantatie studies. Met uitzondering van twee studies die rapporteren over de 
succesvolle overleving van varkenseilandjes voor perioden van enkele maanden, gebruik 
makend van immunosuppressiva die zeer waarschijnlijk klinisch niet toepasbaar zijn, zijn er 
momenteel geen studies die erop wijzen dat klinische trials kans van slagen hebben.
In de toekomst zouden echter nieuwe klinische trials kunnen plaatsvinden. In dat geval is de 
Ethische Commissie van de International Xenotransplantation Association (IXA) van mening 
dat deze gebaseerd dienen te zijn op overtuigende experimentele data uit niet-humane 
primaat onderzoeken. Hierin moeten zowel effectiviteit en waarschijnlijkheid van een 
succesvolle uitkomst onderzocht zijn, alsook de potentiële risico’s. Zorgvuldige observatie, 
in samenwerking met een erkende nationale autoriteit, voor mogelijke transmissie van 
infectieuze micro-organismen is een absoluut vereiste. Alle aspecten van de trial dienen 
onder supervisie van een institutionele (en mogelijk een nationale) commissie of autoriteit 
plaats te vinden. Deze supervisie en monitoring zullen niet alleen de individuele patiënt en 
de maatschappij beschermen, maar zullen ook de kans op het verkrijgen van waardevolle 
data vergroten, zelfs wanneer de trial niet succesvol zou zijn.
Welke resultaten in een niet-humane primaat-studie vereist zijn, alvorens klinische studies 
te kunnen starten, blijft onduidelijk. De criteria voor klinische eilandjestransplantatie trials 
zijn bijzonder moeilijk te definiëren voor diabetespatiënten, aangezien de ziekte niet zo snel 
fataal hoeft te zijn als vele andere ziekten waarvoor xenotransplantatie hoop biedt. Er zou 
gestreefd moeten worden naar een consensus bijeenkomst, en/of het oprichten van een 
adviescomité van experts om deze criteria te bepalen.
Eilandjesregeneratie
Er zijn inspanningen gedaan om een succesvolle behandeling van type 1 diabetes te 
vinden, zoals xenotransplantatie van eilandjes van Langerhans. Ondanks de progressie op 
het gebied van transplantatie heeft dit nog niet geresulteerd in een permanente oplossing. 
Knaagdierstudies hebben ons hoop gegeven op een nieuwe richting: regeneratie van de 
eigen beta-cellen van de patiënt, waarvan Hoofdstuk 10 een review bevat. Pilot studies 
in primaten ondersteunen anekdotische voorbeelden dat beta-cel regeneratie mogelijk 
zou kunnen zijn bij mensen. De auto-immuniteit van diabetespatiënten zou veilig een halt 
toegeroepen kunnen worden door bijvoorbeeld eigen eilandjes te transplanteren, waarbij 
genen ingebracht zijn die resistentie tegen de auto-immuniteit teweegbrengen in HLA klasse 
II beta ketens genen. De ‘natuur’ kan dan zelf de diabetes genezen.  Het zou ook mogelijk 
zijn om dit proces van natuurlijke genezing te versnellen door endoscopisch retrograad in de 
ductus pancreaticus factoren in te brengen die de beta-cel regeneratie bespoedigen. Mocht 
deze benadering werken, dan zouden nieuwe diabetespatiënten voorgoed te genezen zijn, 
zonder de noodzaak voor levenslange insulinetherapie en de lange termijn complicaties van 
de ziekte.
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Deze zeer interessante richting van eilandjesregeneratie dient onderzocht te worden, in het 
bijzonder omdat het een echte genezing van diabetes zou betekenen, terwijl succesvolle 
eilandjestransplantatie  zou kunnen leiden tot permanente behandeling van de ziekte. Echter, 
verder onderzoek op het gebied van xenotransplantatie van eilandjes van Langerhans 
is volledig gerechtvaardigd, in het bijzonder gezien de progressie die de afgelopen jaren 
gemaakt is in preklinische studies.
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Chapter 2, Figure 1: 
(A) Fetal pig ICC, transplanted under the 
kidney capsule of  a mouse, stained with 
anti-insulin antibodies, (B) Neonatal 
pig ICC, after isolation, stained in vitro 
with dithizone (dithizone stains red for 
insulin-containing cells), (C) Adult pig 
islets, after purification, stained in vitro 
with dithizone.
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Chapter 7, Figure 4: 
Insulin-positive cells in pancreatic tissue of  normal monkey (A) and after 
150mg/kg Zanosar STZ (B), 1250mg/m2 (~105mg/kg) Sigma STZ (C), 
and 60mg/kg Sigma STZ (D).  No insulin-positive cells are seen after 
high-dose STZ (B, C); there are still insulin-positive cells present after 
low-dose STZ (D).
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were between 2.7 and 6.2 ng/mL. In the other monkeys, graft
function associated with lower porcine C-peptide levels (0.5–
2.0 ng/mL), which are actually high levels in healthy pigs (Fig.
5), resulted in improvement of the diabetic status, but not in
normoglycemia. A potentially important observation is that
C-peptide levels in healthy nondiabetic monkeys (�1.5
ng/mL in our laboratory) are considerably higher than in
healthy nondiabetic pigs (0.2–0.6 ng/mL). Peculiar charac-
teristics of monkey metabolism and/or of porcine islets may
therefore be relevant to islet function in pig-to-nonhuman
primate Tx models. The metabolic differences between pig
and primate C-peptide are currently under investigation at
our center.
Because the number of porcine islets that could be
made available for any single diabetic patient will be theoret-
ically limitless, this observation may provide a simple way of
overcoming the very considerable barrier raised by IBMIR.
However, to provide 80,000 IEQ per kilogram for an 80-kg
patient might require a total of more than six million IEQ,
although the numbermay be significantly fewer because fast-
ing C-peptide levels in healthy humans (1.18�0.06 ng/mL
[30]) are considerably lower than those in monkeys. Pig islet
insulin production may therefore sustain normoglycemia
more successfully in humans than in monkeys, necessitating
the Tx of significantly fewer porcine islets.
Nevertheless, it would clearly be preferable to reduce
the percentage loss of islets from IBMIR. Furthermore, al-
though the elevation in liver enzymes after islet Tx in the
present study was only transient, there is the potential for
portal vein thrombosis or liver injury after the intraportal Tx
of very large numbers of islets.
In other studies, it has proved difficult to determine
FIGURE 4. Microscopic section of the liver in a monkey (M8405) seven days after the transplantation of 80,000 islet
equivalents/kg demonstrating islet grafted tissue stained for insulin (green fluorescence indicates insulin; magnification
�20).
FIGURE 5. (A) Blood glucose lev-
els, and insulin requirements, pre- and
postislet transplantation in one group 2
monkey (M5204) treated with costimu-
lation blockade and cobra venom
factor�heparin. The arrow indicates
the day of islet transplantation. Al-
though insulin was required to main-
tain blood glucose levels�250mg/dL,
the insulin requirement was reduced
to 25% to 50% of that pretransplanta-
tion. (B) Porcine C-peptide levels and
selected blood glucose levels in the
same group 2 monkey (M5204). The
two continuous horizontal lines indi-
cate the normal range of porcine
C-peptide in healthy nondiabetic pigs,
and the single dotted line indicates the
lower level of monkey C- peptide in
healthy nondiabetic monkeys. Despite
normal or high levels of porcine
C-peptide, the blood glucose re-
mained relatively high, and the mon-
key required some insulin (see Fig.
5A). The rise in porcine C-peptide in
response to a rise in blood glucose in-
dicates survival of viable and func-
tional pig islets.
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Chapter 8, Figure 4:
Microscopic section of  the liver in a monkey (M8405) 7 days after the Tx of  80,000IEQ/
kg, demonstrating islet grafted tissue stained for insulin (green fluorescence indicates insulin; 
magnification x20).
Chapter 8, Figure 6:
Isolated islets from (A) WT and (B) GT-KO pigs, stained with fluorescein-labeled Griffonia 
simplicifolia 1-isolectin B4 (green), a marker for Gal (magnification x20).
(C) Isolated WT pig islets immunostained for insulin (red) and fluorescein-labeled Griffonia 
simplicifolia 1-isolectin B4 (green), demonstrating that the insulin-producing beta cells do not 
stain for Gal (magnification x40).
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free area of islet vs. whole pancreatic tissue. The need for this
new parameter A arose from the observation that in diabetic
NOD mice rendered hematopoietic chimeras, a new mor-
phological state of the endocrine pancreas can be recognized.
The insulitis-free state obtained by the abrogation of the
autoimmune process must be distinguished from the normal,
physiologic condition of the pancreas. The islets in the
diabetic chimeric NOD mice, although cleared from insulitis,
are significantly reduced in size, display an altered morphol-
ogy, and contain cells, none of which has insulin content. In
unmanipulated control NOD mice, Index N (insulitis score/
A) increased in less than 25 weeks from 0.01 (characteristic of
physiological condition) to 0.1 (reflecting the hyperglycemic
condition in overtly diabetic mice); at this point, the animal
dies. In contrast, the chimeric NOD mice were followed to 32
weeks of age and did not become diabetic (Fig. 4). Fourteen
Fig. 3. Scoring of the different stages of destruction of islets of Langerhans during
diabetogenesis. Specimens of pancreata from NOD mice of different age were stained
with H&E. Magnification for A to G, �400; for H, �1000. (A) Score 0: normal
pancreatic tissue. Neither morphological abnormalities nor mononuclear cell (MNC)
infiltration or retention in the pancreatic vessels are present. (B) Score 1: MNC
vascular retention (yellow arrows). No evident pathological features in pancreatic
morphology. (C) Score 2: MNC perivascular infiltration (yellow arrows) of the vessels
adjacent to the islets; islets maintain a normal morphology. (D) Score 3: MNC
infiltration in the periphery of the islets (yellow arrows) and in the perivascular area of
the adjacent vessels (compare to intact area distant from the islets, green arrows). (E)
Score 4: the insulitis in the periphery of islets (yellow arrows) is associated with
apoptosis (red arrows). (F) Score 5: the infiltration of islets by MNC (yellow arrows) is
advanced, but not exceeding one third of islet section. (G) Score 6: more than one third
of the endocrine tissue of the islet is infiltrated by the MNC (yellow arrows). This stage
of insulitis is consistently concomitant with extensive apoptosis, presumably of both
endocrine and infiltrating cells (H: red arrows) (60).
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Chapter 10, Figure 3: 
Scoring of  the different stages of  destruction of  islets of  Langerhans during diabetogenesis.
Specimens of  pancreata from NOD mice of  different age were stained with H&E. Magnification 
for A to G x400, for H x1000. (A) Score 0: Normal pancreatic tissue. Neither morphological 
abnormalities nor mononuclear cell (MNC) infiltration or retention in the pancreatic vessels 
are prese t. (B) Score 1: MNC vascular retention (yellow rows). No evident pathological 
features in pancreatic morphology. (C) Score 2: MNC perivascular infiltration (yellow arrows) 
of  the vessels adjacent to the islets; islets maintain a normal morphology. (D) Score 3: MNC 
infiltration in the periphery of  the islets (yellow arrows) and in the perivascular area of  the 
adjacent vessels (compare to intact area distant from the islets, green arrows). (E) Score 4: The 
insulitis in the per phery of  islets (yellow arrows) is associated with apoptosis (red arrows). (F) 
Score 5: The infiltration of  islets by MNC (yellow arrows) is advanced, but not exceeding one 
third of  islet section. (G) Score 6: More than one third of  the endocrine tissue of  the islet is 
infiltrated by the MNC (yellow arrows). This stage of  insulitis is consistently concomitant with 
extensive apoptosis, presumably of  both endocrine and infiltrating cells (H: red arrows) (60).
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weeks after BMT, arrest of the destructive processes and
total normalization of Index N were observed in all chimeras
subjected to nonlethal doses of TBI. Once normalized, Index
N remained at a plateau for 14 weeks (length of observation),
confirming that normalization of the structure and function
of the insulin-secreting tissue in the endogenous pancreas of
chimeric NOD mice was stable and long-lasting (61). To
prove that the insulin-producing tissue of the endogenous
pancreas can undergo a reparative process, direct detection
of proliferating [i.e., bromodeoxyuridine (BrdU)-positive]
cells can be performed. In the endogenous endocrine pancre-
as, and in islet allografts of diabetic experimental mice, some
Fig. 4. Chimerism abrogates and reverses destruction of islets of Langerhans in NOD
mice prior to the clinical onset of diabetes. NOD mice (8Y12 weeks of age) were rendered
hematopoietic chimeras by the administration of T-cell-depleted allogeneic BM into
recipients conditioned by lethal (A) and nonlethal (B) doses of TBI. Pancreata of these
chimeras were evaluated for the degree of endocrine pancreas destruction and graded
according to Index N. Gray diamonds, squares, and triangles reflect the kinetics of Index
N in mice rendered chimeric at 8, 10, and 12 weeks, respectively. Black circles show
progression of islet destruction with age evaluated in unmanipulated control NOD mice.
This curve was not extended further because untreated animals did not survive long after
reaching an Index N over 0.1 (61).
Fig. 5. Schematic representation of the protocol used to test regeneration (or rescue) of
the beta cell in diabetic NOD mice. In NOD mice, the infiltration of autoreactive T cells
into the islets of Langerhans (resulting in insulitis) begins at around 4 weeks of age. At
20Y23 weeks, ~85% of female mice are diabetic; that is, their glycemia is >300 mg/dl.
When successfully transplanted with bone marrow (BMT) from a nondiabetes-prone
donor and hematopoietic chimerism is established, the NOD mouse no longer shows signs
of autoimmune activity. However, whereas there is no more evidence of insulitis in the
endogenous pancreas, there is also no sign of insulin production (no red staining). Three
to four months after BMT, new insulin-positive cells (shown in red) are present
throughout the endogenous pancreas. Thus, when the islets transplanted under the
kidney capsule (to maintain euglycemia until regeneration takes place) are removed by
nephrectomy, the mice remain nondiabetic (61). For BIndex N’’ morphometric scoring
system, see (60).
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Chapter 10, Figure 5:  
Sc matic representation of  the protocol used to test egeneration ( r rescue) of  the 
beta cell in diabetic NOD ice. 
In NOD mice, the infiltration of  autoreactive T cells into the islets of  Langerhans 
(resulting in insulitis) begins at around 4 weeks of  age. At 20 to 23 weeks, ~85% 
of  female mice are diabetic, i.e., their glycemia is > 300 mg/dl.  When successfully 
transplanted with bone marrow (BMT) from a n n-d abetes-prone do or and 
hematopoietic chimerism is established, the NOD mouse no longer shows signs of  
autoimmune activity. However, while there is no more evidence of  insulitis in the 
endogenous pancreas, there is also no sign of  insulin production (no red staining). 
Three to four months after BMT, new insulin-positive cells (shown in red) are present 
throughout the endogenous pancreas.  Thus, when the islets transplanted under the 
kidney capsule (to maintain euglycemia until regeneration takes place), are removed 
by nephrectomy, the mice remain non-diabetic (61).  For “Index N” morphometric 
scoring system see ref. 60.
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Chapter 10, Figure 6:  
Regeneration (or rescue) of  
the endogenous pancreas 
in a diabetic NOD mouse 
after obliteration of  the 
autoimmune process via 
allogeneic BMT.
(A) The regenerated 
endocrine tissue of  a chimeric 
NOD mouse becomes 
evident after ~4 months 
from the BM transplant 
and takes the shape of  cell 
agglomerates that resemble 
but are not identical to islets 
of  a non-diabetic animal. 
Insulin is in red (61). (B) 
Comparison between an 
islet of  Langerhans of  a 
non-diabetic B6 mouse (A) 
with insulin stained green, 
and a newly formed insulin 
producing cell agglomerate 
(in red) in the pancreas of  
a diabetic NOD mouse 
treated with BM cells from 
a non-diabetes-prone, B6-
GFP-transgenic donor (B). 
It is possible to observe that 
the latter does not have the 
well organized cell structure 
of  a normal islet and that the 
majority of  the transplanted 
BM cells (in green) do 
not directly participate in 
the regeneration of  the 
endogenous pancreas:  there 
are no double-positive 
(orange) cells in the newly-
formed islets.  The donor 
cells appear to be located 
close to possibly existing 
juxta-ductal precursor cells, 
which may be activated by 
BM cell–secreted factors 
(45).
A
B
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Chapter 10, Figure 7:  
Newly formed insulin-producing cells in the diabetic monkey. 
After 3 to 4 months from STZ injection and diabetes induction, insulin-producing cells are 
appearing in the monkey endogenous pancreas, eventually forming islet-like conglomerates 
of  insulin-positive cells indicated by the arrows.  Immunofluorescence on the left (insulin in 
green) and H&E on the right, of  two consecutive tissue sections (Magnification 20x).
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LIST OF ABBREVIATIONS
AAV  adeno-associated-virus
ACT   activated clotting time
AHXR   acute humoral xenograft rejection 
APC  antigen presenting cell(s)
aPTT   activated partial thromboplastin time
AS-ODN  antisense oligodeoxynucleotides
ATG   anti-thymocyte globulin
BM  bone marrow
BMT  bone marrow transplantation
CDC  complement-dependent cytotoxicity
CVF   cobra venom factor
DC  dendritic cell(s)
DKO  double knockout
DM   diabetes mellitus
DS  dextran sulfate
EGF  epidermal growth factor
ELISA   enzyme-linked immunosorbent assay
EMT  epithelial-to-mesenchymal
Gal  galactoseα1,3galactose epitope
GFP  green fluorescent protein
GLP  glucagon-like peptide
GnT III  N-acetylglucosaminyltransferase-III 
GT-KO    α1,3-galactosyltransferase gene-knockout 
GVHD  graft versus host disease
HAR  hyperacute rejection
HD   Hanganutziu-Deicher antigen
hDAF  human decay-accelerating factor
hIPC  human islet precursor cells
HLA  human leucocyte antigen
HSC  hematopoietic stem cells
IBMIR  instant blood-mediated inflammatory reaction
ICA  islet cell antibodies
ICC   islet cell clusters
IEQ   islet equivalents
IFN  interferon
IGF  insulin-ike growth factor
iv  intravenous
ivGTT  intravenous glucose tolerance test
LIF  leukemia inhibitory factor
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MET  mesenchymal-to-epithelial transition
MFI    mean fluorescence intensity
MHC  major histocompatibility complex
MNC  mononuclear cell(s)
NF  nuclear factor
NOD  nonobese diabetic
NS   not significantly different  
PBMC   peripheral blood mononuclear cells
PRA   panel reactive antibodies  
SLA   swine leukocyte antigens
STZ   streptozotocin
T1D  type 1 diabetes
TBI  total body irradiation
TCR  T cell receptor(s)
Tx   transplantation
WT  wild-type
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